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Paediatric Inflammatory Bowel Disease (IBD) can significantly affect a child’s 
physical and psychological well-being, and the incidence is increasing globally. An 
emerging focus of paediatric IBD care that has the potential to improve disease 
outcomes is that of self-management, whereby children are encouraged to develop 
skills and attributes to enable them to manage their own disease and treatment. Self-
management comprises a number of intertwined elements; knowledge, adherence, 
self-regulation, and communication. In order to provide targeted support in these 
areas’ children should be frequently assessed to highlight gaps or misconceptions 
that may affect their disease outcomes. Few self-management outcome measures are 
available for this population group. The aim of this research was to undertake a 
series of projects to develop and validate assessment and reporting tools that 
address components of self-management in order to provide targeted education and 
support for children with IBD. This research also contributed to the design of a 
mobile health app that is aimed at encouraging children with IBD to self-manage 
their disease. 
Section one explains the detailed, iterative development process of a mobile health 
app aimed at encouraging self-management for children with IBD: IBD-Tracker. 
Section two presents the development process of a knowledge assessment tool for 
children with IBD: IBD-KID2. A series of studies were performed to assess the 
validity, reliability, feasibility, and generalisability of IBD-KID2, as well as testing IBD 
knowledge levels in different population groups. 
Section three details the development of a symptom self-report tool for children with 
IBD that uses a series of text and pictorial Likert scales that enables children to 
report their IBD symptoms: IBDnow. A study performed in two tertiary paediatric 
IBD centres showed that children from the age of three years can use IBDnow to 
produce symptom reports with a good level of agreement to reports from their 
gastroenterologist when using standard validated clinical tools. 
Section four contains a systematic literature review undertaken to identify self-
management skills assessment tools specific to the target population, none of which 
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were appropriate for use with younger children with IBD. Using the available 
evidence, a novel self-management skills assessment tool was developed: IBD-STAR. 
A content validity evaluation by a series of experts appraised the relevance, 
appropriateness, and likely effectiveness for the target population. A study then 
compared the children’s skills assessment using IBD-STAR with an assessment 
undertaken by their parents, and gastroenterologist. This showed that children’s 
reported skills using IBD-STAR correlated well with their gastroenterologist’s 
assessment, but their skills were underestimated by their parents. 
Section five assessed whether the content of the mHealth app IBD-Tracker, when 
delivered in an alternative format (booklet) was effective and acceptable regardless 
of the mode of delivery. The results highlighted a positive trend towards improving 
self-management outcomes, but the response rates and feedback suggest that 
interventions aimed at children should prioritise engagement in addition to ensuring 
a strong evidence base for the content.   
Children with IBD should have multi-disciplinary support as they develop self-
management skills. This series of studies has provided a number of outcome 
measures to address the various components of self-management for children with 
IBD that will highlight where targeted interventions, such as a mobile health app, 






The original proposal submitted for this PhD was the design, development and 
testing of a mobile health app aimed at teaching self-management for children with 
Inflammatory Bowel Disease. The intention was to present the app development 
process in a number of phases, culminating in a randomised controlled trial (RCT) to 
test efficacy and user satisfaction. The theoretical framework and app design were 
completed on schedule within the first six months of the PhD, funding was 
successfully obtained, and an external software company were sub-contracted to 
develop the app. The app was under contract for completion within the first year of 
the PhD, thus allowing sufficient time for usability testing, pilot study, and the RCT.  
The external software company had significant problems in producing the completed 
product. By the beginning of the third year of the PhD they had still not produced the 
app to launch due to extensive workforce and production problems on their behalf. 
The company has subsequently been struck off the Companies Register.  
In light of these problems the PhD was reconfigured, as presented. The subject 
matter remains the self-management of children with IBD but is now focussed on the 
development of outcome measures and reporting tools that assess components of 
self-management in order to provide targeted education and support. The design of 
the app has still been included in the thesis as the self-management theory used in 
this process underpins much of the PhD. It is hopeful that the app can soon be 
redeveloped and that the outcome measures developed in this study will provide 
some robust outcome measures with which to test its efficacy at improving self-
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Chapter One: Introduction and Literature Review 
1.1 Introduction  
Inflammatory bowel disease (IBD) is one of the most important and serious chronic 
diseases of childhood 1, 2. Approximately 25% of cases of IBD develop during 
childhood or adolescence and the incidence is rising globally 3-5. IBD is a collective 
term for the conditions Crohn’s disease (CD) and ulcerative colitis (UC) - both are 
complex, relapsing inflammatory conditions of the gut that affect all, or part of, the 
gastrointestinal (GI) tract. 
When IBD is diagnosed during childhood it can be associated with more extensive 
disease, higher disease activity, and a more complicated progression than when the 
diagnosis is made as an adult 6, 7. The implications of this are that treatment regimens 
may be more complex, and children and their families become responsible for 
multicomponent disease management strategies in order to achieve optimal levels of 
remission.  
1.1.1 Problem statement 
For children with IBD, as with any chronic disease diagnosed in childhood, their 
increasing age eventuates in a paradigm shift of responsibility from disease 
management by the parent or family, to health autonomy for the individual. Integral 
to the development of health autonomy is the concept of disease self-management, 
whereby children learn to take control of their own treatment strategies and gain 
those skills and attributes necessary to self-manage their IBD independently 8, 9. Self-
management is a critical component for positive disease outcomes for children with 
IBD, and has great potential to lessen the disease burden and its sequelae and, 
therefore, reduce healthcare utilisation and cost 7, 10. Clinicians recognise the 
importance of self-management for children with IBD but it is an emergent field in 
paediatric IBD, and subsequently there is a dearth of assessment tools to measure 
these skills and attributes. This thereby hinders the development of integrated 
approaches to address any gaps in children’s self-management abilities. Prior to 
developing interventions to maximise the potential of self-management it is vital to 
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have standardised, reliable outcome measures to identify where the support is 
needed, and to establish the impact of any intervention through objective evaluation 
11-13. The aim of this research was originally to address the lack of self-management 
interventions for children with IBD by developing and testing efficacy of a mHealth 
app specifically for this purpose. This research was not able to be completed due to 
factors beyond the candidate’s control, therefore the aim became to develop and 
validate a series of disease specific outcome measures targeting the components of 
self-management for children with IBD. These assessment tools could then be 
utilised with the target population to assess efficacy of interventions such as the app. 
The following chapter presents a literature review of the general background of IBD 
in relation to epidemiology, symptomatology, disease management, and outcomes. 
The components of self-management are then explored in relation to children with 
IBD, followed by a review of effective interventions to address these components and 
their related outcome measures. Gaps in the literature are highlighted as they 
become apparent and hypotheses consequently generated that relate to subsequent 
chapters. A section outline is provided at the end of this chapter to explain the overall 
thesis structure. 
1.2 Inflammatory Bowel Disease  
1.2.1 History and aetiology 
IBD was not differentiated into the two distinct disease entities of CD and UC until 
landmark papers by Wilkes in 1859 and Crohn in 1932 14, 15. While CD and UC are 
diverse clinical subtypes, those children with atypical disease features that cannot be 
definitively categorized as CD or UC are given a diagnosis of IBD-unclassified (IBD-U) 
16. These subtypes share many traits, symptoms, and consequences, and are often 
studied together as a heterogeneous group 17. Despite the many discoveries and 
triumphs that have changed the course of IBD treatment, particularly in the last two 
decades, the precise aetiology of IBD remains unknown, and a cure still elusive 15.  
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1.2.2 Cause, risk and protective factors 
The most recognised causal hypothesis of IBD is that genetic, immunological, 
environmental and microbial influences converge, the result of which is a 
dysregulated immune response to the commensal intestinal bacteria 6, 18. More than 
two hundred genetic IBD risk loci have been discovered 19, alongside a number of 
environmental risk factors, with the most prominent in the paediatric population 
being 20-24:  
 familial IBD 
 bedroom sharing 
 sugar intake 
 maternal smoking 
 atopic disease (patient or parent) 
 previous GI infections   
A number of protective factors have also been identified but their assigned 
importance varies greatly between studies, and their significance is still not fully 
understood. The strength of risk factors, or lack of protective factors, may differ 
depending on the geography or urbanisation of the population 22, 25.  
1.2.3 Epidemiological features 
1.2.3.1 Age of diagnosis 
Approximately 25% of IBD diagnoses are made during childhood and adolescence 26. 
Of these, 4% are diagnosed before the age of five years, and 18% before the age of 
ten years, with the average age in childhood for the diagnosis of both CD and UC 
throughout the literature being twelve years 27. A number of studies have shown the 
age of onset to be decreasing 28-30. However, this is not a universal finding 31, with an 
alternative hypothesis being that this is due to a rising incidence in some age groups, 




The overall incidence of IBD is increasing globally among children 4, 5, and among 
adults 33, 34. IBD is now considered a global health concern 35. Incidence rates in the 
paediatric population show great variability between developed and developing 
countries, migrant and indigenous peoples, and across global gradients. The areas 
with the highest incidence are parts of Europe and North America/Canada (ranging 
from 15.2 to 23 per 100,000 population) 5. A time-trend literature review by 
Benchimol et al 4 showed a significant increase in the incidence of IBD in 78% of 
studies, of CD in 60% of studies, and of UC in 20%, indicating that UC exhibits a more 
stable trend.  
In New Zealand the incidence of paediatric IBD was most recently delineated by 
Lopez et al 36 who demonstrated a dramatic increase in diagnoses between the years 
1996 (2.08 per 100,000) and 2015 (13.06 per 100,000) in the Canterbury region of 
the South Island. This puts the incidence in New Zealand close to the world’s highest 
when comparing global incidence trends 5. When examined by disease group the 
ratio of disease diagnoses was 8.4:1 in favour of CD - one of the highest reported in 
the world and in keeping with a previous study carried out in the same geographical 
area that showed UC incidence as being considerably more stable than CD 37. When 
examined by gender the ratio was 1.3:1 in favour of males, a predominance found 
universally in the paediatric literature. 
1.2.4 Symptomatology  
There are a number of cardinal physical symptoms common to all subtypes of IBD 27: 
 diarrhoea 
 abdominal pain 
 fatigue 
 weight loss 
 mouth ulcers 
 rectal bleeding  
There are, however, myriad other symptoms that may be experienced. Symptoms 
may be constant or episodic and during times of active disease up to sixteen different 
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symptoms can be experienced per week 38. This is at a higher frequency than in other 
chronic illnesses such as cancer, HIV, renal disease, cystic fibrosis, and in palliative 
cohorts 38. These symptoms may be due to active disease, the subsequent prescribed 
treatments, extra-intestinal manifestations (EIM), disease complications, or 
comorbidities. It is noteworthy that even during periods of quiescent disease a 
number of children and adults with IBD continue to experience symptoms 38-40. 
1.2.4.1 Extra-intestinal manifestations and comorbidities  
Both CD and UC are systemic disorders and while the GI tract is the most commonly 
affected organ, EIM can involve almost every organ system 41. People with IBD may 
also experience additional, distinct, clinical entities that either pre-exist, or occur 
during, the clinical course of their disease; these are known as comorbidities 42. EIM 
are experienced by approximately one quarter of children with IBD 43-45 although this 
rate could be substantially higher due to the diversity in how EIM and comorbidities 
are defined 44. Also prevalent are psychosocial comorbidities with stress, anxiety, and 
depression having a significant impact on the Health Related Quality of Life (HRQoL) 
of children with IBD, alongside their physiological symptoms 46, 47. Comorbidities are 
an important consideration as they affect not only the individual, but also IBD-
related morbidity and mortality, thus increasing the potential for polypharmacy and 
treatment implications 48.  
1.2.5 Disease management 
The key concept of any IBD management strategy is to induce and maintain 
remission whilst preventing disease or treatment related complications, thereby 
providing symptom relief, optimising growth and nutrition, and improving HRQoL 17, 
49. Remission may be considered on clinical and biochemical levels but the 
normalisation of histological changes and sustained mucosal healing are now the 
gold standard aims for therapy 17. Treatment strategies are frequently multimodal 
and may involve the use of drug therapy, a prescribed nutrition regimen, surgical 
intervention, multidisciplinary team (MDT) involvement, and the attention to the 
psycho-social aspects and consequences of IBD 17, 50, 51.  
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Medical treatment: As with many chronic disorders, drug therapy for IBD is complex, 
with several classes of drugs utilised including antibiotics, corticosteroids, 
aminosalicylates, immunomodulators, and biologic therapies 6, 52. These may be 
delivered orally, rectally, or parenterally (subcutaneous or intravenously).  
Enteral Nutrition: Enteral Nutrition (EN) treatment involves the sole or partial 
consumption of micro and macro nutrient-replete liquid formulas. When used 
exclusively (EEN) it is as effective at achieving remission in CD as corticosteroids, 
with the benefit of improved mucosal healing without the associated side effects of 
steroid treatments 6, 17. Similar efficacy has not been proven for UC but it is an 
ongoing area of interest 53. Partial EN can be used for all children with IBD to 
supplement food intake as a means of maintaining remission and ensuring continued 
growth.  
Surgical treatment: Surgical treatment may be required for children with both CD 
and UC, with different procedures being required or beneficial for each disease. For 
children with UC a partial or total colectomy may be performed to provide symptom 
relief for intractable disease. For children with CD, surgery may be required for 
bowel perforation, obstruction, inflammatory masses, fistulae, and abscesses 6, 54.  
Complementary therapies: Allopathic treatments are supplemented with 
complementary and alternative medicine (CAM) products or practices in up to 72% 
of children with IBD. Approximately 50% of parents report partial benefits 55, 56. The 
most popular CAM interventions used in this population are 55-57:  
 spiritual interventions 
 chiropractors 
 massage 
 nutritional supplements (probiotics, fish oils, vitamins, herbal remedies) 
1.3 IBD Outcomes 
Children with IBD face a number of additional challenges compared to adults. 
Childhood and adolescence are times of rapid change and IBD may affect the 
trajectories of cognitive, academic, and physical outcomes. This may have a profound 
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influence on future capabilities and achievements. The burden of the disease is 
therefore multifactorial. The top five concerns of children with IBD, according to the 
degree of impact on their life, are reported as 38, 58, 59:  
 the need for surgery 
 the impact of fatigue 
 the need for hospitalisation 
 pain and cramp 
 remembering to take medications  
 the impact of diarrhoea 
The main implications to health and well-being, as determined in the clinical 
literature, are categorised as; growth, school attendance, psychological welfare, 
health-care utilisation, and subsequently cost. 
1.3.1 Growth  
A diagnosis of IBD during childhood or adolescence comes at a time of dynamic 
growth and physical development and can have a substantial impact on weight, 
linear growth, and puberty 60. However, the detrimental effects of ongoing disease 
activity can be seen long after diagnosis with growth issues and pubertal delay being 
strongly correlated with recurrent relapse or lack of remission 60. The causes of these 
growth delays are multifactorial and are a consequence of malnutrition, disease 
severity and location, pro-inflammatory cytokines and treatment side effects 53, 60, 61. 
Weight: Up to 58% of children with CD have exhibited weight loss prior to diagnosis 
and 80% will experience this during their disease course, whereas 31% of children 
with UC will have weight loss at diagnosis 60, 61. This difference may be attributed to 
the earlier diagnosis in UC – with a common presenting symptom of bloody 
diarrhoea - being investigated more rapidly than the more subtle presenting 
symptoms of CD 53.  
Linear growth: Data from the last ten years has shown that up to 27% of children 
with IBD have a reduced height velocity at diagnosis 62, although linear growth 
impairment can continue to be a negative health outcome throughout the disease 
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course 60. As a consequence, up to 11% of adults diagnosed with IBD during 
childhood fail to reach their full growth potential 62. 
Puberty: Pubertal delay is common (predominantly in children with CD), which has 
implications for their psychosocial well-being in terms of looking different, body 
image, self-esteem, and not feeling as mature as their peers 63, 64.  
1.3.2 School attendance  
It is well known that chronic school absenteeism is detrimental to long-term 
educational achievements, a negative outcome for many children with chronic 
illnesses 65, 66. Up to 42% of children with IBD experience absenteeism - in New 
Zealand they miss an average of 21 days of school per year 67, and other countries 
have absenteeism as high as four months in every twelve 68, 69. When studied directly, 
children with IBD report that they miss significant amounts of school due to fatigue 
and pain, and that their school results are affected because of their disease 58. 
However, children with IBD have repeatedly been shown to have educational 
achievements commensurate with control groups 65, 68-71, even if school years needed 
to be repeated 72. One adult with IBD reflected that his disease had helped him to do 
well academically as he had no energy for social and sporting diversions 68, with 
further reports stating that the impact on schooling during times of active disease is 
mitigated during episodes of remission 68.  
1.3.3 Psychosocial outcomes 
The perceived burden of physical symptoms among children with IBD imposes on 
psychological functioning, with the most frequent concerns being worry, difficulty 
sleeping and concentrating, and feeling embarrassed, angry, irritable and fearful 38, 73. 
In addition, or inevitably, children with IBD have a higher risk of clinically relevant 
emotional and behavioural problems than those with other chronic illnesses 74, 75. Of 
this population, 55% display one or more psychiatric disorders such as depression, 




1.3.3.1 Health Related Quality of Life  
HRQoL should be considered as important as those physiological symptoms 
experienced, as it is a fundamental dimension of children’s psychosocial well-being. A 
definition of HRQoL as it relates to children was presented by Taylor et al (page 
1831) 76:  
“It is unique to each individual young person and includes aspects of physical, 
psychological, and social function. It is dependent upon not only the stage of 
development but also the illness trajectory. This involves the achievement of 
goals and aspirations and the constraints imposed through ill-health and 
treatment.” 
HRQoL is a particularly important outcome to examine since children may not 
readily notice a gradual reduction in symptoms but are likely to notice improved 
physical, emotional, scholastic, and social function 77. It also provides a 
multidimensional, dynamic view of the effects of an illness on patients’ lives 76, 78.  
Children with IBD have significantly lower HRQoL than their healthy peers, at a level 
commensurate with children with cancer and rheumatological disorders 78-80. The 
aspects associated with reduced HRQoL are multifactorial for children with IBD but 
include the following elements 78, 81: 
 complexity of treatment regimens 
 symptoms 
 the effect on family functioning 
 the impact on lifestyle and social activities 
A number of predictors have been found to correlate with HRQoL in paediatric IBD, 
the strongest of which is disease activity that shows an inverse correlation 47, 82, 83. 
This finding has been confirmed in children with CD in New Zealand 84. HRQoL has 
been shown to improve in the first year after diagnosis once treatment has been 
implemented 82, 85, and once the disease comes under control following a period of 
activity 49. Children with CD have worse HRQoL than UC, boys worse than girls, and 
older children/adolescents worse HRQoL than younger children 83.  
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1.3.4 Cost and healthcare utilisation 
The management of children with IBD is associated with a substantial economic 
burden, both to society and to the individual. The costs most commonly measured 
are those direct expenditures such as hospital care (inpatient and outpatient) and 
pharmacological treatments, however indirect costs such as loss of parental 
productivity through missed work time and out of pocket expenses should be given 
due consideration 67, 86. Incurred costs are higher during periods of relapse or 
uncontrolled disease, as would be expected due to the increase in health-utilisation 
86.  
1.3.4.1 Cost – New Zealand 
An epidemiological study by Lopez et al 87 presented data for the point prevalence of 
paediatric IBD in New Zealand, which allows an estimate of the financial impact at a 
national level. There were 212 children reported with a confirmed diagnoses of IBD 
in New Zealand in 2015 (161 with CD, 32 with UC, 19 with IBD-U) 87. Cost data 
published in 2012 estimated the direct costs per year for each child in New Zealand 
with CD at $12,583 New Zealand Dollars (NZD) 67, which represents a total cost of 
over $2 million NZD for CD diagnoses alone, a figure that will have subsequently 
increased with inflation.  
While cost data were not available for children with UC in New Zealand, a study by 
Kapelman et al 88 in the U.S in 2008 presented an estimate of UC costs (at current 
exchange rates) for children at $14,600 NZD, with the costs for CD at $13,900 NZD. 
The unexpected results of higher UC costs for children are not representative of the 
literature regarding adult IBD that shows CD costs at approximately 1.7 times that of 
UC 88-90. In addition the Lopez study cohort had a further nineteen children with IBD-
U, the costs for which are unavailable but still represent a significant burden of 
diagnostic tests and interim treatment until a confirmed diagnosis can be attained. 
1.3.5 Disease activity 
The episodes of relapse that characterise IBD are recognised by symptom 
exacerbations along with worsening markers in blood, stool, or endoscopic testing – 
all of which may indicate an increase in disease activity. People with active disease 
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report twice as many physical symptoms, and four times as many psychological 
symptoms, as those with inactive disease 38. The most widely recognised factors 
responsible for increased disease activity are non-adherence to prescribed treatment 
regimens 91-93, poor treatment response in refractory disease 94 and diagnosis at a 
younger age 6, 95. While non-adherence is a factor that may be modifiable in order to 
improve disease activity, the other factors are unchangeable, thereby limiting the 
efficacy of interventions.   
1.3.6 Mortality 
There is a lack of data on IBD related mortality among the paediatric population. A 
number of studies focus specifically on the risk of malignancies, with conflicting 
results ranging from no increased risk of cancer except in a small number of 
European countries 96, to a threefold risk compared to the background population 97. 
The main causes of IBD mortality in the paediatric population were reported as: 
infections, malignancy, uncontrolled disease, or therapy related causes, and suicide 
96, 98, 99. One study that examined the risk of adult mortality for those diagnosed 
during childhood revealed that those with UC had the highest risk of death, almost 
twice that of CD 99. The general consensus, however, is that IBD mortality rates are 
not increasing over time due to improvements in disease management, and that 
disease and therapy related malignancies require prolonged exposure to 
inflammation or drugs to occur 98-101.  
1.3.7 IBD outcomes summary 
The disease outcomes for children with IBD can be devastating to their 
developmental trajectories in a number of domains, with disease activity shown as a 
common element influencing all other outcomes. However, HRQoL in particular is 
affected by additional factors, thus highlighting the importance of proving a holistic 
approach to care as opposed to providing interventions directed at single 
components such as improving adherence. The aim of management strategies, as 
outlined previously, is to provide symptom relief, optimise growth and nutrition, and 
improve HRQoL and therefore it is vital to identify an approach that addresses all of 
these factors.  
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Multi-modal interventions have been studied in adults with IBD, with the focus being 
on self-management, whereby individual skills and attributes are targeted to 
improve personal control of their condition. These studies on self-management have 
seen positive effects across a number of disease outcomes using a variety of 
intervention components 102-106 which will be discussed later in this chapter in 
section 1.6. However, the self-management approach for children with IBD is still an 
emerging concept and attention is gradually being directed towards multi-
component interventions as opposed to targeting single outcomes. The notion that 
self-management, in combination with coordinated clinical care, may have the 
potential to modify disease outcomes for children with IBD warrants considerable 
attention. 
1.4 Self-management 
1.4.1 Definition of self-management 
There are a multitude of self-management definitions but most focus on the 
‘individual’ as the majority of work to date has been in the adult population. In the 
emerging field of paediatric self-management, the family also play a key role 
alongside the child or adolescent, and an appropriate and inclusive definition of self-
management is therefore considered to be, as stated by Ryan and Sawin (page 9) 107:  
“An ongoing process of shared decision-making and responsibility among youth 
with disabilities and their parents to achieve control of their condition, health, 
and well-being through a wide range of activities and skills. The goal of this 
increasing responsibility is to develop skills needed for transition to adulthood 
and independent living.” 
In this description, the emphasis of self-management is on the adolescent 
approaching transition from the paediatric to the adult health care team. When 
approaching transition, a child’s parents tend to fulfil key roles in overseeing 
development and providing guidance until such an age where independence and 
autonomy are appropriate, and at this point these roles naturally diminish as 
children mature and take on more responsibility 108, 109. This then culminates in the 
13 
 
transition to adult services of the adolescent at an age considered developmentally 
appropriate by their MDT.  
1.4.2 Transition  
The process of transition comes with high expectations of health autonomy, 
characterised by attributes such as self-management, self-efficacy, self-advocacy, and 
self-determination 110-112. To meet these expectations, adolescents require many 
additional skills such as communication, decision making and assertiveness 112. 
However, since transition is not prioritised until the child reaches adolescence the 
number of self-management skills to be acquired is disproportionate to the given 
timeframe for developing the necessary expertise 113. If adolescents haven’t mastered 
the necessary self-management skills prior to transition, then forcing them to learn 
at that time might lead to poorer, not better outcomes 113, 114.  
This is particularly relevant for adolescents with IBD as despite well-established 
transition guidelines being utilised at local, national, and international levels, they 
continue to experience adverse health outcomes after transition due to low levels of 
continued treatment adherence and poor clinic attendance 59, 114-116. This finding is 
supported by feedback from adult gastroenterologists who have reported 
deficiencies in the following areas, which they perceive as barriers to successful 
transition: 1, 112, 114, 117 
 independent functioning 
 self-advocacy 
 knowledge of disease characteristics 
 knowledge of medical history and treatments 
 care coordination  
While some consider that there is value in waiting to transition children with IBD to 
adult care until they are old enough to have developed the necessary knowledge base 
118, it should be considered that the development of self-management skills ought to 
be learned gradually and begin far in advance of the transition process 114, 119. It is 
understood that children become capable of logical thinking, reasoning, and problem 
solving during their middle childhood (six to twelve years of age) 120, which would be 
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an appropriate age to consider introducing some basic self-management skills. It is 
now acknowledged that children should be involved in decisions about their own 
health care 121, and children as young as five are considered competent, and have 
expressed the desire, for more involvement in discussions about their illness and 
healthcare choices 122, 123. Children have also shown themselves to understand more 
about concepts of health and illness then has generally been assumed 121 and as a 
consequence some consider that children as young as seven are developmentally 
capable of gradually beginning the progression to independence 113, 124. Remarkably, 
self-management tends to deteriorate as age increases from childhood through to 
adolescence 50 but by gradually fostering the shift in responsibility to children at a 
younger age and in a developmentally appropriate manner, they could gain the 
knowledge, skills, and experience to master and maintain the independence that will 
eventually be required in the adult setting 113. 
1.4.3 Self-management frameworks 
There are many theoretical frameworks aimed at the self-management of people 
with chronic illnesses, but these adult-targeted models cannot be effectively 
translated to paediatrics. They fail to account for the developmental and cognitive 
trajectories of children, involvement of the family network, and the triadic nature of 
paediatric self-management between the individual, family, and health care provider 
10, 13, 50. In recent years, work such as ‘The Individual and Family Self-Management 
Theory’ by Ryan and Sawin 107 and the ‘Self and Family Management Framework’ by 
Grey et al 125 have provided conceptual frameworks that outline the contextual 
elements and domains of child and family self-management alongside distal and 
proximal outcomes. However, these do not provide a pragmatic method for 
identifying and targeting practical modifiable and non-modifiable factors that may 
improve health outcomes for children with chronic illnesses such as IBD. There is a 
dearth of literature available with this specific focus, however, a framework 
published by Modi et al 50 provides a practical approach for addressing paediatric 
self-management for use in research, policy, and practice. The framework presents 
an over-arching approach to the individual, family, health team and community 
elements that can support children and adolescents as they develop practical self-
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management skills. The Modi 50 framework will be referred to throughout this body 
of work. 
Most of the research on self-management for children with IBD has been in recent 
years, indicating that it is a relatively new, and developing, area within the speciality. 
For children with complex, chronic conditions such as IBD, self-management 
activities are very valuable, although sometimes burdensome, everyday 
responsibilities that represent a lifetime task 10, 126. The health behaviours and 
processes that are required of the child with IBD while developing self-management 
skills may be cognitive, emotional, or social in nature, and can incorporate a number 
of different concepts and skills that may promote or detract from effective self-
management 50, 127.  
1.4.4 Who is involved with self-management? 
Modi’s framework determines three entities that are involved with the self-
management process to complement the individual: the family, community and 
health care provider 50. All play important roles in the physical, emotional, and 
cognitive development of a child’s self-management and may influence the process 
positively or negatively. 
1.4.4.1 Family 
Family functioning is a multifaceted concept. Having a child with a chronic condition 
can present the family with a variety of extra responsibilities and worries that can 
dominate family life and have a profound impact on interfamily relationships 128. The 
role of the family in managing their child’s condition is concerned with elements that 
made having the condition easier; how they organise, participate in, and achieve 
tasks that are related to their child’s condition, controlling the treatment regimen, 
and planning for outings and activities, 129. For a child with IBD to achieve successful 
self-management of their condition a high degree of family cohesion is beneficial as 
their efforts are influenced by the degree of family functioning. Family dysfunction is 
related to worse pain and higher bowel frequency, and therefore poorer 
physiological functioning 130, as well as reduced psychosocial functioning in the 
domain of HRQoL 78. Higher family functioning and family involvement has 
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demonstrated positive effects on adherence, therefore improving disease outcomes 
131-133. 
It is undisputed that parents play a vital role in family management of a child with 
chronic illness, but the role of the sibling is often over-looked. Siblings are greatly 
impacted by the change in family routine that may result from the diagnosis of a 
sibling with IBD, such as the burden of care, worry, and the disruption of normal 
activities 134, 135. The many benefits of encouraging the healthy sibling to become an 
active participant in family management include: creating a supportive, nurturing, 
and caring home environment, improved family functioning, and the sibling role as a 
motivator for disease management and adherence 128, 136.  
1.4.4.2 Community  
The broader community domain has had minimal research focus to determine its 
role in self-management, but when possible clinicians should utilise community 
resources for self-management education and support 13.The community 
encompasses many arenas such as schools, peers, neighbourhoods, and 
interpersonal networks 50 and these can provide both positive and negative 
experiences.  
School: School-based programmes to support students with chronic conditions can 
enhance self-management 137 and supportive teacher attitudes can improve school 
engagement 138. Conversely, peer victimisation and bullying may adversely affect 
adherence 139. 
Community: Participation in community based activities such as IBD summer camps 
have been shown to provide vital peer support, as well as positively influence a 
number of health outcomes: HRQoL, self-management, knowledge, and disease 
management 140-143. 
Peers: Friends are a positive source of support for companionship, protection from 
victimisation and bullying, and emotional functioning 144, 145. Positive peer support 
may improve adherence 139, although a proportion of children with IBD hide their 
disease as they find it emotionally taxing to disclose details to their peers 146. 
Public: Public knowledge of IBD is poor 147, 148, which has been shown to have an 
impact on the degree of perceived stigma by IBD patients, as well as affecting 
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functional issues such as access to urgently required bathroom facilities 149-151. 
Perceived levels of stigmatisation are high for people with IBD 152, compounded by 
the fact it is considered by many as a concealable or invisible disease as sufferers 
may not outwardly appear sick 149, 153. Perceived stigma may reduce adherence, self-
efficacy, and HRQoL 152, but is included as a modifiable influence in the Modi self-
management framework 50.  
1.4.4.3 Health-care provider 
The role of the MDT in paediatric self-management encompasses the roles of 
providing education, care, support, encouragement, and assistance to the child and 
their family. These factors serve to have a positive impact on the following 10, 126: 
 improve self-management skills 
 develop a child’s understanding of their own central role in managing their 
illness 
 making informed decisions 
 engage in healthy behaviours  
This holistic, supportive, and collaborative approach should be embedded in all 
encounters with the child and their family and be made a routine part of care 10, 154, 
as it is associated with greater satisfaction and adherence, and reduced health 
utilization, anxiety, and caregiver burden 10, 155, 156.   
1.5 Individual self-management processes and behaviours 
While Modi’s framework 50 provides examples of self-management processes and 
behaviours that should be addressed in the paediatric setting, it was considered 
pertinent to synthesise content from a number of sources pertaining to paediatric 
self-management. This was to identify any gaps in Modi’s framework, and to 
determine the main domains of self-management to examine in more detail. This 
synthesis included Modi’s framework 50, reviews relating to children with chronic 
illness 10, 108, and children with IBD 157. The results of this synthesis (Appendix A) 
allowed for categorisation of identified targets into the specific domains of: 






 Cognitive attributes 
Self-management skills in these domains cannot be developed or achieved in 
isolation as all elements are intertwined. In order to achieve better disease outcomes 
for children with IBD it is vital to understand how the self-management skills and 
attributes in these defined categories can be developed over time, and what support 
networks are beneficial. The following section explores each domain in detail and 
relates each process to the self-management of children with IBD. 
1.5.1 Disease and treatment knowledge 
Health knowledge is defined by the National Library of Medicine 158 as: 
“Knowledge, attitudes, and associated behaviours which pertain to health-
related topics such as pathologic processes or diseases, their prevention, and 
treatment.” 
For children with IBD the acquisition of health knowledge concerning their own 
diagnosis and disease management is an integral component of their ongoing 
treatment adherence and the development of self-management skills 111, 126. 
Acquiring knowledge of their disease and medication regimens are considered first 
steps in the process by which patients begin to develop independence, and represent 
a concrete and tangible accomplishment 111, 159. Acquired knowledge for younger 
children should be gradually developed to include, in concordance with the content 
synthesis in Appendix A 108, 118, 157, 160: 
 Individual disease specific knowledge - diagnosis, disease location and extent, 
surgical history 
 Medication history - current and previous medication regimens, including 
adverse effects  
 General information on IBD natural history  
 The role of disease monitoring procedures and investigations 
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 Importance of preventive health  
Unfortunately, knowledge deficiencies in children and adolescents with IBD are 
frequently reported, with the most common regarding their own medical history are 
reported as: disease characteristics, surgical history, details of their medication 
regimens, and how to contact their health care team 1, 112, 118, 159. Knowledge 
deficiencies such as these have consequences for paediatric self-management, as 
adults with chronic illness have reported that knowledge about their disease 
processes, the role of medications, and of their treatment plan, were critical to being 
able to self-manage their condition 154.  
In addition to knowledge of their own disease and treatment, it is vital to have a 
general understanding of their condition, the implications of this, and the treatment 
available. Deficiencies are also evident across the paediatric literature in this domain, 
and are reported regarding the following 12, 161-163: 
 radiographic tests 
 osteoporosis 
 CAM therapies 
 the role of surgery 
 enteral nutrition 
 maintenance drugs 
 food and nutrition 
 growth  
Parental knowledge 
A number of studies that have measured children’s IBD disease-specific knowledge 
have included their parents, with results indicating that they have higher practical 
knowledge of their child’s IBD history than their children, but that their deficiencies 
are in similar areas 1. Likewise, parent’s general disease knowledge levels are higher 
than that of their children, 162, 163 and their scores correlate with that of their child 12. 
From this, it may be surmised that parents are an influential source of information 
for their child. Therefore, educational interventions should be developed that include 
parents, thereby maximising the information that may be passively absorbed by the 
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child. There is scant research regarding educational interventions involving parents 
as the vast majority are aimed at children and adolescents. One parent education 
study was identified that yielded significant results for improvements to parent self-
efficacy, coping, HRQoL, and levels of depression 164, although the study was disease 
non-specific. 
Identifying opportunities for providing structured education to parents is difficult, 
but events that involve their children with IBD present an ideal occasion. Residential 
camps for children with chronic conditions, including IBD, have been run for many 
years 165 and consistently demonstrate positive and sustained improvements to 
knowledge, self-management skills, and HRQoL for children 141, 142, 166. The annual 
residential camp for children with IBD in New Zealand (Camp Purple) has been 
running since 2015 and includes a weekend long parental education session where 
parents can also stay if attending from satellite hospitals. This provides a convenient 
and practical setting for the provision of parent education, although no studies have 
been identified where parent education sessions such as these have measured the 
effect of the intervention on knowledge levels. In addition, there has been little 
delineation of the knowledge levels of fathers specifically, as studies most frequently 
report results from participants either as mothers, or parents. 
Sibling knowledge 
The consequences of IBD on healthy siblings have been reported so it is, therefore, 
pertinent to look at those factors that may improve their outcomes. A factor 
commonly reported by siblings of children with chronic illness is that they are given 
inadequate, incomplete, or misleading information that contributes to their 
uncertainty regarding their ill sibling 136. Educational interventions demonstrate a 
positive impact on a number of factors for siblings: family functioning, psychosocial 
well-being, isolation, social competence, and knowledge 167, 168. Parents are the 
predominant source of information for siblings and it may, therefore, be surmised 
that their knowledge levels correlate with that of their parents. By increasing sibling 
knowledge via parent input, as well as information from the MDT, sibling anxiety 
may be reduced 169. It is important, therefore, to measure sibling knowledge of IBD in 
order to ascertain any gaps that may adversely affect their adjustment or well-being. 
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No studies were found that have quantitatively measured sibling knowledge levels 
using validated assessment tools. 
Public knowledge 
There is little known about the levels of public knowledge regarding IBD, despite its 
increasing global prevalence and worldwide initiatives to raise awareness 170. A 
small number of studies were identified that demonstrate poor knowledge levels 
among members of the public 147, 148, 150, 151, even those with a close friend or relative 
with the disease 171. Poor public knowledge may affect people with IBD in a number 
of negative ways, as will be discussed in Chapter Five. It is therefore important to 
measure public knowledge levels in order to tailor national education initiatives that 
may enhance understanding of CD and UC, therefore providing much needed support 
to children and adults with IBD. The use of valid and appropriate knowledge 
assessment tools in this population would allow for areas of deficient knowledge to 
be highlighted and, therefore, addressed. However, this research has not previously 
been carried out in New Zealand, and only one study was identified in the literature 
that had formally measured public knowledge levels using a validated tool 171. 
1.5.1.1 Benefits of knowledge for children and adults with IBD 
It has been shown that when higher knowledge levels are achieved in adults with IBD 
they may improve adherence to medications 172, 173, disease outcomes 90, 174 and 
reduce health care costs 90, 175. However, this was not a universal finding for all 
outcomes. A number of sources have shown that improved knowledge does not 
equate to an improved HRQoL in adults with IBD 1, 175, 176, and may lead to greater 
levels of anxiety 177. However, greater knowledge levels have been associated with 
enhanced coping in this population 178. There is a lack of data available for children 
with IBD to be able to make similar comparisons, and research on modifiable factors 
that translate to higher levels of knowledge in the paediatric IBD population is 
scarce.  
1.5.1.1.1 Hypotheses 




That parents attending an education session at Camp Purple will see increased 
levels of disease knowledge following this intervention. 
That the IBD-KID2 scores of children with IBD, and their siblings, will positively 
correlate with the scores of their parents. 
That the level of public knowledge in New Zealand is poor, despite national 
awareness campaigns. 
1.5.1.2 Education 
Given the breadth of knowledge that is required, and the deficiencies identified, the 
MDT involved with each child plays a crucial role in providing education, in a 
developmentally appropriate way, about their disease, treatment, and healthcare 
needs. Systematic, reinforced health education is required to improve the knowledge 
of children with IBD and to maximise the benefits to disease outcomes. Health 
information is accrued over time through a number of sources as knowledge may be 
actively sought or passively absorbed 179. Passive absorption can take place in many 
ways; such as ad hoc information imparted during clinical encounters, educational 
sessions, or take-home material. Self-directed learning should also be encouraged 
but it is important to provide salient, credible sources that may be accessed and to 
provide guidance on how to recognise reliable sources independently as adults with 
IBD find certain information sources increase their anxiety 179, 180.  
The benefit of providing education to the child with IBD, as well as encouraging them 
to seek information independently, is that they should begin to feel a sense of 
empowerment by gaining an understanding of their vital role within consultations 
and becoming an active participant in conversations with the MDT 162, 181. It is also 
their fundamental right to be provided with information in a format that is 
understandable to them, and to participate in decision making regarding their care, 
where appropriate 182. 
 
1.5.1.3 Health literacy 
While knowledge and education are foundational for the development of self-
management, health literacy is concerned with the ability of children to understand 
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and utilise this health information to make decisions about their disease 183. It is vital 
for children to understand how to apply learned knowledge and self-management 
skills to their lives as, if they do not learn how and why they have to manage their 
chronic illness, their self-management efforts will be impeded 154.  
The progression of health literacy development naturally evolves from knowledge 
gained from reading and comprehension, to numeracy, navigation, communication, 
and then decision making and action 183: 
Knowledge: reading, speaking, writing, and understanding health content and 
directions from healthcare professionals.  
Numeracy: the ability to apply and manipulate the information gained when 
expressed as a number, for example calculating drug doses or reading and acting on 
blood sugar levels  
Navigation: a building block stage that incorporates knowledge and numeracy and 
applies them to domains such as communication and decision-making. This helps 
with knowing what questions to ask the clinical team, and how to access the 
healthcare system.  
Communication: the skill of knowing what information to share with the healthcare 
team, such as an accurate and precise description of symptoms and side effects.   
Decision-making: making healthy choices and taking actionable steps to manage a 
condition.  
Developing interventions that improve health literacy in children and adolescents 
should, therefore, provide them with the cognitive tools they need for translating 
knowledge into health behaviours, thus equipping them to undertake health 
decision-making 184. Adults with chronic diseases who have low health literacy have 
lower knowledge levels, poor self-management and health-promoting behaviours, 
report worse health status, increased risk of being hospitalized, and are more likely 
to experience worse health outcomes 185.  
In the paediatric population there are limited data regarding health literacy levels, 
but studies have identified suboptimal levels for children in 15 to 50% of 
participants with chronic illness and at a lower rate than healthy controls 186-188. 
Huang et al 185 studied health literacy as a prelude to transition in adolescents with 
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IBD and found that only 11% had sufficient levels in one crucial domain. On the other 
hand, gastroenterologists had overestimated this and considered 47% had sufficient 
health literacy for transition 160, 185. Of note is that as few as 60% of adults with IBD 
have sufficient health literacy 189. Low health literacy for children and adolescents 
with IBD may affect their ability to understand the importance of screening when 
they reach adulthood, the concept of having an asymptomatic but chronic disease, 
their ability to ask questions, and the subsequent impact on shared decision-making 
190. 
Health literacy and IBD outcomes 
Among the adult population with chronic illnesses, the impact of low health literacy 
is consistently associated with greater health utilisation, poor health prevention 
uptake, worse overall health status, and higher mortality rates in the elderly 
population 189, 191. Conversely, high health literacy relates to better overall adherence 
192, recall of medication names, dosage and frequency 193, and the ability to take 
medications appropriately and interpret drug labels 191. In addition, adequate levels 
increased the likelihood of remission for people diagnosed with CD specifically 189. 
In the paediatric population with chronic illnesses, poor health literacy was not 
associated with greater health utilisation 186, and did not affect adherence or self-
efficacy 187, 194. It does, however, adversely affect knowledge about health behaviours 
and outcomes, is attributed to worse behaviour 195, and has an inverse correlation 
with Body Mass Index in obese children 196. High literacy may therefore contribute to 
better health and health promotion behaviours among children 184 and should be 
measured and addressed where possible by ensuring educational materials and ad 
hoc teaching are tailored to children by improving readability and adapting complex 
instructions.  
1.5.2 Communication  
Communication is an integral part of the development of health literacy and self-
management skills. When communicating with the MDT the younger child in 
particular will be part of a triadic process between themselves, the team, and their 
parents, which will continue until their cognitive and emotional development allows 
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for health autonomy 9, 123. Despite the recent advances in understanding of the 
importance of the child in the communication process, when quantified, children 
were shown to contribute only 4% of time during clinical encounters, parents 35%, 
and doctors 61% 197. However, it has been demonstrated that a more direct 
communication between physician and child contributes to an improved relationship 
in terms of satisfaction with care, HRQoL, reduced worry, adherence to treatment, 
and better health outcomes 121, 122, 156. The MDT can promote children’s involvement 
by encouraging them to express their views, ask questions, and to participate in their 
health care discussions 123. At the same time, the MDT can provide teaching on how 
to cope with questions on health and illness, and how to utilise the information they 
have gained to respond to questions, all of which lead to higher levels of navigational 
health literacy, a necessary attribute for good decision-making 121, 160, 183.  
In order to help children with IBD communicate with their family and the MDT about 
their disease, it should be considered that providing structured methods of reporting 
may be beneficial. Encouraging children to report their disease state, and to discuss 
their response to treatment, is indisputably important and will become more so as 
they develop self-management skills 198. However, defining and describing these 
concepts can be challenging for many children, therefore, education regarding self-
regulation may help clarify these issues for the child and thus enable their discourse 
to be of some value in the clinical setting 198. There is an ongoing need, therefore, to 
provide practical tools to support self-regulation that may help address 
communication gaps, and may encourage the shared-care approach to IBD 
management 181. 
1.5.3 Self-regulation 
The process of self-regulation encompasses three components: self-monitoring, self-
evaluation, and self-reinforcement; skills that are considered valuable attributes for 
self-management 199, 200. These specific skills are related to proactive and reactive 
disease management, whereby individuals perform actions to manage a problem, 
such as self-monitoring, or take action in response to a change in condition or 
circumstance, such as seeking medical help or making lifestyle modifications 200.   
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1.5.3.1 Symptom self-monitoring 
Self-monitoring is a skill that enables tracking of meaningful and important 
symptoms in a structured way that promotes reflection, awareness and can enhance 
communication of disease state with the MDT. Self-monitoring, when collected as 
longitudinal symptom reports, can provide prospective information on the current 
disease state, as well as provide retrospective data that can be used to accurately 
evaluate and reflect on changes in condition. Using a structured format for 
monitoring subjective variables, such as pain, well-being and stool variables, can also 
quantify the disease burden for factors that are not readily observed but may help 
the MDT understand the child’s perspective of symptoms 201, 202. Tracking symptoms 
in this way is perceived as an efficient and cost-effective way for people to develop an 
awareness of their health state, but is also a means of documenting therapeutic 
benefit 198, 201, 203, 204. When used as a therapeutic tool, it has benefits over recall 
reports as it reduces the risk of recall bias, whereby symptoms become generalised 
unless extreme events have occurred which will skew the memory 205. For adults 
with IBD, adherence to symptom self-monitoring is high, attributed to the fact that 
the data being collected is of personal importance 206. In addition, commencement of 
IBD self-monitoring has been reported to transform subsequent clinical encounters 
and adults considered that they were more able to reflect on their disease 206. 
Self-monitoring tools 
The majority of the literature regarding children self-monitoring their disease 
focuses on tangible, objective measures such as blood glucose levels for children with 
diabetes, and peak flow results for asthmatics. The utility of self-reports for children 
with IBD cannot be directly compared to diseases such as these, which can be 
objectively monitored and are highly reversible conditions that can be rapidly 
treated 207. Few studies of subjective symptom self-reports given by children were 
identified in the literature. One study of primary school aged children providing 
general symptom self-report demonstrated that at a young age children are capable 
of producing reliable symptom data 208.  
Self-monitoring for children with IBD should have the discreet but beneficial effect of 
helping create an awareness of their own disease course and prompt the behaviour 
of seeking timely medical help in the case of worsening symptoms 204, subsequently 
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improving disease outcomes, and reducing health utilisation. Qualitative work 
carried out with adults with IBD reinforced that self-monitoring was considered a 
valuable way for patients to enhance consciousness of their health state, and to 
engage with their doctors 198. A high proportion of those studied had tried formal 
tracking (87% of participants) and those symptoms most commonly monitored were 
bowel movement characteristics, medications, and pain 198.  
1.5.3.2 Self-evaluation and reinforcement  
Self-evaluation regarding symptom changes is a skill requiring the assessment and 
reflection of symptoms and should be learnt through education and reinforcement 
from the MDT and parental support. Self-monitoring is intertwined with all levels of 
health literacy development and the process of symptom self-evaluation enables 
children to recognise their symptom levels during remission, and longitudinal 
changes when experiencing an exacerbation. This aspect of self-regulation highlights 
the vital importance of collecting longitudinal symptom data that can be 
comprehensively reviewed by the child and the MDT during clinical encounters.   
When symptom changes are identified the importance of education and 
communication are emphasised. While the MDT can educate each child to recognise 
symptom exacerbations, when this occurs in the pragmatic setting the child needs to 
have actionable instructions as to what they should do and have decision support 
information available; self-reinforcement. Depending on the severity and nature of 
symptoms, it may be appropriate for them, or their parents, to call the GP, make 
contact with the MDT, or seek emergency help. Communication of their longitudinal 
symptoms to the appropriate party would enable a clinical evaluation to be made and 
the sharing of information relevant for this clinical evaluation is vital.  
1.5.4 Adherence 
Extensive research has resulted in the development of treatment regimens for IBD 
that have proven efficacy and positive benefit-to-risk profiles, but in order to 
maximise these advancements and improve outcomes children need to practice 
treatment adherence 209. Adherence has been defined by the World Health 
Organisation (WHO) (page 3) 210 as: 
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“The extent to which a person’s behaviour (in terms of taking medications, 
following diets, or executing lifestyle changes) coincides with medical or health 
advice.” 
Following medical advice, however, is a far more complex phenomenon in childhood 
and adolescence than in adulthood as there can be a confusing dyad between the 
child and their parents over treatment adherence responsibility 211. In addition, there 
is the need for a triadic partnership between the child, parents, and medical team 
that must support multidimensional treatment components and the dynamic 
maturation of the child 212, 213.  
1.5.4.1 Medication adherence rates 
Historically, studies have demonstrated that children with chronic illness 
demonstrate low levels of medication adherence, and rates for children with IBD 
show great variability with 16-80% reported as non-adherent to their prescribed 
regimen 51, 131, 214, 215. This variation may be a function of assessment method, patient 
age, and definition of the level of nonadherence 216. Adherence to non-prescribed 
(over the counter) medications was significantly lower than to prescribed drugs 133, 
as was adherence to complementary medicines - the use of which has also been 
shown to also reduce adherence to prescribed treatments 215, 217.  
Adherence rates are higher for EEN programmes having been reported as 84 to 90% 
218, 219, although up to 33% of surveyed paediatric gastroenterologists reported non-
adherence as the largest barrier to them using EEN 220.  
Treatment adherence also incorporates attending scheduled clinic appointments, 
having investigations performed when required, and such factors as collecting new 
prescriptions to ensure ongoing medication adherence, and performing 
recommended lifestyle changes. Adhering to clinic appointments has been shown to 
improve drug adherence, reduce the frequency of relapses, and improve remission 
rates 114, 221, 222. In addition, improved clinic attendance leads to stronger beliefs in 
the importance of medications, which in itself is a strong predictor of adherence 223.    
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1.5.4.2 Adherence and IBD outcomes 
Medication adherence rates positively correlate with remission, and negatively 
correlate with disease severity, in children with IBD 92, 224. Non-adherence to IBD 
treatment is consistently associated with negative psychosocial outcomes such as 
reduced HRQoL, and increased health utilization and, therefore, cost 77, 225-227. A 
number of risk factors for non-adherence have been identified as; longer disease 
duration, high disease activity, greater age, use of herbal medications (a consequence 
of having too many drugs to take), having fewer follow-up appointments, and poorer 
parent-reported psychosocial HRQoL and family functioning 133, 214, 215, 217, 228, 229. 
1.5.5 Cognitive self-management attributes  
While the focus of this work is on the practical components of self-management, a 
number of cognitive processes are also inextricably linked to the development of 
health autonomy skills: patient activation, and self-efficacy. Cognitive skills develop 
in parallel to improvements in health literacy and the development of self-
management skills and may be considered modifiable by association. 
Patient activation  
Patient activation is defined as an individual demonstrating the skills, knowledge, 
and motivation needed to manage their own health and to participate in making 
health care decisions 230. There are defined stages of activation, which show a natural 
progression from the individual being a passive recipient of care and overwhelmed 
by the task, to gradually gaining knowledge and confidence in their skills to 
eventually take action and perform adequate self-management behaviours 231.  
There is little published research concerning patient activation in children, but it is 
associated with positive effects on health outcomes in adults with IBD. For example, 
those individuals with higher levels have reduced odds for having anxiety and 
depression, and those with high activation are more likely to be in remission 230. 
Overall, adults fulfilling the role of being an active participant in their care are more 
likely to engage in healthy behaviours and adherence, have lower health utilisation, 
and higher rates of accessing preventative care 231. Higher patient activation is 




Self-efficacy describes an individual’s belief and confidence in their own capability to 
organise and succeed in specific situations or complete tasks 110, 111. It is a 
prerequisite for self-management, and has been shown to mediate the relationship 
between physical, psychological, and social functions with disease outcomes in a 
number of chronic diseases 232. Additionally, high self-efficacy has been linked to 
successful health behaviour change and engagement in preventative health 232. 
Studies in diabetes self-management showed adolescents with higher self-efficacy 
levels reported better HRQoL, less depressive symptoms, and better disease coping 
skills 7. Studying self-efficacy in paediatric IBD is a nascent field, but during 
validation studies for self-efficacy assessment tools, higher levels were related to 
greater health care satisfaction, more frequent communication with the MDT, and 
higher IBD-related knowledge 118.  
1.5.6 Benefits of self-management 
Research into the benefits of self-management for children with chronic conditions 
has highlighted positive effects on clinical, behavioural, and psychological outcomes. 
There is evidence of improvements to 233, 234:  
 self-reported health status 
 improved health outcomes 
 reduced school absenteeism 
 fewer restrictions to activities 
 knowledge 
 quality of life 
 health care utilisation 
 self-efficacy  
However, in order to examine the benefits of self-management for children with IBD 
it is essential to identify research that has shown efficacy specifically in this 
population.   
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1.6 Effective self-management interventions  
The multi-faceted nature of self-management has been established, as has the 
importance of providing a cohesive approach to the essential processes involved - 
knowledge, communication, adherence and self-regulation, as well as cognitive 
factors. The identification of interventions that address all of these inter-related 
components is vital in order to improve outcomes for children with IBD. A consensus 
should be reached on which practical self-management activities should be targeted 
in interventions, which should be recommended to children and their parents, and 
which core IBD outcomes should be assessed 235. A number of systematically 
performed literature reviews were therefore performed to identify those studies 
addressing self-management as a whole system, and as individual components, in the 
paediatric IBD population, and self-management alone in the adult IBD population.  
1.6.1 Self-management interventions 
1.6.1.1 Children with IBD 
The studies identified from the literature review pertaining to the paediatric 
population are presented in Table 1.1, outlining the nature of the study, alongside the 
number of essential processes included for each intervention, and significant 
findings.  
Searches identified only one study that specifically identified a self-management 
intervention for children with IBD 236. This was an eHealth home-management 
system incorporating just two of the essential processes: knowledge (in the form of 
education) and self-regulation (symptom monitoring). This study showed significant 
positive outcomes for reduced health care utilisation and improved school 
attendance but failed to affect adherence, HRQoL, disease activity and drug 
escalations. When searches were narrowed to identify interventions targeting the 
essential processes, six further studies were found which focused solely on 
adherence, and two on cognitive factors, but none for knowledge, self-regulation, or 
communication. The heterogeneity in the format of the identified interventions for 
children does not allow for any generalisations to be made in terms of effective 
intervention components as related to outcomes (Table 1.1). While seven included 
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components aimed at improving adherence, only two had a significant effect on this 
outcome (one other improved adherence for one study drug), and of note is that 
those reporting improved adherence did not also improve disease activity. The 
outcome of HCU was measured by hospital admissions 234, 240, 243, health care contacts 
(including emergency and out-patient visits, and telephone calls) 235, 240, 243, 







Table 1.1. Self-management interventions for children with IBD 
SM: Self-management, HCU: Health Care Utilisation, CBT: Cognitive Behavioural Therapy.  
symbol indicates the self-management process was included in the study intervention. 
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Table 1.1 continued. 
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A systematic review by Tran and Mulligan 235 studying self-management 
interventions for children with IBD had similar findings whereby none of their 
presented studies were targeted specifically at self-management, and a number were 
aimed at co-morbid psychosocial issues rather than improving self-management. The 
review contained adherence, psychosocial and cognitive interventions, all with 
similar heterogeneity of components and outcomes. They were not able to make any 
generalisations or recommendations as a result.  
The formats of the included studies showed the most common approach was with 
the use of sessions (individual, group, or tailored) but these were in adherence-
specific studies, not self-management.   
1.6.1.2 Adults with IBD 
While it was established in section 1.4.3 that the theoretical frameworks for adults 
are not appropriate for children, components of self-management programmes for 
adults may be applicable for use with children 10. Thus, searches for interventions 
aimed at adults with IBD were also carried out, which identified a greater number of 
self-management specific interventions (Table 1.2).  
Once again, there was heterogeneity in the intervention formats, included processes, 
and outcomes. It was possible to synthesise the studies to highlight those processes 
most often included in the interventions for adults, and to identify the most frequent 
outcomes that reached significance. None of the studies included all of the essential 
processes, but the three key components most commonly included in the twelve 
papers were knowledge (10 papers), self-regulation (9 papers), and adherence (9 
papers). Of note is that these processes were central to the previously identified sole 




Table 1.2 Self-management interventions for adults with IBD.  
CDSMP: Chronic Disease Self-Management Programme 
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Of the outcomes measured in the adult IBD studies, there was a lack of uniformity in 
those effecting a significant change. A basic assessment of the interventions 
developed for adults (Table 1.2) highlighted that the outcome most frequently 
improved was Health care utilisation (HCU), but the heterogeneity of study 
components prevented any meaningful conclusions to be made as to the most 
efficacious self-management process that may influence this (Table 1.3). 
Table 1.3. Frequency of self-management processes in interventions for adults with IBD  
Frequency of self-management processes in Table 1.2, including the percentage that 






Change n (%) 
Non-significant 
Change n (%) 
HRQoL 9 4 (44) 5 (55) 
HCU 7 6 (86) 1 (14) 
Adherence 5 3 (60) 2 (40) 
Knowledge 4 2 (50) 2 (50) 
Disease activity 3 1 (33) 2 (67) 
Interval to treatment 3 1 (33) 2 (67) 
Self-efficacy 3 1 (33) 2 (67) 
Depression 3 1 (33) 2 (67) 
Self-management skills 2 1 (50) 1 (50) 
 
The format of the identified interventions for both children and adults showed great 
diversity, although the highest frequency (24%) was for interventions focusing on 
eHealth or tele-management. Mobile health (mHealth) represents a growing area in 
the approach to disease management and self-care 234 and is becoming increasingly 
popular due to the opportunities it offers for real time monitoring. mHealth 
harnesses the anywhere, anytime, feature of mobile technology, and can thereby 
maximise on their existing integration into daily lives 251, 252. Mobile technology is 
known to be a medium that engages children, and capitalising on a form with which 
they are familiar represents an opportunity to explore a new avenue of disease 
management in the form of age-appropriate mobile health apps to engage patients in 





It can be seen from the evidence presented that self-management interventions for 
children with IBD are scarce. The studies identified in the paediatric and adult IBD 
populations highlight the variability in the approaches taken and the outcomes 
measured, thereby making it difficult to reach a conclusion on the most effective 
approach to self-management interventions. Opportunities are available for 
harnessing modern mobile technology in disease management strategies for 
children. The paucity of interventions aimed specifically at self-management in the 
target population warrants attention.  
1.6.2.1 Hypotheses 
Due to the gap identified in the literature regarding a self-management intervention 
for children with IBD, the following hypothesis was developed: 
That a targeted mobile health app intervention comprising self-management 
components will be effective at improving disease outcomes, and overall self-
management skills, in children with IBD. 
Should the mobile health app not be completed in time to perform an appropriate 
study to test these outcomes, the following hypothesis was developed: 
That a self-management booklet based on the IBD-Tracker app will be beneficial 
to children with IBD and help improve measurable self-management 
components.  
1.7 Self-management outcome measures 
It is imperative that any intervention delivered is assessed against outcome 
measures that are appropriate for the target population in order to determine 
efficacy of the included components. A number of approaches to measuring self-
management in children have been suggested: by measuring the allocation of 
responsibility for health care tasks between children and their parents, or by 
calculating a numeric score that indicates a tangible level of self-management skills 
that can be measured longitudinally to determine if skills are increasing 255. The 




the progress of interventions. In the clinical setting they can identify children and 
adolescents at risk of sub-optimal health autonomy who could benefit from targeted 
educational and organisational interventions. It should be considered that all core 
processes should be assessed in some way to ascertain the strongest and weakest 
attributes of an intervention and in doing this, by way of an iterative process, 
interventions could be refined until the most effective components are retained. 
Outcome measures should therefore be identified that measure self-management 
skills, knowledge, self-regulation, adherence, cognitive attributes, and 
communication. In addition, IBD outcomes that are the overall target of the 
intervention should be assessed: HRQoL, disease activity, school attendance, HCU, 
and growth. 
1.7.1 Self-management  
Of the studies identified in section 1.6.1 that addressed self-management 
interventions for adults and children with IBD, only a small number of the adult 
studies measured actual self-management skills, and none of the paediatric studies. 
The adult studies used the Health Education Impact Questionnaire that measures 
skills, behaviours, and cognitive aspects across a number of domains 256. The tool is 
generalised, not IBD specific, and has not been validated with children.  
One further study was identified that measured IBD self-management skills for 
adolescents but this tool was not validated and was specific to medication knowledge 
and behaviours 111.  
The literature was searched for studies that addressed self-management skills in 
other chronic conditions (specifically not diabetes or asthma, as discussed in Section 
1.5.3.1), in order to ascertain whether disease specific measures were utilised more 
often than generalised assessment tools. Few were identified, but a study 
investigating self-management for children with Sickle cell disease developed a 
unique tool in line with the established guidelines for disease treatment 257. For 
children with Cystic Fibrosis (CF) a self-management study utilised a disease specific 
assessment tool 258. A study in the population of children with haemophilia 259 used a 





This lack of consistency for self-management outcome measures requires further 
investigation. The following hypothesis were therefore developed: 
That a systematic literature review will identify appropriate, validated, disease 
specific or generalisable tools that can be utilised for children with IBD. 
In the event that this hypothesis proves to be null, the following hypothesis was 
proposed: 
That a novel, disease specific, self-management skills assessment tool can be 
developed that enables children with IBD to report their skills accurately, and in 
concordance with age expectations.   
1.7.2 Knowledge outcome measures 
All paediatric IBD patients should have their disease and treatment knowledge levels 
assessed, as well as their overall level of health literacy, as disease management may 
be adversely effected by gaps or misconceptions in either 261, 262. The most efficient 
way to assess knowledge is with an assessment tool that is appropriate and has been 
validated with the target population. While the concept of knowledge is an abstract, 
subjective notion, questionnaires go some way towards assigning a value to what 
participants understand about a subject. Disease and treatment knowledge levels are 
very different to levels of health literacy and should be measured separately.  
1.7.2.1 Disease and treatment knowledge  
Three studies were identified that measured general IBD knowledge in adults; the 
Knowledge Questionnaire (KQ) 263, the Crohn’s and Colitis Knowledge Score 
(CCKNOW) 11, and a short questionnaire by Keegan et al 264, but these have not been 
validated in children and contain complex items, alongside topics such as pregnancy 
and smoking, that would be inappropriate to ask young children.  
Literature searches revealed two studies presenting tools specifically for measuring 
general disease and treatment knowledge in children with IBD 12, 161, and four studies 
that measured individual disease and treatment information 1, 118, 159, 265 . Of those 




called the ‘IBD Knowledge Inventory Device, or IBD-KID, which is a twenty three item 
long questionnaire that includes a mixture of true/false (T/F) and multiple choice 
questions (MCQ). The Emma electronic quiz developed by Tung et al 161 asked twelve 
IBD questions and four psychosocial questions – these were automatically selected 
from a database of 185 items depending on the age and disease characteristics of 
participants. Of these two papers, only the IBD-KID was available for review, but of 
interest is that IBD-KID was criticised by the authors of the Emma quiz as being too 
long for clinical use and outdated 161. When IBD-KID was reviewed it was noted that 
it was a valid tool with good reliability, and was appropriate for children aged ten 
years and over, based on the authors reports of readability 12. However, a number of 
factors in the content and structure of IBD-KID appeared complex and the authors 
were contacted for permission to access a database of completed IBD-KID 
questionnaires in order to analyse the patterns of children’s responses to each 
individual item. This was to ascertain if the complexity of content or structure was 
adversely affecting completion, or if the tool was appropriate to use to evaluate 
knowledge levels during a self-management intervention study. 
1.7.2.1.1 Hypotheses 
Based on the observations made of IBD-KID the following null hypothesis was 
developed: 
That the content and structure of IBD-KID have no effect on the response 
patterns of children with IBD who have completed the tool. 
In the event that this hypothesis is rejected, the item response analysis results will be 
used to revise IBD-KID and develop a new tool for validation that is more relevant 
and appropriate for children with IBD. This revised tool will undergo a series of 
studies to assess knowledge levels in a number of participant groups, as well as to 
determine the strength of the tool for use in the target population of children with 
IBD. The following hypotheses were therefore developed:    
That the revised knowledge assessment tool (IBD-KID2) will have comparable 




That IBD-KID2 scores do not differ between countries, thereby establishing 
comparable external validity with the original IBD-KID. 
That the reliability of IBD-KID2 is comparable to the original IBD-KID. 
That IBD-KID2 can be utilised in a parent cohort to detect sensitivity to change 
pre and post intervention. 
That IBD-KID2 can be utilised in a cohort of children with IBD to detect sensitivity 
to change pre and post intervention. 
Of the tools measuring individual disease and treatment information, all were 
informal and had not been validated, and were presented in two formats. Two 
studies utilised brief questionnaires regarding disease diagnosis, characteristics, and 
treatment 118, 159. The third study measured individual knowledge by asking children 
and adolescents to fill out their own ‘health passport’ which could then be carried at 
all times to provide information when required. This format provided structure and 
utility compared to the first two studies 1 and would be preferable for use as an 
outcome measure in a self-management intervention study.  
1.7.2.2 Health literacy outcome measures 
Measuring the health literacy levels of children with IBD enables the study of its 
relationship with issues of poor self-management, information seeking, and decision-
making 266. Measuring health literacy levels prior to, and following, a self-
management intervention can determine whether low levels impact study outcomes, 
and whether the intervention itself can improve health literacy. The identification of 
an appropriate, validated, and reliable measurement instrument for assessment is 
therefore crucial for both the research and clinical setting. Without appropriate and 
validated tools a child’s readiness for self-management, and for transition to the 
adult gastroenterologists, may be over-estimated 160, 185. 
Traditional tests such as the Slosson Oral Reading Test (SORT-R) 267 and Wide Range 
Achievement Test (WRAT) 268 are not health literacy tests but are widely used in 
teaching and adult health literacy, and appropriate for wide age ranges. However, the 




from the original authors. A number of adult health literacy specific tests have now 
been adapted for children, and adolescents, and factors such as the time taken to 
complete, and the age range used in the validation process, will determine the most 
appropriate tool.   
The Test of Functional Health Literacy in Adults (TOHFLA) had select elements of the 
adult tool (comprehension and numeracy) tested in adolescents and published as the 
TOFHLAd. This takes fifteen minutes to complete and was validated with children 
aged 13 to 17 years 266. This tool needs to be purchased. 
The Rapid Estimate of Adolescent Literacy in Medicine (REALM-Teen) is a sixty six 
item word recognition test that is used to determine if problems with lower order 
reading skills may indicate a child will have difficulty with comprehension, a higher 
order skill 269. This has no numeracy component, takes just 2-3 minutes to complete 
and was validated in children aged 10-19 269.  
The Newest Vital Sign (NVS) is an adult test comprised of a nutrition label, and six 
related questions, that test the literacy and numeracy of participants 270. The tool has 
also been validated in children aged seven years and over, and studies show that 
children can complete this in three minutes, the same as adults 271, and have similar 
score cut-offs of literacy levels to the adult population 272. 
 
The NVS is the most appropriate tool for paediatric studies given that it is freely 
available, measures numeracy, comprehension, and decision-making, and has been 
validated in the youngest population. 
1.7.3 Communication outcome measures 
Patients with IBD that report poor communication with their clinician demonstrated 
a 19% higher risk of nonadherence than those reporting good communication 273. 
Measuring communication skills should be done in subjective and objective ways. 
Subjectively, ongoing attention to a child’s level of interaction with the MDT during 
consultations will identify areas for encouragement and support. Prompting children 
to bring a list of questions and drugs they are on is a simple way to begin, and then 
they can be encouraged to report their symptoms and join discussions and decision 




symptom reports can facilitate a structured method of communicating their disease 
state in terms of their symptom burden and can promote reflection and flare 
recognition. 
1.7.4 Self-regulation outcome measures 
Self-monitoring is the most widely employed strategy of those interventions aimed at 
influencing health. It allows people to keep track of their past and present state, self-
evaluate, make periodic measurements and record target behaviours 274. For the 
purpose of teaching self-monitoring and symptom evaluation for children with IBD, 
an age appropriate, disease-specific tool is required that can provide symptom 
reports with clinical utility for their communication with the MDT. Any tool utilised 
also needs to be appropriate for children with all levels of health literacy.  
The clinical tools used by gastroenterologists for measuring disease activity via 
symptom categories are the Pediatric Crohn’s Disease Activity Index (PCDAI) and the 
Pediatric Ulcerative Colitis Activity Index (PUCAI). These are not suitable to be used 
for child self-report due to their need for clinical data (PCDAI) and their complexity. 
However, adapted, shortened versions 275 have been used with children with UC 204, 
276 and CD 204 that produce disease activity reports with good levels of crude 
agreement with clinician reports. However, the shortened PCDAI (shPCDAI) 275 that 
was used in the study among children with CD 204 required children to perform their 
own abdominal examination and assess their own EIM so this would not be 
appropriate for all children, in particular those with low health literacy that may 
have poor symptom recognition skills. No universal tools were identified in the 
literature that produced clinically relevant data via patient report that was universal 
and generalisable to both UC and CD.  
A number of disease specific ‘Patient Reported Outcome’ (PRO) measures for 
children with IBD have been developed - PRO’s are derived solely from patient input, 
provide feedback directly from the patient, and require no response interpretation 
by an observer 277. These have been developed in conjunction with children with IBD 
and highlight those symptoms they consider most important. Two UC specific PRO’s 




Ulcerative Colitis signs and symptoms Scale (DUCS) 203. These were developed using 
signs and symptoms derived from interviews with children with UC, with the 
purpose of providing patient reports that are intended to supplement the clinician 
completed PUCAI. The TUMMY-CD 278 is currently in development for children with 
CD using the same methodology. These PRO’s differ from clinical disease activity self-
reports as they do not necessarily concentrate on, or reflect, the degree of 
inflammation or disease activity but are designed to report perceived symptom 
burden 277. These PRO measures consequently quantify a different concept to disease 
activity such as that measured by the PUCAI/PCDAI, and provide additional aspects 
of outcome measurement 277. Once again, there was no tool universal to both CD and 
UC. 
1.7.4.1 Hypothesis 
Drawing on the evidence presented, the following hypothesis was developed: 
That a health literate symptom self-report tool, universal to both CD and UC, will 
enable children with IBD to produce clinically relevant information on their 
disease activity.  
1.7.5 Adherence outcome measures 
In order to design interventions that improve and maximise medication adherence 
there needs to be an understanding of which children are non-adherent to regimens 
and why 213. Accurate assessment of medication nonadherence enables clinicians to 
view it as a diagnosable and treatable medical condition 279 and provides 
opportunities for education, to identify barriers, and to provide targeted 
interventions to minimize nonadherence 237. No gold standard adherence measure 
for children exists, and all techniques have been proven to have limitations 280. Those 
direct, indirect, and subjective measures that are available should be examined for 
feasibility, accuracy, and limitations prior to their use as an outcome measure. 
The top three assessments reportedly used are subjective clinical interviews (with 
patient or parent), biological assay for drug markers (blood or urine), and a daily 




Patient or parent reports and interviews are feasible but subjective and shown to 
overestimate adherence by up to 23% in adolescents with IBD when compared to 
objective measures 15, 216, 280, 282, 283. One such semi-structured interview that is 
widely used in paediatrics is the Medication Adherence Measure (MAM) 284. A 
correction factor for child and parent self-report data has been produced that should 
provide more accurate adherence rates from subjective reports 285. 
Bioassays are accurate and objective but can be costly and invasive and do not 
provide information on practical adherence such as those actual doses missed 126, 207, 
211, 213, 285. 
Daily adherence diaries have a poor history of compliance but it has been found that 
measuring the more universal concept of daily activities, thereby including 
medication taking, have better completion rates 282. 
Electronic medication monitoring devices track adherence to oral and inhaled 
medications, thus providing objective, specific real time information on adherence 
285. This method provides continuous, long-term measures, which can reveal a 
spectrum of problems such as under-dosing, overdosing, dose delays, dose holidays, 
and white coat adherence (improved adherence prior to appointments). This method 
does, however, rely on presumptive data on ingestion, is costly and prone to 
malfunctions 282, 286.  
Pill counts involve counting tablets (can also be done with liquid quantities) at two 
time intervals and comparing the difference to what should be expected from the 
prescribed dosing regimen 213. This is a simple and feasible objective method but 
prone to inaccuracy and does not measure ingestion, just removal of the drugs from 
the container 213. 
Adherence scales are structured questionnaires or surveys that ask specific 
questions regarding adherence that often measure responses using a Likert scale. 
None have been developed for children yet, but the most commonly used scale with 
adults is the Morisky scale 287, which has also been adapted for use with adults with 
IBD 288. However, this scale measures barriers to adherence instead of non-
adherence frequency, and may overestimate or undervalue adherence as items only 
account for daily medication regimens 283. Two adult scales have been developed 
specifically for people with low literacy - the Self Efficacy for Appropriate Medication 




However, these scales have not been validated with children. Studies comparing the 
Morisky scale to a single visual analogue scale (VAS) showed the simple VAS 
provides a more objective measure to quantify adherence 283 and is extremely quick 
to comprehend and complete.  
 Pharmacy records (refill rates, proportion of days covered) provide data on refill 
behaviours that are believed to correspond to medication taking, however they do 
not estimate adherence and once again assume ingestion 126. 
Disease activity indices such as the PUCAI and PCDAI are also frequently 
incorporated into adherence studies as a way of correlating measured adherence 
with symptoms. 
None of these measurement techniques quantify exactly what each patient has taken 
and should be considered as measuring variables that are indicative of adherence 
rather than being measures of absolute medication use 291. They do, however, 
provide an opportunity to triangulate multiple effective methods to provide accurate 
assessments of adherence 282. A consideration for selecting methods for use in 
research should be the time and respondent burden that they represent when used 
as part of a series of outcome measures.  
1.7.6 Cognitive attribute outcome measures 
Cognitive attributes pertaining to self-management for children are that of self-
efficacy, and patient activation.  
Self-efficacy 
Assessment tools for measuring self-efficacy in the adult IBD population were 
developed prior to those for adolescents and young adults. The IBD-Self Efficacy 
scale (IBD-SES) was first developed by Keefer et al for adults with IBD in 2011 232 
and underwent further validation by Graff et al 292 in 2016. This scale was adapted 
for use with adolescents to become the IBDSES-A by Izaguirre et al 7 who performed 
a validation study with children with IBD aged twelve years and over 293. This 
assessment tool is short and easy to understand and is further discussed in Chapter 
Nine. The IBD-Yourself self-efficacy assessment tool was developed by Zijlstra et al 




which may be prohibitive for use in younger children (as discussed in Chapter Nine). 
The SEAMS self-efficacy scale for appropriate medication use, as discussed in Section 
1.7.5, is aimed at adults with low health literacy but has not been validated in the 
paediatric population.  
Patient activation 
The commonly used measure of patient activation is the Patient Activation Measure 
(PAM) developed by Hibbard et al 294 which is a twenty two item long assessment. A 
shortened version (thirteen items) was developed by the same research group 295 
and has been used effectively in a cohort of children with IBD 296. In addition, a 
parent version of the PAM (Parent-PAM) has been developed that may be utilised 
where an assessment is required of parents activation concerning their child’s health 
297. 
1.8 Chapter summary 
It is clear from this literature review that additional research is needed to 
understand which components of self-management are the most effective at 
implementing change. There is a paucity of outcome measures for accurately 
assessing self-management processes for children with IBD, and the hypotheses 
presented aim to identify where improvements can be made. 
This body of work is centred on identifying where there are gaps in the literature for 
the aforementioned assessment tools. The following chapters present the systematic 
development and testing of self-management outcome measures for children with 
IBD, culminating in the development of an intervention aimed at supporting children 
as they learn the process of self-management.  
1.9 Chapter outlines 
The structure of this thesis is divided into sections and chapters in order to group 
together related studies.  
Section One details the development process of a self-management mHealth app and 




 Chapter One presents the design and development process of a mobile health 
app. with a narrative that explains the iterative progression through the 
stages of qualitative interviews with the target population, applying 
behaviour change theory, and highlights the development of the wireframe 
design using the process of intervention mapping. The usability heuristic 
testing tool development is outlined, alongside the content validity testing 
that was to be performed by a series of paediatric IBD experts.  
 
Section Two contains five chapters that describe the development process of an IBD 
knowledge assessment questionnaire for children – IBD-KID2. Within this section are 
the following chapters: 
 Chapter Three presents a participant response pattern analysis that was 
performed on the original knowledge assessment tool: IBD-KID. The results of 
this analysis are used to develop a revised version of this assessment tool: 
IBD-KID2. 
 Chapter Four reports a study testing the internal validity of IBD-KID2 using 
between group comparisons of participants with established IBD knowledge 
levels. This study also reports on internal consistency and test-retest 
reliability of the tool.  
 Chapter Five reports on the public knowledge of IBD, as tested using IBD-
KID2, at a University education showcase event. Knowledge levels were 
assessed against independent variables to determine if any respondent 
attributes influenced the scores.  
 Chapter Six utilises IBD-KID2 to test the knowledge levels of parents of 
children with IBD, and the efficacy of an education programme for them held 
at a residential camp. This allowed for the testing of IBD-KID2 for its 
sensitivity to change pre and post intervention. 
 Chapter Seven focuses on establishing the external validity of IBD-KID2 to the 
wider population of children with IBD. IBD-KID2 was implemented among 
children with IBD, their parents, and their siblings, from seven tertiary care 
centres in three geographically diverse countries. This enabled the 





Section Three contains a standalone chapter: 
 Chapter Eight presents the process of development and validity testing of a 
symptom self-report tool for children with IBD. The validation study 
measures the level of agreement between the children and clinicians when 
reporting symptoms using this assessment tool. 
Section Four relates to the development and testing of a self-management skills 
assessment tool and contains the following chapters: 
 Chapter Nine presents a systematic review carried out to identify self-
management skills assessment tools for children with IBD. This is set out 
according to the Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) guidelines and evaluates the attributes of each tool 
according to content and rigour of development. 
 Chapter Ten sets out in three stages how a self-management skills assessment 
tool for children with IBD was developed. This includes a content synthesis of 
the tools identified in chapter eight, followed by a content validity index of 
this tool by a number of paediatric IBD experts. Validity was tested among the 
target population by examining the relationship between the assessment of 
their own skills against how they were reported by their parents and 
clinicians. 
Section Five details a Proof of Concept study that was performed to ascertain whether 
the content of the app presented in Section One (IBD-Tracker) was effective at 
improving self-management skills. This section includes the following chapter: 
 Chapter Eleven draws on the work of the previous chapters to develop a self-
management skills booklet for children with IBD. The subsequent study 
presented is ‘Proof of Concept’ research that measures applicability and 
acceptance of the booklet to the target population and measures a small 
number of outcomes that may be positively influenced by the intervention. 
This study also aimed to establish sensitivity to change of IBD-KID2 among 




Chapter Twelve brings the collective results together in a discussion and conclusion. 
Each section will be summarised, and a precis given of how it has contributed to the 
literature in terms of its utility and applicability, as well as outlining the direction of 
future research.  
Table 1.4 summarises the publications directly arising from this thesis at the time of 
submission 
Table 1.4 Publications arising from this thesis to date 
Citation Reference Chapter Appendix 
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SECTION ONE: Introduction 
In Chapter One it was established that in order for children with IBD to learn self-
management of their disease a number of integrative elements should be addressed: 
knowledge, communication, self-regulation, adherence, and cognitive attributes. It 
was also highlighted in Chapter One (Section 1.7.1) that there is a paucity of multi-
component interventions aimed specifically at improving self-management for 
children with IBD. It was shown that the primary focus of existing interventions for 
children with IBD were aimed at improving adherence alone. The interventions 
designed for adults with IBD are not directly applicable to children as their self-
management needs are significantly different. This is due to the parent-child dyad of 
responsibility allocation, as well as the need for interventions to be targeted at a 
specific level of comprehension and health literacy. Children also need interventions 
to engage them at the outset, and along a continuum, to ensure their ongoing use.  
In light of this evidence it was thought applicable to develop a self-management 
intervention specifically for the target population which could support the 
combination of Modi 50 self-management domains and processes, and be presented 
in a format that was engaging and appropriate for children. The following chapter 
outlines the process of development of a multi-component self-management 




Chapter Two: Self-Management mHealth App Development: 
IBD-Tracker 
2.1 Introduction 
2.1.1 Self-management intervention format 
Given the scarcity of self-management interventions for children with IBD, there is 
little evidence on which to base the development of a novel programme. When 
considering the format of the new intervention it was, therefore, debated whether it 
should be static and accessible in one environment such as home or hospital, or 
accessible by children whenever it was needed. Traditionally, interventions to 
improve self-management in children with other chronic diseases are delivered 
through in-person sessions delivered over a period of several months, however, this 
approach can be resource intensive and burdensome 300, 301. In addition, children and 
their families can find it difficult to practice and then maintain the skills they have 
learned between the sessions when they were delivered intermittently 301. It was 
thought, therefore, that developing an intervention that children could take with 
them and use as they required would be more effective in this population.  
A previous study by Kennedy et al 104 utilised a self-management booklet among 
adults with IBD that had good effect across a number of outcome measures, and suits 
the format of portability. However, when a number of systematic reviews of 
paediatric chronic disease self-management interventions were examined, only two 
studies had utilised this format, and the booklets were combined with other 
intervention components so efficacy could not be theorised 108, 124, 137, 234, 235, 302.  
An alternative form that is known to engage children and capitalises on a medium 
that they already frequently use and are familiar with is that of mobile technology 234, 
253, which would provide the element of portability and the ‘on demand’ access 
required. The utilisation of mobile devices, such as smartphones or tablets, to collect 
health data for clinical and research purposes is known as mHealth, defined by the 




the achievement of health objectives 303. Mobile phones are ubiquitous among 
children, with 78% of surveyed school pupils in New Zealand owning one in 2017 304, 
a number sure to have risen but with no recent data available for comparison. Mobile 
technology, which is increasingly used by the target population, must be considered 
in a truly contemporary paediatric self-management model 50. 
2.1.2 mHealth technology 
mHealth technology has created a paradigm shift in the arena of chronic disease 
management, and mobile health applications (apps) offer new possibilities to engage 
children in self-management in ways that did not exist in the past 252, 254. In order for 
mobile technology to achieve its potential for transforming health care, it is vital to 
determine which aspects of mHealth work, for which diseases, in which population, 
and to achieve which outcomes 252. While no mHealth interventions were identified 
for the paediatric IBD population, apps have been developed for self-management in 
other disease groups. The most effective were for children with asthma which 
showed improvements in disease control, HRQoL, adherence, school attendance, and 
self-efficacy 305-308 while also showing prolonged engagement with the app 308. For 
children with Sickle cell disease improvements were shown to adherence and 
knowledge but the level of engagement was generally poor 309, 310. An app designed 
for children with diabetes showed improvements to the frequency of blood glucose 
monitoring over time in the pilot study 311 but no improvements to any primary or 
secondary outcomes in the RCT 312. When a number of systematic reviews were 
examined relating to self-management apps for children with chronic disease there 
was a general consensus that the apps being tested lacked a theoretical background, 
and studies were often poor quality that needed well defined clinical outcomes to 
test the apps against 310, 313, 314.  
For the IBD population as a whole there are hundreds of commercial apps available 
in the app stores (Apple and Android), although they have variable functionality and 
most lack professional medical involvement and have limited coverage of 
international consensus guidelines 254, 313. A number of studies were identified that 
tested mHealth solutions in the clinical setting, but methodological shortcomings 




heterogeneity of outcome measures, limited clinician and end-user input, and lack of 
validation against clinical indices 251, 315. The implications of this are considerable 
when it has been shown that 99% of adult IBD patients are willing to use technology 
to help manage their disease 316, yet many of those available lack a theoretical 
framework for their development, implementation, and evaluation 315. This evidence 
highlights that if mHealth technology is intended as an adjunct to clinical treatment 
then it must be developed using a rigorous, evidence-based approach.  
It was considered appropriate to produce a mHealth app for children with IBD to 
help them learn self-management skills. However, it was essential that the 
development process was carried out utilising a rigid framework of sequential steps 
in order to improve reporting of the process. In addition, the content of the app was 
to be based on clinical guidelines, empirical evidence of effective components, and 
involve the target population in development. The proposed app to be developed was 
given the name IBD-Tracker to represent children tracking their disease and 
treatment in order to learn self-management. 
2.1.3 mHealth development framework 
mHealth interventions have theoretical, user-centred, and technological components 
intricately linked and the process of app development should be a transdisciplinary 
endeavour between end-users, health care teams and designers 252, 313, 317-319. It is, 
therefore, important to have a development framework for guidance that enables the 
translation of effective guidelines and practices into mHealth products in a 
transparent, universal, and standardised way 252.  
A number of frameworks were identified in the literature that could be used to 
develop IBD-Tracker. The Intervention Mapping method devised by Bartholomew et 
al 318 presents a well-established format that systematically integrates theory, 
empirical findings from the literature, and input from the target population 318. This 
format has previously been used to develop a transition programme for children 
with IBD 320 and has also been used to develop self-management programmes in 
different population groups; the elderly with chronic conditions 321, people with low 




technological elements of mHealth app development required a more specific format 
and a number of general, iterative frameworks for app development were identified 
251, 252, 324. However, the Integrate, Design, Assess, and Share (IDEAS) framework 
developed by Mummah 317 was selected as it shares many similarities with 
Bartholomew’s Intervention Mapping method 318, while also detailing an iterative 
structure specific to mHealth development. The IDEAS framework contains ten 
comprehensive phases grouped into four overarching themes (Figure 2-1) which will 
be approached sequentially in this chapter.  
2.1.4 Aims and hypothesis 
The aim of this research was to develop a mobile health app for children with IBD. 
The evidence presented thus far led to the following hypothesis: 
That a targeted mobile health app intervention comprising self-management 
components will be effective at improving disease outcomes, and overall self-













2.2 Phase 1 – Empathise with target users 
2.2.1 Introduction 
In order to maximise and maintain user engagement with an app, development 
should adopt user-centred design principles that involve grounding the process in 
the needs, preferences, and understandings of end users. While it has been 
established in the literature that end users generally have a limited understanding of 
the types of intervention that would be most useful, their input is vital to provide the 
rest of the transdisciplinary team with an understanding of their beliefs, 
circumstances, preferences and thought processes 325, 326. This will in turn facilitate 
the ideation of their imaginative design solutions. In the paediatric population the 
engagement of end-users in this way enables researchers to understand how a child’s 
perspective differs from that of an adult, thus minimizing the inherent risk of the 
development team assuming an understanding of the end users’ requirements, 
resulting in a product that does not adequately meet their needs 327, 328. 
Subsequently, an app such as IBD-Tracker will more likely be utilised by end users as 
intended, which will in turn affect intervention evaluation and effectiveness 325, 328, 
329.  
The review presented in Chapter One provided the foundation for the first stage of 
IBD-Tracker development by identifying the requirements for effective disease 
control and self-management as well as specific modifiable behavioural, 
environmental, and social factors associated with it 318. These insights needed to be 
explored further to ensure their relevancy to the target population. Qualitative 
research was undertaken to gain an understanding of how children with IBD 
perceive self-management, and how their everyday experiences could be translated 
in to a mHealth app 318, 330. The following study presents the methodology and results 






2.2.2.1 Methodological considerations   
A number of methodological considerations needed to be reviewed prior to finalising 
the study design for this section. 
Focus groups vs individual interviews  
The literature provides evidence concerning the most beneficial or appropriate 
qualitative data collection method when working with children. Focus groups and 
interviews both have their merits and disadvantages, and it was important to 
determine the correct methodology for the study and the target population.  
Focus groups are preferred when looking to show divergence or convergence 
between different views, and for generating a wider, richer bank of data as a result of 
group interactions, which may generate more than the sum of individual interview 
inputs 331. However, there is a drawback when using focus groups with children in 
that they may tag onto the views of others without imparting their own meaning, or 
may feel intimidated by the group scenario and not contribute at all 331. In contrast, 
individual interviews consist of a question-and-answer approach, with the 
researcher selecting the content and focus using a more formal structure 332.  
Previous research has shown that significantly more unique ideas emerged from 
individual interviews than from focus groups, and issues concerning highly sensitive 
or complex issues were more likely to be vocalised in personal interviews without 
contamination from their peers 331-333. It was considered that individual interviews 
would be the preferred methodology to garner end-user input for IBD-Tracker as the 
aim was to gain insights from children with a range of ages, genders, disease types, 
and both urban and rural locations. These factors made the formation of focus groups 
logistically prohibitive and enabled a greater amount of data collection from 
opportunistic interviews when participants attended hospital for out-patient 
appointments from across the South Island of New Zealand. 
Parent participation 
Prior to carrying out the interviews it was important to consider that children of all 




child’s interactions to be supported by a parent, and parental contributions often 
provide scaffolding to the interaction that could add a richness and completeness to 
an interview 334. Parents may also help children to articulate strategies they use to 
cope with their IBD in everyday life, and to gain insight into the family participation 
in IBD management that may be missing in the child’s subjective recall 335. Children 
were therefore given the choice as to whether they wished to have a parent present, 
and if not, parents could choose to be interviewed separately.  
Interview format 
The interviews were carried out by the researcher and included a combination of 
direct closed questions to gain specific information, and open-ended questions to 
prompt a spontaneous narrative 336. If a child needed help to understand what was 
being asked then the type or format of question was altered to help their 
understanding, but not to lead them in researcher-defined directions 336. The rate of 
progression through the questions was determined by the participant responses, 
level of development, and engagement with the interview as it evolved 332.  
Interview structure  
In order to develop a structured guide for the interview process a question 
framework was generated that was expected to elicit sufficient data for analysis 
(Appendix B). Questions were based on themes concerning the following topics: 
 Everyday impact of IBD on the child and their family 
 Self-management of IBD 
 Mobile device usage and mHealth apps 
 Suggested features and content of an IBD app  
 Overall perceptions of value and satisfaction to be gained from an IBD app.  
Interview transcription 
The process of transcription for the audio-recordings was determined by the 
purpose and research questions underpinning the interviews. The interviews 
performed for this study were focussed on investigating what was being said, not 
how it was being said, therefore non-verbatim transcriptions were made by the 




not include non-verbal interactions, thereby providing a more readable transcript 
that stays true to the voice and intended meaning of the participants 337. 
2.2.2.2 Participants 
Children aged ten years and over with a confirmed diagnosis of IBD were identified 
by the Paediatric Gastroenterologist and IBD Outreach Nurse working at 
Christchurch Hospital, New Zealand. Those identified were due to attend the 
paediatric out-patient IBD clinic and parents were contacted in advance of the 
appointment to explain the study, offer participation, and send out study 
information. Appointments were scheduled to follow their clinician consultation in 
IBD clinic. Written parental consent was sought for each child’s participation prior to 
the interview, and either verbal or written assent from every participant. For those 




Ethical approval for the interviews was granted by the Otago University Ethics 
Committee (Health) (H16/116). 
2.2.2.4 Interview process  
Prior to commencing the interview a predetermined format of introduction was 
followed that re-established the purpose and format of the interview, including a set 
of ground rules which detailed what the children could expect from the interview 
and interviewer, and safety matters regarding stopping the interview 327. Time was 
made available for questions, and then consent was obtained. The interview 
commenced once the participant indicated they were ready to start, and all 
interviews were recorded for later analysis.  
2.2.2.5 Interview analysis 
It was determined that a qualitative content analysis approach should be taken for 
the interviews. This is a method of analysing text content using a systematic and 




The interviews were carried out specifically to gather information regarding ideas 
for app content, so the approach was further refined to that of manifest content 
analysis. Manifest content refers to the visible, countable components of text which 
can be used when the purpose of analysis is not to infer meaning but simply to 
explore the usage and frequency of words, categories, or themes 339-341. This differs 
from latent content which includes the exploration of abstract concepts and the 
analysis of hidden meaning 341.  
Despite the domains of self-management having been established prior to this stage 
of app development, it was decided not to use pre-determined categories for analysis 
based on these over-arching themes. An inductive approach was thereby taken for 
transcript analysis, which allowed the findings to be data-driven as they emerged 
from the frequent, dominant, or significant themes inherent in the raw data, as 
opposed to trying to fit a preconceived analytical framework 342, 343. All interview 
transcripts were read repeatedly, and a systematic coding and categorising approach 
used for exploring the text, and identifying trends, frequency, and patterns in the 
ideas as they became apparent 344. This coding data was then reduced in to 
meaningful groupings using a block and file approach 345 which assigned the codes in 
to topic specific sub-categories, and then in to overarching categories of self-
management processes, as discussed throughout this body of work 50. This process 
allowed for the development of objective inferences to be made from the data, and 




Twelve children were approached to participate, eleven agreed to take part, and two 
children were unavailable on the day. Nine children and ten parents were 
interviewed for this design phase. Participant demographics for the children were 
examined (Table 2.1). Three children were interviewed with no parent present (one 




For all interviews the children were interviewed first, parents second, and then both 
could discuss ideas together. 
Table 2.1. Participant demographics (children) 
Category Group Number 
(%) 
Age group 
11-12 years 2 (22) 
13-14 years 3 (33) 
15-17 years 4 (45) 
Gender 
Male 5 (56) 
Female 4 (44) 
Disease type 
CD 7 (78) 
UC 2 (12) 
Location 
Christchurch 5 (56) 
South Canterbury 3 (33) 
West Coast 1 (11) 
 
2.2.3.2 Interview transcripts 
The results of the interview analysis were synthesised into a frequency table in order 
to identify the number of participants endorsing each a priori theme (Table 2.2).  
All suggestions provided in the interviews were considered and underwent a process 
of review. Ideas were accepted for design consideration if they were feasible to 
include, did not breach confidentiality issues, and were applicable to the majority of 
the target population 324. Those ideas that were not included are indicated with an ‘*’ 
in Table 2.2. The children interviewed were also asked to comment on design and 
aesthetic features that would encourage or discourage them from using the app and 








Table 2.2. Participants interview analysis  











Monitor how feeling  4 4 Symptoms Self-regulation 
Pain/cramp tracker  1 1 
Poo tracker 1 2 
Vomiting record 1 1 
List of symptom triggers  7 7 
Ways to help when symptoms bad* 2 0 
Height + weight tracker  2 3 Growth 
List of drugs taking 1 2 Drugs list Adherence 
Track when drugs taken or not 2 1 Drug adherence 
Reasons for not taking drugs * 2 1 
Drugs reminders 9 3 
Reminders for when prescription needed 0 2 
Infusions appointment reminder 1 1 Treatment adherence 
Enteral nutrition reminder  1 2 
How much enteral nutrition needed each day 4 3 
Reminder to get supplies (Gastrostomy feed sets) 1 0 Supplies 

















Free text area to record private thoughts * 0 1 Mental health Cognitive 
attributes Messaging with other kids * 0 1 Peers 
Social media: Facebook group link in app * 1 3 
Buddy system * 1 1 
Links to healthy eating sites* 0 2 External links Knowledge 
Links to find research information * 2 3 
Link to IBD information 1 1 
Links for transport – bus timetables etc * 0 1 
Treatment options, IBD information 2 4 Learning area 
Research information 2 1 
Nutrition 2 2 
Body parts, anatomy  1 1 
Link app to parents * 0 2 Parents Communication 
Email results of data input to team * 0 2 Team  
Being able to look back at data  2 5 History 
Food portion diary * 1 3 Nutrition 





The methods used in this study had practical value in helping children provide 
information and ideas that were genuine, important, and credible, and cemented the 
theory that children are the best sources of information about themselves and their 
own situation 336.  
2.2.4.1 Limitations 
The inclusion criteria of interview participants being required to be aged ten years or 
over may have introduced the element of selection bias, therefore limiting 
generalisability of IBD-Tracker to children below this specific age. However, the 
established age for beginning the self-management process is approximately ten 
years and it was therefore considered that the selected interview participants were 
more likely to be performing self-management in some form. In addition, children 
aged ten years and over were more likely to have experience of mobile technology 
and understand how its capabilities may be applicable to their own self-management 
needs and provide related app content ideas.  
2.2.4.2 Strengths  
The interview participants were selected to capture variation in location, gender, age, 
and diagnosis, in order to maximize the likelihood that their ideas would be 
generalisable to other children with IBD 325. It has been suggested that performing 
six in-depth interviews provides enough for ‘data saturation’ but that researchers 
should continue until no new ideas are generated 346. After nine interviews, no new 
ideas were being suggested by the children with IBD, so it was considered the point 
of data saturation had been reached. 
2.2.4.3 Conclusion 
The ideas for app development generated from the children’s interviews and from 
the MDT were amalgamated and used for Phase Two that specifies the target 




2.3 Phase 2 – Specify target behaviour 
The ‘Specify’ phase is where broad behavioural goals are translated into highly 
specific target behaviours, taking into account how actionable they may be, the 
potential health impact, and user acceptability 326. The broad target behaviour for 
IBD-Tracker was defined as the performance of self-management tasks by children 
with IBD. In order to stratify this overall target to specific behaviours, the children’s 
suggestions presented in the interview analysis (Table 2.2) were categorised in to 
the appropriate self-management processes and target behaviours from the 
previously outlined framework by Modi 50 (Table 2.3):  
 Self-monitoring of symptoms 
 Communication with the medical team 
 Lifestyle modifications 
 Taking medications or treatments 
 Refilling prescriptions 
 Attending clinic appointments 







Table 2.3. Interview analysis stratified in to target behaviours for IBD-Tracker. 
 
 Domain Interview Analysis Specific Target Behaviour 
Self-regulation Monitor how feeling  Self-monitoring of symptoms 
 Pain/cramp tracker  
Poo tracker 
Vomiting record 
Height + weight tracker 
List of symptom triggers  Lifestyle modifications 
Adherence Track when drugs taken or not Taking drugs and treatment 
 List of drugs currently taking 
Drugs reminders 
How much EN needed each day 
Enteral nutrition reminder  
Reminder to get supplies (feeding sets) 
Reminders for when prescription needed Refilling prescriptions 
Infusions appointment reminder Attending appointments 
 Appointments reminder 
Knowledge Link to IBD information Seeking disease and treatment 
related information Treatment options, IBD information 
Research information 
Nutrition 
Body parts, anatomy  




The health benefits of these self-management processes have been addressed in 
Chapter One, and are also summarised as follows to outline the evidence of a 
significant health benefit for each process in order to validate their inclusion in IBD-
Tracker: 
Self-monitoring of symptoms: For adults with IBD, self-monitoring of their symptoms 
has been shown to increase awareness of their disease state and improve their 
communication with the MDT during subsequent clinical encounters 198, 206.  
Making lifestyle modifications: Consumption of particular foods represent a 
significant proportion of IBD triggers and the use of dietary modifications has been 
shown to improve disease control and symptoms in adults with IBD 221.  
Taking medications or treatments: Medication adherence has been inextricably 
linked to reduced disease severity 92, 347, alongside improved HRQoL 77, 225-227. 
Adherence to nutrition regimens such as exclusive enteral nutrition (EEN) can 
induce disease remission in up to 80-90% of children with CD and can improve 
growth and nutritional state 348-350. Adherence to maintenance EN can be used for all 
children with IBD to supplement their regular diet in order to help maintain 
remission and ensure continued growth.  
Refilling prescriptions: The rates of remission in paediatric IBD have been shown to 
positively correlate with the rate of prescription refills 224.  
Attending clinic appointments: Poor attendance to scheduled clinic appointments 
among adolescents with IBD has an association with increased hospitalisations for 
disease relapse and worse treatment adherence 114, 221.  
Seeking disease and treatment information: The acquisition of knowledge regarding 
disease and treatment has the potential to improve adherence 172, 173, and lead to 
better disease outcomes 90, 174. 
 Communicating with the medical team: Improved communication with the MDT 
reduces the level of worry regarding gastrointestinal symptoms, and subsequently 




treatment adherence, health care satisfaction, and a superior understanding by the 
patient of their condition 122.  
These self-management processes were then addressed in Phase Three (Section 2.4): 
Ground in behavioural theory, whereby appropriate behaviour change techniques 
are identified for the app that would theoretically be well accepted by the target 
population given their level of involvement in the development process 317.  
2.4 Phase 3 – Ground in behavioural theory 
Having identified the target behaviours to be addressed in IBD-Tracker, the next 
phase of app development was to identify the theoretical basis behind each self-
management process identified in the interviews. It is apparent in the literature that 
interventions based on behaviour change theory (BCT) are more effective than those 
lacking a theoretical basis 351. Strategies were therefore explored to integrate app 
development with BCT to facilitate the creative translation of participant suggestions 
in to tangible and specific intervention components 317. This task began with a review 
of the BCT frameworks of Michie et al 352, 353 and Cane 354, with the conclusion that 
the BCT taxonomy by Michie et al 352 provided sufficient detail to align each proposed 
function of IBD-Tracker to a specific BCT technique. The BCT Taxonomy consists of 
ninety three BCT techniques that can be applied to an intervention intended to 
promote behaviour change, with the aim of modifying target behaviours to produce 
significant health benefits 326, 355. 
The appropriate BCT techniques from the Taxonomy were assigned to the target 





Table 2.4. Behaviour change techniques relating to each specific target behaviour 
 
The overall principle of the app is to encourage and enable children with IBD to 
perform self-management tasks, therefore Action planning (1.4) was considered the 
overarching behaviour for encouraging children to consistently use IBD-Tracker. The 
Monitoring of outcomes (2.4) was assigned to the behaviour of symptom self-report. 
Identifying lifestyle modifications was determined as encompassing the behaviour of 
Problem solving (1.2) whereby children can identify specific symptom triggers and 
strategize for overcoming the barrier, such as temporary avoidance.  
The capability of IBD-Tracker to generate reminders to alert children to take their 
prescribed treatment, and attend appointments or infusions, for example, would 
provide a stimulus with the purpose of prompting a specific behaviour using Prompts 
and cues (7.1). The reminder prompts in IBD-Tracker would also contain a format for 
recording adherence to the drug or treatment they had been alerted to, an action 
represented by Self-management of behaviour (2.3). The requirement to consume a 
specific amount of EN each day utilised the Goal setting (1.3) behaviour which 
allowed for a daily target to be set with a positive outcome of wanted behaviour in 
reaching this goal. The delivery of information regarding disease and treatment 










Self-management Using IBD-Tracker 1.4 Action planning 
Self-regulation Self-monitoring of 
symptoms 
2.4 Monitoring of 
outcomes 
Lifestyle modifications 1.2 Problem solving 
Adherence Taking drugs and 
treatment 
7.1 Prompts and cues  
2.3 Self-management of 
behaviour Attending appointments 
Refilling prescriptions 
Taking treatments (EN) 1.3 Goal setting 




8.6 Generalisation of a 
target behaviour 
Communication Communication with  
the MDT 





applied to the action of accessing web links included in the app, and Generalisation of 
a target behaviour (8.6) for reading the static information pages in IBD-Tracker, 
whereby children seek evidence-based information in the app instead of the internet 
or health education materials. The behaviour of utilising the app to review their 
recent IBD symptoms or adherence behaviours using the ‘history’ section of the app 
was determined as Feedback on behaviour (2.2). This behaviour could be performed 
to learn such self-management skills as self-regulation but will also benefit their 
communication with the MDT when discussing their recent disease and treatment 
history.  
These BCT techniques were then required to be integrated into the design of IBD-
Tracker in the form of mHealth or self-management components, preferably with an 
evidence base of positive outcomes. This process was performed in Phase four – 
Ideate.  
2.5 Phase 4 – Ideate implementation strategies 
The Ideate phase was concerned with integrating the end-user input, identified BCT, 
and empirical findings from the literature, in to effective intervention components 
for a mHealth delivery system 318, 356. Targeted literature searches were performed to 
identify what is already known about similar evidence-based interventions, and 
these were used to classify a broad set of supporting actions for each BCT 
component, with the emphasis specifically on those actions that could be supported 
through mHealth interventions 252, 357.  
2.5.1 Monitoring of outcomes 
Self-monitoring of symptoms 
Patient based disease activity monitoring has been proposed as a valuable addition 
in the current health era of self-management 276. It has been suggested that validated 
self-report tools should be incorporated in to remote management interventions in 
order to follow disease activity longitudinally, and to provide tools for self-
management 276. The development and validation of IBDnow (Chapter Eight) has 




be adapted for use in IBD-Tracker in order to enter symptom metrics in real-time. 
The component categories of IBDnow were therefore included in the intervention 
design to help children develop self-regulation skills and help them communicate 
their current and recent disease activity to their parents and MDT.  
Monitoring growth 
Children with IBD undergo regular growth monitoring in order to ensure their 
weight and linear growth are not adversely affected by their disease. This monitoring 
is performed each time they attend the hospital out-patient IBD clinic and while the 
results are recorded in the child’s hospital notes, it was considered that tracking 
their own growth would be beneficial. For children who have recently achieved 
remission it may be encouraging to see their growth responding positively to 
treatment. When developing self-regulation skills, a weight and height tracker could 
be used to associate longitudinal symptom changes to growth fluctuations. A section 
was therefore included in IBD-Tracker to record weight and height, thereby helping 
to develop self-monitoring and self-regulation skills. 
2.5.2 Problem solving 
Lifestyle modifications  
It was thought that the simple addition of a page where children could make an 
editable list of their IBD triggers would be sufficient. This would enable them to list, 
for example; foods that cause symptoms and may wish to eliminate temporarily 
(under dietetic supervision). Children could then determine the effect on symptoms 
using the longitudinal data from the app version of IBDnow. This would benefit the 
children by helping them develop self-regulation skills and to communicate their 
symptom triggers to the MDT. 
2.5.3 Prompts and cues, and self-management of behaviour 
Drug adherence 
A number of the mHealth apps designed for adherence promotion in the paediatric 
and adult population contain design and content failings in that they do not 




While many commercial mHealth apps provide drug reminder alarms, few contained 
the additional behavioural or educational elements that are known to induce the 
greatest improvements when delivered as a multi-component intervention 301, 358. An 
app such as IBD-Tracker had the potential to address adherence on multiple levels by 
including components which address known barriers to adherence, as well as 
providing education and information pertinent to this behaviour change.  
The highest perceived barriers to drug adherence by children with IBD and their 
families are:  forgetting to take them (≈88%), regimen complexity (≈65%), being 
away from home (≈47%), and interfering with activities (≈45%) 51, 132, 359. The 
current evidence regarding mHealth adherence promotion apps highlights that their 
designs limit efficacy as they do not specifically address these barriers. In providing a 
simple reminder alarm the user is expected to react immediately so that the 
reminder is not forgotten 358, therefore failing to address the barrier of being away 
from home or interfering with activities. Many reminder apps do not adapt the drug 
alerts to the requirement of multiple drugs, or enable the user to keep a list of their 
drugs, therefore failing to address the barrier of regimen complexity 358. Few 
mHealth apps have been found that allow the user to track whether their drugs have 
been taken or not, or to review their previous adherence record, therefore limiting 
the chance for reflection of the required behaviour change 301. Very few apps 
provided options or information to support habit formation of regular adherence, 
thereby encouraging reliance on technology for prompts and cues 358.  
In light of this evidence the essential components that were included in the IBD-





– A drug specific reminder alarm at user determined times, including the 
drug name and how much was required to be taken 
– Include a snooze option to postpone until free to take, or at home again 
– Create a list with the name, dose, and quantity required of each drug 
Behaviour 
– Ability to record if each drug has been taken (also Self-management of 
behaviour) 
– Ability to review and reflect on previous adherence patterns  
– Encourage habit formation by including suggestions to associate activities 
with drug taking  
Education 
– Provide information on the drugs taken 
– Provide disease specific information 
– Provide information on the benefits of adherence 
Treatment adherence 
Treatment adherence should also be considered beyond the behaviour of taking 
prescribed drugs, as continued medical care depends on children also performing 
other crucial behaviours such as attending appointments and getting requested 
bloods taken. As discussed in previous chapters, not all self-management skills are to 
be expected of all children as skills acquisition will increase with age. However, 
providing children with the means to begin the development of these skills will be 
beneficial for when they reach the age of transition and there is an expectation of 
health autonomy. One of the additional recognised barriers to adherence is running 
out of drugs due to not refilling the prescription 51, 132, 359 and while for younger 
children this would be a task commonly performed by the parents, teaching children 
how to read a prescription label will begin the process of learning self-management 
of this task. The provision of this information is addressed in the Instruction section 
below (Section 2.5.2.4).  
In light of this evidence, a reminder alarm system was included in the design that 




 Hospital appointments 
 GP appointments 
 Nurse specialist appointments 
 Infusion or injection appointments 
 Blood test appointments 
 Reminder to order prescriptions 
 Reminder to order supplies (e.g. stoma or gastrostomy supplies) 
The addition of these two separate reminder functions were included to help 
children develop self-management of their treatment adherence for a number of 
elements and aimed to include multiple components to maximise efficacy. 
2.5.4 Goal setting 
The addition of a section in IBD-Tracker to monitor enteral nutrition requirements in 
the form of a daily target was considered applicable. However, while there may be 
children required to take enteral nutrition as part of a temporary EEN programme, 
or as maintenance treatment, there could be many who do not require any liquid 
nutrition at all. While it would be feasible to expect some children to simply not use 
this section, it could also make some feel excluded. The goal setting section was 
therefore kept neutral and designated for ‘Taking drinks’ so those not requiring 
enteral nutrition could use it to set a goal for drinking water to maintain adequate 
hydration. In studies among adults, mHealth apps for monitoring fluid intake have 
been shown to facilitate accurate recording and checking of cumulative totals 360, 
with 75% of those surveyed finding the apps helpful 361. The behaviour of self-
regulation based on setting goals, tracking behaviour, and modifying the level of 
effort to minimise goal discrepancies is known to be a positive influence on fluid 
consumption 362. This section was therefore included in IBD-Tracker to enable 
children to adhere to their enteral nutrition regimen, where applicable, and to 
increase awareness of attaining goals relevant to their treatment. 
2.5.5. Instruction 
In order for children with IBD to be actively involved in their own health care and 




patient education is accepted as a valid component of chronic disease management, 
increasing knowledge alone by passively providing information is rarely successful 
and it should be included as part of a behaviour-orientated programme such as IBD-
Tracker 174, 210, 262, 364. The format of the information provided to patients should 
reinforce the advice given by the MDT, be aligned with consensus guidelines, and 
should suggest further sources of information 256. In addition, the use of a symptom 
escalation advice card can help guide patients to the appropriate course of action if 
their symptoms change, an intervention that has shown efficacy and user satisfaction 
105. 
The knowledge sections contained within IBD-Tracker were therefore designated as 
static pages but came in a number of forms: 
Disease and treatment information on the following topics, taken from the national 







 Anatomy and gut function 
Instructional information on the following: 
 How to read a prescription label to calculate refill dates 
 ‘When to get help’ triage system using traffic light colours for escalating 
symptoms with advice on who to contact in each instance 
A number of external web links to find information regarding 
 Support pages for youth with IBD in New Zealand 




2.5.6 Feedback on behaviour 
It was considered crucial for children’s ongoing engagement with IBD-Tracker that 
the app should contain a feature for them to review and reflect on the information 
they input in a ‘History’ section that could produce graphs of their data. This feature 
would provide behavioural feedback on their overall action planning of using the app 
and would benefit by providing reinforcement of their developing self-management 
skills of adherence and self-regulation. Being able to animate the history of their 
previous data would greatly benefit their communication with the MDT by providing 
time-frame reports (e.g. one week, two weeks, and one month). This section would 
support all facets of self-management. 
2.5.7. Health passport  
In addition to the suggestions from the end-user interviews, it was decided that a 
feature for entering children’s disease history in the form of a structured health 
summary for each user would be beneficial. This form of medical summary, known as 
a ‘health passport’ has been trialled previously in the IBD population and has been 
shown to be a useful adjunct to patient recall, imparts independence and a sense of 
responsibility, and can be used as a portable health record in case of emergency 1, 159, 
365. This feature was therefore included in IBD-Tracker to provide a summary of the 
following information: 
 Name 
 Date of birth 
 Diagnosis 
 Date of diagnosis 
 Allergies 
 Date of last endoscopy 
 Location of disease 
 Current treatment 
 Triggers 
 Name of clinician 
 Name of IBD Nurse 




 Number for emergency contact 
2.5.8 Push notifications 
The addition of PUSH notification capabilities to IBD-Tracker was designed to 
support user engagement by allowing the research team to communicate with users 
as a group, or individually, by delivering short messages that would appear via the 
app. This could be used by the MDT to encourage children with IBD to, for example, 
monitor their symptoms in preparation for their clinic visits, or to update their 
health passport following treatment changes.  
2.5.9 Phase 4 Summary  
With this phase complete it was vital to start collaborating with an app development 
company so that advice could be sought on whether the BCT strategies and proposed 
design ideas could be translated in to engaging, interactive app features 319. An 
external software development company was sub-contracted to develop the app and 
the first design phase began, which was to devise a ‘blueprint’ for IBD-Tracker that 
would guide their progress. The next phase of Prototype was where the app design 
features, and layout were planned.  
2.6 Phase 5 – Prototype potential products 
Using the ideas and theoretical background provided in the first four phases, a 
prototype of IBD-Tracker was developed as a ‘wireframe’ by the candidate, which is 
when all of the required app elements (images, text, and buttons) are positioned on a 
sample screen in black and white 366. This was carried out using wireframing 
software (MockplusTM) that allowed for the design concept and proposed app 
features to be outlined in both a static ‘map’ of pages and connections, alongside a 
working interactive mock-up of IBD-Tracker to be viewed on a computer.  
The design for IBD-Tracker began with a simple flowchart of sections (Figure 2-2) 
that would contain the targeted self-management behaviours (Level One), and any 




Figure 2-2. Flowchart of basic IBD-Tracker sections for inclusion in the wireframe.  
Sections highlighted in red represent the tiers of the proposed app pages. 
 
 
This flowchart was then transformed in to the first homepage in the wireframe using 











The Level One sections tabs in this homepage would then lead on to the Level Two 
pages – these could be a new menu page if there was more than one metric being 
measured, or a targeted page if it was the only metric in that section. The Level Two 
pages were all designed to have identical action buttons that would allow the user to 
view a separate instruction page for that section, return to the homepage, to cancel 
the data they had input, or go back to the previous page they visited. An example of a 
Level Two page is for measuring stool metrics (Figure 2-4), which shows the 






Figure 2-4. Example of a Level two page from the IBD-Tracker wireframe. 




Pages were included that would contain interactive content such as recording pain 
location and severity, and goal setting for the amount of drinks to be consumed each 





Figure 2-5. Interactive Level Two wireframe pages for recording pain and nutrition. 
 
A number of pages also required integration with the calendar function on the users’ 
mobile device to be able to set reminders for drugs and appointments (Figure 2-6). 
The drugs and appointments entered in these pages would then populate separate 
lists so users could keep track of their current drugs, or upcoming appointments.  






Static pages were also included for sections such as the learning area where a menu 
list would direct users to the pages they wished to read (Figure 2-7). 
Figure 2-7. Wireframe static pages 
 
 
When all pages had been designed from the Level One and Two menus (including 
instruction pages), the active connections were made between each action button, 
page and feature in Mockplus™. When the wireframe was complete this design was 
taken to the app development company to begin developing a minimal viable product 
to begin testing and getting user feedback.  
2.7 Phase 6 – Gather user feedback 
This phase of gathering user feedback was not able to be completed. It was outlined 
in the Preface that the app development company were unable to complete IBD-
Tracker in time for testing. It was considered whether to gather feedback from the 
target population using the very basic images used in the wireframe. However, it was 
thought that this would be detrimental to the process as their ability to assess the 
interactive components when viewed as static, black and white pictures may lead to 
negative feedback and subsequent disinterest in using the app. The decision was 




and working efficiently so children could visualise how they would use the app. 
However, few sections of IBD-Tracker were ever working simultaneously and 
efficiently due to the production problems, and therefore could not be shown to the 
target population with the purpose of gathering feedback on their functionality, 
aesthetics, or appeal. This phase will be implemented during the re-development of 
IBD-Tracker with an alternative software company.  
2.8 Phase 7 – Build minimal viable product 
For this phase of building the minimal viable product, the app development company 
began developing IBD-Tracker from the Mockplus™ wireframe design devised by the 
candidate. During the interviews carried out in Phase 1 (Section 2.2) a number of 
participants made suggestions regarding aesthetics and design features that would 
encourage, or discourage them from using the app. In addition to these end user 
preferences, the literature regarding design features for mHealth apps was searched 
to identify any further considerations that should be passed to the app development 
company. Developing mHealth apps for children requires focussed attention to 
particular factors such as health literacy, engagement, and usability 367. These 
features should be at the forefront of app design in order to maximise prolonged 
adherence to the intervention, thereby minimising the challenges users may face in 
trying to understand and act on the health information contained 367, 368. Apps should 
be designed with consideration to usefulness, and usability, and while design 
features have been recommended for web pages these challenges may also translate 
to mHealth apps that have smaller screens for content display, and tricky text-entry 
methods 367-369.  
A list of design requirements were therefore given to the app development company 
to ensure they adhered to the requirements for low health literacy users, as well as 
those requested by the interview participants 369-375: 
 Minimise screen clutter 
 Use well recognised icons and present consistently  
 Minimise use of contrasting colours 




 Minimise scrolling 
 Provide basic, clear instructions and navigation 
 Easy to read font with use of emphasising for links and headings 
The subsequent development of IBD-Tracker was an iterative process between the 
app development company and the candidate.  
2.8.1 Homepage 
The Level One menu from the wireframe was developed into a static set of headings 
that appeared on each page (Figure 2-8).  
Figure 2-8. Development of the wireframe homepage in to the IBD-Tracker design. 
 
 
This provided a more consistent navigation system and also allowed the candidate to 
develop a ‘Dashboard’ which aimed to provide users with a running summary of 




show their progress towards their daily targets. However, the dashboard was due to 
be the last page developed once all other app sections were stable and this was not 
completed at the time of thesis completion.  
2.8.2 Instructions 
A central set of pictorial instructions was accessed by users tapping on the ‘?’ icon in 
the homepage (Figure 2-9), and each separate page also had an individual set of 
instructions that was accessed in the same way.  
Figure 2-9. IBD-Tracker main instruction page.  




As in the wireframe, some of the target icons in the static menu directed the user to a 
further menu, such as can be seen for the ‘My Symptoms’, ‘My IBD’, and ‘Learning 
area’ sections (Figure 2-10). Within these menus’ users are then directed to the 





Figure 2-10. IBD-Tracker menus for navigation within the static icons  
 
2.8.4 Digital images 
The pages presented in the wireframe that contained images were adapted by the 
company’s digital designer who created original images to be used in IBD-Tracker. 
One such example was the page for ‘Sickness and Eating’ which contained a number 
of graphics in the wireframe, which were then developed according to the required 





Figure 2-11. Digital image creation from wireframe ideas to IBD-Tracker icons.  
 
 
2.8.5 Interactive pages 
A number of pages also contained interactive features, such as the pages for 
recording pain, and the number of drinks consumed each day. The pain page 
required users to select whether they had pain or not and this choice determined 






Figure 2-12. Series of IBD-Tracker pages where users record their pain.  
 
 
The page where users entered a daily goal for their drinks (water, enteral nutrition, 
or other liquids) also contained an interactive function whereby users added the 
amount of liquid they had most recently consumed and the outline image of a body 





Figure 2-13. IBD-Tracker page where users record their drinks target and amount 
consumed.  
 
2.8.6 Recording stool metrics 
For users to record information relating to their stool output (time of day, 
consistency, urgency and blood), the metrics used in IBDnow (as presented in 
Chapter Eight), were adapted for this mHealth platform (Figure 2-14). This ensured 
that this data collection format was a valid and reliable way for children to self-
report their symptoms and could be utilised as a communication tool with the MDT. 
In order for all measurement categories to be included users were required to scroll 





Figure 2-14. IBD-Tracker page for recording stool output using an adapted version of 
IBDnow. 
 
2.8.7 Reminder functions 
For those pages that required integration with the calendar function on the user’s 
mobile device, the process of setting up reminders and appointments was kept as 
simple as possible. The page for creating drug reminders (Figure 2-15) required 
users to select the name, amount, and times of each drug. This would automatically 
set up the reminders for them at their specified times and would also populate a list 





Figure 2-15. IBD-Tracker drug list and reminders set-up. 
 
The drug reminders appear at the times chosen and require action to be taken by the 
user for them to disappear (Figure 2-16). Users had to indicate if they had taken the 





Figure 2-16. IBD-Tracker drug reminder page, and appearance in phone notifications. 
 
The method for setting up reminders for infusions/injections (Figure 2-17) and 
appointments (Figure 2-18) was slightly different than for drugs, but only a small 
number of steps were required to set up reminders and populate their ongoing list. 
The reminders that appeared for infusions/injections and appointments were simple 











Figure 2-18. IBD-Tracker page for setting up appointments. 
 
2.8.8 History pages 
The section where users could view their historical data was designed so that any 
section where users entered information (excluding the health passport) could have 
data reviewed for between seven days and three months (Figure 2-19). The history 
page was not yet complete at the time of last contact with the app development 
company and further edits were required. As an example, the radio buttons were 





Figure 2-19. IBD-Tracker history selection page. 
 
The pages for reviewing data entered for pain and stool metrics are shown (Figure 2-
20) to provide an overview of how data was to be displayed. These images are 
elongated as they required some scrolling to view all data together, and clearly, so 





Figure 2-20. IBD-Tracker history ages displaying pain and stool data. 
 
This minimal viable product was not completed, as discussed, but the theoretical 
background to the following stage of usability and pilot testing had been established 
in preparation. 
2.9 Phase 8 – Pilot potential usability and efficacy 
2.9.1 Introduction  
This phase of performing pilot testing on IBD-Tracker will be carried out in a number 
of ways. Assessments of usability were to be made using a number of methods so as 
to gather feedback from experts in a number of fields, as well as from the target 
population. The following section outlines the different methods developed for 






2.9.2 Usability overview 
It was established in this chapter that mobile devices have presented new 
opportunities and challenges in the management of chronic disease. Such advances in 
healthcare technology have also prompted the development of new methods of user 
experience evaluation to assess the appropriateness of mobile applications for users 
against the core constructs of accessibility and usability 376. The most relevant and 
inclusive definition of usability was given by Shackel in 1991 (p24) 377 who stated 
that it was:  
“The capability in human functional terms to be used easily and effectively by 
the specified range of users, given specified training and user support, to fulfil 
the specified range of tasks, within the specified range of environmental 
scenarios.”. 
This definition states that usability depends upon the dynamic interplay of the four 
components of the user, task, tool, and environment 377. In the context of the IBD-
Tracker app, the specificity of the core components are as follows: 
 Users: children with IBD  
 Task: learning self-management of their chronic disease 
 Tool: mHealth app technology 
 Environment:  their normal home and school surroundings 
Given the importance of maintaining integration between these components in a 
mHealth app it was decided that a number of usability evaluation methods should be 
employed. This would enable the triangulation of results in order to optimise 
usability for the target population 378. While objective measures of usability were 
crucial to determine whether IBD-Tracker works in the way it was intended, 
subjective measures of the user experience are equally important as they express the 
users’ perceptions, expectations, and satisfaction with the system. Objective and 
subjective usability should be measured in markedly different ways and the 





Objective measures  
Usability heuristic evaluations: Inspection methods that help to identify problems in 
the user interface design. This testing should be done by experts in the field of IT and 
usability. 
Usability content evaluations: To evaluate information accuracy, and the degree to 
which instrument elements are relevant and appropriate for the target population. 
This testing should be done by experts in the subject matter. 
Subjective measures  
Usability satisfaction evaluations: The target users’ perception of usefulness, ease of 
use, enjoyment, and satisfaction. This testing should be done by the users of the 
technology. 
 
Having identified the types of usability testing to be carried out, a literature review 
was undertaken to identify whether appropriate tools were available for each 
specific measure, as orientated to the specifics of this IBD-Tracker research.  
 
2.9.2.1 Usability heuristic evaluations 
‘Usability heuristics’ refer to a methodology that experts use to investigate ease of 
use for a system or prototype by comparing its features and functionality against an 
established set of guidelines (the heuristics) 379, 380. The engagement of users to an 
app that lacks essential operational features, and is unaligned to the consumer’s 
requirements, can result in declined usage 381. Conversely, a user who finds mHealth 
technology easy to use will generally perceive it to be useful as well 382. Researchers 
have shown that heuristic usability problems are among the most significant barriers 
to adoption of health technology, and they can negatively affect user’s decision 
making, time management, and productivity. This can lead to fatigue and confusion 
for the user, potentially leading to rejection of the system 383. Developing mHealth 
apps for children also requires focussed attention to health literacy factors as any 
difficulty understanding and acting on health information may be compounded by 




methods, and poor instruction 367, 368. The heuristic usability testing of IBD-Tracker 
therefore required a comprehensive assessment tool that could capture metrics 
specific to the target population. 
Heuristic evaluation tools 
Finding evaluation methodologies for usability that are appropriate to the specificity 
of a project and its’ population is challenging 376. The concept of formal usability 
testing was developed in the 1990’s by Jakob Nielsen who designed a set of ten 
usability rules for the assessment of interaction design 375. Nielsen’s ten generic 
heuristics remain the most popular, however they were not designed for testing 
prototypes on modern mobile devices and are not user specific, focus mainly on 
software components, and neglect the content and presentation issues vital for users 
with low health literacy 368, 384.  
 
A literature search was therefore undertaken to identify heuristic evaluation tools 
specific to mobile technology. The first tool by Bertini 373 was based on Nielsen’s ten 
heuristics but became too broad in its definitions, no longer providing adequate 
guidance to evaluators on how they should categorise issues 384. Two further tools 
expanded on the original ten heuristics 372, 374 but became overly complex with up to 
230 sub-heuristics, thus becoming too specific 384. One instrument developed for 
medical apps 369 lacked the depth of Nielsen’s and focussed predominantly on display 
factors. A further tool based on health literacy guidelines 368, 371 lacked other 
components and the authors suggest it would benefit from being complemented with 
other assessments to provide a more comprehensive set of principles. One 
instrument developed specifically for mHealth interventions 385 drew on existing 
evidence and rating scales that were largely related to website quality, not all of 
which were health related, and the guidelines were rigidly structured and did not 
allow for subjective assessment that may identify issues outside their framework. 
The final identified tool was written for chronic disease self-management mHealth 
apps 381 which was based on the previous tool, a theoretical framework, and Nielsen’s 




structure once again did not allow the assessor to identify issues outside this 
framework.  
Evaluation tool development 
Despite the body of research identified, none of the existing evaluation tools 
adequately captured the unique usability dimensions required for the heuristic 
evaluation of IBD-Tracker. However, when the domains and heuristics of all the 
evaluation tools were amalgamated there was a strong convergence of themes. It was 
decided to identify those key components relevant to the study contexts (user, task, 
tool, and environment) from each tool and synthesise them into a unique evaluation 
model. The categories of Nielsen’s original ten heuristics were preserved, then the 
individual components of each reviewed tool were categorised according to these, 
thus providing a recognised and validated framework against which to categorise the 
combined components.  
The amalgamated heuristics were systematically assessed to remove duplicate 
concepts, items were removed if they were not suitable for the target population, 
environment, technology, or tasks. The resulting heuristic assessment tool, and the 
corresponding references (Table 2.5) formed the basis of the heuristic evaluation of 
IBD-Tracker. This assessment was to be carried out by IT experts recruited 
specifically for the task. The methodology for implementing the assessment is 








Table 2.5. Heuristic usability guidelines for the evaluation of IBD-Tracker. 
 
 Heuristic Description References 
1 System status Users can always see their system information (battery, network, 
notifications). 
373-375 
2 Match to real 
world 
Content is written in plain language, using iconography and 
symbols that are globally understood.  
Topics are presented in clear, meaningful, logically ordered 
categories/lists with concise, easy to read content.  
369-371, 373-375 
3 User control 
and freedom 
There are basic, clear navigation controls. 
Actions and data entry are confirmed with meaningful feedback 
to acknowledge activity. 
369-371, 374, 375 
4 Consistency Intuitive, logical, and consistent mapping means that learning 
how one task works helps understand others.  
369, 370, 373, 375 
5 Error 
prevention 
Errors are minimized by avoiding small touch areas, crowded 




Elements for a task are grouped on a single page, reducing the 
need to memorise actions between screens.  
Instructions list concise logical steps and are consistent, task 
focused, in small portions, and easy to find. 
369-371, 373-375 
7 Efficiency The number of steps needed to complete a task are kept to a 
minimum. 
The user interface is simple and includes suggestions, buttons, 
menus, and pre-defined values. 
User interaction is simple with navigation controls in easy thumb 










Table 2.5 continued 
 Heuristic Description References 
8 Aesthetic The design works within mobile limitations (no hover text, 
adapted to small display, minimal scrolling). 
Screens have data as the main focus and do not contain unused 
clutter.  
There is consistency in design style throughout. 
369-375 
9 Recover from 
errors 
Error warnings provide simple alerts to identify incomplete or 
unsaved data entry.   





Colours are used sparingly but appropriately to enhance 
information, interaction, tasks, and user experience.  
Layout allows intuitive eye scans, and screens avoid visual 
breaks that force a focus shift between areas.  
The font is easy to read and enhanced to communicate meaning, 
context and interactivity.  




2.9.2.2 Usability content evaluations 
The majority of the tools available for objective usability heuristic evaluations fail to 
assess the quality, accuracy, and appropriateness of the health information contained 
in the intervention 385. While the static information provided in IBD-Tracker is based 
on evidence-based clinical tools and guidelines, assessing the validity of the content 
and BCT components is vital as information inaccuracies or incorrect component 
intervention activities could compromise user health and safety 385, 386. Content 
validity was defined by Haynes et al (p238) 387 as: 
“The degree to which elements of an assessment instrument are relevant to and 
representative of the targeted construct for a particular assessment purpose.” 
Formal assessment of content validity can ensure that the processes of the tool 
match the underlying program and behaviour change theory they are trying to 
implement 386 and this methodology has previously been used in Chapter Ten to 
assess the content of IBD-STAR. To summarise, the three core dimensions of content 
validity in the context of behaviour change mHealth interventions 386 are as follows;  
 Relevance – the extent it is pertinent to the intended intervention  
 Likely effectiveness – would it successfully modify the intended intervention 
target 
 Appropriateness for a specific audience – age, culture, development level 
IBD-Tracker should therefore be assessed by a number of clinical experts to 
determine if specific intervention components are likely to achieve the behaviour 
change, they are intended for. A specific evaluation tool was developed using the 
Kassam-Adams et al 386 framework.  
Evaluation tool development 
The first step was to select specific BCT intervention targets from IBD-Tracker and 
pair them with the skills acquisition activities of the app component intended to 
prompt that self-management behaviour. A number of self-management frameworks 
were identified in the literature that guided development of these target-activity 
pairings, all of which are related to distal and proximal outcomes of overall self-




tool (Table 2.6), all of which were to be assessed for their relevance, effectiveness, 
and appropriateness by a number of clinical experts. The methodology for 
implementing the content validity assessment is outlined later in this chapter 
(Section 2.9.2.4). 
2.9.2.3 Usability subjective measures  
Satisfaction 
In the context of subjective usability, ‘satisfaction’ refers to the satisfaction a user 
may experience when using a system 369. While as a measure it is highly subjective, 
the use of questionnaires and attitude scales to measure satisfaction can provide 
good insight into problems or issues users may have with a system 369, 388. The most 
reliable and extensively validated tool is the System Usability Scale (SUS), which was 
developed in 1986 by John Brook 388. The SUS has become the most popular 
questionnaire for end-of-test subjective assessments of usability satisfaction and has 
been utilised extensively across a multitude of entities such as websites, textbooks, 
and mobile apps 389. The SUS is a simple, ten-item scale giving a global view of 
subjective assessments of usability and was considered to be in an acceptable format 
for measuring user satisfaction of IBD-Tracker 388. However, no evidence was found 
of the SUS having been used in the paediatric population. In order to ensure the tool 
was appropriately worded for the study participants, the readability of the SUS was 
reviewed. The readability level of SUS was calculated using the Flesch-Kincaid 
readability calculation tool in Microsoft Word™ (methodology previously outlined in 
Chapter Three, section 3.2.3) as having a required reading age of eleven years. The 
intended users of IBD-Tracker were to be ten years and over, so the reading level 
was considered too complex for our users. While ensuring the format of the SUS was 
maintained, whereby odd-numbered items were worded positively and even-








Table 2.6. Content validity index assessment tool - target-activity pairings. 
Activity 
IBD-tracker 





Learn to monitor and manage 
symptoms. Maintain a health record. 
User enters their current state for pain, stool, 
well-being, appetite and ‘other symptoms’ in 
real-time. 
50, 107, 200, 
390-396  
2 My Drugs Learning behaviours to improve 
treatment adherence. 
User enters their current drugs (name, dose, 
frequency) and can record adherence in the 
reminder 
50, 107, 200, 
390-396    
3 My 
Reminders 
Learn to independently complete 
health tasks. 
Set reminders for appointments, tests and 
supplies 
50, 392, 395, 396    
4 My Drinks Goal setting, tracking treatment 
adherence, keep up with changes. 
Set a daily target amount and add drinks as 
consumed. Monitor progress. Target can be 
changed. 
50, 107, 200, 
390-393, 395, 
396   
5 My Growth Self-monitoring of health status and 
goal setting. 
Input weight and height measurements. 107, 200, 390, 
393, 395, 396 
6 My History Learn to interpret and report 
symptoms correctly. Use to 
communicate effectively with the 
health care team. 
Review symptoms, adherence to drugs, and 
growth. 
50, 390, 393, 394, 
396 
7 Dashboard Learn to interpret symptoms 
correctly. Self-monitoring of health 
status. 
Users review their most recent symptoms, 
upcoming drugs and appointments 
50, 107, 200, 390, 
391, 393-396 
8 My Triggers Learn to understand their condition. 
Modify behaviours to improve 
symptoms. Use to communicate with 
health team. 
Enter IBD triggers to populate an editable 
list. 











Table 2.6 continued 
Activity 
IBD-tracker 
section Intervention target Skills activity 
References in  
support 
9 My Health 
Passport 
Create, use, and maintain a portable 
health summary. Use to 
communicate with health team. 
Fill in details and keep up to date in case of 
emergencies away from carer. 
50, 107, 200, 392, 395, 
396 
10 When to Get 
Help 
Learn to assess symptom severity. 
Understand when to seek help from 
the healthcare team. 
Access the ‘When to get help’ section when 
experiencing an exacerbation of symptoms. 




Learn to understand their condition. 
Independently seek health 
information. 
Access the learning area to better understand 
disease and treatment. 





The new readability score was calculated with a reading age of seven to eight years, a 
level deemed more appropriate for our intended users, and the five item Likert 
scoring scale remained the same as in the original. 
The ten items of the revised SUS scale are as follows: 
1. I would like to use this app all the time. 
2. I found the app too complicated. 
3. I thought the app was easy to use. 
4. I think I need some technical help to be able to use the app. 
5. I found the different functions of the app were well combined. 
6. I thought there was too much variation in the app. 
7. I think most children could learn to use the app very quickly. 
8. I found the app very slow to use. 
9. I felt confident using the app. 
10. I had to learn a lot before I could start using the app. 
A second sample questionnaire was also devised that enabled the inclusion of 
questions more directly related to IBD-Tracker and its users. This was to align 
specifically with the study goals of engagement and was to gauge user preference 
and experience of the app as a whole, and of individual sections. These questions 
were not designed to constitute a scientifically reliable tool, but as a simple means of 
collecting structured, subjective responses from participants 369. It was 
acknowledged a priori that there would be no official means of scoring user 
responses to these questions, and that they represented face-value impressions 369. 
This satisfaction questionnaire is included in Appendix C. The methodology for 
implementing these subjective assessments is included in this chapter in Section 
2.9.2.4. 
2.9.2.4 Methodology for implementing usability evaluations 
The methodology for implementing the three measures of usability were markedly 





Objective usability measures 
The two objective measures of usability; heuristics and content validity, were to be 
assessed by two different sets of experts measuring two significantly different 
concepts. However, it was considered that providing a structured uniform approach 
to both sets of assessors for accessing the app and performing tasks would be 
beneficial to both them and the researchers. IBD-Tracker was to be provided to all 
assessors with app data ‘pre-loaded’ which was considered essential for both 
objective usability tests in order for all the features to be reviewed, and the usability 
and functionality to be assessed 381. In addition, assessors were given a set of 
scenario based, realistic data to enter for each section as a series of tasks, which 
allowed for the usability to be assessed under pragmatic conditions 369. This method 
of task orientated usability testing is known as Cognitive Walkthrough (CW) and was 
devised by Polson et al 397. During the CW process the reviewers step through the 
actions of the users, consider the behaviour of the interface and its effect on the user, 
and attempt to identify actions that would be difficult for the proposed user 
population to choose or to execute 397. This method has been shown to identify more 
issues with the interface and system than heuristic evaluation alone 383, 398. The CW 
tasks are included in Appendix D. 
Usability heuristic evaluation method 
Usability heuristics require no more than five experts to carry out an evaluation 
inspection as it is considered that this number will capture most flaws 399. Experts in 
the field of Information Technology (IT) had been recruited from Otago University to 
evaluate IBD-Tracker upon its completion, including two IT PhD students who had 
carried out mHealth heuristic usability testing for their theses. All testers were to be 
given a set of instructions for download and login which would provide them with 
the IBD-Tracker app, all with identical pre-loaded dummy profile data. Assessors 
were also to be given details of the assessment format, the CW tasks, and a link that 
would take them to an online form facility (Cognito Forms). While using the app and 
completing the CW tasks the experts could identify problems and use the online form 
to categorise the heuristic breach according to Table 2.5, then score the violation 
according to Nielsen’s five-point Severity Ranking Scale (SRS) 400 which ranks 




problem at all’ to 5 which equates to ‘Usability catastrophe: imperative to fix this 
before product can be released’. The heuristic evaluation form is included in 
Appendix E. 
Content validity evaluation method 
The content validity assessment requires the recruitment of eight to twelve clinical 
experts who have relevant content knowledge, with some disciplinary and 
geographic diversity across the reviewers to provide balance 386. All experts were to 
be given the same set of instructions for download, login, and CW tasks. All were to 
be given an explanatory document with instructions on how to score the activity-
target pairings for relevance, effectiveness, and appropriateness. A link was to be 
provided to an online form facility to complete their content evaluation and submit 
their results. The content validity evaluation form is included in Appendix F. 
Subjective usability measures 
The subjective satisfaction questionnaires were to be distributed to end-users as a 
post-test outcome measure to all study participants at the end of the pilot study 
(design in section 2.9.3) and the RCT study outlined in Phase Nine (section 2.10).  
2.9.3 Pilot study design 
 A pilot study of IBD-Tracker was to be implemented in the target population in order 
to assess the safety and feasibility of the app 401. This was to evaluate recruitment 
potential, the respondent burden of the outcome measures, and to identify any initial 
usability and data download concerns. A pilot study would increase the expertise of 
the candidate for assessing the back-end data being developed by IBD-Tracker and 
would refine the content and frequency of PUSH notifications to be sent to users.  
Twelve participants were to be recruited for the pilot study, and IBD-Tracker 
distributed to them immediately after baseline data collection (baseline data and 
outcome measures are included in Phase nine study design methodology). The 
cohort would use IBD-Tracker for six weeks to assess feasibility, and the outcome 
measures would be repeated at study end, with the addition of the SUS usability 




The results of the usability studies, and pilot study, would identify any app specific 
issues that needed to be addressed prior to commencing the main efficacy trial. The 
results of the pilot study would also highlight any changes required to the 
implementation of outcome measures that may have been identified in the pilot 
study, such as respondent burden. 
2.10 Phase 9 – Evaluate efficacy with a RCT 
For the evaluation of a mHealth intervention such as IBD-Tracker there is no 
consensus on the preferred process of evaluation from among the spectrum of 
available methodologies 402. At this near-end stage of IBD-Tracker development, 
when a pilot study will have been performed to establish safety and feasibility, it was 
essential to determine the method most appropriate for establishing efficacy 402. The 
use of a randomised controlled trial (RCT) provides the most rigorous method for 
establishing efficacy 403 and the RCT design can be adapted in a number of ways to 
suit the evaluation of mHealth interventions and their intended outcomes. Using a 
traditional parallel RCT method would lead to the exclusion of a proportion of the 
study cohort while the study was carried out. As efficacy would not yet have been 
established this design could be considered ethical and appropriate. However in the 
case of interventions such as IBD-Tracker, where it is predicted that the intervention 
can do more good than harm, with minimal chance of safety or risk implications, an 
RCT design that distributes the intervention to all participants would be preferable 
404, 405. The stepped wedge RCT is a variant of the cluster design whereby all 
participants are randomised to groups that have the intervention sequentially rolled 
out to them at a set time following a control phase of data collection 404-406. This 
method still contains randomisation, therefore increasing internal validity 407. 
Horizontal comparisons can then be made between the groups based on their 
outcome measure results prior to exposure to the intervention, and following 
prolonged use 407.  
It was considered that this stepped wedge RCT design would be beneficial for the 
evaluation of IBD-Tracker as they are shown to improve recruitment rates if all 






Inclusion criteria  
Children over the age of ten years with a confirmed diagnosis of IBD.  
Exclusion criteria 
Children who did not own, or have consistent access to, a mobile phone or tablet 
device. Children whose parents were not happy for them to have increased exposure 
to their mobile phone or tablet device. 
2.10.2 Outcome measures 
Baseline demographic and disease history data will be collected on all participants. 
The following outcome measures will be implemented at baseline, at the end of the 
control data collection phase prior to receiving IBD-Tracker, and at the end of the 
IBD-Tracker study: 
 Knowledge: IBD-KID2 (Development in Chapters Three to Seven) 
 Self-management skills: IBD-STAR (Development in Chapter Nine) 
 Symptoms: IBDnow (Development in Chapter Eight) 
 Adherence: VAS (Discussed in Chapter One, Section 1.7.5) 
 HRQoL measure: KidScreen10 409, 410. 
 Health literacy: NVS (Discussed in Chapter One, Section 1.7.2) 
Adherence and disease activity (using IBDnow) will be measured every two weeks 
during the control phase, and every four weeks during the intervention phase. 
During the intervention phase data will be collected from the IBD-Tracker database 
on app usage (overall, and individual sections used).  
At the end of the study a quantitative and qualitative user satisfaction survey will be 
completed by all participants to report usefulness, perceived efficacy, usability, 





Randomisation will take the form of random size block allocation which will ensure 
equal numbers of participants in each group and reduce the chance of group 
allocation predictability. This process will be performed by a statistical analysis 
computer programme. The nature of the trial dictates that it will be open-label 
randomisation. 
Once recruited to the study, participants will undergo randomisation in order to 
assign them to one of three treatment groups. All three groups will undergo a period 
of control data collection. IBD-Tracker will then be introduced at three different time 
periods after baseline, depending on the group that participants have been 
randomised to: three weeks, five weeks, and seven weeks after baseline data 
collection. All groups will be exposed to the intervention for twenty-four weeks.  
2.10.4 Sample size 
The power calculation for this study was based on the primary outcome, the change 
in self-management skills, as measured using IBD-STAR. The study in Chapter Ten 
provided a mean participant score for IBD-STAR of twenty-seven with a standard 
deviation of six. Without prior data to inform the power calculation for the change in 
IBD-STAR, we estimate the standard deviation of the change will be approximately 
six (the same as the cross-sectional measure) and that a minimum clinically relevant 
change in IBD-STAR scores would be no less than three. To show a difference 
between the IBD-Tracker intervention and the waitlist of three points or more (a 
10% change, equating to a within-subject effect size of 0.5) as statistically significant 
(using a two-tailed test with significance set at 0.05), with 80 % power would require 















2.10.5 RCT Discussion 
This trial design using a stepped wedge RCT to assess efficacy of IBD-Tracker aimed 
to address the limitations of other RCT designs that exclude participants from 
receiving the intervention, thereby maximising recruitment.  
2.10.5.1 Limitations 
The use of a stepped wedge RCT may lead to the completion of outcome measures at 
extra time points than in traditional parallel RCT’s, which represents a greater 
burden for study participants. However, the previous studies presented in this body 
of work have utilised electronic forms for collecting outcome measure data, a system 
which has been shown to elicit a good response rate and be an acceptable alternative 
to distributing paper copies. This method of data collection aims to reduce the 
respondent burden by making completion quick, easy, and convenient. 
Due to variable lengths of the control phase for each group, prolonged engagement 
will be required by the group receiving IBD-Tracker at five and seven weeks post-
baseline 404. This may be achieved using incentives, a method which would be 
considered ethically appropriate as they would be used to encourage them to wait 
for IBD-Tracker, not to improve engagement to the app, and would not be used in a 
coercive manner 411.  
2.10.5.2 Strengths 
The use of stepped wedge RCT’s has become more widespread and as such there now 
a set of Consolidated Standard of Reporting Trials (CONSORT) recommendations for 
reporting the results of studies utilising this trial design 412. This will provide 
guidance for the reporting of this efficacy research which can be done in conjunction 
with the CONSORT recommendations for mHealth technology interventions that 
include standards for disseminating the design, engagement, usability, and dropout 





2.10.5.3 RCT Conclusion 
When IBD-Tracker does get completed there is now an established methodology for 
testing the app to measure efficacy against a number of outcome measures with 
proven validity, as established in this body of work.  
2.11 Phase 10 – Share intervention and findings 
This phase was unable to be completed due to the issues previously explained in the 
Preface. However, dissemination of the results of the design, development, and 
efficacy trial will be guided by the CONSORT guidelines for stepped wedge RCT’s and 
mHealth technologies 412, 413.  
2.12 Chapter Discussion 
The application of the IDEAS framework allowed for a rigorous and staged approach 
to the development of IBD-Tracker. The thoughtful and realistic input of target users 
provided direction for the intervention plan. These ideas were then translated into 
product features and content that had been identified as being able to deliver optimal 
outcomes to meet target behaviour objectives in the most effective means possible, 
with the goal of a highly engaging user experience 252. The inclusion of iterative 
testing methods will ensure that the design is progressively refined before 
embarking on a full scale evaluation 357.  
In addition to the design and development of IBD-Tracker, extensive work has been 
carried out with the University of Otago IT Department to ensure that the data 
download storage was HIPAA compliant. HIPAA compliance is legislation that 
provides data confidentiality and security for safeguarding all individually 
identifiable medical information 414. This ensured that the back-end data produced 
by IBD-Tracker was secure and inaccessible by anyone except the candidate. 
Information on data security was included in the initial log in area of IBD-Tracker to 
provide users with confidence regarding the security of the information they added 





It is not possible to speculate on the level of user engagement that may be exhibited 
to IBD-Tracker. Many mHealth interventions face challenges around declining 
retention rates, and the rapid pace of evolution of technology development makes it 
difficult for researchers to develop, pilot-test, and evaluate such interventions before 
the technologies become outdated or obsolete 317. The significant delays experienced 
during the development of IBD-Tracker may mean that the features contained in this 
design of the app will have been out-paced with innovative new ideas. However, any 
new software development company contracted to re-develop the app will be given 
free rein to upgrade the page designs with elements they consider fitting given the 
contemporary mobile technology climate. 
Dissemination of the results of the development and evaluation phases of IBD-
Tracker will be crucial if digital health interventions overall are to fulfil their 
potential 317. Those apps that are publicly or commercially available for the IBD 
population are frequently not evidence based and lack theoretical backgrounds, 
however those that have been developed in the clinical sphere are frequently not 
reported on sufficiently. IBD-Tracker has been designed and developed with rigour 
using a transparent methodology, however problems were still experienced, and it is 
important that pitfalls as well as successes are reported to help refine the approach 
for future researchers in this area. 
2.12.1 Chapter Conclusion 
It was not possible to prove or disprove the hypothesis presented for this chapter as 
IBD-Tracker was not completed prior to thesis submission. However, the design and 
development process, including the multi-level evaluation stage, has established the 
framework for IBD-Tracker to be re-developed and evaluated in the target 
population in a way that should provide clarity regarding this matter.  
The original aim of this thesis was to develop and test IBD-Tracker. Due to the 
prohibitive delays by the app development company in getting IBD-Tracker 
completed, the thesis was not able to be written as intended. The focus therefore 
became to address the lack of self-management outcome measures, as outlined in 




tools presented in the following sections, validated measures are now available to 
test the efficacy of self-management interventions, such as IBD-Tracker. When IBD-
Tracker is re-developed and the results disseminated, the aim is to pave the way for 
similar mHealth self-management interventions for other chronic disease groups in 






SECTION TWO: Introduction 
As was established in Chapter one, disease and treatment knowledge is an integral 
component for the development of self-management skills for children with IBD. 
Conversely, disease management may be adversely affected by gaps or 
misconceptions in understanding 261, 262. The most efficient way to measure 
knowledge levels is to use an assessment tool that is appropriate for the target 
population. As previously outlined (Chapter 1.7.2.1), Haaland et al 12 developed IBD-
KID in 2013 – an IBD disease and treatment questionnaire aimed at children aged ten 
years and over with IBD (Appendix G).  
When IBD-KID was reviewed for use as an outcome measure to assess the efficacy of 
self-management interventions, it was determined that there was a degree of 
complexity to a number of the individual items. Given the age range of the IBD-KID 
target population it was considered that these complex items may negatively affect 
participant responses by eliciting inaccurate answers due to lack of comprehension 
and reading skills, rather than a lack of knowledge. It was, therefore, considered 
pertinent to evaluate IBD-KID statistically to assess its suitability for the target 
population of children with IBD. 
The following section is comprised of sequential studies that test IBD-KID against a 
number of quantitative metrics. The series begins with a review of IBD-KID using an 
item response analysis of completed IBD-KID assessments, which highlights a 
number of areas where the evaluation tool could be improved. The subsequent 
development process of a revised tool (IBD-KID2) is then presented and this revised 
version is tested to establish validity, generalisability, feasibility, responsiveness, and 
reliability. In addition to establishing the strength of IBD-KID2, the series of studies 
attempted to delineate a hierarchy of IBD knowledge levels between different 






Chapter Three: IBD-KID Item Response Analysis  
3.1 Introduction  
The assessment tool IBD-KID was developed to evaluate disease and treatment 
knowledge in children with IBD 12, and it was considered for use as an outcome 
measure for the self-management intervention studies in Sections One and Five. As 
part of the review process to consider its suitability for the target population in this 
thesis, a search was performed for studies that had used the tool in order to assess its 
validity, feasibility and generalisability to the wider paediatric IBD population 12. The 
SCOPUS bibliographic database was accessed that showed the original development 
paper had been cited just eight times between 2014 and 2019. Three studies had 
used IBD-KID as an outcome measure and shown the tool to be valid, feasible, 
reliable and generalisable, as carried out by co-authors on the original paper 162, 163, 
415. Four other papers cited IBD-KID in transition guidelines for adolescents with IBD, 
and one paper criticized the tool when outlining the development of their own 
knowledge assessment tool. The paper criticizing IBD-KID stated that it was too long 
for clinical use and outdated161.  
Together, these aspects prompted a basic review of the content and structure of IBD-
KID to determine which items may have prompted the criticism. This revealed that 
the tool contained some complex items, and content that may require updating. 
Furthermore, researchers who carried out a study using IBD-KID at Otago University 
received feedback from a small number of participant’s parents who were critical of 
the content of some items in the tool. This constructive criticism, combined with the 
basic content review and poor uptake of the tool as an outcome measure, prompted 
an in-depth review of IBD-KID.  
This research has been published (Appendix H) 298.  
3.1.1 Item Response Theory 
Once an assessment tool such as IBD-KID has been developed, it is prudent to 
conduct item and test analyses to evaluate its quality and performance. When 




their actual disease and treatment knowledge, not due to their comprehension of the 
items or content, thereby leading to a misrepresentation of knowledge levels 416. For 
the purpose of reviewing IBD-KID, the Item Response Theory (IRT) methodology was 
used as it is a quantitative statistical approach to assessing performance of a tool 416. 
IRT uses actual participant responses to produce empirical data to determine 
whether IBD-KID items were scored incorrectly by children due to lack of knowledge, 
or to external factors. These factors could include critical components such as 417, 418: 
 difficulty of items 
 reading level of items 
 complexity of each multiple-choice question (MCQ) 
 efficiency of each MCQ 
 age appropriateness  
 item relevance   
 discriminatory ability of items 
IRT metrics can address these components using participant response patterns, 
either in relation to pre-determined values or external criteria, or in relation to the 
other items on the test 416, 419, 420.  
3.1.2 Aims and hypotheses 
The study aim was to determine whether any measurable factor of the individual 
items in IBD-KID, or of the test as a whole, could provide evidence for revision or 
elimination of outdated, ambiguous, complex, or misleading items. The first 
hypothesis to be explored in this chapter is: 
That the content and structure of IBD-KID have no effect on the response 
patterns of children with IBD who have completed the tool. 
In the event that this hypothesis is rejected following the participant response 
analysis, the results of the analysis will be used to revise IBD-KID and develop a new 
assessment tool that is more relevant and appropriate for the target population of 




3.2 Study Methods 
3.2.1 IBD-KID format 
IBD-KID is a twenty-three item questionnaire that is comprised of a brief set of 
instructions, followed by thirteen T/F items and ten MCQ’s, with all items also 
containing a ‘Don’t know’ (DK) option. Completed IBD-KID assessments are scored as 
each correct response being assigned one point, to a maximum total of twenty-three. 
The overall IBD-KID score is representative of the knowledge level of each individual 
respondent, and the correct or incorrect score of each item can identify knowledge 
gaps for individuals and across cohorts.  
3.2.2 Study data and participants 
The data from completed IBD-KID assessments were obtained from two independent 
cohorts of children with IBD recruited in Sydney, Australia 163 and Christchurch, New 
Zealand 415. Ethical approval for these studies was granted by the South East Sydney 
Area Health Service Research Ethics Committee and the New Zealand Health and 
Disability Research Ethics Committee respectively. Informed consent was obtained 
from the parents of all participants. In both studies, the inclusion criteria for the IBD-
KID component was of children aged ten years and over who had an established 
diagnosis of IBD.  
 
IBD-KID data from the two cohorts were combined and the item response analysis 
was carried out in Christchurch, New Zealand. The original study data were entered 
into a database in two formats; the actual answer provided by the participant, and 
whether this answer was correct or incorrect. This allowed for response patterns to 
be identified among the MCQ items, and to identify how many respondents answered 




3.2.3 Statistical methods: IRT metrics 
A number of IRT criteria were employed to assess the performance of IBD-KID and 
its individual items. The principal issues addressed were the validity, reliability, and 
feasibility of the tool, each of which used a number of statistical metrics.  
3.2.3.1 Validity 
The validity of a tool determines the degree to which it measures what is intended 
421, and it is important to clarify that it is not a property of the instrument, but of the 
instrument’s scores and their interpretations 422. IRT can examine a number of 
aspects of validity; construct validity, content validity and face validity 421.  
Construct validity  
Construct validity concerns the statistical indicators collected to describe the 
function of test items, such as measures of item discriminating power, item difficulty, 
or the number of alternative answer selections to MCQ’s 417.  
Discrimination index 
The discrimination index is an indicator of how well an item is able to distinguish 
between respondents who scored well on the test overall, and those who did not. If 
the test, and the items it contains, are measuring the same concept then one would 
expect people who do well on the test overall to answer each item correctly, and 
those who do poorly to answer the item incorrectly 416, 423.  
In computing the discrimination index of IBD-KID, respondents were ranked in order 
of their total score, and the upper and lower 27% of the total were selected to serve 
as standard groups for the differentiation of test items 424. The figure of 27% is used 
as this has been shown to maximize differences in normal distributions while 
providing sufficient cases for analysis 416. Item scores of the lower group (L) were 
then subtracted from the upper group (H) and divided by the number per group (N) 
using the formula 
𝐻−𝐿
𝑁
 419, 424. A discrimination score of ≤0.19 is considered a poor 
discriminator of knowledge, 0.2-0.29 marginal, and ≥0.3 acceptable 425, 426.  
For the purpose of this review, the scores were further categorised to consider those 




discriminatory ability is often caused by items being too hard or too easy whereby 
items fail to discriminate between good and poor responders and add nothing to a 
test 419, 426. 
Difficulty index 
The item difficulty index represents the proportion of respondents who answered 
each item correctly. Item difficulty has a profound effect on both the variability of 
test scores and the precision with which test scores discriminate among different 
groups of respondents 416. When all test items are difficult the majority of scores will 
be low, and vice versa, and test scores will show very little variability 416. The 
difficulty index was calculated by dividing the number of correct answers to each 
IBD-KID item (n) by the total number of participants who completed the tool (N) 
using the formula  
𝑛
𝑁
 . The ideal index of difficulty ranges across the literature. The 
original IBD-KID development article 12 referred to early work by Hubbard 419 with 
an upper limit of 0.75 (easiest = 1.0). Early work by Lord 427 determined that the 
ideal upper level of difficulty for a four-response multiple choice item is 0.74. Recent 
literature has used the upper and lower limits of 0.3-0.7 425, 428-430, with the 
recommendation that items outside this range be revised or discarded. For this 
review, the reference range of 0.3-0.7 was used.  
Distractor efficiency 
The distractor efficiency (DE) examines the functionality of the alternative, incorrect 
answers provided for each MCQ. Efficient distractors may be plausible to those 
without the knowledge that the item is measuring, yet are clearly incorrect to those 
who possess the knowledge required for that MCQ 431. Therefore, a good distractor 
will be selected by those scoring low on the test and ignored by those who perform 
well 421, 432. The non-functioning distractors (NFD) of an MCQ have been defined as 
those items selected by less than 5% of responders 425, 433, 434. The combined DE score 
is determined by the number of distractors per item that are NFD.  
The DK answer option has not been included in the distractor analysis, but the 





Content validity pertains to the degree to which an instrument fully assesses or 
measures the construct of interest 435, and whether items can be considered relevant, 
appropriate and representative of the overall knowledge being tested 421. There is no 
objective method of measuring content validity but an expert panel is generally 
considered appropriate to provide judgement and to reach consensus decisions 421.  
Other considerations 
Individual items in an assessment tool should be designed to test one specific content 
element, and independent from one another to avoid one question providing cues for 
another 431. Item themes were reviewed to identify any cross-over topics. 
Face validity  
Face validity concerns the appearance of an assessment tool, and for IBD-KID this 
was predominantly related to the construction of the MCQ’s. MCQ’s consist of three 
parts: the question/statement, the correct answer, and a selection of incorrect 
answers – respectively called the stem, key and distractors 431. IBD-KID uses the 
‘correct answer format’ for its key and distractors, whereby there is only one right 
response 431. The selection of the correct/incorrect response for an MCQ is intended 
to mean that the participant has enough of the necessary knowledge to select the 
correct answer, or conversely that the person is deficient in some critical component 
417. In assessing face validity this review aimed to ensure that the critical component 
causing incorrect responses was lack of IBD knowledge, not lack of comprehension of 
a convoluted MCQ. The construction of MCQ’s themselves is complex, with the 
general consensus being that the more difficult the items, the less reliable the tool 
becomes 427, 432, 436.  
There are certain elements of MCQ construction that are known to have a negative 
effect on item difficulty and discrimination, and thus reliability 434. The following 
procedural guidelines, taken from Haladyna, Payne, Linn, and Lord 427, 432, 434, 436, 
were used to assess the construct of IBD-KID MCQ items:   
 The inclusion of 'none/all of the above' options has a negative effect on item 
and test characteristics making it 4.5% more difficult and less discriminating. 




 'Type K' items are multiple completion items with more than one correct 
response, where the respondent must choose the distractor with the correct 
combination. These include 'both of the above' type items whereby the 
discriminators are not mutually exclusive. These increase the difficulty of a 
test, are laborious to read, make a heavier cognitive demand on the 
respondent, and should be avoided. 
 The stem should contain the majority of the information and the distractors 
kept short. This reduces the complexity and reading time. 
 The inclusion of a 'don't know' option divides the literature but reduces the 
bias of guessing and avoids measurement error. It may also identify potential 
problems with the tool that can be addressed for revalidation.  
2.2.3.2 Reliability 
Internal consistency 
Reliability measurements of IBD-KID were performed to illustrate how well items 
complemented each other, and measured different aspects of the same variable, thus 
assessing the homogeneity of the test as a whole 437. Internal consistency is typically 
associated with the Cronbach’s alpha coefficient 438, but a distinct, equivalent, and 
comparable version of coefficient alpha is specific to dichotomous data; the Kuder 
Richardson 20 (KR20) 437. Reliability coefficient scores are an expression of the 
relationship between variability in test scores and range in value between zero and 
one, with a value closer to one indicating higher internal consistency; a value greater 
than 0.7 being classed acceptable 437.  
Inter-item correlation 
Further reliability analysis was performed using inter-item correlations (IIC), a test 
that assumes that items correlating well with the test overall should also correlate 
positively with each other 437. IIC scores are given for each item and represent what 
the overall KR-20 score would increase, or decrease, to if that item was removed 




2.2.3.3 Feasibility  
The feasibility of IBD-KID was related to the ease with which it could be completed 
by the participants and can include factors such as readability and ease of 
administration 421.  
Readability 
Reading comprehension assessments determine the readability level a text should 
have for a reader to understand the written material. The Flesch-Kincaid reading 
ease and grade level formulas are validated instruments that use word and sentence 
length to determine the readability of written materials 439, 440. The resulting score 
equates to age, and formal years of schooling, that a reader requires to understand 
the tested sample 440. The readability of IBD-KID was measured with the Flesch-
Kincaid readability formula using the advanced proofing analysis tool in Microsoft 
Word™.  
The purpose of a knowledge assessment tool is to test knowledge, rather than the 
ability to read or translate what is written. The vocabulary used should, therefore, be 
simple enough to be understood by the weakest readers in the group and the amount 
of reading required should be minimised where possible 421, 431. The 
recommendations are that for low health literacy groups such as children, health 
care literature should be written at or below a grade five (age ten years) reading 
level 440. By keeping vocabulary appropriate and simple, an item will be more 
efficient at discriminating between those with high and low knowledge levels, and 
will reduce the reading time 434, 441. 
 Data quality 
Data quality measures the number of items answered incorrectly, either by omitting 
the question or selecting more than one answer, and is a way of assessing the ease of 
completion by respondents 12. 
3.2.4 Expert panel review 
It is considered essential that a rational analysis of an instrument by a panel of 
experts familiar with the construct of interest is undertaken 435. An expert panel was 




IRT review could be accepted or rejected. The expert panel convened consisted of the 
candidate (Hurley), two Professors of Paediatric Gastroenterology (both developed 
IBD-KID originally), one Professor of Gastroenterology, and one Professor of 
Biostatistics. The IRT analysis results were reviewed by the panel and discussions 
were held both face to face and via video link to consider the original hypothesis, and 
then the appropriate course of action for each item in the event of the second 
hypothesis being actioned.  
3.3 Results  
3.3.1 Participants 
The two study cohorts provided data from 105 children (sixty-six from Christchurch, 
New Zealand, and thirty-nine from Sydney, Australia) who had completed IBD-KID. 
The participant response patterns to the twenty-three items in IBD-KID provided 
data for an in-depth critique of the performance of the assessment tool, which 
produced measures of validity, feasibility and reliability. Equal weight was given to 
all of these categories and the results and content of all twenty-three items went 
through a process of expert panel review.    
3.3.2 Validity 
3.3.2.1 Construct validity  
Difficulty and discrimination 
Twelve (52%) of the twenty-three IBD-KID items had a difficulty index in the 
acceptable range of 0.3-0.7 (mean 0.46, SD 0.23), indicating that these items were 
answered correctly. Eighteen (74%) items were good discriminators with a score of 
≥0.3 (mean 0.43, SD 0.15), indicating that these items were answered correctly by 
the highest scoring respondents, and incorrectly by the lowest scoring respondents. 
When represented graphically (Figure 3-1), the combined ideal range is represented 





Figure 3-1 Difficulty and discrimination levels of IBD-KID items. 
The ideal levels of difficulty and discrimination are represented by the shaded box, 
and the numbers next to each data point represent the IBD-KID item number. 
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The shaded area inside the dotted box (Figure 3-1) represents the combined 
acceptable levels for both difficulty and discrimination. Items outside the dotted box 
have either or both indices outside the acceptable range. The shaded area contains 
11/23 items, and when the difficulty and discrimination indices are considered in 
isolation from the other study measures, it could be assumed that these items have 
‘construct validity’.  However, when the results of all IRT analysis results were 
examined (Table 3.1), other factors were identified that may be problematic. The 
results in bold in Table 2.1 indicate scores that are outside the acceptable range and 
require review. Results in the DK column are highlighted to indicate that it was the 
highest scoring response. The IIC scores are highlighted to show those items that 
would increase the overall KR-20 score if they were removed.  
It can therefore be observed that of the numbered items previously highlighted in 
Figure 3-1, 7/11 (64%) had additional category results that were outside the 





3.3.2.2 Face validity and distractor efficiency 
Of the ten MCQ’s in IBD-KID, nine had elements in conflict with the previous 
guidelines (section 3.2.3.1), including combinations of 'none/all of the above' 
answers, type K items, or overly long distractors. These findings are reflected in the 
fact that overall 9/10 of the MCQ items had a DE score of less than 100% (Table 3.1), 
showing that these items contained NFD; distractors that were not being selected 
due to being unrealistic, complex or ambiguous alternatives to the correct answer. Of 
these nine items, four (44%) showed poor discriminatory ability, six (67%) had a 
‘hard’ difficulty index indicating that the question was answered incorrectly, and six 
(67%) had DK as the highest answer response. This suggested that these elements 
may be causing a level of complexity or ambiguity in the item distractors, and 
subsequently an inflated incorrect or DK response pattern. The structure of all 




Table 3.1. IRT results for each IBD-KID item 
Level of difficulty (P), discrimination (D), distractor efficiency (DE), ‘Don’t know’ 
response rate (DK), readability (R), and inter-item correlation (IIC) for each item. 
Item DE results that include this symbol * contained violation of the face validity 
guidelines. 
The MCQ answers are not included in this table.  
 
# Item original text. Format P D DE DK R IIC 
4 Doctors and 
scientists know 
what causes IBD. 
T/F 0.68 0.64 N/A 17% 78.8 .757 
6 IBD can affect 
organs other than 
the bowels. 
T/F 0.57 0.64 N/A 23% 71.8 .760 
8 IBD that is in 
remission can slow 
down a young 
person’s growth. 
T/F 0.45 0.39 N/A 15% 88.9 .764 
1 The large bowel is 
longer than the 
small bowel. 
T/F 0.51 0.71 N/A 17% 84.9 .755 
10 People with IBD 
don’t usually live as 
long as other people. 
T/F 0.67 0.5 N/A 28.5% 72.6 .765 





should stop taking 
the drug 
immediately. 
T/F 0.43 0.43 N/A 26% 38.1 .765 
19 A child whose 
parents both have 
IBD will eventually 
develop IBD. 






# Item original text. Format P D DE DK R IIC 
20 Removing certain 
foods from the diet 
(for instance milk) 
will prevent flare-
ups of IBD 
T/F 0.33 0.46 N/A 27% 65.7 .761 
9 People with IBD that 
has involved the 
colon for more than 
ten years will 
probably develop 
colon cancer. 
T/F 0.34 0.39 N/A 57% 61.6 .768 
2 From start to finish, 
the correct order of 
the digestive tract is: 
MCQ 0.49 0.5 33% 10.5% 74.8 .764 
7 Osteoporosis 
(weakening of 
bones) can be 
caused by: 
MCQ 0.34 0.54 66%* 29% 40 .761 
18 IBD tends to run in 
families. 
T/F 0.58 0.25 N/A 19% 87.9 .778 
5 Emotional stress can 
trigger a flare-up of 
IBD. 
T/F 0.71 0.57 N/A 18% 50.6 .760 
21 IBD patients can 
always get the 
nutrients they need 
if they eat the right 
foods. 
T/F 0.22 0.36 N/A 17% 90 .765 





MCQ 0.13 0.36 100%* 56% 49.5 .762 
14 Corticosteroids can 
cause which of the 
following side 
effects in children? 






# Item original text. Format P D DE DK R IIC 
22 Enteral nutrition 
(liquid diets that 
patients usually take 
orally or by 
nasogastric or gastric 
tube feeds): 
MCQ 0.27 0.5 66%* 35% 31.9 .756 
23 When doctors are 
testing a new drug 
for IBD in a study, 
some study patients 
might receive a 
“placebo”. If a person 
receives a placebo, it 
means that: 
MCQ 0.26 0.57 66%* 59% 67.3 .756 
13 If a person with IBD 
has been free from 
symptoms for several 
months, she/he 
should stop taking 
his/her medications. 
T/F 0.86 0.21 N/A 8.5% 68.6 .770 
3 A person can get IBD 
if they: 
MCQ 0.87 0.21 0%* 5.5% 100 .767 
11 The reason(s) a 
doctor might perform 
a colonoscopy is/are 
to: 
MCQ 0.73 0.29 33%* 11% 57.2 .771 
17 Which of the 
following statements 
about surgery for IBD 
is/are true? 
MCQ 0.1 0.29 33%* 49.5% 60.7 .765 
12 For an IBD patient 
who is free from 
symptoms, which of 
the following 
medications can help 
keep symptoms from 
coming back. 






The reliability coefficient KR-20 score was calculated as 0.77, indicating acceptable 
internal consistency. This score is marginally higher than that found in the original 
IBD-KID validation paper that showed a Cronbachs Alpha score of 0.75 12. However, 
the IIC scores showed that the overall KR-20 score would be improved by the 
removal of two specific items (Table 3.1), thus indicating that these items were not 
measuring the same underlying concept as in the rest of the tool and should be 
reviewed or removed by the expert panel.  
3.3.2.4 Content validity  
A further 7/23 (30%) IBD-KID items had DK as the highest answer response 
indicating that these items were testing a subject that was either an unrealistic 
expectation of knowledge, was age inappropriate, or had overly complex distractors. 
These items were considered not to have content validity and underwent review by 
the expert panel. Items shown to have acceptable construct validity were also 
reviewed by the panel as it should not be assumed that those items also have content 
validity.  
3.3.3. Feasibility/readability 
The original IBD-KID development paper 12 was validated in children aged 10-17 
years. The Flesch reading ease score for IBD-KID overall was calculated in this 
analysis as 66.1 (original paper 69.0), which equates to a school level of Grade 8 and 
9, and deemed 'plain English, easily understood by 13-15 year olds' 441. However, the 
individual item results depict a substantial variation in Flesch reading ease (Table 
3.1). A total of 14/23 (61%) items had a readability level below the acceptable Flesch 
reading ease score of 70. Items ranged from having a readability score of 100, classed 
as very easy and easily understood by an average ten year old, to 31.9 which is 
classed as difficult and only understood by university/college students 441. The 
expert panel reviewed those items scoring below the acceptable range.  
3.3.3.1 Other considerations 
On reviewing the content of IBD-KID, three pairs of items appeared to be addressing 




concerning stopping drugs, two items regarding side effects of steroids, and two 
items about IBD in families. The content of these items were reviewed by the expert 
panel.  
3.3.3.2 Data quality 
Of the total items answered, only 0.38% (4/1050) were answered incorrectly by 
respondents circling more than one option.  
3.3.4 Expert panel review. 
An expert panel was convened to review the IRT results, and to determine whether 
any factor related to the items in IBD-KID may be causing children with IBD to 
answer incorrectly. Consideration was given equally to all IRT measurement 
categories, as the individual results were merely statistical indicators, and all factors 
should be measured in conjunction to provide detailed guidance for review 432. A set 
of guidelines were developed and distributed to all panel members to help explain 
and address each of the IRT metrics that had results outside the acceptable range.  
The results of the IRT analysis, as decided by the panel, highlighted a number of 
components that may have caused respondents to answer incorrectly for reasons 
other than a deficiency in knowledge. It was therefore decided to use the results to 
develop a revised version of IBD-KID: IBD-KID2. Subsequent panel discussions took 
place regarding each individual item, with the results categorised as ‘no revisions’ if 
they were to be included unchanged in IBD-KID2, ‘revise’ denotes improvements to 
readability were required, or the removal of a NFD. Items categorised as ‘rewrite’ 
were deemed important topics to include, but that the item needed to be changed 
substantially. Those items not to be included in IBD-KID2 had the action ‘remove’ 




Table 3.2 IBD-KID Expert panel review results  
Item  Panel review outcome summary Action 
4, 6, 8 Keep items with no changes.  No 
revisions 
5 The panel discussed that although this had an ‘Easy’ 
difficulty level it was a good discriminator and may help 
prevent the test favoring mid-range scoring respondents.  
No 
revisions 
21 The panel discussed that although this had a ‘Hard’ 
difficulty level, it was a good discriminator and may help 





The panel agreed to improve readability.  Revise 
2 The panel determined that the least functioning 
distractor should be removed to make a 3 answer MCQ. 
Revise 
7 The panel decided that the distractors should be revised 
and made in to a 3 answer MCQ, alongside readability 
improvements.  
Revise 
13 The panel concluded that while this item was ‘easy’ and a 
poor discriminator, it was important to continue testing 
this knowledge. Make improvements to readability.   
Revise 
11 The panel agreed that it is essential to keep testing this 
knowledge. Change the distractors to make a 3 item MCQ 
and improve readability. 
Revise 
16 The panel agreed that herbal medicine, or 
Complementary and Alternative Medicine (CAM) use is 
high in children with chronic disease and IBD specifically 
56, 57, 442 and the subject is therefore important. The item 
was complex and needed simplifying, and readability 
improved.  
Rewrite 
17 The panel considered that while this may be more 
relevant for children with a specific type or severity of 
IBD, it is important knowledge to assess.  
Rewrite 
12 The panel concluded that the subject was vital to assess, 
but this item was not feasible to keep. It was decided to 
use a simpler format with up-to-date treatment 
modalities. 
Rewrite 
1 The panel concluded that there was some duplication 







Item  Panel review outcome summary Action 
10 The panel agreed that this item is no longer accurate. 
Mortality rates have increased beyond those of the 
general population for people with Crohn’s Disease 443 
and in people with UC who have extensive disease 444.  
Remove 
9 The panel discussed whether the subject is routinely 
addressed with all children and whether it is age 
appropriate. It was considered whether introducing 
knowledge of long term consequences may increase 
anxiety 163, 177, and consideration was given to negative 
parental feedback around inclusion of this item.  
Remove 
18 The panel concluded that this item was negatively 
impacting the test and that there was some duplication 
with item 19.  
Remove 
14 The panel acknowledged that introducing knowledge of 
drug side effects may increase anxiety and reduce 
treatment adherence 159, 445.  Steroid use is still an 
important therapeutic modality but this item skews 
results towards those prescribed them and, therefore, 
may be aware of side effects.   
Remove 
22 The panel agreed that an enteral nutrition (EN) item 
represents an unrealistic expectation of knowledge for 
children with UC. The current lack of treatment efficacy 
of EN for UC means the topic is unlikely to be discussed 
with those respondents 446. Continued inclusion would 
consistently skew results towards respondents with 
Crohn’s Disease, and lacked relevance to the whole target 
population.  
Remove 
23 The panel determined that the topic of placebos targets 
knowledge that would only be acquired if taking part in a 
trial. This was considered an unrealistic expectation of 
knowledge for respondents.  
Remove 
3 The panel determined that this item was an ‘essential 
knowledge’ test item from the original IBD-KID and its 





3.3.5 IBD-KID2 development summary 
The revised knowledge assessment tool: IBD-KID2 contains items that have been 
reviewed against a number of IRT metrics and have been tailored to participant 
response patterns, thus reducing respondent burden when completing the tool 447. 
IBD-KID2 (Appendix I) contains fifteen items, reduced from twenty-three in the 
original version, and items relate to updated treatment modalities, are generalisable 
to both diagnoses, and contain simplified text.  
3.4 Discussion 
It is of paramount importance that a knowledge assessment tool used in the 
paediatric population is valid, feasible, and reliable, as well as being appropriate and 
relevant to its intended purpose 419. Item level analysis is a critical component of the 
development process for assessment tools such as IBD-KID2 and it has been used in 
this review to produce a detailed description of respondent performance in order to 
assess item characteristics 419, 420. The participant response patterns observed in this 
study indicated a number of issues within IBD-KID. The difficulty level was the most 
prevalent indictor of item performance, while poor readability was the most common 
problematic factor. The proportion of poor discriminators was low, indicating that 
fixing the fundamental problems would produce an effective tool for measuring 
varying knowledge levels. Overall, it was found that the complexity of the distractors, 
readability, and topic content, had caused the majority of item issues.  
The T/F items in IBD-KID showed more frequent acceptable levels of both 
discrimination and difficulty and had fewer issues for review. All but one of the 
MCQ’s had NFDs and breached the face validity guidelines. It was, therefore, deduced 
that the distractor construct was a consistent source of error. Predominantly, it is 
important to reduce the ambiguity and complexity of the distractors and apply the 
guidelines previously stated (Section 3.2.3.1).  
Having identified the NFDs in IBD-KID, it was important to consider what action to 
take on those items. There is no concrete guidance for the ideal number of 
distractors per question but it is agreed that it is the quality, not the quantity that 
matters 433, 434. A higher number of distractors has been proved to marginally 
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improve reliability, but only when those distractors are performing adequately 432, 
433, 448. Previous work has addressed the removal of NFDs from a four response 
question, to make it a three response question 432, 434, 448, 449. No significant difference 
is found between difficulty, discrimination or overall score between four and three 
item questions, but response times were reduced by 15-20% and respondents 
overwhelmingly prefer fewer options 448, 449. Removing the confusing elements from 
IBD-KID such as all/none/both of the above, naturally reduced the number of answer 
options for each MCQ. 
The simplicity of the wording in IBD-KID warranted review as it was vital the tool 
measured respondent's knowledge and not their level of understanding, cognitive 
skills or reading ability 417. The panel considered that the wording in IBD-KID2 
should be simple enough to be understood by the weakest expected readers 434 to 
prevent results being skewed by item complexity causing them to be answered 
incorrectly, or as DK 432. The inclusion of medical terminology may adversely impact 
readability but may be unavoidable when the provision of an alternative description 
makes the item overly long. IBD-KID2 was, therefore, targeted at, or below, an age 10 
equivalent reading level to account for the low health literacy of the target 
population 440. Improving the readability of items will make them more efficient at 
discriminating between differing knowledge levels, and will reduce the reading time 
434, 441.  
While the inclusion of a DK answer option is controversial, it can reduce the bias of 
guessing and avoid measurement error. In this analysis it served to identify problems 
with IBD-KID, in particular content and face validity issues that could be addressed. 
The exclusion of this choice in IBD-KID2 would force selection of the key or a 
distractor but may increase the degree of guessing. The revised assessment tool will 
require item response analysis following a period of data collection, and the 
continued inclusion of the ‘don’t know’ option may once again provide valuable data 
on those items that are assuming a knowledge level above what is to be expected, or 
that is age appropriate.  
It is widely accepted that increased knowledge equates to improved self-
management, but for a review such as this it must also be considered that there are 
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different types of knowledge. There is basic knowledge that the IBD patient ‘must 
know’ which may influence self-management of the disease, knowledge that may 
allay needless worry or concern, and generally useful or background knowledge 262. 
Conversely, knowledge of topics such as long term consequences and treatment side 
effects may be considered developmentally inappropriate and subsequently increase 
anxiety and reduce treatment adherence 159, 163, 177, 445. For items in IBD-KID that 
were specific to CD or UC, the results may have been skewed towards those with that 
specific condition. These items were not included in IBD-KID2 and all revisions were 
made generalisable to both diagnoses.  
The removal of items from an assessment tool, based on the assumption that 
respondents may not know or understand a particular topic, is controversial. Eaden 
et al 11 made the argument that it was paternalistic to remove items for these 
reasons. When developing an assessment tool for the paediatric population it should 
also be acknowledged that children and adolescents increasingly seek independent 
information from alternate sources such as the internet and may therefore 
understand more than is assumed 179, 439. However, making this conjecture of all 
children, and including disease specific items, would unfairly skew results against 
those who had no external exposure to information outside the clinical environment. 
Consideration was given to both viewpoints by the expert panel.  
3.4.1 Limitations 
A limitation of this study was that incomplete demographic and disease data were 
available for the cohort, thereby preventing further analysis of response patterns 
between comparison groups. This aspect was addressed in a number of studies that 
utilised IBD-KID 12, 162, 163, and is included in the studies using IBD-KID2 in Chapters 
Four to Seven. 
3.4.2 Strengths 
This analysis has highlighted the importance of taking a holistic view of item 
response pattern data. No single metric was shown to identify the problems with 




The hypothesis statement for this study was that the structure and content of IBD-
KID would have no effect on participant response patterns for children with IBD. The 
IRT performed in this study leads to the rejection of this null hypothesis, which 
subsequently allowed for the IRT analysis to be utilised to develop a revised tool. The 
validity, reliability, and feasibility metrics were instrumental in deciding which items 
from the original IBD-KID should be retained, revised or rejected during the 
development of IBD-KID2.  
The emphasis for development of IBD-KID2 was the elimination of components that 
caused children with IBD to answer incorrectly for reasons other than a deficiency in 
knowledge. The aim of developing IBD-KID2 was to make the instrument more 
concise and simpler, and therefore improve the ease of use in the clinical and 
research environment by providing a more practical format for knowledge 





Chapter Four: IBD-KID2 Validation Study. 
4.1 Introduction 
The development of IBD-KID2 (Appendix I), as outlined in Chapter Three, was 
performed in recognition of the importance of having a simple, age-appropriate, and 
generalisable knowledge assessment tool that can be used for children with IBD. 
While knowledge is considered an artificial construct whose quantity is not precisely 
defined, it can be assessed in a broad sense using questionnaire scales such as IBD-
KID2, which ask a series of carefully selected questions among their target 
population and combine the answers into a single numerical value 450. When children 
with IBD complete IBD-KID2 the resulting score will be an important indicator of 
their overall disease and treatment knowledge, however focusing on this overall 
score in isolation can be misleading. Absolute knowledge levels can not identify 
individual patient misconceptions or general areas of deficient knowledge in a cohort 
- in particular those that may negatively affect disease management 262, 263. 
Therefore, it is also important to explore patterns of patient knowledge, alongside 
the total score, to allow for identification of those areas in need of targeted education. 
In addition, the total score, and highlighted areas of poor understanding, may be used 
to study the interplay of knowledge on other patient and disease-related variables. 
These may include treatment adherence rates, self-management, disease outcomes, 
health-care resource utilisation, and quality of life 162, 264. 
Following the revisions made to the original IBD-KID to produce IBD-KID2, it was 
important to determine whether IBD-KID2 performed as well as the original in 
providing an overall assessment of disease-specific knowledge, and in highlighting 
areas of poor knowledge that should be addressed. By implementing IBD-KID2 in a 
cohort of the target population, the overall score data could then be used to evaluate 





4.1.1 Methodological considerations  
4.1.1.1 Validity 
Validity refers to whether the tool actually measures the intended research concept, 
and a number of factors are studied to determine this.  
The construct validity of a tool should be tested when it is measuring an attribute that 
is not ‘operationally defined’, such as knowledge 452. Testing construct validity uses 
statistical analyses to examine the expected relationships with other variables, such 
as being able to distinguish between respondent groups, or being responsive to 
changes in participant circumstance 453. For this testing of IBD-KID2 it was 
considered feasible to examine whether IBD-KID2 could distinguish between the 
knowledge levels of a number of comparator groups. Previous studies have 
established a hierarchy of knowledge levels of IBD among a number of health 
professional and participant groups. Studies carried out to confirm the validity of 
knowledge assessment tools aimed at adults have shown that the CCKNOW 11, and a 
short knowledge questionnaire by Keegan et al 264 both had the highest to lowest 
score order as; medical staff, nursing staff, adults with IBD, administrative staff. The 
original IBD-KID validation study 12 and generalisability 163 study provided the 
additional elements of parent and control group scores to this hierarchy (in 
descending order); medical staff, nurses and parents of children with IBD 
(comparable scores), children with IBD, administrative staff, control group parents, 
control group children. This understanding allows for hypothesis generation as to 
whether similar results can be produced when IBD-KID2 is tested among similar 
groups, with this approach being utilised to test the validity of IBD-KID2.  
4.1.1.2 Reliability 
The reliability of a tool is established by testing for consistent responses, whereby 
the scale must be sufficiently repeatable so as to produce similar results for different 
observers, or for the same observer across time 435, 453. Questionnaire reliability can 
be assessed in three ways; alternate form reliability (equivalence), test-retest 




Alternate form reliability 
Alternate form reliability requires the concurrent administration of two different 
questionnaires that contain similar content. There are three knowledge 
questionnaires for adults that could be considered comparable for content– the KQ 
263, CCKNOW 11, and the short IBD questionnaire 264. However, only the CCKNOW has 
been tested in the paediatric population 163. This study showed that children scored 
lower on the CCKNOW overall than on the original IBD-KID, and parents and children 
found the adult questionnaire harder to follow and complete 163. In addition, the 
content of the CCKNOW was developed for adults, and some of the topics covered by 
the CCKNOW could be considered inappropriate or too complex for children. The 
only other knowledge questionnaire found that is aimed specifically at children with 
IBD, and could be considered to establish alternate from reliability, was an electronic 
tool, the ‘Emma’ 161, which is in a format that makes it inaccessible for other 
researchers to use as a tool for comparison (as discussed in Section 1.7.2.1). It was 
therefore not considered feasible to test the equivalence of IBD-KID2 using alternate 
form reliability.  
Test-retest reliability 
Test-retest reliability is measured by repeat administrations of the questionnaire to 
participants at a pre-determined interval that must be far enough apart in time for 
the initial responses to be forgotten (memory effect), yet not so distant in time that 
the underlying quantity being measured might have changed (testing effect) 435, 453. 
The ideal time lapse between tests is considered to be no less than two weeks, and no 
more than six weeks so that participants will not have learned much, nor 
remembered how they responded the first time 454. It was considered feasible to 
perform test-retest reliability on IBD-KID2 among a cohort of children with IBD. 
4.1.1.3 Feasibility 
Following the amendments to the original IBD-KID, it was also considered 
appropriate to assess the impact of the changes to the response patterns to the IBD-
KID2 items in a number of ways. The first factor considered was readability, whereby 
IBD-KID2 items, and the tool overall, had readability levels calculated to ensure that 
they complied with the guidelines established in Chapter Three (Section 3.2.3.3). In 
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addition, those items that had been revised from the original IBD-KID were assessed 
against participant answers to determine whether the changes affected responses in 
a positive or negative way.  
4.1.1.4 Participant response patterns 
In order to establish the areas of good and poor knowledge among the participants of 
children with IBD, their response patterns to each IBD-KID2 item were examined. 
This can provide an instant summary of where knowledge deficiencies lie, and in the 
pragmatic sense can be used for instant targeted teaching. These results may also be 
tested for their association with other outcomes, as previously mentioned, thus 
indicating whether knowledge in certain areas of disease and treatment knowledge 
can impact other disease outcomes. Assessing knowledge patterns overall will 
contribute to a greater understanding of age-related knowledge patterns in this 
target population, and to other independent variables. In addition, these knowledge 
patterns will provide comparison data for future studies using IBD-KID2, as 
presented in Chapters Five, Six, and Seven.  
 
4.1.2 Aims and hypothesis 
The aims of this study were to assess the internal validity, and reliability of IBD-KID2 
by administering the assessment tool to a number of participant groups, thereby also 
establishing a hierarchy of knowledge levels as a benchmark for future studies. The 
hypotheses proposed for this study are as follows:  
That the revised knowledge assessment tool (IBD-KID2) will have comparable 
internal validity to the original version. 





IBD-KID2 is a fifteen-item long knowledge assessment tool comprising six MCQ’s and 
nine T/F items. Participant responses are scored as one for each correct answer, to a 
maximum total of fifteen. Knowledge domains included general information, 
treatment modalities, nutrition, and lifestyle. 
4.2.1 Participants 
IBD-KID2 was to be administered to four groups of participants, all recruited at 
Christchurch Hospital, New Zealand: children with IBD, children without IBD, 
medical staff, and administrative staff.  
The children with IBD satisfied the inclusion criteria if they were between the ages of 
eight to eighteen years. Participants in this group were recruited from a number of 
settings; out-patient IBD clinic, in-patient medical ward, and identified from a 
previous study (the interviews in Chapter Two) and contacted via phone.  
The children without IBD were recruited as a control group and satisfied the 
inclusion criteria if they were between the ages of eight to eighteen years, did not 
have a GI condition, and did not have a close family member with IBD. Participants 
were recruited from the medical and surgical inpatient wards while they were 
admitted for treatment.  
The medical staff were recruited during their working day in the clinical or office 
environment. Participants were a combination of junior doctors, senior doctors, and 
consultants, and from a number of paediatric and adult specialities. 
Administrative staff were recruited in their working areas and were from a number 
of hospital administration environments: ward clerks, medical secretaries, and 
departmental receptionists. Admin staff were excluded from participating if they, or 
a close family member, had IBD.  
Within the hospital setting all IBD-KID2 assessments were completed with the 
candidate present. The parents of the children with IBD who were recruited by 
phone were emailed a link to complete an electronic version (format identical to 
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paper version) using a secure, Health Insurance Portability and Accountability Act 
(HIPAA) compliant, online form facility (Cognito forms). 
4.2.3 Ethics 
The study took place at Christchurch Hospital, New Zealand. Ethical approval for the 
research was granted by the Otago University Human Ethics Committee (Health) 
(H16/116). Written, informed consent was obtained from all adult participants, and 
from the parents of the paediatric participants. Written assent was obtained for all 
child participants. 
4.2.4 Study metrics 
4.2.4.1 Validity  
The discriminatory ability of IBD-KID2 was measured by comparing the mean scores 
of the four participant groups, assumed to have divergent levels of IBD knowledge. 
For the children with IBD additional data was collected on age, gender, disease type, 
and disease duration, to determine if knowledge was associated with demographic or 
clinical variables. The children without IBD had data on age and gender collected. 
4.2.4.2 Reliability 
Initial reliability testing was performed by asking the participant group of children 
with IBD to repeat the IBD-KID2 assessment two weeks after the initial completion. 
Repeat assessments were implemented by emailing a link to complete the online 
version of IBD-KID2 (Cognito forms). Explicit instructions were included in the initial 
email that answers were not to be looked up or asked of a family member. In order to 
assess the influence of a change of environment for the repeat test the response 
given to each item (not just whether it was answered correctly/incorrectly) were 
examined to determine the number of identical responses between repeat 
administrations.  
4.2.4.3 Participant response patterns 
The IBD-KID2 response patterns of each individual group were examined for 
patterns of knowledge deficiencies - considered as those items answered correctly by 
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under 50% of the cohort. In addition, for the children with IBD, the difficulty index 
for each item was assessed as the percentage of group respondents who answered 
each IBD-KID2 item correctly – the ideal range is between 30% to 70% – with lower 
than 30% signifying that an item may be too hard, and over 70% too easy (as 
outlined in Section 3.2.3.1) 425, 429. 
4.2.4.4 Impact of IBD-KID revisions 
A readability comprehension assessment of IBD-KID2 was performed using the 
advanced proofing analysis tool in Microsoft Word™. This was calculated to allow 
direct comparison with the original version of IBD-KID. The recommended Flesch 
reading ease score for paediatric patient material is >70.0 455. The impact of the 
structure changes to those revised items were measured as the number of correct 
answers given to the items, and the response rate of the ‘Don’t know’ answer option.  
4.2.5 Statistical analysis 
To measure construct validity the mean scores were calculated for each group, 
between group differences tested using the Analysis of Variance (ANOVA), with post 
hoc analysis comparing the scores of the children with IBD to the other group scores 
using Tukey’s test. Within group analysis of the data from children with IBD were 
compared for the independent variables age, gender, diagnosis, and disease duration 
using independent sample t-tests for categorical variables, and linear regression for 
continuous variables. Group sizes were determined from previous literature that 
conducted similar validation studies for knowledge questionnaires aimed at adults 
and children with IBD 11, 12, 163, 263. 
Test-retest reliability in the group of children with IBD was examined by comparing 
means between the two assessments, and reproducibility tested using the intraclass 
correlation coefficient (ICC). Reliability would be established if there was no 
significant difference between mean scores between the two administrations of IBD-
KID2. Reliability using the ICC score would be moderate if between 0.5 and 0.75, 
good if between 0.75 to 0.9, and excellent if greater than 0.9 456, with the statistical 
significance of this result also reported. Internal consistency was examined with the 





IBD-KID2 was administered to four groups of participants: children with IBD (n=22), 
children without IBD (n=20), medical staff (n=15) and administrative staff (n=15). 
Children with IBD were recruited in the following settings: out-patient clinic (n=16), 
in-patient medical ward (n=2), and contacted by phone (n=4). 
The mean ages of the paediatric groups were; children with IBD: 13.6 years (SD 2.5) 
(range 8 to 18), children without IBD: 11.9 years (SD 2.2) (range 8 to 15). Of the 
children with IBD, twenty had a diagnosis of CD and two of UC. Mean duration since 
disease diagnosis was 40.6 months (SD 34) (range 0-133 months), with nine having 
been diagnosed within two years of the initial IBD-KID2 assessment, and thirteen 
had been diagnosed over 2 years. 
4.3.2 Construct validity 
The group means (SD) for the IBD-KID2 total score (maximum fifteen) were; children 
with IBD: 8.5 (SD 2.3), children without IBD: 3.7 (SD 2.2), medical staff: 13.5 (SD 1.3), 
administrative staff: 6.3 (SD 2.5). The overall difference in mean scores between 
groups was significant (p <0.001) and group mean comparisons with children with 
IBD were; children without IBD (p <0.005, CI: 3 to 6.5), medical staff (p <0.005, CI: -






Figure 4-1. IBD-KID2 scores for participant groups.  







































































The significance of the independent variables on the mean score of the group of 
children with IBD were examined for diagnosis, gender, age, and duration of disease 
(Table 4.1). No single independent variable had a significant effect on IBD-KID2 
scores. 
Table 4.1. IBD-KID2 scores by independent variable for children with IBD.  
Categorical Variable (N) Mean (SD) Significance 
Gender  
Male (11) 8.0 (1.5) 
p 0.367 Female (11) 8.9 (2.9) 
Diagnosis  
CD (20) 8.6 (2.4) 
p 0.552 UC (2) 7.5 (0.7) 
Disease 
duration 
<2 yrs (9) 9.1 (3.2) 
p 0.276 >2 yrs (13) 8.0 (1.4) 
Continuous variables Regression (R) Significance 
Age (years) 0.354 p 0.107 
Disease duration (years) 0.108 p 0.634 
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4.3.3 Test-retest reliability 
IBD-KID2 assessments were repeated in the children with IBD at a mean of 28 (SD 
11) days apart. The mean scores at the baseline completion, (8.4, SD 2.4) and the 
repeat completion (9.0, SD 2.4) were not significantly different (p 0.21) (Figure 4-2). 
The ICC score was high at 0.82 (p <0.005), showing good correlation of the group 
scores. Testing for the effect of two different completion methods showed that 81% 
of respondents gave identical answers between the baseline and repeat for ≥10/15 
items. 
Figure 4-2. IBD-KID2 scores for test-retest assessments 





























4.3.4 Internal consistency 
The internal consistency score using the KR-20 test was high at 0.85 (CI 0.8 to 0.9). 
Item-total statistics showed that this score would not be improved by the removal of 
any specific items. The reliability score of the original IBD-KID was given as 0.75 12.   
4.3.5 Participant response patterns 
The participant response patterns of the children with IBD to each individual IBD-
KID2 items were assessed (Figure 4-3). Areas of good knowledge were considered as 
those items answered correctly by over 50% of the cohort of children with IBD, and 
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areas of poor knowledge less than 50%, as was considered in previous studies using 
IBD-KID 12, 162, 163. 
Figure 4-3. Frequency of correct IBD-KID2 answers for children with IBD. 
The mid-line delineates areas of good (>50%) or poor (<50%) knowledge. The ‘easy’ 
(>70% scoring correctly) and ‘difficult’ (<30% scoring correctly) areas represent the 
index of difficulty.  
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4.3.6 Impact of IBD-KID revisions 
The cohort of children with IBD in this study had higher percentage scores to the test 
overall than all previous studies using the original IBD-KID 12, 162, 163. This cohort of 
children with IBD also scored fewer ‘Don’t know’ responses overall when compared 
to the data from the item response analysis in Chapter Three. Of the fifteen items in 
IBD-KID2; five were unchanged from the original version, five were MCQ’s that had 
been simplified or re-written, four had readability improvements, and one was new.  
The original IBD-KID was shown to have a Flesch reading ease score of 66.1 12, which 
is deemed plain English, easily understood by thirteen to fifteen year olds 441. The 
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readability of IBD-KID2 was calculated at 77.2, appropriate for children aged ten to 
eleven years441.  
Of the five items that were kept the same as the original, three had scores similar to 
other research that used the original IBD-KID (within the minimum and maximum) 
and two items had marginally lower scores.  
All five of the MCQ items that had improvements made to their structure with 
reduction and simplification of distractors (three also readability improvements) had 
increased numbers of correct answers (range 7-72% better).  
Of the nine items from the original IBD-KID that had improvements made to their 
readability, structure, or were re-written, all had more children scoring these items 
correctly than in their original format.  
The difficulty index of IBD-KID2 items overall was; acceptable 73% of items, easy 
20% and hard 7% (Figure 3-3). The original IBD-KID had items that were; acceptable 
52%, easy 17% and hard 30%.  
4.4 Discussion 
The validation of IBD-KID2 was performed using similar methods to other 
knowledge assessment tools (CCKNOW 11, KQ 263, IBD-KID 12). Testing of IBD-KID2 
was carried out to determine the discriminatory ability between groups with 
established knowledge levels - the resulting mean scores were significantly different 
between groups and followed the expected hierarchical pattern. Repeated tests 
showed good intraclass correlation, and the overall reliability of IBD-KID2 was high. 
The readability and structure improvements that were made in the process of 
development improved the individual item, and overall scores. The children with IBD 
who were assessed in this study demonstrated patterns of knowledge similar to 
those seen in previous studies using the original IBD-KID, and also among the adult 
population with IBD. These patterns of knowledge are discussed below. 
Not all IBD knowledge assessment tools measure the level of understanding about 
osteoporosis – the CCKNOW and other IBD questionnaires (for both children and 
adults) do not address the subject 11, 110, 161, 264. However, when tested, knowledge 
concerning osteoporosis has been shown to be low in both adult and paediatric 
groups with IBD as measured by the KQ 263 and IBD-KID, with results ranging from 
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29-41% in children 12, 163, 415 and 45% in adults 263. This is an important subject to 
address as osteoporosis can be caused by both IBD and by corticosteroids – a 
common treatment for IBD 457. Inclusion of this item allows for targeted teaching and 
nutrition advice specifically.  
The understanding of the effect of IBD on growth was low, similar to findings 
reported in a previous study using IBD-KID in New Zealand (38-41% correct 
answers) 415 and among adult IBD groups (6-49%) 11, 90, 458-460. Of interest is that the 
group of medical staff completing IBD-KID2 also scored poorly on this item (47%), 
highlighting that knowledge deficiencies on this topic are not isolated to patients 
with IBD. In the medical field, improved awareness to those practicing outside the 
speciality should lead to the ongoing promotion of adherence in any patients with 
IBD they encounter, and an improved understanding of the importance of remission 
to IBD outcomes.  
The level of knowledge about the mechanism of biologic medications was 41%, and 
the importance of not stopping steroids if experiencing side effects was understood 
by 36% of participants. Knowledge of medications is historically poor among the 
adult and paediatric population with IBD. Previous research that utilized the original 
IBD-KID in the paediatric IBD population 12, 162, 163, 415, as well as studies specifically 
testing medication knowledge 111, 461, all reported knowledge deficiencies in this area. 
Adults with IBD who had their knowledge tested using the assessment tools 
CCKNOW 11, 90, 458-460 and KQ 262, 263 all highlighted confusion among participants on 
the subject, with the frequency of correct answers for medication related questions 
being below 50%. Confusion about drug therapy could, in part, reflect patients’ poor 
recall of drug names or types, but when taken together these studies have 
highlighted a universal knowledge deficiency that needs to be addressed with 
education strategies 262.  
Deficiencies in knowledge levels about medications and treatment modalities in 
general may be due to the de-emphasis of side effects by clinicians in an effort to 
bolster patient adherence 111. This fact is supported in a study by Moradkhani et al 178 
that found no relationship between knowledge levels and adherence. It is imperative 
that all recipients of steroid treatments be made aware of the consequences of 
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tapering their medications, however, the lack of knowledge in this area could be 
representative of the number of children who have actually taken them. This item 
inherently skews results against those that have not taken steroids but is considered 
a vital component to include. 
The use of CAM is high in children with IBD (72% of surveyed participants) 56 and in 
the paediatric gastrointestinal out-patient setting in general (67% of surveyed 
participants) 57. The levels of knowledge among cohorts completing IBD-KID and 
IBD-KID2 (including this study) ranged from 7-41% 12, 162, 163, 415, but understanding 
was highest in the current study, possibly due to the effect of simplifying the MCQ 
structure. While a number of studies have measured the extent of CAM use among 
the paediatric population, none of the identified studies measured the level of 
knowledge about CAM among children. One study measured the knowledge levels of 
parents, which highlighted that although all study participants used CAM products, 
up to 82% of parents admitted to withholding this information from their medical 
team, and knowledge of CAM among the parents was insufficient 462. Given their 
widespread use, conversations between clinicians and children with IBD (and their 
parents) about CAM should become more prominent in order to improve 
understanding of the safety implications and possible benefits. 
There is a general misconception among the IBD population about whether the 
removal of certain food groups from the diet is beneficial. The most commonly used 
example is milk, or dairy products: 30-39% of paediatric patients using IBD-KID and 
IBD-KID2 (including this study) had poor knowledge on this topic 12, 163, 415. Results 
are varied in the adult population ranging from 36% giving correct answers in a 
developing country 458 to 89% in the US and UK 460, 463. The perception among 
children and some adults with IBD that they should restrict milk, as an example, from 
their diets is a matter of concern as if this translated into practice it could result in a 
suboptimal nutritional intake 262.  
There are scant data available on whether children and adults with IBD are 
knowledgeable about nutrient absorption from food, but data were available from 
two studies, alongside the current study, showing that the frequency of correct 
answers to this topic range between 14-24% 163, 415. Of note again is that the group of 
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medical staff in this study showed relatively poor knowledge on this topic with 60% 
answering correctly. Micronutrient deficiencies are widespread in children with IBD, 
predominantly due to malnutrition secondary to malabsorption and decreased 
intake 464, 465. Some deficiencies are dependent on disease location, medications or 
surgery 464. Up to 78% have been reported as deficient in iron 466, and up to 38% in 
vitamin D 467, 468. Further deficiencies have been reported in essential fatty acids 465, 
water and fat soluble vitamins 464. Targeted nutritional education in recognition of 
knowledge deficiencies may contribute to improvements to intake and an enhanced 
understanding of the importance of a varied and balanced diet in order to maximize 
the potential for appropriate micronutrient status from dietary intake. 
No independent variable (disease, disease duration, age or gender) tested in this 
study had any significant effect on total score for the children with IBD. This pattern 
matches the other studies using the original IBD-KID 12, 162, 163, with the exception of 
disease type in the original validation study 12. This study, and one carried out in 
Australia 163 had insufficient numbers in the group with UC to make meaningful 
comparisons of total score between the two diagnoses. 
 
It is noteworthy that disease duration does not have an impact on knowledge scores, 
as has been displayed in other disease groups such as asthma and diabetes 12. 
However, with the exception of one study among adults performed in Sri Lanka 458, 
all identified studies have shown that knowledge levels are independent of disease 
duration in adults and children with IBD 11, 12, 111, 118, 162, 163, 262-264, 458, 459. It has been 
hypothesised that those recently diagnosed would have less time to understand and 
learn aspects of their disease, and those with a longer disease duration would have 
higher knowledge levels due to a cumulative process 163. It has been concluded, 
however, that core information may be obtained through patient education shortly 
after diagnosis, and that this provides a similar extent of knowledge to those with 
longstanding disease 12, 163. Subsequently, either minimal new information is 
attained, or a plateau of understanding is reached which remains over time or is 
eventually forgotten 12, 163. It may also be the case that some clinicians spend less 
time imparting medical information to patients with longer disease duration, 
assuming that previous education has been retained and will still be appropriate 
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years later 111. It is clear from this evidence that patient education for children and 
adults with IBD should be an ongoing process, with reiteration of important issues 
and continual reinforcement at each clinic visit 11, 469.  
Increasing disease and treatment knowledge in patients with IBD may not have the 
same impact as for patients with diabetes, for example, as these patients have control 
over their own treatment, and education may be expected to improve adherence and, 
therefore, disease control 11, 263. This effect could not be expected in the same way for 
patients with IBD due to the complex, relapsing, and remitting nature of the disease, 
although education and improved knowledge should help to improve treatment 
adherence 11. All patients with IBD need to have a comprehensive knowledge base as 
it is reasonable to predict that an increased understanding of IBD may lead to fewer 
complications 11. In addition, self-management may be improved in both children and 
adults as it is known that knowledge of the disease and treatments are considered 
the first steps in the process of self-management 11, 111. Improved knowledge will also 
help with the decision-making process, a component of health literacy, as discussed 
in Chapter One (Section 1.5.1.3). 
4.4.1 Limitations 
This study was limited by the disproportionate distribution of diagnoses among the 
group of children with IBD, limiting meaningful comparisons between participants 
with CD and UC. This disparity of numbers, with CD patients being better 
represented, was universally found among the studies carried out in the paediatric 
IBD population. The opposite was found for all of the adult studies whereby UC 
participants were predominant. This mirrors local and international trends among 
children, as discussed in Chapter One (Section 1.2.3.2). The shift in ratio to a 
predominance of UC among the adult population may be explained by the age of 
diagnosis for patients with CD being, in general, 5–10 years earlier than those of 
patients diagnosed with UC, alongside some studies showing a peak of incidence in 
UC diagnoses later in adulthood 470. 
This validation study was limited in that it did not include a parent group to allow 
score comparisons between children with IBD and their parents, did not establish 
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external validity, and did not evaluate the ability of IBD-KID2 to assess sensitivity to 
change before and after an intervention to provide disease and treatment knowledge. 
In order to address these limitations, further research was carried out and the results 
are presented in Chapters Four to Seven.  
4.4.2 Strengths  
Having data available from the studies that used the original IBD-KID as an outcome 
measure allowed for meaningful comparisons to be made between scores on the two 
instruments to assess whether the performance of the tool had improved. The overall 
mean percentage scores of IBD-KID2 were higher than that of the original, which 
may be attributed to a number of factors. The improvements to structure, content, 
and readability are likely to have had an effect on respondent’s scores as the tool may 
now be considered more appropriate for the target population, and easier to 
understand. The improved scores may also have been a marker of this particular 
study cohort being well informed, or could be an indication of how patients with IBD 
increasingly, and independently, seek disease-related information from the internet 
and other sources outside the health-care team 178, 179. Further studies among a 
larger cohort of children with IBD may provide some clarity on this matter and 
should establish whether overall scores are reflective of this trend, as presented in 
Chapter Seven. 
4.4.3 Conclusion 
The original hypotheses for this study were that IBD-KID2 would have comparable 
internal validity and reliability with the original IBD-KID. It was also intended to 
examine the hierarchy of knowledge produced to determine whether levels were in 
line with established literature. This research has established that IBD-KID2 
produced between group comparisons that display the same hierarchy of knowledge 
as has been empirically established in the literature, thus confirming internal validity 
and leading to the acceptance of the first hypothesis. Scores achieved using IBD-KID2 
did not change between repeat administrations, and had good internal consistency, 
thus confirming that reliability is comparable to the original. This led to the 
acceptance of the second hypothesis. The changes to item structure and readability 
 
162 
made during the development of IBD-KID2 improved the tool’s performance among 
the target population when compared to the original version. IBD-KID2 was found to 
be appropriate for children aged eight years and over and can therefore be used as 
an outcome measure to assess the impact of education and self-management 
initiatives directed to children with IBD, such as in Chapters One and Eleven. IBD-
KID2 should now be utilisable in both the clinical and research settings as the time 
taken to complete, as well as the respondent burden, should have been reduced by 
making improvements to readability and the length. This revised assessment tool 
may be used by clinicians to help identify topics requiring directed attention during 





Chapter Five: IBD-KID2 Public knowledge study 
5.1 Introduction 
An important component for effective self-management of children with IBD is the 
community they live in 50, as described in Chapter One. The community setting 
comprises many elements – children’s peers, school, whanāu (Māori-language word 
for extended family), their immediate neighbourhood, and members of the public. 
The community can provide both positive and negative influences, depending on the 
degree of knowledge and understanding about the disease. Community support may 
be beneficial in the form of peer relationships, school programmes, and activities 
such as residential camps for children with IBD. However, the knowledge levels of 
the general public regarding IBD can greatly influence whether experiences are 
positive or negative, such as stigmatising the disease, peer victimisation, and 
accommodating the need for urgent bathroom access in public establishments. The 
self-management framework presented by Modi et al 50 includes perceived stigma as 
one of the modifiable influences for the individual (the child), and social stigma as a 
modifiable influence for the community. This highlights the important role the 
community plays in the development of self-management skills of children with 
chronic illness. 
5.1.1 Stigma and peer victimisation 
For many people with IBD their disease is concealable or ‘invisible’ to those around 
them and they do not outwardly appear to be sick, which can lead to insensitivity by 
the public due to a fundamental lack of understanding of the disease 149, 153. This poor 
public perception contributes to a general belittling of IBD symptoms as they deal 
with a less socially acceptable part of the body, which can be a key factor in the daily 
challenges of someone with IBD 148, 149. Up to 84% of IBD patients have perceived 
stigma, whereby they comprehend a social stereotype to be against them 147, 152. The 
perceived stigma for people with IBD has been shown to be as high as people with 
HIV/AIDS and mental illness 152. This is supported by the fact that the public 
perception of IBD can be highly negative with it being rated as having greater social 
stigma than sexually transmitted diseases, alcoholism, cancer, diabetes, obesity and 
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HIV 147. The perceived stigma by people with IBD may reduce adherence, self-
efficacy, and HRQoL, as well as increase anxiety and depression 139, 152. For children 
with IBD there is also an increased risk of victimisation from their peer group with a 
number of factors attracting negative attention: frequent trips to the bathroom, 
needing to follow their medication regimen during school time, short stature, special 
diets, and the possibility of a restricted ability to partake in normal social activities 
471. Such peer victimisation has been shown to reduce adherence, whereas prosocial 
support from peers may be protective against this negative effect of bullying 139.   
5.1.2 Bathroom access 
Public knowledge levels can also have consequences for matters such as needing 
urgent bathroom access in retail and restaurant establishments. A number of surveys 
carried out in the United States (US) demonstrated that not one of the 101 
retail/restaurant managers approached had any knowledge about IBD, or about the 
bathroom legislation in their state that allowed for people with medical needs to use 
the bathroom in public establishments 150, 151. After receiving information about IBD 
63% would allow bathroom access but 37% remained opposed to allowing urgent 
admission to the toilet facilities. Problems have even been encountered in the 
hospital setting whereby adults with IBD have been located on in-patient wards far 
from bathroom access, and children in particular may not be able to express their 
needs in an unfamiliar environment such as a hospital ward 149. A number of 
initiatives have been introduced to raise awareness of the needs of people with IBD 
in this respect. One local example is the ‘I Can’t Wait’ card that was introduced by 
Crohn’s and Colitis New Zealand. This card can be carried by IBD sufferers to show 
public establishments that the bearer has a medical condition requiring urgent 
bathroom access. A number of countries have legislation passed, or going through, to 
enforce access for those with medical needs: Australia, US (fifteen states currently 




5.1.3. Knowledge levels and awareness 
A study by Groshek et al 147 demonstrated that a higher public knowledge level was 
the only factor that demonstrated a positive relationship towards decreasing public 
stigma 147. The authors recommended that IBD stigma might be diminished by 
increasing knowledge through media campaigns that specifically target social media 
content and users 147. Worldwide awareness campaigns such as World IBD Day 170 
aim to increase public knowledge, yet understanding still appears to be low and few 
surveys have been carried out to assess these levels. A national survey in Austria 
showed that of 1001 participants only 31% had heard of CD and 20% of UC, and less 
than 21% correctly associated these terms with intestinal disease 148. A study carried 
out with 1200 participants comprising the American public established that on a 
scale of one to ten, the median rated awareness level was 5.5, with 11% overall 
having no knowledge of IBD 147. In contrast, the public awareness levels of diseases 
such as diabetes are high 148. The only study into public knowledge levels of IBD that 
utilised a validated knowledge survey was by Quan et al 460 whose participants 
competed the CCKNOW 11. Study participants included people with IBD and their 
family and friends, but knowledge levels were still relatively low at 50% mean score 
on the CCKNOW 460. 
5.1.4 Benefits of public awareness 
Besides the benefits of reduced stigma and improved bathroom access, heightened 
public awareness of IBD will have the crucial impact of promoting early detection 
and diagnosis that may prevent primary complications from undetected disease 
progression 148, 472, 473. Increasing awareness of IBD among the public, and in the 
primary health care sector, may lead to more self-referrals to the GP, and 
subsequently a more rapid referral to gastroenterologists, thereby instigating early 
access to therapy that may improve the prognosis and reduce health care costs 148. A 
European study of 5000 adult participants found that 52% had seen a 
Gastroenterologist within a year of experiencing symptoms, but 21% had symptoms 
for five years before being referred to a specialist 474. There is no recent comparable 
data available for New Zealand, but in 2008 the average time between presentation 
and diagnosis for a child with IBD was eight months 475.  
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The highlighted lack of public understanding of IBD is clearly a fundamental factor in 
the daily challenges faced by children with IBD, and increasing awareness may result 
in improved outcomes, and help with practical issues related to the disease. No 
studies have been found that report the public knowledge levels of IBD in New 
Zealand so as to identify deficiencies in understanding that may be addressed with 
awareness campaigns.  
5.1.5 Aims and hypothesis 
The objective of this study was to implement IBD-KID2 at the University of Otago 
Open Day (September 2018) with the aim of measuring the public knowledge levels 
of IBD using a validated survey tool. The evidence presented led to the following 
hypothesis: 




The University of Otago (Christchurch) Open Day is a Health Research and Education 
showcase event where all Departments present displays of their latest research and 
technology related to their area of speciality. This is a free event open to all members 
of the public and is advertised through the University website, social media and local 
High Schools. 
5.2.2 Population and ethics 
All people over the age of 8 years who were attending the University of Otago 
(Christchurch) Open Day event in September 2018 were invited to participate in the 
research. There were no exclusion criteria. Ethical approval for the study was 
provided by the University of Otago Human Ethics Committee (Health) (H16/116). 
Written informed consent was obtained from all participants. 
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5.2.3 Outcome measures 
All participants were asked to provide some basic demographic data. The sole 
outcome measure of the study was the IBD-KID2 knowledge survey. The format of 
IBD-KID2 (Appendix I) has previously been discussed in Chapters Three and Four.  
5.2.4 Statistical analysis 
Baseline demographics were collected to provide comparisons of baseline mean 
scores against the following independent variables:  
 age  
 gender  
 education level 
 personal or family history of IBD 
The comparison of mean scores between categorical variables was performed using 
independent t-tests, and the ANOVA. For continuous variables, significance was 
tested using linear regression. The significance level was considered as p ≤ 0.05. 
Knowledge levels were examined for each item on IBD-KID2 to ascertain areas of 
good and poor knowledge among study participants. Poor knowledge was 
considered as less than 50% of participants answering an item correctly. 
5.3 Results  
5.3.1 Participants 
One hundred attendees agreed to participate in the study, and the demographic 
distribution of participants examined (Table 5.1). 
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Table 5.1. Demographic distributions of the study cohort.  
* one participant did not provide this information 
Linear variable Mean (SD) Range 
Age (yrs) 39.9 (20) 12 to 82 
Categorical variables Group N = % 
Gender 
Male  29 
Female 71 
Level of education 




Family history of IBD* 
Yes 12 
No 78 
Don’t know 9 
5.3.2 IBD-KID2 scores 
The mean IBD-KID2 score (maximum fifteen) of all attendees was 8.7 (SD 2.9), 
representing a percentage total IBD-KID2 score of 58% (SD 19). When examined 
against the independent variables the scores were not significantly different for any 
groups (Table 5.2). The 100 participants gave the ‘Don’t know’ response 339 times in 
total (out of 1500 item responses), representing 23% of all answers given. 
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Table 5.2. The distribution of IBD-KID2 scores between independent variables. 
Categorical  




Male  8.8 (2.9) 
0.89 
Female 8.7 (2.9) 
Level of education 
High School 7.7 (3.2) 
0.159 
College 9.6 (2.7) 
University 9.3 (2.8) 
Post-Graduate 8.9 (2.7) 
Family history of IBD 
Yes 9.8 (2.5) 
0.17 No 8.7 (3) 
Don’t know 7.3 (2.2) 





Age (yrs)  0.105 0.301 
 
When the association between the age of participants and their IBD-KID2 score was 
explored graphically it showed great variation (Figure 5-1). 
Figure 5-1. Association of IBD-KID2 scores against the linear variable of age in years. 





When the scores of IBD-KID2 were plotted against the education level of participants, 
the results were not significantly different between groups (Figure 5-2).  





























































5.3.3 Knowledge gaps 
The frequency of correct answers, and thus knowledge levels for each IBD-KID2 item, 
were examined (Figure 5-3). Ten items (67%) were answered correctly by more than 
50% of participants. 
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Figure 5-3. Frequency of correct answers given to IBD-KID2. 
The midline represents good knowledge (>50% scoring correctly) or poor 
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Little is known about the levels of public knowledge of IBD in New Zealand, but the 
benefits of improved awareness are far reaching. This assessment of knowledge 
levels among members of the general public in Christchurch has provided a summary 
of where the general understanding lies, and where there are deficiencies that could 
be addressed to maximise community support for children with IBD.  
When comparing the group of participants in this study to others who have 
completed IBD-KID2, the mean score overall was at a similar level to the children 
with IBD in the validation study (Chapter Four), but higher than the administrative 
staff who could also be considered as ‘general public’. While the level of education 
did not significantly affect scores in this study, in previous research measuring   
knowledge specifically in people with IBD, it has been a positive influence 12, 263, 264, 
458. This may indicate that more years of education for people with IBD may motivate 
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people to learn about their own disease and allows a greater understanding of health 
information, but that this does not necessarily translate to members of the public 
knowing more about health conditions in general. This lack of association between 
education level and IBD-KID2 score adds to the validation of construct validity 
presented in Chapter Four; in a group with no expectation of disease knowledge, 
questions were answered similarly by those across all levels of education. It may be 
surmised that this confirms IBD-KID2 is simple and easy to read and that the items 
are measuring knowledge, not reading comprehension, as was considered of IBD-KID 
(Chapter Three).  
Previous studies among adults with IBD have shown an inverse correlation between 
knowledge level, and age 263, 264, 476, however, it may not be feasible to make 
comparisons for such variables as age in a population without IBD as they will not 
have received disease specific teaching or education materials. In the population 
with IBD, age has been shown to correlate with a deterioration of knowledge levels, 
possibly due to the fact that people of lower age are engaged in more active social 
activities and therefore seek more information to better manage their disease 476.  
When comparing variables such as a family history of IBD, a number of factors may 
influence the strength of this effect. When gathering such data, parameters should be 
defined as to what constitutes ‘family history’, as demonstrated by Day et al 162 who 
stated the number of their parent cohort who had a family history of IBD (other than 
their child), and then provided greater detail of how many of this number had a first 
degree relative with IBD. The same parameters of ‘first degree relative’ were also 
used in the study by Keegan et al 264 who found this significantly influenced scores. In 
this study, as in the Haaland et al 12 paper that developed the original IBD-KID, 
participants were asked if a close family member had IBD, without further definition, 
and neither study found this a significant influence.  
The five items of IBD-KID2 that were scored highest (≥75%) by this study population 
could be regarded as those most generalisable to other diseases or conditions. The 
item regarding colonoscopy could be answered correctly by people with knowledge 
of certain cancers, coeliac disease, or other gastrointestinal conditions. The use of 
CAM is widespread for many conditions so this item could be understood in relation 
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to many other aspects of health care and general well-being. The importance of not 
stopping drugs may be generalisable to a number of other medication groups, and 
the effect of stress on the disease may be linked to that of irritable bowel syndrome 
of which stress is a key factor for triggering symptoms 477.   
Those items with the lowest correct scores are common to the population of children 
and adults with IBD too, as discussed throughout Section Two, so it would be more 
unexpected if these items had scored well. However, these deficiencies highlight 
areas for public education that may reduce the perceived stigma for children with 
IBD, such as increasing the knowledge that poor growth may indicate active disease 
and therefore explain their greater need for bathroom trips or time away from 
school.  
A discussion regarding the domains of poor knowledge among all participant groups 
that have completed IBD-KID2 is included in the conclusion at the end of this section 
(Section Two).  
5.4.1 Limitations 
It must be acknowledged that members of the public attending the University Open 
Day represent a proportion of the local population whose interest in health and 
education may be greater than average by virtue of the fact that they attended a 
health showcase event. In addition, the study population does not represent the 
general population’s education level of New Zealand according to the country’s 2013 
census 478. The census gave evidence that the New Zealand distribution among 
education levels were: High School 28%, College 52%, University 14%, and Post 
Graduate 6%. The current population had a comparable number that completed High 
School as their highest level of education, but higher numbers of those with 
University and Post-Graduate education. However, the level of education made no 
difference to mean scores, therefore providing further proof of content validity, as 
discussed in Chapter Four.   
IBD-KID2 does not include items regarding, for example, the cardinal symptoms that 
may be experienced by people with IBD. It should be acknowledged that public 
knowledge levels regarding factors such as this, in relation to the disease burden of 
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people with IBD, may have greater understanding due to public awareness 
campaigns. However, IBD-KID was developed to be appropriate to the paediatric IBD 
population and asking questions regarding common symptoms would increase the 
questionnaire length with no clear benefit.  
5.4.3 Strengths 
Using a validated knowledge assessment tool to measure the level of understanding 
among members of the New Zealand public has provided insight in to where 
opportunities may lie for improving awareness. While the tool was developed for 
children, the readability and structure are appropriate for people with all levels of 
health literacy. The fact that only one participant scored 100% on the tool reflect that 
the answers were not ‘guessable’ for those with higher education levels. 
5.4.4 Conclusion 
It was hypothesised that public knowledge of IBD would be poor. This hypothesis has 
been disproved based on the results presented in this study. The mean IBD-KID2 
score of the public attending the University Showcase event were above 50%, thus 
indicating that knowledge levels were at a level considered to be good. While IBD-
KID2 was developed for use in children, it has been shown to be acceptable for use in 
a number of different population groups. This assessment tool was developed to be 
more easily understandable than IBD knowledge surveys such as the CCKNOW 11 
which examine the disease and treatments in greater depth and may be too complex 





Chapter Six: IBD-KID2 Parent Education Study 
6.1 Introduction 
Effective self-management for children with IBD is dependent on a number of crucial 
elements, such as their family, community, and health care team 50, as outlined in 
Chapter One. The main source of support within the family setting is most commonly 
the child’s parent(s). Those factors known to enhance self-management for the child 
with IBD, such as knowledge, should also be addressed with other family members. 
Parents are logically the primary source of information for children regarding their 
disease and treatment and measuring their knowledge levels should be considered 
as important as measuring that of their child, in order to identify areas where they 
may need support and education.     
6.1.1 Information needs 
Parents of children with chronic illnesses have long expressed a need for greater 
information regarding their child’s condition. Parents report a need for information 
regarding their child’s diagnosis, disease management, the expected outcomes of 
treatment, prognosis, and the future development of the condition and its potential 
complications 479. Greater levels of information may help the parents with the 
following aspects 479-481: 
 feeling better prepared for the future 
 empowerment 
 coping with their child’s diagnosis and ongoing illness 
 reassurance 
 re-establishing a sense of control  
The majority of parents believe that they are their child’s main source of information 
regarding their condition and treatment 479. Subsequently, in this role of 
intermediary, they want to have sufficient and appropriate information so they can 




The provision of accurate, comprehensive information is regarded as an entitlement, 
and a prerequisite, for an effective and supportive partnership between parents and 
health professionals 479. The increased role of parents and children in disease 
management requires that they have greater involvement in decision-making about 
treatment and care, and crucial to this process is the effective exchange of knowledge 
and information between the MDT and the family 479. The MDT’s role therefore 
incorporates teaching to help parents and children develop the skills and knowledge 
to manage the condition when away from the hospital environment, and plays a 
central role in supporting parents 482, 483.  
6.1.2 Aims of education 
The aim of parent education is to enhance the parent’s knowledge, behaviour, or 
cognition as a caregiver in order to improve the following 164, 484, 485: 
 parent–child interactions 
 parent disease management 
 child disease outcomes 
 parent outcomes such as well-being 
 family outcomes such as family functioning  
 parent coping skills 
 parent anxiety 
The majority of parent teaching is done informally in the clinical setting, the time for 
which is frequently limited due to clinical schedules, and may be particularly 
challenging in complex interactions involving the triad of parent, child and 
professional 479, 484. Formal parent education can be described as those interventions, 
programmes, or services, which deliver direct or targeted education, training, or 
support to parents 485. Formal educational interventions are superior to ad hoc 
teaching 175, yet programmes for families of children with chronic disease remain 
scarce. This is despite their proven efficacy at improving knowledge and disease 
outcomes, and disease-specific recommendations for integrating such strategies in to 
service provision 486. Following education programmes, positive gains and 
improvements for families have been shown across a range of outcomes and 
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functioning such as knowledge, disease outcomes, mental health, parenting 
competencies, communication, and problem-solving skills 481, 484, 485. Few education 
programmes were identified that have been designed specifically for families of 
people with IBD. Quan et al 460 delivered an education programme specifically 
orientated to improving IBD knowledge for patients, families and friends, and 
showed significant improvements in knowledge levels for all participants. Waters et 
al 175 provided formal education that significantly improved knowledge after the 
intervention, and showed improvements to adherence.   
In order to circumnavigate the problems surrounding informal teaching in the 
clinical setting, identifying opportunities for delivering formal education is 
important. For parents, fitting in structured teaching programmes with regular 
family life may be problematic 486 but utilising situations where their children are 
already involved may be beneficial and logistically appealing. Residential camps for 
children with chronic conditions, including IBD, have been run for many years 165. 
These camps have been shown to improve confidence and acceptance due to the 
social engagement opportunities for parents and children that allow for comparisons 
with similar families, give perspective about disease trajectories, and help form 
meaningful peer connections 140, 142, 143. They also consistently demonstrate positive 
and sustained improvements to knowledge, self-management skills and HRQoL for 
children with IBD 141, 142, 166, and improved knowledge for siblings of children with 
chronic illness 487.   
The annual residential camp for children with IBD in New Zealand (Camp Purple) is 
organised in association with the Crohn’s and Colitis New Zealand (CCNZ) charitable 
trust and has been running since 2015. The residential camp also includes a weekend 
long parent education seminar. Parents attending from around NZ can reside at camp 
in order to attend. Camp Purple provides a convenient and practical setting for the 
provision of parent education, although no studies have been identified that 




6.1.3 Aims and hypotheses 
The objective of this study was to test the disease and treatment knowledge levels of 
parents before, and after, attending a two-day education programme as part of a 
residential camp for children with IBD. The overall aim of the study was to assess the 
effect of the education programme on the knowledge levels of parents using a 
validated knowledge assessment tool (IBD-KID2). In parallel with this research aim, 
the study was also designed to establish whether IBD-KID2 has the sensitivity to 
detect change pre and post intervention. The following hypotheses were therefore 
developed: 
That parents attending an education session at Camp Purple will see increased 
levels of disease knowledge following this intervention. 
That IBD-KID2 can be utilised in a parent cohort to detect sensitivity to change 
pre and post intervention. 
6.2 Methodology  
6.2.1 Setting 
The study was undertaken during Camp Purple in January 2019 at the Living Springs 
Function Centre in Christchurch, New Zealand.  
6.2.2 Population and ethics 
All parents attending the Camp Purple parent education programme were invited to 
participate in the research. Ethical approval for the study was provided by the 
University of Otago Human Ethics Committee (Health) (H16/116). Written informed 
consent was obtained from all parents. 
6.2.3 Content of the education programme 
The education programme was carried out over two days at the beginning of Camp 
Purple on the first afternoon and evening of day one, and the morning of day two. 
Meals and refreshments were provided for parents, and accommodation if required, 
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all of which were fully sponsored. The sessions that made up the education 
programme were presented by experts in the field from within New Zealand.   
Day one delivered sessions on: 
 An IBD overview – Paediatric Gastroenterologist 
 Surgical aspects – Paediatric Surgeon 
 Adolescent health – Paediatrician and Adolescent Health Specialist 
 Coping with chronic illness – Paediatric Psychologist 
 Crohn’s and Colitis New Zealand support group - Paediatric 
Gastroenterologist 
 Question and answer session - Paediatric Gastroenterologists 
Day two delivered sessions on: 
 Old and new IBD therapies - Paediatric Gastroenterologist 
 The nursing role in management of IBD – Paediatric IBD Nurse Specialist 
 Nutrition and IBD – Paediatric IBD Specialist Dietitian 
 The psychosocial impact of IBD - Paediatrician 
 Epidemiology of IBD - Paediatric Gastroenterologist 
 Discussions and questions - Paediatric Gastroenterologists, Nurse Specialist, 
Dietitian. 
6.2.4 Outcome measure 
Knowledge levels were assessed using IBD-KID2 at two time points. The initial 
completion was in paper form before the education programme began. For the 
second completion a link was emailed to all participants fourteen days later for them 
to complete an online version of IBD-KID2 (Cognito Forms). If the second IBD-KID2 
was not completed within one-week parents were emailed a reminder. 
6.2.5 Statistical analysis  
Baseline demographics were collected to provide comparisons of baseline mean 




 age (parent and child) 
 gender (parent and child) 
 child’s diagnosis 
 time since diagnosis 
 if either parent has IBD 
 parent education level 
 family ethnicity 
 number of Camp Purple parent education sessions previously attended.  
The comparison of mean scores between categorical variables was performed using 
independent t-tests, and ANOVA with Tukey’s post-hoc analysis. For continuous 
variables, significance was tested using linear regression. The significance level was 
considered as p ≤ 0.05. Knowledge levels were examined for each item on IBD-KID2 
to ascertain areas of good and poor knowledge among study participants. Poor 
knowledge was considered as less than 50% of participants answering an item 
correctly.  
For participants with two complete IBD-KID2 assessments, the mean scores for the 
baseline and repeat administrations were compared using paired sample t-tests. 
Consistency was examined using the ICC, with a value over 0.8 showing good 
reproducibility. The change in percentage scores for items were examined between 
the two time points, in parallel with the percentage of ‘don’t know’ answers given.  
6.3 Results 
6.3.1 Participants 
Thirty-six parents attended the education programme at Camp Purple, and thirty-
four consented to participate in the study. Four parents did not complete multiple 
items on the baseline IBD-KID2 completion (they failed to complete the second page) 
so were excluded from the study. Thirty parents completed IBD-KID2 at baseline, and 
 
181 
twenty-five of these completed the repeat administration, and hence had complete 
data from both time points. 
6.3.2 Demographics 
The demographic distribution of the study cohort between independent variables 
were examined (Table 6.1).  
6.3.3 IBD-KID2 scores at baseline 
The mean score for IBD-KID2 at baseline for the group overall (n=30) was 10.6 (SD 
2.9) out of a maximum of fifteen points. When examined against the independent 
variables, the scores were not significantly different for any categorical or continuous 




Table 6.1. Demographic distributions of the Camp Purple study cohort.  
 
Linear variables Mean (SD) Range 
Parent age (yrs) 41 (7.2) 28 to 54 
Child’s age (yrs) 12.5 (2) 9 to 16 
Child’s age at diagnosis (yrs) 8.7 (3.8) 1 to 16 
Time since diagnosis (yrs) 3.9 (3.3) 0.5 to 13 
Categorical variables Group N (%) 
Parent gender 
Male  9 (30) 
Female 21 (70) 
Child’s diagnosis 
CD 25 (83) 
UC 5 (17) 
Parent level of education 
High School 9 (30) 
College 9 (30) 
University 9 (30) 
Post-Graduate 3 (10) 
Family ethnicity 
NZ European 24 (80) 
Maori 2 (7) 







Other 3 (10) 
Parent also has IBD 
Yes 2 (7) 
No 28 (83) 
Other children have IBD 
Yes  2 (7) 
No 28 (83) 
Parents have attended  
Camp Purple before 
Yes 13 (43) 
No 17 (57) 
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Table 6.2. Mean IBD-KID2 scores: association with independent variables 
 
Linear variables Regression (R) P value 
Parent age 0.024 0.898 
Child’s age 0.319 0.085 
Child’s age at diagnosis 0.249 0.185 
Time since diagnosis 0.079 0.678 






Male 9.8 (2.9) 0.297 
Female 11 (2.9) 
Child’s diagnosis 
CD 10.8 (3.1) 0.601 
UC 10 (1.4) 
Parent level of education 
High School 9.2 (3.7) 0.283 
College 10.7 (2.4) 
University 11.4 (2.5) 
Post-Graduate 12.3 (1.2) 
Family ethnicity 
NZ European 10.6 (3.1) 0.61 






Other 11.3 (0.6) 
Parent also has IBD 
Yes 10.5 (2.1) 0.948 
No 10.6 (2.8) 
Other children have IBD 
Yes  11 (2.8) 0.857 
No 10.6 (2.9) 
Time since diagnosis 
< 2 years 10.7 (2.9) 0.951 
> 2 years 10.6 (2.9) 
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6.3.4 Previous camp attendance 
Parents were asked to report how many times they had attended the education 
sessions if their child had previously been to Camp Purple. The mean scores between 
respondents at baseline were measured against the number of attendances as a 
categorical variable, which showed no significant difference between group means (p 
0.498) (Figure 6-1), and as dichotomous data of having attended or not, which was 
also non-significant (p 0.553). 




6.3.5 Participant response patterns  
The frequency of correct answers at baseline for each of the fifteen items on IBD-
KID2 was examined (Figure 6-2). This showed that only one item was scored 





Figure 6-2. Frequency of correct responses given to IBD-KID2 items. 
The vertical line delineates areas of good knowledge (>50% correct answers) and 
poor knowledge (<50% correct answers). 
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6.3.6 Baseline and repeat IBD-KID2 comparisons 
The twenty-five participants who completed IBD-KID2 at both time points 
represents an 83% response rate. The mean time between the baseline and repeat 
completion of IBD-KID2 was 18.7 days (SD 3.9, range 14 to 25). The mean score at 
baseline for the participants with both data sets was 10.9 (SD 2.8), and at the repeat 
completion was 12.6 (SD 2.0), which was a significant increase following the 




Figure 6-3. Change in IBD-KID2 scores from baseline to the post-education session 
repeat. 




























These score changes were examined at the individual level (Figure 6-4), from which 
it can be seen that participant scores increased for 18/25 parents (72%), stayed the 
same for 5/25 (20%), and decreased by one point for 2/25 (8%). 




6.3.7 Correct answers at baseline and repeat IBD-KID2 
The number of correct answers given to each individual IBD-KID2 item at the 
baseline and repeat administrations, and the change in percentage of correct 
answers was examined (Table 6.3). The twenty-five participants responded ‘don’t 
know’ 74 times out of a total of 375 items overall (19.7%) in total when completing 
the baseline IBD-KID2, and 34 times (9.1%) when completing the repeat IBD-KID2. 
 





The ICC of the participants repeat assessments was measured to determine how 
consistent their answers were when compared as a group. The ICC between the two 









1 – Gut order 19 (76) 22 (88) + 12 
2 – IBD cause 19 (76) 25 (100) + 24 
3 - Stress 22 (88) 25 (100) + 12 
4 - Colonoscopy 25 (100) 25 (100) 0 
5 - EIM 20 (80) 20 (80) 0 
6 - Osteoporosis 14 (56) 17 (68) + 14 
7 - Growth 17 (68) 13 (52) - 16 
8 - Biologics 15 (60) 21 (88) + 24 
9 – Stopping drugs 23 (92) 25 (100) + 8 
10 - Parents 17 (68) 22 (88) + 20 
11 - CAM 15 (60) 20 (80) + 20 
12 - Steroids 16 (64) 21 (84) + 20 
13 – Food triggers 8 (32) 17 (68) + 36 
14 - Surgery 24 (96) 25 (100) + 4 




Parent education, and high knowledge levels regarding IBD and treatments, has 
many positive benefits for the individual and their family unit. However, 
opportunities for the MDT to provide teaching are invariably limited to the clinical 
setting where time and practical constraints are prohibitive. A residential camp for 
children with IBD provides the ideal opportunity to present an IBD parent education 
programme where time is allocated not just for education but also for questions and 
socialising. While evidence that proves efficacy for programmes such as this is scarce, 
this study has shown that an IBD education programme can significantly improve 
parent knowledge levels. 
None of the independent variables in this study correlated with the parent’s scores. 
Three previous studies testing IBD knowledge among parents of children with IBD 
did not generate a clear picture of expectations in this respect. Having a child whose 
disease duration was longer than two years was shown to generate significantly 
higher parent scores on IBD-KID (the original) in a study carried out in Australia 163, 
but in other studies there was no effect when studied as a linear variable 12, 162. In the 
current study, the time since diagnosis was studied as a linear and dichotomous 
variable (less than, or more than, 2 years since diagnosis) and neither showed a 
significant difference to IBD-KID2 scores. 
The level of parent education in this study had no significant effect on scores, as 
opposed to the study by Haaland et al 12 that showed parents with a post-secondary 
education had significantly higher knowledge levels. Further analysis in the current 
study population showed that the mean scores of parents with a High School 
education level (9.2, SD 3.7) did score lower than those with post-secondary 
education (11.24, SD 2.3) but this difference did not reach significance (p 0.08, CI -4.3 
to 0.3). It should be acknowledged that this could represent differences in health 
literacy, not necessarily parental education level, however this trait was not 
measured in either study. 
A number of studies among children and adults with IBD have shown that 
membership of an IBD support group or society has produced significantly higher 
scores for respondents 11, 12, 175, 263, 488. It is possible that our study population 
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exhibited selection bias having been recruited at Camp Purple, but it is also likely 
that this group comprises those motivated to learn, as opposed to knowing more at 
baseline than those who chose not to attend. The generalisability study presented in 
Chapter Seven provides comparison data for parent knowledge levels for those that 
belong to support groups.  
While previous work measuring IBD knowledge among children and parents using 
the original IBD-KID highlighted a number of gaps in understanding, the item 
response analysis in Chapter Three identified a number of construction and content 
issues in IBD-KID that may have contributed to these deficiencies. Having developed 
IBD-KID2 to be more generalisable to both CD and UC, and having simplified the 
items, the knowledge gaps have been considerably reduced in the parent population. 
Even though IBD-KID2 was developed specifically for children it has been shown in 
this study that it is also appropriate for use with parents and can identify a difference 
in knowledge levels following an education programme. The two lowest scoring 
items were regarding food triggers and osteoporosis, which were scored correctly by 
33% and 58%, respectively. These items have been poorly scored by all respondents 
in studies using IBD-KID and IBD-KID2, however, this is not considered a flaw of the 
item construction as similar gaps in knowledge have been found in studies using the 
CCKNOW tool, which was developed for measuring IBD knowledge in adults 11. This 
is reinforced by the finding that following the education programme, correct scores 
for both items improved by up to 38%, thus highlighting the importance of education 
and teaching.  
Two IBD-KID2 items were found to have a lower percentage of correct answers 
following the education session than at baseline, with the item regarding children’s 
growth while in remission having a decrease of 16%. The topic of growth in children 
with IBD has universally poor understanding in the adult, child, and parent IBD 
population with correct answers to the corresponding item in the CCKNOW ranging 
from 13% to 50% 11, 90, 460, 476. In this instance, clarification of whether the topic was 
specifically covered in the education programme was sought. When it was confirmed 
that this topic was not discussed with parents the issue was raised with those 
running the education programme so that it can be addressed in future years. 
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The repeat administration of IBD-KID2 in this study population was performed no 
more than twenty-five days after the baseline completion. While this was carried out 
to test changes in IBD-KID2 scores, the time-period was too short to measure 
whether the knowledge was retained in the long term. The IBD education 
programme carried out by Quan et al 460 measured knowledge levels three months 
after the intervention, which showed that the knowledge was retained for this 
duration. Kennedy et al 489 found that knowledge scores were similar nine months 
after providing an education handbook, and Waters et al 175 found that knowledge 
was retained for at least eight weeks after education sessions. 
This Camp Purple study showed no significant difference in knowledge levels for 
those parents having attended previous Camp Purple education sessions, some of 
whom had attended three other times. However, with no previous knowledge 
assessments with which to compare, conclusions cannot be reached. It may be 
argued that parents’ exposure to different treatment modalities, or their child’s 
disease course, may not have changed in that time-period. Similarly, they may not 
have been exposed to other IBD teaching or educational materials, thus there should 
be no expectation of higher knowledge levels compared to parents whose children 
have been recently diagnosed and may have been exposed to teaching and 
educational material. This highlights, as has been discussed in Chapter One (section 
1.5.2), that education should be reinforced during clinic visits for all participants and 
families regardless of disease duration and should be regarded as an ongoing 
endeavour.  
6.4.1 Limitations 
This study had no comparator control group that could determine whether parent 
knowledge levels may have increased without the intervention of the education 
programme. In future studies parents who chose not to attend camp could act as a 
control group. However, some form of control intervention would be required as 
increased awareness of the study purpose could motivate the control group to seek 
knowledge independently. However, the IBD-KID2 validation study (Chapter Four) 
and the generalisability study (Chapter Seven) confirm that IBD-KID2 scores in those 
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populations did not increase during the same time-period when there was no 
intervention present. 
The sole focus of this study was to measure knowledge levels pre and post 
intervention. Given that there is a wealth of information available on the benefits of 
residential camps such as Camp Purple, it would have been of interest to assess other 
outcome measures with the parents at both time points, such as HRQoL, or anxiety 
levels. However, children with IBD and their parents are frequently approached to 
participate in research, and it was considered that it may have been intrusive in that 
setting to increase the respondent-burden.  
The two administrations of IBD-KID2 were performed using different formats – the 
first was on paper and the second via an online form facility. It was previously shown 
(Chapter Four) that this had no effect on children’s scores so it could be surmised 
that the same would be applicable to parents. The use of the electronic format may 
have contributed to the relatively high response rate of 83% for the second 
completion due to the convenience of not having to return paper versions.  
This study did not assess whether IBD-KID2 can assess sensitivity to change among 
children with IBD. However, this will be addressed in the study presented in Chapter 
Eleven. 
6.4.2 Strengths 
The study had a good respondent return rate for the second IBD-KID2 
administration. The online version of IBD-KID2 has been used previously with good 
effect and has been shown to be an acceptable alternative to the paper version of this 
outcome measure. This alternate, electronic format has allowed for IBD-KID2 score 
comparisons between numbers of different respondent groups, as discussed in 
Chapter Seven. 
Performing this study at Camp Purple harnessed a rare opportunity. Camp Purple 
allows time for parents and clinicians to communicate and share knowledge in a 
setting that is conducive to clinical discussions, but does not have the constraints of 
children, time, and other clinical pressures that are present in hospital. The format of 
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the education programme allowed for question and answer sessions at the end of 
both days, which gave parents time to reflect on the teaching and formulate 
questions or seek clarity.  
6.4.3 Conclusion 
The hypotheses for this study were that the Camp Purple parent education session 
would improve parent’s knowledge levels of IBD, and that IBD-KID2 could detect the 
sensitivity to change pre and post education session. The education programme 
significantly improved parent’s IBD-KID2 scores, thus proving both of these 
hypotheses. This information can be disseminated to the Charitable Trust that 
supports Camp Purple (CCNZ) so they can distribute this information among parents 
to encourage more to attend.  
The benefits of residential camps for children and their parents are multifactorial, 
and this study adds to the growing literature by showing that parent education 
sessions can make a significant difference to the disease-specific knowledge of 





Chapter Seven: IBD-KID2 Generalisability Study 
7.1 Introduction  
The family component of the self-management framework by Modi et al 50 highlights 
the importance of parents, siblings, and the extended family, to a child’s development 
of self-management skills, as highlighted in Chapter One (Section 1.4.4). When a child 
is diagnosed with a chronic disease such as IBD, all family members are affected and 
the family unit as a whole is faced with the challenge of the condition, and the 
emotional and social consequences that this may bring 136, 483, 490. Parents and 
siblings of children with IBD experience many problems that may affect their quality 
of life, such as psychological and emotional sequelae, relating to the consequences of 
the illness and side effects of its treatment 491. Family members should, therefore, 
also be considered to benefit from addressing the modifiable factors of the Modi 
framework, such as disease and treatment knowledge, so as to improve outcomes for 
the child with a chronic illness as well as their family 13. The assessment of disease 
and treatment knowledge among children with IBD has the benefit of being able to 
provide targeted education for those areas where gaps or misunderstandings lie, as 
discussed in Chapter One (Section 1.7.2). The same process should be applied to 
family members, especially the parents and siblings who are in close proximity to the 
health needs of the child with IBD, so as to address any concerns that may adversely 
affect their well-being. 
7.1.1 Sibling knowledge 
A number of studies have emphasized how the active participation of healthy siblings 
in the family management of an ill child can positively influence their illness and life 
course, with benefits such as caring sibling relationships, a strong sense of family, 
support, and courage 136. The importance of sibling support is also highlighted as a 
specific element in the self-management framework by Modi et al 50, and a positive 
association has been shown between the quality of the healthy sibling relationship 
and their knowledge of the unwell siblings’ condition 492.  
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The information needs of the siblings of chronically ill children have been studied in 
a number of disease groups, and have been summarised to include: the condition and 
any impairments it may cause, the types and purpose of treatments, and ways to 
support their sibling to develop and adapt new skills 136. Despite this understanding 
that siblings have a need for disease information, education programmes are 
predominantly focused on enhancing knowledge of the parent and the child with the 
condition 128. Siblings gain knowledge mainly through that provided indirectly or 
directly through their parents, or through the experience of living with a child with a 
chronic illness, and little information is provided directly to the well sibling 128, 168, 492. 
However, siblings of children with IBD have voiced concerns over their parents' 
keeping them uninformed about the illness as a way of protecting them, but the effect 
of this may also be negative 491. Well siblings frequently experience psychosocial 
issues such as internalising and externalising symptoms and low self-esteem, which 
may be in addition to, or due to, negative peer reactions, and disruptions in social 
activities and schooling 168, 487, 493. Protective factors against these psychosocial 
issues are known to be the provision of disease and treatment information, and good 
parent-sibling communication about the illness 136, 169, 487, 490.  
Establishing the knowledge levels of IBD among siblings has had very little attention. 
One study was identified from 1992 which found that only seven of the twenty IBD 
siblings studied could name the disease affecting their sibling, few knew anything 
about the disease and its symptomatology, and only three had a serious discussion 
with their parents or siblings about IBD 490. No validated tools for children with IBD 
have been utilised in the sibling population to assess their knowledge levels. 
 
7.1.2 Parent knowledge 
Considerably more is known about the knowledge levels of the parents of children 
with IBD. A number of studies have utilised the original IBD-KID to assess where 
their strengths and limitations of knowledge lie, and have shown a correlation 
between parent knowledge levels and that of their child with IBD 12. Parents’ 
acquisition of disease specific knowledge is vital to maximize disease control and to 
nurture their children’s understanding of the illness and treatment, and this 
 
195 
increased parental involvement is associated with more effective self-management 
for children 50, 494. In addition, higher parent knowledge is shown to be a protective 
factor against chronic sorrow, a phenomenon frequently experienced by parents of 
children with chronic illness 480. Parents of children with chronic illness have 
expressed the desire for information regarding the diagnosis, management, expected 
outcomes and prognosis, and possible future developments, and wish to know both 
positive and negative aspects in order to prepare for the future 479. The reasons for 
wanting this information are multifactorial 479, and include: 
 To help with decision making 
 To understand the clinical decisions made 
 Reassurance 
 Adjusting to the future 
 As a resource to help with the day to day medical and psychological care of 
their child 
 Establishing control 
 To provide confidence in answering their child’s questions 
 To help feel involved 
By assessing parent knowledge we can identify whether their levels are associated 
with their child with IBD, as well as their siblings, so as to establish where the 
greatest impact of education strategies may lie; in teaching the parents so they can 
impart information, or to additionally target education at siblings to directly enhance 
their understanding. This would have the effect of maximising the positive benefits of 
increased knowledge on the individual and the family unit as a whole, and 
subsequently the support given to children with IBD in their home environment 11. 
7.1.3 External validity 
While the IBD-KID2 efficacy study in Chapter Four established internal validity of 
IBD-KID2, validity should be considered not as a property of the instrument but of 
how it is used 495. The original validation study may have presented an optimistic 
reflection of the tools performance, thus making duplication of the methodology and 
results in independent population’s necessary 495. It was therefore important to 
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assess external validity with an effectiveness study to determine whether the original 
findings can be repeated in different populations and environments 495, 496. In testing 
IBD-KID2 in a number of geographically diverse populations, it should contribute to 
the previous studies presented in this section to demonstrate that it is a robust and 
generalisable tool for paediatric gastroenterologists to use in a variety of settings.  
7.1.4 Aims and hypotheses 
The aims of this generalisability study were to use IBD-KID2 to measure the 
knowledge levels of all family members in a number of geographic locations, thereby 
providing data for group comparisons and to add to the hierarchy of knowledge as 
established in Chapter Three. The following hypotheses were generated:  
That the IBD-KID2 scores of children with IBD and their siblings will positively 
correlate with the scores of their parents. 
That IBD-KID2 scores do not differ between countries, thereby establishing 
comparable external validity with the original IBD-KID. 
That the reliability of IBD-KID2 is comparable to the original IBD-KID. 
7.2 Methods 
7.2.1 Collaborating centres and ethics process 
This generalisability study was performed as a multi-centre collaboration in a 
number of tertiary care hospitals in three different countries. These centres were 
chosen for their geographic diversity within their respective countries and having 
English as the first language spoken in their region. Ethics and Research Governance 
approvals were obtained by the candidate and local investigator from all 





Christchurch Hospital, Christchurch, Christchurch (South Island) 
– The University of Otago Human Ethics Committee (Health) (H16/116) 
Starship Children’s Hospital, Auckland (North Island) 
– Auckland DHB Research Office (A+8353) 
Australia 
Multi-centre site approval was granted via the Australian National Mutual 
Acceptance Scheme, which allows for a single ethics review by multiple public health 
organisations for collaborative studies (HRC/18/SCHN/432).  
Individual applications were then made for Site Specific Research Governance 
approval: 
 Sydney Children’s Hospital, Sydney (SSA/18/SCHN/465) 
 Queensland Children’s Hospital, Brisbane (SSA/18/QCHQ/47719)  
 Perth Children’s Hospital, Perth (0000001398) 
 Royal Children’s Hospital, Melbourne (SSA/47719/RCHM-2018-157604) 
Canada 
 IWK Health Centre, Nova Scotia (1023997) 
 BC Children’s Hospital, Vancouver (H18-02697) 
7.2.2 Population and setting 
Children with IBD and their families were approached during IBD outpatient clinics 
at each collaborating centre. Inclusion criteria for the study are as follows: 
 children with IBD aged 8 years and over 
 at least one parent for every child with IBD 
 any siblings aged 8 years and over 
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7.2.3 Study process 
The study process was determined by the Research Ethics Board (REB) stipulations 
at each collaborating centre: 
All New Zealand and Australian sites 
Local Gastroenterologists or researchers identified eligible participants in IBD clinic 
and obtained and documented their verbal consent to send a participation referral 
(parent name and email address) via secure data transfer to the candidate in 
Christchurch, New Zealand. The study was then completed remotely via email with 
the parents, who were provided links to the online version of IBD-KID2 and a form to 
collect demographic data (Cognito Forms).  
Canadian sites 
Nova Scotia 
Local Gastroenterologists or researchers identified eligible participants in IBD clinic, 
obtained written consent on-site, and then sent the participation referral via secure 
data transfer to the candidate in Christchurch, New Zealand.  
Vancouver 
Local Gastroenterologists or researchers identified eligible participants in IBD clinic 
and obtained written consent on-site. The research team in Vancouver then 
completed the study process, as stipulated by their REB who would not allow data 
sharing between centres. 
7.2.4 Statistical analysis 
Demographic data were collected from all participants regarding their age and 
gender, and from children with IBD information on their diagnosis. We asked parents 
for their highest level of education achieved, whether they also had IBD, and whether 
they belong to an IBD support group. Siblings were also asked if they had IBD. 
We tested data distribution using the Shapiro Wilk test of normality. If the data were 
normally distributed, we would present the mean and SD with parametric tests of 
between group differences. If the data were skewed, we would present the median 
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and inter-quartile range, with non-parametric tests of distribution. Results were 
considered significant at P <0.05 with a 95% confidence interval. 
The mean IBD-KID2 scores were calculated for each participant group: children with 
IBD, mothers, fathers, and siblings. Scores were compared against demographic data 
using independent sample t-tests or ANOVA for categorical variables, and linear 
regression for continuous variables. For categorical variables with significant results 
in the ANOVA further analysis was performed using the post-hoc Tukey’s test to 
determine where the differences lie. The IBD-KID2 scores of the children with IBD, 
and their siblings, were explored for associations with their parent’s scores using the 
Pearson correlation coefficient, with results closer to one indicating good correlation 
– the significance of this result will also be reported.   
Reliability between the baseline and follow-up completion of IBD-KID2 was 
measured using paired sample t-tests as well as the ICC. Reliability would be 
established if there was no significant difference between mean scores between the 
two administrations of IBD-KID2. Reliability using the ICC score would be moderate 
if between 0.5 and 0.75, good if between 0.75 to 0.9, and excellent if greater than 0.9 
456, with the statistical significance of this result also reported. 
The two-sample z test was used to determine whether the sample mean scores of 
children with IBD were significantly different from the known mean score provided 
in the validation study in Chapter Four. Scores were also compared between each 
parent group in this study with the mean and standard deviation scores from the 
Camp Purple study in Chapter Six. 
Generalisability between the three countries was first examined by comparing 
population demographics using categorical and linear variables for each country to 
establish the degree of similarity between the cohorts of children with IBD. 
Univariate analysis was used where applicable. Mean IBD-KID2 scores were then 





A total of seventy-two children with IBD were included in the study at the time of 
performing this analysis. Of these participants, sixty-seven (93%) had their mother 
participating, and thirty-seven (51%) their father, with 56% having one parent and 
44% both parents taking part. There were twenty-seven (38%) children with IBD 
who had at least one sibling participating. Of note is that eight mothers completed 
the IBD-KID2 assessment with no other family members, and these results were 
included in the comparison of participant means analysis only. The number of 
families approached to take part in the study per country, and the subsequent 
number providing consent, withdrawing from the study, and completing baseline 
and repeat IBD-KID2 assessments, are presented (Figure 7-1). Recruitment is 
ongoing and will continue until a pre-determined target of fifty children with IBD per 
country is achieved. 
7.3.2 Demographic data 
The demographic distribution of the children with IBD was provided by all but eight 
participants (Table 7.1). Variables are explored in greater depth, and between other 
participant groups, in subsequent analyses.  
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Table 7.1. Demographic data for children with IBD.  
*Eight families did not provide data. 
Categorical variables Category 












































Linear variables   
Age (Years) 
Mean (SD) [Range] 
 13.9 (2.4) 
[8 to 18] 
Time since diagnosis (years) 
Mean (SD) [Range] 
 
3.5 (3.2) 
[0.2 to 14.2] 
Age at diagnosis 
Mean (SD) [Range] 
 
10.4 (3.9) 
[2 to 16.7] 
 
7.3.3 IBD-KID2 scores 
The data were normally distributed (Shapiro Wilk p = 0.184), therefore mean and 
standard deviations were calculated, and associations examined with parametric 
tests. 
The mean IBD-KID2 scores (maximum score fifteen) for each participant group were 
calculated (Table 7.2), with the hierarchy of scores between family members being 




Table 7.2. Mean IBD-KID2 scores for each participant group 
* Eight mothers completed the baseline IBD-KID2 with no other family members. 
Participant N 
IBD-KID2 score 
Mean (SD) Range 
Child with IBD 72 9.3 (2.6) 2-15 
Mother 75* 11.8 (2.2) 7-15 
Father 37 10.8 (2.5) 4-15 
Sibling 32 8.3 (3.2) 2-13 
 
The scores of the participant groups were compared using a one-way ANOVA to 
establish between group differences, which showed the scores were significantly 
different (p <0.005). This result was further explored using a Tukey post hoc test 
(Table 7.3) that showed children with IBD and their siblings had significantly lower 
scores than their parents, but no significance difference was found between mothers 
and fathers, or children with IBD and siblings. 






Child with IBD 
Mother -2.5 <0.005 
Father  -1.5 0.019 
Sibling 0.3 0.25 
Mother 
Father  1.0 0.2 
Sibling 3.5 <0.005 
Father Sibling 2.5 <0.005 
 
7.3.4 Independent variables  
The scores achieved on IBD-KID2 by each participant group were then examined for 
their association with a number of independent linear and categorical variables to 
determine if any single variable can predict score patterns. 
 
7.3.4.1 Linear variables 
A number of linear variables were examined, including the age of each individual, as 
well as the effect of the child with IBD’s age at diagnosis, and time since diagnosis, for 
all participants (Table 7.4).  
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Table 7.4. Effect of linear variables on IBD-KID2 scores. 






Participant R P R P R P 
Child with IBD 0.230 0.065 0.174 0.166 0.041 0.748 
Mother 0.124 0.333 0.151 0.237 0.117 0.361 
Father 0.041 0.822 0.161 0.377 0.196 0.282 
Sibling 0.457 0.011 0.017 0.930 0.159 0.400 
 
The only variable with a significant influence on any participant group was shown by 
a positive association between IBD-KID2 scores and the increasing age of siblings, a 
factor further explored as a series of scatter plots (Figure 7-2). All other results were 
non-significant. The two siblings with the highest scores at the youngest age had 
their IBD-KID2 answer patterns and scores compared with that of their mother and 
father to ascertain if either had completed the survey on their child’s behalf, but they 
were dissimilar thereby implying that these scores were a true representation of the 
sibling knowledge.  
The variable of time since diagnosis was further examined as a categorical variable 
with the linear times being divided into the time periods of less than, or more than, 
two years since diagnosis. The IBD-KID2 scores were not significantly different 
between the two diagnostic periods for the child with IBD (p 0.683), mothers (p 
0.342), or fathers (p 0.452). However, the IBD-KID2 scores of siblings where the 
diagnosis was less than two years ago (mean 7.0 (SD 3.3)) were significantly lower (p 
= 0.029) than those siblings of children diagnosed more than two years ago (mean 












7.3.4.2 Categorical variables 
A number of categorical variables were available to test for association with IBD-
KID2 scores (Table 7.5). Of note is that the effect of having a sibling with IBD could 
not be examined as there was only one sibling matching this category. 
Mothers scored significantly higher than the fathers in this study. The significant 
effect of the mother’s education level on the mothers score was inspected using post-
hoc analysis. This showed IBD-KID2 scores were significantly lower for mothers 
whose highest level of education was High School compared with those who had 
attended University. When this factor was further explored by comparing the scores 
of mothers with a High School education level (mean score 10.6 (SD 2.0)) versus 
post-High School education level (mean score 12.2 (SD 2.2)), the result was 
significant (p 0.005) The mothers’ IBD-KID2 scores also showed a positive 
association with belonging to an IBD support group, but no effect on other 
participant groups was seen. 
7.3.5 Score correlations 
The correlation of IBD-KID2 scores between the child participant groups and their 
parents was examined using Pearson’s correlation coefficient (R) (Table 7.6). The 
scores of children with IBD scores were weakly, but positively correlated with those 
of their mother using listwise comparisons (matched family pairs), but no other 
significant results were shown for children with IBD or their siblings. These patterns 
of correlation were also explored graphically for the children’s groups (Figure 7-3). 
Table 7.6. Score correlations between participant groups. 








Child IBD Mother 67 0.276 0.024 
Child IBD Father 36 0.115 0.506 
Child IBD Sibling 25 0.344 0.092 
Sibling Mother 25 0.190 0.364 




Table 7.5. Effect of categorical variables on IBD-KID2 scores 
 Gender  
Female Male P value 













Parent has IBD 
Yes No P value 

















Parent in a support group 
Yes No P value 


















CD UC IBDU P value  






















































































7.3.6 Test re-test reliability 
Forty-two (58%) of the cohort of seventy two children with IBD completed a repeat 
IBD-KID2 assessment, as well as forty six mothers (61%) and twenty four fathers 
(65%). The mean number of days between the completion of the baseline and repeat 
IBD-KID2 administrations for each participant group was between twenty and 
twenty-three days (range fourteen to fifty six). The mean IBD-KID2 scores between 
the baseline and repeat administrations were not significantly different for children 
with IBD (p 0.288), mothers (p 0.253) or fathers (p 0.059) (Figure 7-4), thus 
establishing test-retest reliability.  
Figure 7-4. Baseline and repeat IBD-KID2 scores.  
 
The intraclass correlation coefficient between the baseline and repeat 
administrations of IBD-KID2 for each participant group were calculated, alongside 
the significance of the results. This showed good reliability for the children with IBD 
(ICC 0.81, p <0.005) and mothers (ICC 0.87, p <0.005), and moderate but highly 
significant reliability for the fathers (ICC 0.70, p 0.003). The ICC reliability score of 
the original IBD-KID 12 was 0.84 as measured by parents and child participants 




highly significant (P <0.005). The IBD-KID2 validation study (Chapter Four) had an 
ICC for children with IBD over repeat administrations of 0.82, with similar results in 
this study for the children with IBD (0.81).  
7.3.7 Generalisability 
In order to determine if the participant demographic data were comparable between 
the three countries contributing data to the study, the data for the children with IBD 







































Mean (SD)  
Range 
13.4 (1.9) 
9 to 17 
14.2 (2.6) 
8 to 18 
13.9 (2.7) 































0.2 to 12.1 
3.9 (3.6) 
0.25 to 14.2 
3.5 (1.6) 
1.9 to 6.0 
0.492 
Age at  
diagnosis 
Mean (SD)  
Range 
10.5 (3.7) 
2 to 14.8 
10.3 (4.2) 
2 to 16.7 
10.3 (3.5) 
































Mean (SD)  
Range 
45.7 (5.4) 
37 to 60 
47.3 (6.5) 
34 to 60 
44.9 (4.7) 
39 to 51 
0.43 















































Fathers age  
(years) 
Mean (SD)  
Range 
46.6 (5.2) 
39 to 57 
49.8 (6.0) 
38 to 59 
49.8 (6.5) 



























Sibling age  
(years) 
Mean (SD)  
Range 
14.7 (3.8) 
10 to 21 
14.3 (3.6) 
9 to 21 
11.5 0.705 














This analysis showed that there were no significantly different variables for the 
groups of children with IBD between the three geographic locations. 
The mean IBD-KID2 scores for each group in each country were calculated, and 
compared using an ANOVA which showed there were no significant score differences 
between locations for any participant groups: children with IBD (p 0.355), mothers 
(p 0.104), fathers (p 0.457) or siblings (p 0.767) (Figure 7-5).  
Figure 7-5. Mean IBD-KID2 scores for participants group in each country. 
 
 
7.3.8 Comparison of scores 
The mean (and SD) IBD-KID2 scores achieved in this study by children with IBD, 
mothers, and fathers, were compared with the known IBD-KID2 mean scores from 
previous studies among these participant groups. The two sample z test showed that 
the mean scores were not significantly different for children with IBD between this 
study and the validation study (p 0.17), for mothers between this study and the 
Camp Purple research (p 0.241) or fathers between this study and the Camp Purple 




7.3.9 Patterns of knowledge 
The frequency of correct answers given to each IBD-KID2 item were reviewed 
between participant groups (Figure 7-6). This showed that for each participant 
group, the number of items answered correctly by at least 50% of each group were:  
 Children with IBD: 12/15 
 Mothers: 15/15 
 Fathers: 14/15 
 Siblings: 9/15. 
The frequency of IBD-KID2 responses were also compared for the children with IBD 
from each country (Figure 7-7). This highlighted similar patterns of knowledge 
between the three countries. When the level of difficulty was inspected, none of the 
items were scored correctly by under 30% of children with IBD from any country, 
thus indicating that the items weren’t too hard. Three items were scored correctly by 
over 70% of the children with IBD, indicating that these items are easy. The IBD-
KID2 response patterns from all studies included in this section will be addressed in 





Figure 7-6. Frequency of correct answers for each IBD-KID2 item by participant group.  
The vertical line delineates areas of good knowledge (>50% correct answers) and 






Figure 7-7. Frequency of correct answers to each IBD-KID2 item for children with IBD 
in each country  
The mid-line delineates areas of good (>50%) or poor (<50%) knowledge. The ‘easy’ 
(>70% scoring correctly) and ‘difficult’ (<30% scoring correctly) areas represent the 
index of difficulty.  
 
7.4 Discussion 
The study in Chapter Four showed IBD-KID2 to have been validated in a specific 




this tool would be generalisable to children with IBD elsewhere in the world. By 
performing this external validity study in a number of centres, the patterns of 
knowledge could be compared across geographic areas, between ages, and among 
family members. This has shown IBD-KID2 to have generalisability to the wider IBD 
population and to be an appropriate tool for measuring the IBD knowledge levels of 
mothers, fathers, and siblings. When disseminated, this research may enable 
gastroenterologists to apply the findings with confidence to their local setting and to 
begin using IBD-KID2 as a clinical and research knowledge assessment tool.  
The hierarchy of knowledge levels between participant groups in this study mirror 
those found in studies that used the original IBD-KID, as well in other disease groups. 
In all studies using IBD-KID, parents had significantly higher scores than their 
children 12, 162, 163, 415, and the one study that compared parents showed that mothers 
had significantly higher scores than fathers 12. This gender disparity was also found 
in studies of knowledge levels among children with diabetes and their families 497. 
None of the studies using the original IBD-KID tested knowledge levels of the siblings 
of children with IBD, however among children with Cystic Fibrosis (CF) the same 
hierarchy was demonstrated as in this study: mothers had the highest scores, 
followed by fathers, children with CF, then siblings 498. Among children with diabetes 
it has been shown that the scores of the fathers were not significantly different from 
that of their children 497, with the overall cohort in this study showing fathers to 
score significantly higher. However, visual inspection of the country scores (Figure 6-
5) showed the fathers in New Zealand to be scoring lowest of all the countries. 
Further analysis showed that the scores of children with IBD and the fathers in the 
New Zealand cohort were not significantly different (p 0.12), whereas the fathers 
scores were significantly higher in Australia (p 0.03) and Canada (p 0.016). This 
highlights that fathers in New Zealand are not as knowledgeable about their child’s 
condition, but the previous Camp Purple research (Chapter Six) has shown a group 
education session to be effective at significantly improving knowledge levels. This 
education intervention should therefore be promoted to both parents during clinical 
visits and both parents encouraged to attend where possible.  
The finding of a significant correlation between the scores of children with IBD and 




IBD-KID 12, and ties in with the parent’s belief that they are the primary source of 
disease and treatment information for their child 479. However, it was also 
hypothesised that the scores of the siblings would also positively correlate with that 
of their parents, but this association was not found in the study cohort for either 
mothers or fathers. One explanation may be that the children with IBD gain 
information through various settings such as clinical encounters and educational 
material they are given, whereas siblings may not receive such input. The positive 
association between sibling knowledge and increasing age in this study, as well as 
time since diagnosis being over two years, suggests that as the siblings grow older, 
they may be independently seeking information on the condition. It has been shown 
that the internet is the primary source of health information for adolescents 179 and 
they may be utilising this medium in a desire to better understand their brother or 
sisters IBD in order to provide support or to fill gaps in understanding that have not 
been addressed. The sibling IBD-KID2 scores were not significantly different from 
the children with IBD, but it should be acknowledged that those siblings participating 
in this research may represent those with an established knowledge base who were 
not concerned about getting the answers wrong or achieving low scores. In order to 
maximise sibling knowledge it has been shown that sibling education programmes 
are effective at increasing knowledge of a condition 168 and a sibling session at events 
such as Camp Purple should be considered.  
Only eleven (10%) of the 112 parents in this study cohort reported that they 
belonged to a support group, of which seven were in New Zealand, four in Australia 
and none in Canada. In this cohort the IBD-KID2 scores for mothers belonging to a 
support group were significantly higher than those who did not, but this variable had 
no impact on the IBD-KID2 scores of the child with IBD or sibling participant groups, 
and belonging to a support group had no effect on father’s scores. This finding is in 
contrast to previous research that found the mothers score unaffected if they 
belonged to an IBD support group, but the score of their child with IBD was 
significantly higher 12. In the adult IBD population, belonging to a support group has 
shown significant positive effects on knowledge scores 11, 175, 263, 488. Previous 
research in the adult IBD population has highlighted that higher disease specific 




membership to disease specific support groups. A systematic review of research 
relating to disease support groups, as well as health advisory organisations, 
identified the perceived benefits of membership as being; reducing anxiety, 
interaction with others, learning, self-management, emotional support, sharing 
feelings, learning coping skills, empowerment and hope, and advocating to improve 
healthcare 499, 500. All of the parents belonging to a support group in this study cohort 
reported that they were members of Facebook groups, a medium known to offer a 
mutual support platform for the management of chronic diseases 501. All of the 
countries in this study have a national ‘Crohn’s and Colitis’ charitable organisation, 
and all have affiliated Facebook groups. Membership to such support forums are 
likely to be beneficial to all parents of children with IBD and the local clinicians 
should ensure that information on support groups is provided to their families, and 
the possible benefits explained.    
7.4.1 Limitations 
The primary limitation of this study was that the countries selected for participation 
represent English speaking developed countries, which therefore limits 
generalisability to areas not matching these criteria. A study design was developed to 
perform a translation study of IBD-KID2 into Hebrew but the participating centre 
was not able to undertake the research at the time (Appendix J). Future research may 
address this limitation by translating IBD-KID2 into languages commonly used 
throughout the world, thereby maximising the centres that can incorporate 
knowledge assessments in to their clinical IBD care and research activities. 
The use of IBD-KID2 to assess parent knowledge could be considered to skew their 
scores towards the upper limits due to it being a child orientated assessment tool 
and the questions may be too easy. There are adult IBD knowledge assessment tools 
available, such as the CCKNOW and the KQ 11, 263, which could have been used to 
assess parent knowledge. However, these tools contain items that would only be 
relevant to adults or older adolescents with IBD, such as pregnancy, smoking, and 
colon cancer, and parents of paediatric patients may not have been exposed to this 
information yet. Previous research has shown that parents of children with IBD score 




scores were higher at 79% for mothers, and 72% for fathers thus suggesting that the 
questions may be easier, but also more relevant to them given the age of their 
children with IBD being eight years and up in this cohort.    
It must be considered that the participant groups of children with IBD and their 
siblings may have had their online IBD-KID2 assessment completed by their parents. 
In order to assess this possibility a visual inspection of family scores was made which 
revealed ten pairs of mother and child scores were the same, but no fathers or 
siblings. Six of these ten pairs had dissimilar answer patterns, despite the identical 
scores, so it may be surmised that these were completed by the correct participant. 
Four of the pairs had identical answer patterns but with no way of assessing if these 
were completed by the same person it is impossible to speculate as to who 
completed them. These four pairs represent 5.5% of the cohort of children with IBD. 
7.4.2 Strengths 
Implementing IBD-KID2 at multiple sites across three geographically diverse 
countries has provided data to establish external validity. No significant difference in 
scores was found between the counties for any participant group, thus adding 
strength to the evidence base that IBD-KID2 can be used with confidence in the wider 
population of children with IBD. The established hierarchy of knowledge levels is in 
concordance with the literature available, thereby showing that this assessment tool 
has been written at an acceptable level of understanding in that participants don’t all 
score very high, very low, or all the same. The lack of influence of the majority of 
independent variables once again adds to the evidence base of generalisability in that 
understanding of the tool is not related to age or diagnosis, and therefore it is not too 
difficult for the younger participants, and items are not skewed to those with a 
particular condition as in the original IBD-KID (Chapter Three).  
The percentage scores achieved on IBD-KID2 by children with IBD in this study (aged 
eight years and over) was 62%, which is consistently higher than previous studies 
using the original IBD-KID (aged ten years and over) that showed scores ranging 
from 43% to 51% 12, 162, 163, 415. This suggests that IBD-KID2 is either easier to 




response analysis in Chapter Three. The reliability of IBD-KID2 established in the 
validation study (Chapter Four) has been confirmed with the test-retest analysis in 
this study.  
The response rate of families participating in the study, when those that withdrew 
were excluded, was 33%. This was acceptable for online surveys, with response rates 
ranging from 20 to 45% 502-504. With no data available to determine the 
characteristics of non-responders, or those that subsequently withdrew, it was not 
possible to assess whether the response rates implied methodological shortcomings 
or bias 504. 
7.4.3 Conclusion 
The original hypotheses for this study have been adequately addressed. The 
hypothesised correlation of IBD-KID2 scores between parents and their children 
with IBD and siblings was not evident for all comparator groups. Significant 
correlations between children with IBD and their mothers enables us to accept that 
aspect of the hypothesis, but no correlation was found with their fathers, or for 
siblings with either parent, thereby leading us to reject the hypothesis for these 
combinations. The IBD-KID2 scores did not differ between countries and we can 
therefore accept the hypothesis that IBD-KID2 has generalisability to the wider 
population of children with IBD, which is comparable with the original version of 
IBD-KID 12. The reliability of IBD-KID2, as established in this study, was comparable 
with the original IBD-KID 12, and with the previous validation study (Chapter Four), 
therefore this hypothesis can be accepted and the results disseminated accordingly. 
The hierarchy of knowledge levels between participant groups has been established 
as commensurate with that of other disease groups and has added to the data 
collected in Chapter Three. 
This study has added to the evidence base of IBD-KID2 being a valid and reliable 
knowledge assessment tool for children with IBD and their families. This is the first 
study to establish the knowledge levels of the siblings of children with IBD and to 
identify independent variables that influence their scores. The results have 




recommending national support groups and encouraging parents to include siblings 
in discussions regarding IBD and the treatment their brother or sister may have. It 
should also be considered that siblings may also benefit from education initiatives 
such as Camp Purple that may not only improve knowledge but also enhance the 
emotional and behavioural outcomes in well siblings 505. Data collection is ongoing 
for this generalisability study, but these interim results can be disseminated at 
national and international scientific meetings to encourage the evaluation of 







Section Two summary 
The series of studies presented in this section have shown the progression of IBD-
KID2 from the initial process of development through to establishing validity, 
reliability, and feasibility in a number of ways. Internal and external validity 
(generalisability) have been confirmed among different groups of the target 
population, and face, construct, and content validity relating to the format of the 
assessment tool have been addressed. Reliability was established using a number of 
methods including internal consistency, test-retest, and pre and post-test study 
designs. Feasibility was acceptable when measured as readability, as well as ease of 
administration of the online format which showed acceptable response rates. 
The two studies performed using IBD-KID2 with parent groups were synergistic in 
that while the Camp Purple study (Chapter Six) showed that knowledge levels 
improved following a targeted education programme, it could only be assumed that 
their knowledge would not have improved independently in the same time frame 
with no intervention. The generalisability study (Chapter Seven) added strength to 
this assumption by proving that parent knowledge levels did not increase when no 
intervention was present.  
Utilising IBD-KID2 in a number of participant groups established that there is a 
hierarchy of IBD knowledge among these cohorts which are in line with expectations 
from the literature. This hierarchy (highest to lowest) is as follows: 
 Medical staff 
 Mothers 
 Fathers 
 Children with IBD 
 Members of the public 
 Siblings of children with IBD 
 Administrative staff 





The studies presented in this section produced some confirmatory knowledge 
patterns to suggest that IBD-KID2 is appropriate for the target population. The item 
regarding CAM products was scored poorly by all the child groups (children with 
IBD, siblings, children without IBD), who could be expected to have limited exposure 
to such a topic. Children with IBD also scored lowest on the items regarding growth 
when in remission, cutting out food groups to reduce flares, and nutrient absorption. 
These may be considered among the more advanced topics of IBD knowledge and it 
would be of interest to assess whether the frequency of correct answers for these 
items are affected by any independent variables, specifically age or duration of 
disease. Of note is that the item regarding the cause of IBD was answered correctly 
by more children with IBD and their parents than the medical staff, and parents also 
correctly answered items regarding growth and nutrients with greater frequency 
than the medical staff. This knowledge may be considered more relevant, and 
therefore better understood, to those in close contact with children with IBD. Those 
groups consisting of the general public (including administrative staff) had the 
highest correct response rates for items that could be generalisable to other 
conditions.  
In comparing the study results against a number of independent variables it has been 
established that for children with IBD, IBD-KID2 is easy to understand for those aged 
eight to eighteen years, is generalisable to both disease groups, and contains items 
that are understood by those who have been diagnosed with recent or longstanding 
disease. That the knowledge level of siblings increases with age and duration of 
disease suggests that they are independently seeking information, as well as being 
exposed to more over time. The positive association of mothers belonging to an IBD 
support group confirms the value of IBD organisations, and the positive correlation 
of their scores with their child with IBD suggest that they are sharing the knowledge 







Chapter Eight: A Symptom Self-Report Tool: IBDnow 
8.1 Introduction  
The importance of self-regulation as a self-management skill for children with IBD 
was discussed in Chapter One (Section 1.5.5). Self-regulation is comprised of three 
components that are developed sequentially:  
 Self-monitoring: keeping track of symptoms 
 Self-evaluation: recognising longitudinal changes in symptoms  
 Self-reinforcement: taking appropriate action when changes are recognised 
The skill of self-regulation will naturally develop over time as children become 
familiar with their own unique disease course and its manifestations, however, these 
skills can be encouraged by enabling children to self-report their symptoms. If 
subjective information such as pain or fatigue could be quantified, children could 
provide measurable, structured reports of symptom metrics that could be utilised for 
reflection and evaluation, and could also be used to aid in communication with their 
parents and the MDT 506.  
There is increasing recognition that self-reporting is the gold standard for subjective 
health status indicators during clinical encounters. The complex processes involved 
for clinicians in interpreting symptom reports given by children, and proxy reports 
from their parents, may lead to discrepancies in understanding 507. For children with 
IBD their own perceived symptoms may not always correlate with their underlying 
clinical pathology as many continue to experience symptoms even during times of 
inactive disease 38, 508-510. Clinicians may underestimate this factor as their symptom 
interpretation will account for concurrent physical, histological, and laboratory 
markers of disease activity as well as being benchmarked by their observations of 
many similar patients, whereas patients express their symptoms in relation to their 
own perception and concept of health and disease 507. Self-report serves as a way to 




as well as avoiding the bias in proxy reports from parents who may be reporting 
their own impression of their child’s symptom burden 511-513. In addition, the 
recognition of self-reported symptoms by patients has been demonstrated to 
improve disease management, patient-provider communication, and patient health 
status 514. 
In light of this evidence it was considered that providing paediatric IBD patients with 
a symptom self-report tool to monitor, assess, and report their own disease activity 
would increase patient autonomy and help develop vital self-management skills. It 
was revealed in Chapter One (Section  1.7.4) that no such tool was identified in the 
literature, and that the clinical assessment tools (PCDAI 91 and PUCAI 515) were not 
appropriate for children to use for self-report. It was therefore relevant to devise a 
brief, non-invasive, multi-symptom reporting scale - universally appropriate for 
children with both CD and UC – that would be beneficial on a patient and clinical 
level. A symptom self-report tool was subsequently developed to enable children 
with IBD to provide a structured assessment of their subjective symptoms. The self-
report tool was developed with a high degree of integrity with the symptom 
categories of the clinical tools in order to maximise their utility in the clinical setting.  
This research has been published (Appendix K) 299. 
8.1.1 Aims and hypothesis 
The objective of this study was to adapt the subjective constructs of the PUCAI and 
PCDAI into an assessment tool for children with IBD to report their symptoms across 
multiple physiologic metrics. The aim of the study was to assess the level of 
agreement between the child and clinician reports and to determine reliability of the 
child self-report tool. The hypothesis to be examined in this chapter is: 
That a health literate symptom self-report tool, universal to both CD and UC, will 
enable children with IBD to produce clinically relevant information on their 




8.2 Methods  
8.2.1 Scale Development 
The self-report tool was called IBDnow to represent the snapshot of symptoms it 
provides for children with IBD. A number of factors needed to be considered when 
developing IBDnow to account for the developmental abilities, and format 
preferences, of the target population. IBDnow was to be implemented in all children 
with IBD attending out-patient clinics and was therefore required to be appropriate 
for all ages and diagnoses.    
8.2.1.1 Health literacy 
When a child is prompted to provide a self-report they must be able to understand 
what they are being asked to deliver, as well as being provided with an effective and 
appropriate method to communicate their response 516. To account for 
developmental characteristics the use of appropriate language and imagery are vital 
for self-report measures in children where low health literacy and low reading ability 
may create barriers to understanding 517, 518. It was therefore decided that IBDnow 
would combine images as well as a text description in the symptom scales so as to 
aid understanding and be appropriate to a wider age range.  
8.2.1.2 Scale type 
The format of IBDnow needed to be evaluative, and needed to represent the items 
from the PCDAI and PUCAI that were empirically designed to quantitatively measure 
subjective variables 519. In order to provide an appropriate scoring system to match 
that of the PCDAI and PUCAI a Likert scale or Visual analogue scale (VAS) was 
considered best suited. VAS and Likert scale results have been shown to correlate 
strongly and are considered of comparable reliability in children, so preference, and 






The VAS format is a simple linear scale that is placed between two extremes of 
measurement, whereby the user is required to indicate their own level of intensity of 
the measured variable. While the VAS may be relatively easy for adolescents and 
older children to use, it has been found that younger children need simpler tools to 
help them interpret abstract concepts such as subjective variables 521.  
Likert 
Likert scales require users to respond to a statement by selecting their degree of 
agreement, with numerical weights being assigned to the response categories to 
allow for score calculation 519, 520. When Likert scales are used with children a 
pictorial scale can be included to provide images as anchor points alongside the text, 
an addition that is greatly preferred by children compared to using text alone 516. The 
Likert format is most often used in younger children because of the low cognitive 
demand it places on respondents, and is the preferred option of both young and 
older children who found them easier than the VAS to complete 516, 520. It was 
therefore decided to develop IBDnow using a series of text and pictorial Likert scales. 
8.2.1.3 Scale categories 
The symptom categories for the IBDnow Likert scales were taken directly from the 
subjective sections of the PCDAI and PUCAI and included pain (abdominal), stools 
(blood, consistency, day and night frequency), and well-being (feeling tired and 
poorly).  
The PUCAI measures stool categories as three separate scales (blood, consistency, 
and frequency), however the PCDAI measures them all as one category, thus relying 
on the assumption that a worsening of one element of stool measurement equates to 
a worsening of others. The combined stool category of the PCDAI was considered to 
be too complex for children, therefore the format of IBDnow followed that of the 
PUCAI with separate stool scales. Subsequently, the three elements of stool 
measurement were also measured separately in the PCDAI based clinician’s tool for 




The number of Likert options in the PCDAI and PUCAI categories vary from three to 
four. For IBDnow, the Likert scales were all assigned four options to allow for a more 
comprehensive report by children. The text describing each category was written to 
be simple and appropriate for all ages and levels of health literacy. The text of the 
Likert scale anchor points also aimed to provide an objective measure for responses, 
such as whether pain could be ignored. 
IBDnow was developed to include two categories of ‘well-being’ to determine 
whether the clinician tool measuring ‘functioning, well-being, and activity level’ 
correlated best with the children’s reports of feeling tired or feeling poorly.  
8.2.1.4 Image development 
The scale imagery development for the categories measuring pain and well-being 
began by studying the traditional smiley faces scales such as the Wong Baker Faces 
Pain Rating Scale 522. In order to maximise their appeal the standard line drawn 
smiley faces were evolved into a dramatized, emoji version with an appropriate 
aesthetic for the age group that was not gender or race specific but considered 
relatable to this technological age 516. The scales for stool blood, consistency, and 
frequency were based on the images in the modified Bristol Stool Form Scale 523, a 
self-report instrument for children to assess their stool form, and on advice from 
paediatric and adult gastroenterologists. A digital graphic designer was shown the 
ideas and developed a series of images that were representative of the scales. These 
were then combined with the text anchors in to the completed IBDnow. 
8.2.1.5 Scale scoring 
Child self-report tool 
IBDnow (Figure 8-1) was developed to be universal for those with either CD or UC, 
however the scoring systems of the PCDAI and PUCAI do not match, and categories 
are scored between zero and thirty depending on reported symptom severity with a 
lower score indicating less disease activity. Scores were assigned to each category 
response on IBDnow following completion so as not to cause confusion for the 









The assigned score for each category was determined by the child’s diagnosis and 
therefore allocated the same scores from the PCDAI or PUCAI as appropriate, and 
then a total percentage score calculated to account for the different scoring systems.  
For those categories that were four item Likert scales in IBDnow, and a three item 
scale in the PCDAI or PUCAI, a consensus decision was taken from the study 
collaborators in Christchurch and Sydney to determine face validity of the scales and 
assign the appropriate scores to match the PCDAI and PUCAI. 
Clinician tools 
The clinician report tool was different for patients with CD or UC as the PUCAI and 
PCDAI do not follow the same format. The scoring system for the clinician reporting 
tools were taken directly from the PCDAI and PUCAI and a total percentage score 
calculated to account for the different scoring systems. The clinician symptom 
scoring scale is included in Appendix L. 
8.2.2 Participants and ethics  
All children considered by their clinician as being capable of completing IBDnow, and 
with a confirmed diagnosis of CD or UC, were included in the study. Participants were 
recruited from the paediatric IBD outpatient clinics in Christchurch Hospital, New 
Zealand, and Sydney Children’s Hospital, Australia. Ethics approval was granted by 
the University of Otago Human Ethics Committee (Health) (H16/116), and the 
Sydney Children’s Hospitals Network Human Research Ethics Committee 
(LNR/17/SCHN/412), respectively. 
8.2.3 Research questions 
This study had two main research questions that were developed to address the 
previously stated hypothesis: 
 How congruent are children’s symptom self-reports and clinician’s 
interpretation of child/parent recall?  
 Can the PCDAI and PUCAI scoring be applied to IBDnow to provide 
appropriate levels of agreement for scoring child-reported symptoms in the 




8.2.4 Study process 
Participants and clinicians completed their symptom reports during the same out-
patient appointment. Consent was obtained at the beginning of the consultation, and 
the routine format for a clinic visit was then followed. At the end of the consultation 
IBDnow was explained to the child and given to them to complete – parents/carers 
could help with reading the text if it was required, but not with completion of the 
tool. Based on the symptom reports given during the appointment the clinician 
would complete the corresponding section of their report depending on whether the 
child’s diagnosis was UC or CD. If a child had a repeat appointment within 28 days 
then both reporters completed IBDnow again with the intention of determining test-
retest reliability, a methodological issue addressed in the discussion later in this 
chapter (section 8.4).  
8.2.5 Statistical analysis  
A number of measures were calculated to assess congruence at the individual, 
category, and aggregate level between participants and clinicians.  
Individual agreement 
At the individual level the agreement score represented the proportion of identical 
symptoms provided by both sources. This was calculated by dividing the actual 
number of congruent pairs of symptoms (those symptoms reported the same by both 
the participant and clinician) by the highest possible number of congruent pairs 
(total of seven), with perfect agreement being a score of 1, and no agreement being a 
score of 0. The ideal agreement level score is above 0.75. A univariate general linear 
model determined whether any single variable could predict the degree of 
agreement between the scores.  
Category agreement 
Each symptom category was examined using contingency tables to determine the 
percentage of identical agreement, underestimation, and overestimation of reported 
symptom severity between the participants and clinicians for the whole population 
sample. The level of inter-rater reliability between the two reporters (child and 




rater reliability are considered as follows: 0-0.2 poor, 0.21-0.4 fair, 0.41-6 moderate, 
0.61-8 good, 0.81-1.0 very good 403.  
Aggregate agreement 
At the aggregate level, the resulting raw scores from the child and clinician 
assessment tools were transformed to percentages to account for the difference in 
scoring methods between the PUCAI and PCDAI. The mean scores of the participants 
and clinicians were calculated and their significance tested with a paired sample t-
test. The difference between percentage scores were explored against the 
independent variables of age, diagnosis, gender, and research site using independent 
sample t-tests for categorical variables and linear regression for continuous 
variables.  
Further comparisons between the two measurement techniques were made by 
plotting the combined mean score of both reporters against the difference in scores 
using a Bland Altman plot, whereby data points lying between two standard 
deviations from the mean indicate that both tools are in agreement 526. Further 
comparisons were made between the congruence levels of the category and 
aggregate measures, with aggregate scores being considered in agreement if there 
was ≤10% difference between the clinician and participant total score percentage.  
The reliability of IBDnow was tested using Cronbach’s alpha, which was calculated 
for the whole cohort, and by diagnosis, to determine internal consistency 438. Inter-
item correlations were also studied to assess whether reliability of the tool would be 
improved by the removal of any particular items. 
The external validity of IBDnow was determined by comparing the agreement results 
between the two centres where the study was carried out and comparing the 






A total of 100 participants were recruited from the two research sites in 
Christchurch and Sydney and the demographic distribution of participants examined 
(Table 8.1). Two paediatric gastroenterologists completed the clinical tools (one at 
each research site). The wide age range of participants allowed for analysis as a 
linear variable of age (years), as well as a categorical variable of age group, as 
determined by the following levels of development: early childhood (3-8 years), 
middle childhood (9-11 years) and adolescence (12+ years).   








































Age (yrs): mean (SD) 
[range] 
13.9 (3.6) 
[3.6 to 19.8] 
13.5 (3.8) 
[3.6 to 19.8] 
14.6 (3.0) 
[8.3 to 18.5] 
 
8.3.2 Individual agreement  
The level of individual agreement was first studied as a function of the mean 
congruence score between the participant and clinician reports, which was 
calculated as 0.76 (SD 0.19), therefore, showing good agreement levels. When 
compared against the independent variables the individual agreement was not 















When age (years) 
was analysed 
using linear regression against the individual agreement score, no significant 
association was found (R 0.181, p 0.071) (Figure 8-2). 
 
Figure 8-2. Individual agreement score by age (years). 
Includes the line of best fit.  
 
The frequency of the individual agreement levels between the clinician and 
participants were examined for the seven symptom categories. Overall 47% of 
participants and clinicians agreed on ≥6/7 items (≥ agreement score 0.86), and 76% 
agreed on ≥5/7 items (≥ agreement score 0.71) (Figure 8-3).  
Figure 8-3. Frequency of items in agreement between participant and clinician.  
 Mean agreement 

























Perfect agreement score = 7/7. 
 
 
The differences between agreement scores for each age group were further explored 
to clarify the applicability and accuracy of IBDnow reports at different ages (Figure 
8-4). The percentage of each age group that achieved each possible agreement score 
was examined, with the percentage shown to account for the differences in group 
numbers.  This graph highlights that the age of the participants did not influence the 
level of agreement between the child self-report and clinician report of symptoms. 







Figure 8-4. Percentage of each age group that achieved agreement scores. 
 
8.3.3 Category agreement  
In order to explore the degree of agreement for each symptom category, each one 
was examined for the congruence of reported severity between participants and 
clinicians, along with the level of underestimation and overestimation of the 
children’s reports by the paediatric gastroenterologists. For each category the inter-
rater reliability was calculated using Gwet’s AC1 coefficient. The overall agreement, 
underestimation, and overestimation for the whole cohort, and by diagnosis was 
calculated, including the level of inter-rater reliability (Table 8.3).  
All categories except feeling poorly had agreement levels at or above 70%, with the 
general trend being towards the underestimation of reported symptoms by the 
clinician, especially for children with UC. Inter-rater reliability ranged from moderate 
(stool frequency and feeling poorly), to good (pain, consistency and feeling tired) and 
very good (blood and nocturnal frequency).  
Category agreement between the children and clinicians was considered to be good, 
with some important considerations highlighted regarding the underestimation of 
symptoms. 
 






Table 8.3. Level of agreement, underestimation, and overestimation of symptom severity. 
N=% for whole cohort, n (%) for group data. Gwet’s AC1 = inter-rater reliability coefficient. 
 








Pain 70  29 1 0.64 
Stool: Blood 86 10 4 0.86 
Stool: Consistency 74 13 13 0.71 
Stool: Frequency 72 25 3 0.47 
Stool: Nocturnal frequency 87 13 0 0.83 
Well-being: Tired 79 7 14 0.73 
Well-being: Poorly 63 28 9 0.41 
OVERALL 531 (76%) 125 (18%) 44 (6%)  
CD 474 (77%) 99 (16%) 43 (7%) 
UC 57 (68%) 26 (31%) 1 (1%) 
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8.3.4 Aggregate agreement 
To ascertain the level of aggregate agreement, the percentage total scores of the 
assessment tools were calculated for the clinicians and participants. The mean 
clinician score (14.9 (SD 18.8)), and participant score (21.6 (SD 19.4)) were 
significantly different (p <0.005). The agreement level of the two measurement 
techniques was explored as a Bland Altman plot, with data points expected to lie 
within the limits of agreement, as represented by the lines of two standard 
deviations from the mean (Figure 8-5). 
Figure 8-5. Difference in mean percentage score between clinicians and participants. 
Horizontal lines represent the mean (centre), and 2 standard deviations for the mean 
(upper = +2SD, lower = -2SD).  
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All but four of the data points lie within the expected limits and these outliers were 
examined to identify common trends. All four participants had CD, but this is not 
unexpected given the distribution of diagnoses. All three age groups were 
represented, there were three male and one female, and the disagreements were 
scattered throughout categories therefore making the influence of a single variable 
unlikely.  
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The overall degree of difference between the mean scores of the participants and 
clinicians was also examined against the independent variables, which determined 
that there were no differences according to study site (p 0.27), gender (p 0.61) or age 
group (p 0.161). The mean difference in scores between clinicians and participants 
was significantly greater in those with UC (mean difference-15.69 (SD 10.1) than 
those with CD (mean difference -5.44 (SD 11.3) (p 0.004).  
For those participants with UC it was possible to compare the category of disease 
activity scores that would be assigned according to the PUCAI thresholds of <10 no 
activity, 10-34 mild, 35-64 moderate, ≥65 severe 515 by using the IBDnow category 
scores for pain, stool: blood, consistency, frequency (day and nocturnal), and feeling 
tired. This additional analysis showed that 50% of participants had symptom scores 
in the same category of severity, and 50% had scored their symptoms one category 
higher than clinicians. This comparison was not possible for the children with CD as 
the PCDAI also contains objective measures of disease severity that comprise the 
severity scores and these were not measured in IBDnow.  
8.3.5 Agreement comparisons 
The overall level of congruence was compared between the category severity 
agreement (measured as the number of identical reports) and the aggregate 
percentage total score agreement (measured as the child and clinician scores being 
within 10% of each other), along with the degree of underestimation and 
overestimation of participants by clinicians. Data were analysed for the whole cohort 
and by diagnosis (Table 8.4).   





All CD UC All CD UC 
Agreement 76 77 68 60 65 25 
Underestimation of participants 18 16 31 34 28 75 
Overestimation of participants 6 7 1 6 7 0 
 
These data highlight that IBDnow had better levels of agreement when scores were 
not assigned according to the PCDAI or PUCAI scoring systems. 
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8.3.6 Reliability 
The reliability of IBDnow was calculated using Cronbach’s alpha, with a result of 0.74 
that showed good internal consistency. Studies of inter-item correlations for the tool 
overall showed that this score would not be improved by the removal of any 
individual items. When analysed by diagnosis the scores were 0.75 for CD, and 0.69 
for UC, and further inter-item correlations showed no possible improvement for the 
CD score, but an improvement for the UC cohort on removal of the category 
measuring tiredness. 
8.4 Discussion 
There are a number of tools available to clinicians for the assessment of disease 
activity in children with IBD, but there are few that enable children to self-report 
their own symptoms. A small number of child participant report tools were found in 
the literature, as outlined in Chapter One (Section 1.7.4), but these were complex and 
either CD or UC specific. It was considered that one simple tool universal to both 
conditions would be of great benefit in the clinical setting. The development of 
IBDnow has provided a means for children with IBD to communicate their own 
perception of their current disease state to the MDT. It also supports the growing 
emphasis on the paediatric patient as an important source of information on their 
own health and encourages the development of self-management skills by providing 
a means of simple symptom evaluation when self-monitoring.    
The small number of previous studies described testing patient-reported symptoms 
in the paediatric IBD population produced divided opinions on whether children are 
capable of providing symptom reports that are congruent with clinicians. Patients 
with UC are consistently better represented than those with CD in the self-report 
literature, most likely due to the wholly subjective nature of the PUCAI, thus making 
it less complex to adapt and develop an equivalent participant report. When Turner 
et al 507 made comparisons between clinician reported PUCAI and paediatric patient 
reports of health related quality of life (bowel symptom specific), both groups also 
provided a global assessment of disease state using a visual analogue scale (VAS). 
The clinician reports correlated better with measures of overall disease activity than 
the participant reports. While the symptom reports were produced using quite 
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different tools, the conclusion was given that disease indices should be reported by 
clinicians as they are more accurate. However, when Lee et al 276 developed a 
simplified PUCAI for children and compared it with clinicians the results were in 
direct contrast to Turner. The study by Lee et al 276 showed high levels of agreement 
and inter-rater reliability for disease activity, with the conclusion that children can 
accurately report their symptoms using an adapted PUCAI. Diederen et al 204 
developed adapted versions of the PUCAI and Short PCDAI (shPCDAI) 275 to enable 
direct comparison between the clinician and children’s reports. The shPCDAI 
includes subjective measures and some of physical examination – the physical 
metrics were accompanied by instructions for the children participating to enable 
them to perform these themselves. The levels of crude agreement in this study were 
once again high. This evidence supports the results presented in this study, which 
showed that even young children can produce valuable data for direct comparisons 
with clinician reports when using tools that had high integrity with the original 
clinician tools but had been adapted for their use.  
It should be acknowledged that while IBDnow is a symptom self-report tool, it does 
not represent a true PRO. A small number of PRO’s have recently been developed in 
conjunction with children with IBD, as outlined in Chapter One (Section 1.7.4); 
TUMMY-UC 277, the DUCS 203, and the TUMMY-CD 278. These PRO’s differ from the 
self-report tool presented here in that PRO development is done with direct patient 
input to generate items important to them without necessarily concentrating on, or 
reflecting, the degree of inflammation or disease burden 277. In contrast, IBDnow was 
developed to be directly comparable with the clinical tools currently in use in order 
to address those symptoms considered most important to the clinical team who are 
providing treatment, and subsequently assessing efficacy for each individual. 
The ‘well-being’ category of the PCDAI and PUCAI was explored against two separate 
categories in IBDnow to determine whether ‘functioning, well-being and activity 
level’ as measured in the clinician tool correlated best with the patient reports of 
feeling tired, or poorly. Feeling tired had higher agreement with the clinician’s report 
of well-being, but the high degree of underestimation of feeling poorly is note-
worthy. Further analysis showed that 71% of participants rated the severity of the 
feeling tired and poorly categories the same, but 28% rated feeling poorly at greater 
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severity than feeling tired. The consequences of this underestimation could have a 
significant impact on children’s quality of life when it comes to measuring treatment 
efficacy, and previous work has shown that clinicians may underestimate functional 
disabilities and quality of life related concepts that are reported by their patients 507. 
Inter-item correlation for the participant tool when divided by diagnosis (but not 
overall) showed that the item ‘feeling tired’ would improve internal consistency if 
removed for those with UC. However, the number of participants with UC was low 
and this category scored well for the cohort overall, so it was not considered 
appropriate to remove the item. 
As in this study, other research among paediatric groups has revealed that compared 
to the child’s self-report, clinicians and parents consistently under-report both the 
prevalence and severity of subjective treatment-related symptoms and pain 511, 513, 
527. It should be acknowledged that clinicians must exercise a necessary filter to 
reported symptoms when assessing disease activity as they must assess whether, for 
example, the pain relates to IBD, or whether there may be a comorbid condition 
present such as irritable bowel syndrome 40, 507. The underestimation by parents 
becomes more significant when it is recognised that in the doctor-parent-child triad 
that occurs during most clinical encounters, discrepancies in informant accounts sees 
practitioners systematically agree more with the parents proxy report 509. Children 
have been shown to be as accurate, if not more so, than their parents in reporting 
objectively measured symptoms of asthma 528 and mental health 529 and further 
studies will explore this comparison between children and their parents using 
IBDnow. The child’s role in medical conversations deserves special attention as 
children appear to be able to understand more about concepts of health and illness 
than has generally been assumed 121, as has been demonstrated by children using 
IBDnow. 
The differing perspectives between clinicians and participants does not mean that 
either is right or wrong, they are both equally valid, but failure to acknowledge these 
differences may result in a less effective evaluation of treatment effect 507. 
Inaccuracies in report and interpretation can affect the conclusions of clinical 
evaluation outcomes and subsequent decision making 509, 510, but utilising IBDnow to 
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enable children to provide accurate symptom reports may reduce the chance of 
potential clinical consequences if used to determine therapy changes.  
As part of the original study design a limited amount of longitudinal data were 
collected in order to explore the temporal profiles of the IBD symptoms. IBDnow and 
the clinician’s assessment were repeated with ten participants within 28 days of the 
initial study visit. It was intended to perform repeat reliability measures such as the 
ICC and test re-test analysis with this data in order to examine sensitivity to change 
over repeat visits. The ICC was not considered feasible to perform as each child is 
reporting on their individual symptoms and could not be expected to correlate as a 
group. The test re-test analysis makes the assumption that there would be no change 
in symptoms within that time period, thus the tool should be reporting the same 
results and showing reliability that symptoms were being scored consistently and 
appropriately 435. The dynamic nature of IBD, treatment adjustments, and the 
rapidity with which symptoms change, means that the IBDnow scores could have 
changed between times for reasons other than random errors on reproducibility. 
This could not be controlled for by selecting those in remission as even children and 
adults with quiescent disease may still experience symptoms and their scores could 
vary over short timeframes 38-40. Therefore, the repeat reliability measures were not 
possible, and the repeat assessments were therefore excluded from the rest of the 
analysis. 
When IBDnow categories were assigned scores corresponding to the same sections 
of the PCDAI and PUCAI, the total scores were significantly different between the 
clinicians and participants. When the mean difference was presented as a Bland 
Altman plot all but four participants had their results between two standard 
deviations from the mean, as is ideal when inspecting agreement between two 
assessment tools. However, this allowed for overestimation of total score percentage 
of 16%, and an underestimation of -30% which would not be an acceptable margin of 
measurement between the two tools in the clinical setting. The large differences in 
the percentage total scores could be attributed to the weighting of the scoring 
systems of the PUCAI/PCDAI as one category with a response that differs by one level 
may cause a difference of ten points. This effect was highlighted when comparing the 
disease activity thresholds for children with UC (12/100 participants), whereby 50% 
 
 245  
 
had symptom scores in the same category of disease severity, and 50% had scored 
their symptoms one category higher than clinicians. In contrast, children with UC had 
an individual agreement level of 0.68, thereby indicating that nearly 70% of 
symptom categories were scored the same by children and clinicians. 
8.4.1 Limitations  
Further work will address the primary limitation of this study that saw the 
generalisability to both disease groups being restricted due to low numbers of 
participants with UC. This was not considered to be selection bias as the 
disproportionate ratio of CD to UC in this study of 7.3:1 was in line with population 
studies in New Zealand that showed a ratio of 8.4:1 36, and in Australia of 4.7:1  530 
and was thus in line with the Australasian paediatric IBD population norm. The age 
distribution between groups was skewed towards the 12+ group but this is to be 
expected with the incidence being highest, and increasing most rapidly, at this age 26, 
470, 531. The wide age range of participants included in this study was essential to 
assess efficacy and relevance to participants across ages and diagnoses. 
Two possible sources of bias were recognized. One was introduced by allowing 
involvement of the parents of young participants to help read IBDnow items. 
Although all parents were requested not to help with completion, some may have 
assisted. However, the age of participants had no impact on any of the category 
metrics in the study, so this was considered unlikely, and clinicians confirmed that 
parents followed these instructions without exception. These results are reflective of 
previous research that has shown that children as young as four years of age can 
provide important insights in to their health experiences 334, and children from the 
age of five have been shown capable of providing accurate scale ratings for concrete, 
physical questions 532, 533. In the pragmatic sense it is likely that parents may help 
younger children with disease-related tasks. Providing assistance to complete 
IBDnow may confirm how images relate to symptoms and ensure the accuracy of 
symptom reporting. Symptom recognition is an important part of self-management, 
therefore this may be seen as a positive factor. 
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The possibility of cultural and ethnic bias was introduced through the use of Likert 
scales with smiley faces. Decoding emotive facial expressions is a cultural construct 
with different meanings relative to cultural background, which could impact 
respondent choices 518. While this study did not collect data on ethnicity, previous 
research performed in the same population in Canterbury (New Zealand), showed 
that 87% of the paediatric IBD population identified as European, 3% Maori 
(indigenous peoples), 4% Asian and 1% Pacific Islanders (remaining data missing in 
published study) 36. Similar ethnicity data for the paediatric IBD population in 
Sydney has not been published, but according to the 2016 census 48% of Sydney 
residents identified as European, 24% Australian, 10% Chinese, 4% Indian and 3% 
Lebanese 534. It was therefore imperative to maximise the appeal of the Likert scales 
to all users and by using modern emoji type imagery in the assessment tool the 
chance of introducing cultural and ethnic bias was minimised by providing neutral, 
caricature faces. 
Gathering information from the clinician on whether their assessment of symptoms 
was made using information given by the caregiver, participant, or both, would have 
allowed some comparisons to be made of the accuracy between the two sources. 
Similarly, if parents had been requested to fill out IBDnow separately, the 
congruence could have been assessed between the parent and child. This, however, 
may form the basis for a further study.  
8.4.2 Strengths 
IBDnow was easily administered, well understood, and was quick and easy to 
complete, thus indicating that it does not impose an undue time or comprehension 
burden on either the patient or clinician. The wide age range of participants included 
in this study was considered essential to assess efficacy and relevance to participants 
across ages and diagnoses. The skewed distribution between age groups was to be 
expected in line with the international incidence of paediatric IBD 26, 470, 531, and the 
preponderance towards CD is also reflective of local 36, 530 and worldwide trends 531. 
The demographic similarities between the current study cohort and the global 
patterns of paediatric IBD suggest good generalisability of this self-report tool to the 
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wider population. Generalisability was also supported by the lack of impact of age, 
diagnosis, gender, or research site on any of the study metrics.   
This self-report tool benefits from the use of pictorial scales as well as text to enable 
greater generalisability for younger ages than in the previous studies, and a lesser 
reliance on proxy assistance to complete, thus providing a true ‘self-report’ tool. This 
could be considered as a useful supplement to objective CD outcome measures such 
as the modified PCDAI which comprises laboratory markers alone 535.  
8.4.3 Conclusion 
The original hypothesis for this study stated that IBDnow could enable children with 
IBD to report clinically relevant information on their disease activity. Participant 
symptom reports using IBDnow had good proportionate agreement with their 
clinicians, and good crude severity agreement for symptom categories. IBDnow has 
been shown to be a valid, reliable, and generalisable tool and the hypothesis is, 
therefore, accepted.  
This research has produced an evidence based, pictorial self-report tool that can 
obtain clinically valid information from children of all ages with IBD that is congruent 
with the clinician’s interpretation of subjective symptoms. Assigning scores to match 
the PUCAI/PCDAI caused the agreement level to drop considerably and discrepancies 
between the raters were misleadingly magnified, thus reducing efficacy. Assigning 
scores to the tool was therefore considered an unnecessary complication given the 
simplicity and accuracy of the tool prior to this step. The underestimation of 
children’s symptoms has been highlighted and should be given due consideration by 
clinicians in their future communications with children and adolescents with IBD.  
IBDnow enables the sharing of a common language about disease activity between 
self-report and the clinical tools, and may improve communication between patients 
and clinicians 536. The use of IBDnow in the clinical setting will encourage children to 
be involved in clinical conversations around their disease and treatment, which has 
been shown to improve adherence, disease outcomes, and self-management 121. 
Disseminating IBDnow for use in the paediatric IBD population will assist in 
expanding the body of knowledge on congruency between clinical and child reported 
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measures for rating subjective symptoms. The current emphasis on the use of 
mHealth to keep track of longitudinal disease activity could harness this self-report 
tool to encourage self-management in children with IBD 276. This research embodies 
the concept that only the patient can really understand what they are feeling, and 
that children can provide their own perspective to a health assessment 121, 517, 521, 529.  
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SECTION FOUR: Introduction 
Children’s self-management skills evolve over time as they learn to undertake day-to-
day tasks and make decisions concerning disease management, and as the 
involvement of their parents gradually diminishes to allow for their independence 
and health autonomy 13, 108. Skill development may begin at different ages 
depending on factors such as the child’s cognitive ability, their self-efficacy, and 
parental support for the process. As such, their IBD self-management skills should be 
routinely assessed so as to identify areas that may need further education or support 
13.  
The following two chapters describe the process of establishing the current evidence 
base regarding self-management assessment tools for children with IBD and 
addressing an identified gap in the literature.   
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Chapter Nine: Systematic Review of Self-Management Skills 
Assessment Tools 
9.1 Introduction 
The Pediatric Self-Management Framework developed by Modi et al 50, as discussed 
in Chapter One, identifies a comprehensive list of processes and behaviours that are 
integral to the development of self-management skills for children with chronic 
illnesses. These include seeking disease and treatment knowledge, self-regulation, 
adherence to treatment regimens, cognitive attributes, and communication with the 
medical team. For children with IBD the development of these self-management 
skills contributes to optimal disease outcomes, and maximises their chance of a 
successful transition from the paediatric to adult health care team 273. It is therefore 
appropriate to identify those methods available for assessing their skills in this area 
in order to provide targeted interventions for those skills requiring additional 
support.   
An initial search for IBD specific self-management assessment tools that could be 
used in the target population revealed a wide range of approaches, subjects, and 
formats for self-management appraisal. The literature contains assessment tools 
published as self-management, but that actually pertain to transition, knowledge, 
self-efficacy, and education among others. It was therefore considered imperative to 
perform a systematic review in order to identify the scope of tools available that may 
be appropriate for the target population, and to identify which may be used to 
evaluate those interventions aimed at increasing self-management skills, as in 
Chapters Two and Eleven.   
9.1.1 Aims and hypothesis 
The primary aim of this systematic review was to identify literature containing self-
management skills assessment tools for children with IBD. The secondary aim was to 
critique the identified tools to determine which was most appropriate for the 
evaluation of self-management skills in the target population of the intervention 
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studies in Chapters Two and Eleven. The following hypothesis was therefore 
developed:  
That a systematic literature review will identify appropriate, validated, disease 
specific or generalisable tools that can be utilised for children with IBD. 
9.2 Methods 
9.2.1 Format 
The systematic review protocol, search strategy, and implementation were 
developed and performed using the PRISMA guidelines 537, 538. This ensured that 
appropriate planning and documentation of the intended process was undertaken 
before the review started, therefore promoting consistent conduct, accountability, 
integrity, and transparency of the subsequent completed review 537.  
9.2.2 Search strategies 
The following databases were considered suitable for searching the literature: 
Medline, Embase, Cumulative Index to Nursing and Allied Health Literature 
(CINAHL), PsychInfo, Cochrane database, SCOPUS, and the Joanna Briggs Institute. 
The individual search strategies are included in Appendix M, but the main terms 
included were: self-management, transition, inflammatory bowel disease, Crohn’s 
disease, ulcerative colitis, and children. Additional limits were applied where 
possible for the ages 18 years and under, and from the year of 1998 onwards. While 
the theory of paediatric self-management began in the 1960’s 539, it was considered 
that medical care and expectations for self-management have changed most 
significantly in the last twenty years, alongside the increased incidence of paediatric 
IBD, so the date limit was considered sufficient. Applying limits to those studies 
published in English were not considered as many foreign language papers include 
an English translation of the abstract. It would therefore be possible to screen these 
for relevance and include them if a complete translation was available from the 
authors. Reference lists of identified papers were searched for additional research. 
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9.2.3. Paper selection and data extraction 
Following the implementation of searches all of the identified papers, and those 
included from other sources, were synthesised into a database containing the 
publication source, author, year, and title. The duplicates were removed, and the 
remaining titles examined to identify potentially relevant articles for a full text 
review. All relevant articles were then read in full text and those not considered for 
inclusion were categorised with a reason for their exclusion. For the remaining 
articles the details of the paper and the included self-management assessment tool 
were extracted and organised in to a synthesis table to display the author, year, title, 
study population (age, diagnosis), format of the assessment tool and whether it had 
undergone a process of validation. 
9.2.4 Quality assessment criteria 
The criteria for selection of a skills assessment tool for use in the intervention studies 
described in Chapters Two and Eleven focused on a number of factors:  
Self-management skills  
The tool needed to address the processes and behaviours outlined in the Pediatric 
Self-Management framework, as defined in Chapter One 50; knowledge, adherence, 
communication, self-regulation and cognitive factors.  
Health literacy 
The target population of the studies in Chapters Two and Eleven were children over 
the age of ten years, and therefore attention was given to factors appropriate for 
populations with low health literacy, as discussed in Chapters One and Three; 
brevity, simplicity, and readability. This was to ensure that the respondent burden of 
length, complexity, and comprehension were deliberated.  
IBD appropriate 
In order to ensure relevance to the target population the tool was required to have 
been tested among children with IBD to ensure that the unique characteristics of the 
disease did not preclude it from use.  
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Validity and reliability 
To ensure methodological rigour the identified tool must have been validated, and 
preferably undergone reliability testing.  
Skills assessment 
When critiquing the identified articles, it was important to ascertain whether those 
tools that were classified as transition or self-efficacy tools contained skill 
assessment items and therefore met the criteria of assessing practical self-
management skills. Transition tools may have items that concentrate on topics that 
may be too mature for children aged ten years. With regards to self-efficacy, there is 
a distinct cross-over between that and self-management, with the former referring to 
an individual’s perception and belief of their ability to engage in IBD self-
management behaviours 7, 273 and may not pertain to actually being capable of 
performing practical tasks. While self-efficacy is included in the Modi framework 50 
as a modifiable health belief and perception, it may be measured in a different way to 
practical skills.  
9.3 Results 
9.3.1 Search results 
Five hundred and thirty-three publications were identified from the literature 
searches and ten met the inclusion criteria of containing self-management 
assessment tools for children with IBD. The details of the search process are included 
as a PRISMA flow diagram in Figure 9-1. 
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9.3.2. Study characteristics 
The ten identified studies that were included in the final analysis presented a variety 
of approaches to measuring self-management across a wide age range of 
participants, and all but one tool originated in the US or Canada. The development 
methods of the tools were diverse, as was the methodological rigour used for testing 
reliability and validity. When summarised, it is possible to examine the basic 
attributes of each tool prior to an in-depth evaluation (Table 9.1).   
In the simplest form the assessment tools presented by Hait 2 and the North 
American Society of Gastroenterology, Hepatology and Nutrition (NASPGHAN) 540 
were transition checklists that had been developed from literature review, expert 
opinion, and anecdotal evidence. These tools were both divided in to sets of 
transition skills that could be expected to be attainable by specified ages, and both 
included a set of expectations for both the patient and healthcare team.  
Fishman 111 and Whitfield 116 presented transition and self-management assessment 
tools that used Likert scales to denote whether self-management tasks could be 
performed by the participants on their own, or with varying levels of help. The 
Fishman tool included a medication survey using patient report that was checked 
against health records to assess accuracy. The tool presented in the Whitfield paper 
was that devised by the ImproveCareNow network in the U.S 541 and is included in 
their self-management manual 542.  
Two studies by Zijlstra 110 and Izaguirre 293 assessed self-efficacy. Both used Likert 
scales, and Zijlstra’s ‘IBD-yourself’ tool also incorporated two VAS to provide an 
overall score for independence and disease burden. Izaguirre’s ‘IBD Self-efficacy Scale 
for Adolescents and Young Adults (IBDSES-A)’ was developed using qualitative 
interviews carried out with the target population to produce a PRO measure 7. IBD-












Table 9.1. Self-management assessment tool characteristics. 
Country of origin: US=United States, CAN = Canada, NDL=Netherlands 
Development process: Qual=qualitative research, Quant=quantitative research, PRO=patient reported outcome measure 






















































































































































































11-23 N/A Checklist - - 17 C No No No 
Fishman  










5 Help 19 S No No No 
Ziljstra  









4 Mixture 74 S No Yes No 
Whitfield  






10-21 67 Likert 3 Help 23 C No No No 
 


















































































































































































































12-17 - Checklist - - 27 C No No No 
Klassen  









Likert 3 Frequency 14 S Yes Yes Yes 
Ferris  









Likert 5 Frequency 18 S No Yes Yes 
Ferris  











3 Mixture 33 C Yes Yes No 
Williams  









Likert 5 Agreement 21 C Yes Yes Yes 
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The final four studies contained generic transition and self-management assessment 
tools that had also been tested specifically among groups of children with IBD, or 
non-classified gastroenterology patients. These consisted of the STARx questionnaire 
544 and the UNC TRxANSITION scale 545, both by Ferris et al. A tool developed for the 
Alberta Children‘s Hospital and tested by Williams et al 260, and the TRANSITION-Q by 
Klassen et al 543. All four tools employed Likert scales to determine the individual’s 
ability to perform tasks, but the UNC TRxANSITION scale was unique in that the tool 
was tested by being completed by health-care professionals following participant 
interviews that assessed their transition readiness. The TRANSITION-Q was 
developed as a PRO, the two Ferris tools; UNC TRxANSITION scale and STARx, were 
developed using a mixture of qualitative and quantitative methods, and the Alberta 
Children‘s Hospital tool was developed using a synthesis of other available tools. 
9.3.3 Quality assessment criteria 
9.3.3.1 Self-management skills 
In order to define the breadth of content in the identified tools the items contained in 
each tool were categorised in to the processes and behaviours from Modi’s self-
management framework 50. Each tool was examined to determine how many of the 
elements from the Modi defined self-management skills framework they contained 
(Table 9.2). 
The most frequently represented of the thirteen self-management elements from the 
Modi framework were adhering to treatment, attending clinic appointments, and 
communicating with the medical team. The least frequently represented were 
lifestyle modifications, health care utilization, and self-care. Six of the ten identified 
self-management tools also contained items that were more relevant to an 
adolescent or young adult population with items regarding sexuality, pregnancy, 
drugs, alcohol, and smoking 2, 110, 116, 260, 540, 545. In addition, four of these tools 
contained items specific to health insurance, thus reducing their generalisability for 
use in countries with different health systems. 
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The assessment tool containing the highest number of self-management processes 
and behaviours was that presented by Whitfield 116, written by the ImproveCareNow 
network 541. This tool contained ten of the thirteen processes or behaviours, while 
the IBDSES-A by Izaguirre 293 contained just five, and the UNC TRxANSITION scale by 
Ferris 545 covered six.   
Table 9.2. Frequency of the self-management processes contained in the identified tools. 
 indicates a process was included, blank space indicates it was excluded. 



























































































Taking drugs/treatment           
Personal disease/ 
treatment knowledge 
          
Attending clinic           
Communication with  
the medical team 
          
Refill prescriptions           




          
Self-management 
 of symptoms 
          
Self-efficacy           
Determining health 
 care needs 
          
Self-care           
Lifestyle modifications           
Health care utilisation           
Totals 6 7 8 7 7 8 5 7 10 8 
 
9.3.3.2 Health literacy 
The elements specifically examined to determine how appropriate the tools were for 
populations with low health literacy (simplicity, brevity, and readability) were 
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assessed (Table 9.1), which states whether the tools contained simple or compound 
items, how many items were in the tool, and whether readability had been calculated.  
Brevity 
The ideal number of items for an assessment tool such as this has not been 
established, but it has been suggested that the response burden imposed by 
increasing survey lengths may result in lower response rates, reduced completion, 
and reduced data quality 447. Given the required self-management processes and 
behaviours that would ideally be included in the tool used in the research in Chapters 
Two and Eleven, the number of items would need to be adequate to address all of the 
required elements from the Modi framework 50. The studies by Zijlstra 110 and Ferris 
545 had the greatest number of items (seventy four and thirty three respectively), 
while also missing up to seven of the elements from the Modi framework. The 
shortest assessment tools were by Klassen 543 and Izaguirre 293 (fourteen and 
thirteen items respectively), which were a more appealing survey length, but again 
both were missing six of the Modi elements. The Whitfield 116 tool was an acceptable 
twenty three items long and had the highest numbers of SM elements of the Modi 
Framework 50.  
Simplicity 
There are a number of ways to assess simplicity when it comes to tools that are 
aimed at a target audience of children. The simplicity of the question format, and the 
way in which they can be answered, should be considerations. Six of the tools 
included a number of compound items, whereby more than one query was combined 
in to one single question. This may cause confusion when the format of answering 
includes a Likert scale that may warrant a different answer for each query. The type 
of scoring scale used to elicit an answer, and the number of response options, are 
also relevant factors as children prefer Likert scales to VAS 520, prefer text Likert 
scales to numbered Likert scales 533, and prefer three Likert options to five 519.  
One assessment tool used a VAS, in combination with Likert scales 110, and seven 
other tools included Likert scales. The Likert scales presented were asking 
respondents to rate different concepts: agreement with a statement about self-
management tasks 260, 293, the frequency of performing self-management tasks 543, 544, 
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needing help to do self-management tasks 111, 116, and a mixture of Likert response 
options 110, 545. Four of the tools included five Likert response options 111, 293, 544, one 
included four 110, and three had three options 116, 543, 545.   
Readability 
The importance of readability and comprehension has been discussed repeatedly in 
this body of work, yet readability levels are infrequently reported in the health 
literature presenting original assessment tools for children. Among the tools in this 
review readability was referred to in just four of the ten studies, and to various 
extents. In their study, Izaguirre et al 293 reported that the readability and clarity of 
IBDSES-A had been assessed by a number of participants during the development 
process but no readability scores or grade level were included in the results. Ferris 
544 reported an overall Flesch-Kincaid readability Grade level of 4.4 for their STARx 
tool, indicating that this tool had an acceptable level of readability for 9-10 year olds 
441. Klassen 543 reported a Flesch-Kincaid readability Grade level for every item in the 
TRANSITION-Q, at each stage of development and following revisions. The overall 
reported grade level for the whole tool was also 4.4, an acceptable level of readability 
for the target population. Williams 260 reported the readability of their tool at a 
Flesch-Kincaid readability Grade level of 4.9 for the children’s questionnaire, and 5.9 
for the comparison tool used for parent reporting, although no clarification was given 
on what these levels equated to as a reading or comprehension age. 
9.3.3.3 IBD appropriate 
Six of the ten tools were developed specifically for the paediatric IBD population, 
three more included a cohort of children with IBD in their testing schedule, and one 
stated they included children with a ‘gastrointestinal’ condition. This latter study by 
Williams et al 260 was included in this review as the chronic gastrointestinal 
conditions experienced during childhood and adolescence that require a structured 
self-management or transition strategy are mainly limited to IBD. Other conditions 
may include coeliac disease, functional GI disorders, or those requiring long-term 
enteral or parenteral nutrition, however these conditions would not have the same 
self-management requirements 546, and it was considered likely the study cohort 
 
 262  
 
included children with IBD. The authors of the paper were contacted for clarification 
of this point, but no response was received. 
9.3.3.4 Validity and reliability 
No validation or reliability testing was performed on the checklists by Hait 2 or 
NASPGHAN 540, or on the Fishman 111 and Whitfield 116 tools.  
The self-efficacy scale IBDSES-A 293 measured concurrent validity against established 
measures of self-esteem, depression, anxiety, and quality of life. Reliability was 
examined using the Cronbach’s alpha test for internal consistency and test-retest 
analysis. IBD-yourself 110 had no validity tests performed, but parents and clinicians 
completed a modified assessment for comparison. Reliability was tested using 
internal consistency.  
Validity testing was not performed on the STARx 544. Construct and content validity 
was inferred for the UNC TRxANSITION scale 545 based on the development process. 
The Alberta Children‘s Hospital tool 260 had concurrent validity tested against a scale 
of functional independence, and construct validity for the TRANSITION-Q 543 was 
established using hypothesised score patterns and Rasch-based score testing. All four 
tools had their reliability tested using the Cronbach’s alpha measure of internal 
consistency. The TRANSITION-Q, STARx, and UNC TRxANSITION scale also tested test-
retest reliability, and the UNC TRxANSITION scale included inter-rater reliability.  
9.4 Discussion 
The studies identified in this systematic review provided a small number of 
assessment tools that may be used to determine self-management skills in children 
with IBD. By using pre-determined, empirically based criteria for the selection of an 
appropriate tool for use with the target population it was possible to objectively 
assess each one presented. The diversity in strengths and limitations of the 
assessment tools precluded any from being an obvious choice for selection. The 
following discussion provides reasons for inclusion or elimination of the identified 
instruments. 
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The processes and behaviours that were poorly represented in the literature 
(lifestyle modifications, healthcare utilisation, and self-care) warrant review to 
consider their importance for inclusion.  
Lifestyle modification opportunities in the paediatric IBD population are 
considerably different to the adult population. The deleterious effects of smoking, 
alcohol and recreational drug use have been well studied 547-549, but these factors are 
more appropriate for adolescents, not younger children. For younger children the 
main modifiable influences are stress 550, 551 and trigger foods 552, 553, both of which 
may cause exacerbation of symptoms and may be monitored through self-
management processes such as self-regulation.    
The issue of healthcare utilisation is highly relevant to the promotion of self-
management for IBD patients as medical costs per patient lifetime are suggested to 
be higher than those for diseases such as cancer and heart disease 554. Effective self-
management has huge potential for cost savings to the health care system by 
reducing morbidity related to nonadherence or problematic self-management 50. 
However, the poor representation of HCU in the paediatric tools may be attributed to 
the fact that by virtue of improving self-management, HCU will decrease and is not 
considered a ‘skill’ that children should master. This item could be considered more 
pertinent for children living in countries with insurance-based healthcare systems, 
but with 7/10 of the tools originating in the US and it still not being included this 
would not appear to be the case. 
For children with IBD the opportunities to carry out self-care tasks are limited unless 
a very specific individual need such as stoma care is required. This is in contrast to, 
for example, children with cystic fibrosis who may learn to perform their own 
physiotherapy regimen, or children with type 1 diabetes who begin to monitor their 
own blood glucose levels.  
It was therefore considered that the selected tool was not required to contain items 
pertaining to these three elements. 
A number of the tools may have been appropriate for the target population following 
the exclusion of specific items regarding smoking, drugs, pregnancy, sex, and alcohol. 
In addition, a number of tools contained items regarding health insurance and 
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therefore have limited generalisability for use in other countries with different 
health care systems. However, changing validated tools for one’s own purpose by 
removing items will render the tool, and any results produced, invalid. These six 
tools were therefore excluded from the selection 2, 110, 116, 260, 540, 545. Of the four 
remaining tools two had not any validity testing performed and were therefore 
excluded from the selection 111, 544.  
The two final tools both contained the smallest number of items and were lacking the 
highest numbers of self-management processes and behaviours. The self-efficacy tool 
IBDSES-A 293 had methodological rigour having had validity and reliability testing 
performed with the appropriate age group. The items had good readability but 
contained compound items to be answered by a single Likert scale. In addition, the 
tool lacked some of the aspects considered crucial to self-management in children 
with IBD, as highlighted in Chapter One: personal disease and treatment knowledge, 
attending appointments, and communication with the medical team. It was therefore 
excluded from selection. The TRANSITION-Q tool by Klassen 543 also had 
methodological rigour, although the minimum age tested during the validation 
process (twelve years) was higher than the target population of the studies in 
Chapters Two and Eleven. The tool was missing another vital component in that it 
did not contain self-management of symptoms and was also missing components 
relating to adherence and behaviour compliance. It was therefore excluded from 
selection. Following these elimination criteria, no study remained that could be 
considered for use in the studies presented in Chapters Two and Eleven. 
9.4.1 Limitations 
In developing search strategies that included tools for assessing transition readiness 
among children with IBD, there was an increased risk that they may include items 
relevant to older children or adolescents. The tools containing these items were not 
exclusively categorised as transition assessment instruments, most likely due to the 
fact that the promotion of self-management is traditionally aimed at increasing 
responsibility for disease management in adolescents, not younger children.  
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In using the self-management framework by Modi 50 to define the selection criteria 
for an appropriate assessment tool, it could be considered that this limited the scope 
of the analysis of identified studies. The content synthesis of paediatric self-
management frameworks in Appendix A, as referred to in Chapter One (Section 1.5), 
examined the breadth of the Modi framework and showed it to be a highly inclusive 
model that was only minimally added to by the additional papers. Only one of the 
papers identified in this systematic review referenced any theoretical frameworks, 
with the Ferris UNC TRxANSITION scale being based on the Self Determination 
Theory, and an Academy of Science framework on the promotion of learning 545. It 
was therefore considered important to have specific criteria against which the tools 
could be evaluated, and the processes and behaviours outlined in the Modi 
framework 50 were utilised for this purpose.  
9.4.2 Strengths 
The identification of assessment tools from a variety of fields and focal points 
indicate that the search strategies were adequate and performed well. The evident 
cross-over between self-management, transition, and self-efficacy resulted in a 
diverse selection of assessment tools for comparison, each with their own self-
management criteria. 
9.4.3 Conclusion  
The hypothesis outlined at the beginning of this chapter theorised that an 
appropriate self-management assessment tool would be identified from the 
systematic review. Of those instruments studied, those that contained the highest 
number of self-management behaviours and processes lacked the methodological 
rigour of development and testing required for use. No assessment tool satisfied all 
the criteria for inclusion as a suitable outcome measure for the studies in Chapters 
Two and Eleven and the hypothesis was therefore rejected.  
The overlap of topics, questions and scoring systems will be examined further in 
Chapter Ten to determine the most relevant and feasible approaches that could be 
synthesised to develop a unique self-management assessment tool for children with 
IBD.  
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While other chronic conditions of childhood may have a relatively predictable 
disease course, easily anticipated symptomatology, and well-established treatment 
pathways, IBD is atypical in that the relapsing and remitting pattern of the illness is 
unique and unpredictable for each patient and the required treatment regimens may 
differ between individuals. These factors can affect the extent that self-management 
skills are required, or limit the opportunities for development, and it was important 
that the tool used in the studies presented in Chapters Two and Eleven could 
adequately gauge this diversity. Generic self-management or transition tools may 
provide an overview of general issues pertaining to all long-term health conditions 
but may not capture the multiplicity of IBD management.  
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Chapter Ten: Validation of a Self-Management Skills 
Assessment Tool: IBD-STAR 
10.1 Introduction  
Children with IBD, and their families, are responsible for managing complex, multi-
factorial treatment regimens that may include the administration of multiple 
medications, dietary prescriptions, lifestyle changes, and attendance at hospital 
appointments with the MDT. Chapter One (Section 1.4.4) emphasised the importance 
of the child’s ability to learn self-management of these tasks, but that support from 
their family and the MDT is vital to help acquire these new skills. In order to assess 
self-management skills for children with IBD it was considered imperative to use a 
validated tool specific for this task, the benefits of which would be multifactorial: 
 To identify areas requiring support or targeted teaching 
 To provide a structured format for introducing new self-management skills 
 To evaluate skills longitudinally to gauge improvements in line with age 
specific checklists as presented in Chapter Nine, and therefore subsequent 
readiness for transition 
When the literature was searched with a systematic review methodology, as 
presented in Chapter Nine, it was concluded that no appropriate and validated tool is 
available. It was therefore considered appropriate to devise such a tool, and the 
following chapter outlines the development and validation process of a self-
management skills assessment instrument for children with IBD. The development 
process is divided in to three stages: 
Stage 1: A content synthesis of the tools identified in Chapter Nine  
Stage 2: A content validity review of the completed tool by paediatric 
gastroenterology experts 
Stage 3: An internal validity study to examine the strength of reports produced using 
the tool.  
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10.1.1 Aims and hypothesis 
The objective of this study was to develop an assessment tool that would provide 
quantifiable data on individual self-management skills in the paediatric IBD 
population. The aim of the study was to determine whether the tool can produce an 
assessment of self-management skills given by children with IBD that is consistent 
with that given by their parents and paediatric gastroenterologist and is consistent 
with the age-related expectations as defined in the literature. The following 
hypothesis was therefore developed: 
That a novel, disease specific, self-management skills assessment tool can be 
developed that enables children with IBD to report their skills accurately, and in 
concordance with age expectations.   
10.2 Stage 1: Content synthesis 
10.2.1 Methods 
For the initial development phase of the new skills assessment tool, 
recommendations were followed that state in order to evaluate self-management 
skills a theory-based, core set of outcomes should be followed 108. These outcomes 
were identified as those processes and behaviours considered essential for 
individual self-management, as outlined in the Modi framework discussed in Chapter 
One (Section 1.5) 50:  




 Cognitive attributes 
These outcomes were used to categorise the items from the self-management 
assessment tools identified in Chapter Nine according to how each skill, task, and 
attribute could be associated with each outcome. This exercise was carried out as a 
content synthesis, with all items and their source entered into a table under the 
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relevant outcome, and similar questions or statements summarised to avoid 
duplication. Items were not included in this analysis if they were not generalisable to 
the target population in different environments – as an example, items regarding 
health insurance were not included as this is not a requirement in all countries and 
would therefore limit generalisability. In addition, items regarding topics considered 
more relevant to young adults or adolescents were not included as the tool was to be 
aimed at children ten years and over. An example of excluded items were those 
regarding pregnancy, alcohol and sexuality as these would be addressed when 
children are approaching transition to the adult health team. These items would not 
be appropriate in the target population of children aged ten and over.   
10.2.2 Results 
The results of this content synthesis are presented in Table 10.1. 
The most frequently represented, or most relevant, self-management skills, tasks, 
and attributes identified were subsequently considered for inclusion in the new tool, 
ensuring that all of the outcomes from the Modi framework were represented. The 
items were grouped into a number of themes that could be easily understood by the 
target population and would provide a logical structure to the new skills assessment 
tool: 
 My IBD and symptoms 
 My appointments 
 My treatment 
 Taking my drugs and nutrition drinks 
 Managing my IBD 
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Table 10.1 Self-management skills, tasks, and attributes from instruments identified in 
Chapter Nine.  
Item Source Total 
Disease Knowledge and Self-Regulation 
Can tell others diagnosis 2, 110, 111, 116, 545 5 
Can describe own IBD and symptoms 
2, 110, 116, 260, 293, 
540, 543-545 
9 
Can explain own medical history 2, 111, 540, 543 4 
Can describe future consequences 110, 260, 545 3 
Can get through day even if have symptoms  293 1 
Knows what makes symptoms worse 116, 293 2 
Can tell when flare starting and when improves 110, 116, 293 3 
Communication 
Talk to MDT about concerns, treatment, symptoms 
110, 116, 260, 293, 
543, 544 
6 
Answer MDT questions in appointments 111, 116, 260, 540, 543 5 
Ask MDT questions in appointments 
110, 111, 116, 260, 
543, 544 
6 
Helps make decisions about health 110, 543, 544 3 
Speak to MDT instead of parents 110, 260, 543 3 
See MDT on own in appointments 
110, 111, 260, 540, 
543, 544 
6 
Know Doctors name and role 2, 116, 540 3 
Bring list of questions to appointments 111 1 
Tell others what was discussed in appointment 110 1 
Adherence 
Follow prescriptions and changes made 116, 544 2 
Know what drugs/EN are for 110, 116, 293, 545 4 
Know consequences of not taking drugs 2, 110, 116, 540, 544, 
545 
6 
Know names, amount, times, and dose of my drugs/EN  2, 110, 111, 116, 260, 
293, 540, 545 
8 
Describe side effects of my drugs 2, 110, 540 3 
Know drugs interactions  116, 540 2 
Can tell when drugs aren’t working  110 1 
Can describe effect of dose reduction on symptoms 110 1 
Can organise drugs for trips away from home 116 1 
Need no reminding to take drugs/EN at home or away 110, 111, 293, 544, 545 5 
Using things to remember drugs (pillbox, schedule, 
alarm) 
2, 544 2 
In charge of taking and preparing drugs/EN  110, 116, 260, 543-545 6 
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Table 10.1 continued 
 
10.2.3 Item development 
The items presented (Table 10.1) were written as an aggregate summary of similar 
questions or statements asked in different ways across the tools. The first task 
therefore was to write new items to match these statements in a way that could be 
easily understood and easily responded to by children. The new items were written 
according to a number of considerations that have previously been highlighted in 
Chapter Three (Section 3.2.3.1) as essential for populations with low health literacy, 
and to ensure generalisability to both IBD disease groups:  
 No compound elements that may require more than one response per item. 
 Appropriate readability levels  
 Items generalisable to both UC and CD 
 Items age appropriate 
 Items generalisable to different modes of treatment.   
Item Source Total 
Cognitive Attributes 
Know how to find IBD information  
2, 111, 293, 540, 543, 
544 
6 
Can tell parents when running low on drugs/EN 116 1 
Drop off and pick up prescriptions  
2, 110, 111, 116, 260, 
540, 543, 545 
8 
Contact MDT when need to 2, 110, 111, 543, 545  5 
Can read and use thermometer 2, 540 2 
Can manage medical tasks at school 540 1 
Know names of IBD support groups 2 1 
Travel on own to appointments 110, 260, 543 3 
Manage appointments (book, reminders, attend) 
2, 110, 111, 116, 260, 
540, 543-545 
9 
Know who to call in emergency 260 1 
Know what other services (e.g. dietitian) available 116 1 
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10.2.3.1 Readability 
The first draft of the self-management skills assessment tool comprised twenty-two 
items divided in to five sections. The readability of the tool overall, and of each 
individual item, was assessed to ensure they were below the recommendations of a 
school grade five reading level (pertaining to the school year grading system) 440, or 
above the reading ease equivalent of 70 (easiest 100) 455, deemed ‘Fairly easy to 
read’ 555. Overall, the tool had a reading level of Grade 3.6 and reading ease of 90, 
suitable for children aged 8-9 years, and very easy to read 441. When the individual 
items were examined, 19/22 had a reading level above 95 at a grade level 5 and 3/22 
were within the reading ease range of 50-70 at a grade level 7-8. These three items 
contained words such as pharmacy, hospital, appointments, and treatment, but it was 
highlighted in Chapter Three (Section 3.4) that while medical terminology may 
adversely impact readability, they are words commonly used around children with a 
medical condition so are most likely more easily understood. In addition, these terms 
are unavoidable when the provision of an alternative description would make the 
item overly long. 
10.2.3.2 Item scoring 
Once the items had been developed and allocated to the relevant sections, it was 
imperative to devise an appropriate format for the children to respond to each 
statement. The scoring system was therefore developed to reflect a combination of 
the two approaches to assessing self-management; to measure the allocation of 
responsibility for skills between children and their parents, and to quantifying 
tangible self-management skills by allowing the calculation of a numeric score to 
indicate a level that may be measured longitudinally 255. The tools utilised by 
Whitfield and Fishman 111, 116, as outlined in Chapter Nine, measured the degree of 
help required to perform certain self-management skills. The known preference of 
children for three Likert items over five also guided the response format. A three-
option scale for responses was therefore developed to allow children to indicate 
whether they could perform the self-management tasks on their own, with help, or 
not at all. These responses were allocated scores of two, one, and zero, respectively. 
This allowed for scores to be measured longitudinally across repeat administrations, 
with scores monitored for change. 
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10.3 Stage 2: Content validity assessment 
Once the first draft of the tool was completed, a number of experts in the field of 
paediatric IBD were invited to perform a specifically designed evaluation of the skills 
assessment tool. This process of gathering structured, quantitative feedback is 
known as a content validity index (CVI); an assessment of the degree to which 
elements of the tool are relevant to, and representative of, the targeted construct for 
a specific purpose 386. In addition, all reviewers were invited to provide qualitative 
feedback which, when gathered alongside the CVI might also be useful for identifying 
errors and refining content during the development phase of an assessment 
instrument 556. The recommendation for performing a CVI is for eight to twelve 
experts to perform the assessment 556 and for the purpose of this analysis, ten 
experts were invited via email to take part, and eight agreed to participate. The 
experts comprised four paediatric gastroenterologists, one adult gastroenterologist, 
two IBD nurses (one transition, one paediatric), and one IBD researcher whose area 
of interest includes self-management.  
9.3.1 Methods 
The CVI tool was formulated to assess the level of relevance, effectiveness, and 
appropriateness of each of the five sections of the self-management tool 386. The CVI 
tool contained the individual sections of the self-management tool separated out and 
placed sequentially. Each section was immediately followed by a rating system for 
the experts to quantify their opinion of the relevance, effectiveness, and 
appropriateness using a five-point Likert scale ranging from strongly disagree (score 
1) to strongly agree (score 5). A free form field was included after each section so the 
experts could also provide qualitative feedback. The CVI tool was developed using an 
online form provider (Cognito Forms), and the link emailed to the expert panel for 
completion. The CVI tool is included in Appendix N. 
On completion of the CVI tool, the ratings given by the experts using the five item 
Likert scales were transformed to scores of one to five. The Individual CVI (I-CVI) 
were then calculated for each assessment item by transforming the score to a 
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proportion of the maximum possible score for all expert reviewers 557. The same 
method was applied to each whole section to give the section CVI score (S-CVI). The 
recommended levels of CVI agreement vary, with the general consideration being 
that scale items may be judged ‘excellent’ with I-CVI greater than 0.78 if performed 
by 6 to 10 experts, and an overall S-CVI of 0.90 or higher 556.  
10.3.2 Results  
The scores from the content CVI for the self-management skills assessment tool were 
calculated (Table 10.2). 
Table 10.2. Results of the content validity index of the self-management skills 
assessment tool 
Section Construct Item Assessment I-CVI S-CVI 
1 My IBD and 
symptoms 
1i Relevance 0.98  
1ii Effectiveness 0.93  
1iii Appropriateness 0.93 0.95 
2 My appointments 2i Relevance 0.98  
2ii Effectiveness 0.93  
2iii Appropriateness 0.93 0.95 
3 My treatment 3i Relevance 1.0  
3ii Effectiveness 0.98  
3iii Appropriateness 0.93 0.97 
4 Taking my drugs 
and nutrition 
drinks 
4i Relevance 1.0  
4ii Effectiveness 0.98  
4iii Appropriateness 0.86 0.95 
5 Managing my IBD 5i Relevance 0.95  
5ii Effectiveness 0.93  
5iii Appropriateness 0.86 0.91 
 Mean 0.95 
 
As can be seen (Table 10.2), the range of I-CVI scores ranged from 0.86 to 1.0, and the 
S-CVI ranged from 0.91 to 0.97, with an overall score for the tool of 0.95. The tool 
was therefore considered to have excellent content validity. 
All experts provided additional feedback, comments, and suggestions on each 
section. The main suggestions were to provide greater clarification for terms such as 
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‘symptoms’ and ‘treatment’. It was universally acknowledged that children’s scores 
should increase over time as their skills improved, and the suggestion was given to 
explain to children there was no expectation of being able to perform all tasks 
immediately.  
10.4 Stage 3: Validity study 
Once the final version of the tool had been developed, it was titled the IBD-Skills 
Tasks and Abilities Record: IBD-STAR. The process of establishing internal validity of 
IBD-STAR was undertaken to determine whether the tool adequately and 
appropriately assessed the self-management skills of children with IBD. As 
established in Chapter Eight, there are inherent difficulties in establishing agreement 
between different reporters for subjective data. When validating IBDnow, 
disagreements were recognised between the child and clinician reports, but were 
also understood to be a consequence of children reporting personal symptom 
information that then required clinical interpretation by the paediatric 
gastroenterologist. The validation process for IBD-STAR therefore aimed to minimise 
this bias of reporting by establishing validity using the process of data triangulation, 
a method used to test validity through the convergence of information from different 
sources, or by using more than one methodological approach to answer a research 
question 558, 559. The objective of using data triangulation is to increase the confidence 
in findings by providing a more comprehensive picture of the results than could be 
presented using a single methodology 558. This technique can be approached in four 
ways 559: 
 Methodological: comparing results from different data collection methods 
 Investigator: collecting the same data using different researchers 
 Theoretical: using different theories to analyse and interpret data 
 Data source: collecting data from different sources to provide multiple 
perspectives 
For the purpose of this study, validity was tested using the data source and 
methodological triangulation methods, and by assessing the results to determine if 
IBD-STAR produced age appropriate data, with comparisons made as follows:  
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 Comparing the skills assessments given by the child with that given by their 
parent, and their clinician 
 Comparing children’s responses to IBD-STAR items against open-ended 
questions, completed by children and their parents, in order to cross-validate 
accuracy of their report  
 Comparing the children’s skills assessment produced using IBD-STAR against 
established age appropriate expectations 
Self-management abilities may be influenced by a number of non-modifiable factors 
such as age, diagnosis, and gender 50 so these results were examined against a 
number of independent variables.  
The face validity of IBD-STAR was examined in order to assess clarity, and ease of 
administration, and also to evaluate whether each item matches the conceptual 
domain 421, 435. This was done following data collection so as to study participant 
response patterns, and inter-item correlations.  
10.4.1 Methods 
10.4.1.1 Participants and ethics 
All children over the age of ten years of age and considered capable of completing 
IBD-STAR, and with a confirmed diagnosis of IBD, were included in the study. One 
parent of each child was also recruited for the study. Participants were approached 
in the paediatric IBD outpatient clinic in Christchurch Hospital, New Zealand. Ethical 
approval was granted by the University of Otago Human Ethics Committee (Health) 
(H16/116). Written informed consent was obtained from parents, and written assent 
from children.  
10.4.1.2 Assessment methods 
10.4.1.2.1 Data source triangulation 
Following the consent process the child and parent completed their assessments 
simultaneously in the presence of the researcher to ensure there was no help given 
by either party. A brief demographic survey was then completed, and the clinician 
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tool attached to the clinical notes. The clinician completed their assessment at the 
end of the consultation, not in the presence of the child or parent participants. The 
assessment tools for each participant group were as follows: 
Children’s assessment tool 
The children with IBD completed IBD-STAR (final version in section 10.4.2.8). 
Parent assessment tool 
The parent assessment tool consisted of a series of six VAS, with the scale extremes 
representing the scores 0 (cannot self-manage) to 100 (independently self-manage). 
Each of the first five VAS corresponded to one section of IBD-STAR, and included a 
summary of self-management tasks expected in that area. The sixth VAS scale was an 
overall opinion of their child’s self-management skills. The parent’s assessment tool 
is included in Appendix O. 
Clinician assessment tool 
The tool completed by the clinicians was identical to that of the parents except the 
wording and consisted of a series of six VAS scales to report their opinion of the 
child’s self-management skills for each corresponding IBD-STAR section, and overall.  
10.4.1.2.2 Methodological triangulation 
In addition to completing the skills assessment tools, children with IBD and their 
parent were also requested to answer four open-ended cross-validation questions 
which were different for both groups; each question corresponded to one item from 
IBD-STAR. These cross-validation questions were to ascertain if the answers given 
using IBD-STAR were a true representation of self-management skills:  
Child participant questions: 
 What type of IBD do you have? 
 What is the name of your IBD doctor? 
 What are the names of your IBD treatment? 
 How often do you remember to take your treatment yourself? 
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Parent participant questions 
 Does your child use any reminders for their appointments (example: in a 
diary, calendar, phone) 
 Does your child use any reminders to take their drugs (example: weekly 
pillbox, set an alarm etc) 
 Does your child get their own drugs ready if they are going away for at least 
one night? 
 Has your child ever ordered and collected their own drugs from a pharmacy? 
 
Agreement levels were considered acceptable if the questions were answered the 
same in IBD-STAR and to the qualitative items by over 75% of participants. The 
clinician was not required to answer any cross-validation questions. 
10.4.1.2.3 Age appropriate expectations 
The systematic review in Chapter Nine, identified a small number of checklists 
related specifically to children with IBD that categorises self-management skills by 
those that could be achieved within set age limits 2, 119, 540. In order to address the 
aspect of age appropriate skills, the results from the cohort of children with IBD were 
compared to the expectations set out in the checklists.  
10.4.1.3 Statistical analysis 
IBD-STAR scores were assigned according to the child’s response to each statement 
of whether they were able to perform the self-management tasks by themselves 
(score 2), with help (score 1) or not at all (score 0).  
Face validity was assessed by studying the response patterns given to each item, and 
an arbitrary cut off of less than 40% answering ‘Yes’ to an item considered cause to 
further examine face validity. Those items that were appropriate for younger 
participants (as determined by age appropriate checklists 2, 119, 540), could be 
expected to be answered as ‘yes’ by the majority. If less than 40% of the cohort were 
able to perform this task the item was further examined. Inter-item correlations 
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were also calculated for the tool overall, and for each section, to assess item 
homogeneity.  
For IBD-STAR the percentage score was calculated for each of the five sections, and 
for the test overall. The mean scores of each section of IBD-STAR were compared to 
that of the parent and clinicians corresponding VAS scale score for that section, and 
the overall score of IBD-STAR with the sixth VAS score of the parent and clinician. 
Scores were compared using paired t-tests with significance considered at the level p 
≤ 0.05. 
Children’s IBD-STAR scores were tested for their association with a number of 
independent variables using linear regression for continuous data and independent 
t-tests or ANOVA for categorical data. One particular variable that was included for 
consideration was whether participants with IBD had attended Camp Purple in the 
same year as the study took place (2019). The benefits of attending residential camps 
have previously been discussed (Chapter One, Section 1.4.4.2), one of which is 
improvements to self-management.   
The answers given to the cross-validation questions by children and their parents 
were compared to the answer given to the relevant item of IBD-STAR. The results 
were assessed by the percentage of answers that were identical in both reports, and 
as the percentage underestimated, and overestimated in the responses given using 
IBD-STAR. 
To assess IBD-STAR responses against the identified age appropriate expectations, 
the cohort of children with IBD were divided in to age groups and their results 
compared to the checklists to ascertain if IBD-STAR could produce reports in 
concordance with the age expectations. 
Reliability of the participant self-report tool was tested using Cronbach’s alpha. This 
was calculated for the whole tool, and for each section, to determine internal 
consistency 438. Levels for a Likert scale tool such as IBD-STAR should be expected to 
be over 0.8 overall 560, 561. 
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10.4.2 Results 
10.4.2.1 Face validity and reliability 
The participant response patterns to each item were examined (Figure 10-1). 
Figure 10-1. Participant response patterns to each IBD-STAR item.  
The vertical black line represents a 40% cut off to indicate items should be reviewed 
 
 
As seen, (Figure 10-1), seven items were scored as ‘Yes’ by less than 40% of the 
paediatric cohort, indicating that under half the children could perform those tasks 
independently. When these items were compared to the checklists from the 
literature 2, 119, 540, three were pertaining to skills expected of older participants. 
These three items could be expected to score more ‘Yes’ responses among older 
children, and were therefore considered to have face validity.  
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The other four items all outlined self-management tasks that may not be required, or 
used, by all children and therefore had the reverse response pattern to other skills: 
2c - set reminders for appointments 
2d - make a list of questions for appointments 
3d - keep a list of treatments 
4d - using prompts to aid adherence (pill boxes etc)  
In order to establish whether these four items were measuring the same underlying 
concept as the rest of the items in the tool, inter-item correlation analysis was 
performed for IBD-STAR overall and by individual section. When studied overall, the 
internal consistency of IBD-STAR would be improved by the removal of two of the 
four items identified above. When studied by individual section, the removal of all 
four identified items (2c, 2d, 3d, 4d) would improve the consistency of the section 
they originated from. For the purpose of the analysis it was deemed appropriate to 
remove these four items, thus ensuring that the children’s scores for IBD-STAR were 
not skewed by measuring tasks that should not be expected to increase over time 
and which would subsequently affect the score comparisons between their parents 
and clinician. These items are discussed further in section 10.4.2.8.  
10.4.2.2 Participants 
Twenty five children were recruited for the study, and each also had one parent 
participate. The demographic distribution of the children with IBD were examined 
(Table 10.3). The time since diagnosis is presented as a continuous variable, and as a 
categorical variable of less than, or more than, two years. 
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Table 10.3. Demographic data for participants 
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Age (years)  
 
14.03 (1.7) 
[10.75 to 16.92] 
Age at diagnosis (years) 10.98 (3.6) 
[2.3 to 15.8] 
Time since diagnosis (years)  
 
3.04 (3.6) 
[0 to 12] 
Parent age (years) 45.4 (5.7) 
[35 to 62] 
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10.4.2.3 IBD-STAR scores  
The mean IBD-STAR score for the children overall was 27.1 (SD 5.7) out of a 
maximum possible score of thirty six, which equates to a mean score of 75% (SD 
15.7). The mean percentage scores were compared against the independent 
variables (Table 10.4). Family ethnicity was not included in the analysis due to the 
disparate distribution between groups. 







Age 0.472 0.017 
Age at diagnosis 0.03 0.886 
Time since diagnosis 0.256 0.216 













































75.9 (15) 0.513 




76.3 (16.9) 0.525 
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Age was the only factor found to have a significant effect on IBD-STAR scores (Figure 
10-2). 
Figure 10-2. IBD-STAR percentage scores against the child’s age  
Line of best fit included.  
 
 
10.4.2.4 Data source triangulation 
The children’s IBD-STAR percentage scores for each section, and overall scores, were 
compared with the corresponding VAS score (0-100) of their parents and clinicians 
(Table 10.5).  
The children’s mean scores were significantly different for section two 
(appointments) when compared to both parents and clinicians, with the children 
rating their self-management skills higher. Parents also rated their child’s skills 
significantly lower for section four (adherence) and overall. The difference between 
the child and clinician scores were not significant for any other section, or overall. 
The differences between the scores given by the three reporters were examined 
graphically (Figure 10-3). 
 


























One 81 (17) 76 (17) 79 (15) 5.4 (23.9) 0.267 2.5 (21.6) 0.572 
Two 83 (18) 75 (18) 74 (19) 8.2 (17.8) 0.03 9.1 (19.5) 0.029 
Three 83 (26) 77 (22) 79 (16) 5.2 (33.8) 0.447 4 (30.5) 0.519 
Four 85 (21) 68 (30) 77 (22) 17.1 (26.5) 0.004 7.2 (28.4) 0.213 
Five 49 (25) 39 (29) 58 (23) 10.2 (33.5) 0.139 -8.5 (25.7) 0.111 
Overall 75 (16) 63 (24) 70 (19) 11.9 (22.5) 0.015 5.5 (19) 0.159 
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Figure 10-3. Difference in self-management score patterns between children, parents, 
and clinicians.  
Bars marked with * were significantly different to the child’s report (p < 0.05). 
 
As can be seen (Figure 10-3), parents underestimated their child’s self-reported self-
management skills in all sections, and overall. Clinicians also rated the child’s skills 
lower than the children’s self-reports with the exception of ‘managing their IBD’ 
which contained skills that would be expected to be achieved by the older children in 
the cohort.  
The impact of the child’s age was further explored against the difference between 
child scores and those of the parent and clinician given in each section, and overall, to 
determine if increasing age improved the level of agreement. The parent and 
clinician scores were subtracted from the children’s percentage score for each 
section, and overall. These results were then compared using linear regression 
against the child’s decimal age (years). The results (Table 10.6) show that the 
difference in scores, and therefore agreement, were not significantly related in any 
section, or overall, with increasing age of the child. 
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Table 10.6. Effect of the child’s age on their score difference with parent and clinician.  












IBD and symptoms 
0.047 0.823 0.004 0.985 
Two 
Appointments 
0.077 0.716 0.007 0.975 
Three 
Treatment 
0.122 0.560 0.207 0.321 
Four 
Adherence 
0.212 0.309 0.277 0.180 
Five 
Managing IBD 
0.123 0.558 0.012 0.956 
Overall 0.171 0.414 0.066 0.755 
10.4.2.5 Methodological triangulation 
The responses given by the children and parents to the cross-validation questions 
were compared to those responses given by the children using IBD-STAR. The 
frequency of answers that were the same, were underestimated in IBD-STAR, and 
over-estimated in IBD-STAR were examined (Figure 10-4). 
Overall, children gave the same answer in both data sources for 85% of responses, 
underestimated their abilities in IBD-STAR by 12%, and overestimated by 3%. 
Parents responses were the same as the child’s IBD-STAR rating for 78% of 
responses, IBD-STAR underestimated 1% of responses and overestimated 21% of 
responses according to the parents’ qualitative answers.  
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Figure 10-4. Frequency of responses to cross-validation questions. 
 
 
10.4.2.6 Age expectations 
In order to further explore the concept of age-related self-management skills, the 
scores overall and in each IBD-STAR section were analysed using a linear regression 
against age (years) (Table 10.7). This analysis showed that the section scores 
regarding their diagnosis and symptoms, and knowing about their treatment, were 
not age related. All other sections showed significant age-related differences. 








Section 1: IBD and symptoms 0.215 0.301 
Section 2: Appointments 0.418 0.037 
Section 3: Treatment 0.011 0.959 
Section 4: Adherence 0.616 0.001 
Section 5: Managing IBD 0.488 0.013 
Overall 0.472 0.017 
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The checklists previously identified 2, 119, 540 all presented differing age ranges for 
their skills expectations. The lowest age groups of the three checklists differed in 
year ranges between 12 to 14, 11 to 13, and 10 to 12 years. However, all of the 
checklists stated that within that lowest age group children with IBD should be 
expected to know their diagnosis and how it affects them (Section 1), and to know 
the names and doses of their treatment (Section 3). All three checklists categorised 
self-management skills pertaining to appointments (Section 2) and managing IBD 
(Section 5) to be expected of children aged over 14 years. None of the checklists 
specifically addressed adherence to treatment (Section 4), but as can be seen (Table 
10.7), this skill was also significantly related to increasing age.  
10.4.2.7 Reliability  
The internal consistency of IBD-STAR was measured as a whole scale, and for each 
section/sub-scale, the results of which showed that the tool overall had good internal 
consistency (Table 10.8). Those sections with lower Cronbach’s alpha scores 
(Sections One and Two) contained items that had been included with the assumption 
that even the youngest children in the target population could respond to the item 
with a ‘Yes’ or ‘With help’ answer, such as knowing their diagnosis or the name of 
their IBD doctor. The implications of this to reliability analyses are that the expected 
skew of responses to these items may affect the reliability scores, but that the items 
are important to include.   





Section 1: IBD and symptoms 0.393 
Section 2: Appointments 0.562 
Section 3: Treatment 0.853 
Section 4: Adherence 0.644 
Section 5: Managing IBD 0.661 
IBD-STAR: Overall 0.844 
10.4.2.8 IBD-STAR 
The four items that were excluded from the analysis of IBD-STAR (Section 10.4.2.1) 
were considered important to keep in the tool as they were empirically determined 
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as relevant self-management skills. These four items were included as a new sixth 
section at the end of the tool that will not be allocated scores. The benefit of including 
these items is that when a child marks certain IBD-STAR items as ‘no’ or ‘with help’, 
such as taking their medications without being reminded, their answers could be 
checked against whether they use a pill box to remind them. These items could 
provide guidance for the MDT on ways to support the child by suggesting they use 
these prompts to help learn self-management skills, and may also trigger awareness 
for the child of additional ways they could self-manage their IBD. It was not 
considered that IBD-STAR would have been completed any differently by 
respondents whether in the original format, or as a separate section. The final 
version of IBD-STAR is shown in Figure 10-5. 
 
10.5 Discussion 
The evaluation of self-management skills for children with IBD is vital to identify 
areas where they may need additional support or education. The paucity of 
appropriate assessment instruments in the literature led to the development of this 
novel self-management skills evaluation tool: IBD-STAR. The rigorous process 
executed when developing the items, verifying the content, and validating IBD-STAR, 
has produced a tool that may now be used to assess self-management skills in the 
clinical environment.  
Children’s self-management skills showed a significant, positive association with the 
increasing age of the study cohort, a finding in accordance with other studies among 
children with IBD 110, 116, 543, 562, and in other disease groups such as heart disease 563, 
Cystic Fibrosis 564, transplant 565, and mixed chronic conditions 544, 545. Children can 
be expected to gain self-management skills as they advance in age, and therefore 
their IBD-STAR scores could be expected to increase. The current findings suggest 
that IBD-STAR is sensitive to developmental differences as children grow older 260. It 
may be inferred that individual scores may be compared with similarly aged 




Figure 10-5. IBD-STAR 
Children read each statement and mark in the column that indicates whether ‘Yes’ 
they can do this independently, ‘With help’, or ‘No’ they can’t do it at all. 
 
 MY IBD AND SYMPTOMS 
(symptoms are like clues for your IBD – how much pain you are in, or 




1a I can tell others what type of IBD I have.    
1b I can tell others what my IBD symptoms are.    
1c I can tell others what makes my IBD symptoms worse.    
1d I keep track of my symptoms to see when my IBD is better or worse.    
 
 MY APPOINTMENTS Yes With 
help 
No 
2a I can tell others the name of my IBD doctor.    
2b I keep track of when I have appointments. (Example: Dr, bloods, 
infusions). 
   
2c I can talk to my doctor about my recent IBD symptoms.    
2d I can talk to my doctor about my IBD treatment.    
 
 MY TREATMENT  




3a I can tell others the names of my IBD treatment.    
3b I can tell others the times I take my IBD treatment.    
3c I can tell others how much of each IBD treatment I have to take.    
 
 TAKING MY DRUGS or NUTRITION DRINKS  




4a I remember to take my drugs or EN    
4b I can get my drugs or EN ready when it is time to take them    
4c I can organise enough drugs or EN to last me if I’m going away from 
home  
   
 
 MANAGING MY IBD Yes With 
help 
No 
5a I keep track of when I need to order more treatment    
5b I can order and collect treatment from the hospital or pharmacy    
5c I can find information about my IBD, treatment, or tests.    
5d I can contact my IBD team if I need their help    
 
 MY IBD TASKS Yes With 
help 
No 
6a I set reminders for appointments     
6b I make a list of questions to take to my appointment    
6c I keep a list of what treatment I am on and any changes made to it    
6d I use things to help me remember my drugs or EN (example: alarms, 
pill box) 




IBD-STAR scores did not show an association with time since diagnosis, or age at 
diagnosis, a finding mirrored in other IBD studies 116, 293, 562, thus indicating that it is 
age, rather than disease duration, that has the greater impact on the acquisition of 
disease related self-management skills. The current findings confirm that in this 
study cohort, self-management skills are not being achieved until the age considered 
appropriate in the literature, even when diagnosed at a young age 111.  
When the specific section related to taking their treatment, or adherence (section 
four), was measured it showed a positive association with increasing age, as in other 
studies identified in the systematic review (Chapter Nine) 110. However, this is not a 
universal observation with other adherence specific studies finding that increasing 
age was associated with worse adherence to some medications for children or 
adolescents with IBD 215, 229. When studied as a factor of self-management skills for 
children undergoing organ transplants, higher allocation of responsibility for self-
management tasks was associated with poorer adherence 255. When the overall IBD-
STAR scores were measured by linear regression to the scores for section four 
(taking treatment/adherence) there was a significant positive association (R 0.697, p 
<0.005), suggesting that increased allocation of responsibility was associated with 
improved adherence in this cohort as measured by IBD-STAR. It must be 
acknowledged that the study did not use a validated adherence scale to measure this 
factor, therefore extrapolation is limited.   
The effect of all other independent variables were non-significant. For IBD diagnoses, 
the current findings are consistent with the literature 110, 293, however, children with 
UC were poorly represented in the current cohort with a ratio of 7:1 for CD 
diagnoses. The influence of gender shows no consistent trend in the literature for 
acquisition of self-management skills and is infrequently reported. Some studies 
show no significant effect 260, 293, and some with males 110 and females 562 scoring 
better in select domains but not overall. While having a parent with IBD was not 
associated with improved IBD-STAR scores, there were not sufficient numbers for 
meaningful comparison. This could have been improved by asking whether a first 
degree relative had IBD instead of limiting it to parents. One study measuring self-
efficacy among children with IBD found that family history had a significant effect on 




better self-management skills 293. This factor could be further explored in a larger 
study.  
The concordance of IBD-STAR responses with the categories of age appropriate skills 
found in the literature suggest that this tool can provide an age related report of self-
management skills. This finding was made using approximations of lowest and 
highest age groups, as all the checklists, and all other studies examined, used 
different age ranges. When developing IBD-STAR it was ensured that it contained 
items that children in the lower age groups could complete, such as their diagnosis 
and name of their doctor. While the inclusion of such items in a psychometric Likert 
scale would run the risk of this causing a floor or ceiling effect, whereby less than 
15% participants score items on scale extremes 566, 567, this tool is measuring 
practical skills with the intention that children will, over time, score highly. When 
utilising IBD-STAR the situation may arise that children with elevated self-
management skills may score well when they are first assessed, and therefore there 
is minimal change to be detected longitudinally across time except to achieve a 
consistent full score. This should not be perceived negatively as the child would be 
sufficiently self-managing 567, and in this instance it would be appropriate to check 
with the parent that the child’s report is accurate and continue to check their skills 
over time. When older children have learned self-management skills and are scoring 
highly on IBD-STAR they will be approaching the process of transition and will be 
required to attain additional knowledge and skills, such as knowing the effects of 
smoking and pregnancy on their disease, or being able to travel independently to 
appointments. The results shown in this study may simply be a reflection that the 
study cohort were developing self-management skills appropriately for their age, and 
a larger scale study is needed to address these findings.  
The self-management skills evaluation completed by the parents show that for all 
IBD-STAR sections, and overall, they rated their child’s skill levels lower than those 
reported by the children themselves. The level of agreement did not improve with 
age, as has been found in children with asthma when their self-management skills 
were compared with their parent report 568. While this universal underestimation of 
children’s self-management skills by their parents has been mirrored in other 




children with IBD. In a study measuring self-efficacy there was general disagreement 
between children and their parents but the significant differences in certain domains 
(overall independence, knowledge, and appointment skills) were both overestimated 
and underestimated 110. In the broader scope of paediatric IBD care, parents have 
been shown to significantly underreport emotional functioning and HRQoL 570 and 
report worse somatic and psychosocial IBD symptoms than their children 571.  
This evidence suggests that parents may not always accurately assess the level of 
their child’s abilities, which may be a reflection of parental stress and concern for 
whether their child can responsibly manage their own health tasks 260, 571. This could 
also be a reflection of children reporting their perceived self-management skills as 
opposed to their demonstrated skills, as found in a cohort of children undergoing 
transplant whose perceived skills were significantly correlated with age, but their 
demonstrated skills were not 565. This study cohort may consider themselves capable 
of performing the self-management skills, however in reality they may not actually 
carry them out and are reporting self-efficacy as opposed to self-management. This 
may account for the difference in scores between children and their parents as the 
parents are reporting those their children actually perform. However, the summary 
scores provided by the clinicians were more closely aligned with those given by the 
children. This may illustrate that in contrast to parents, who are more emotionally 
involved when reporting on their child’s development of health autonomy, clinicians 
were able to objectively assess self-management skills and therefore their evaluation 
was empirically based and a factual reflection of the child’s abilities.  
This phenomenon could be further explored in a future study by asking parents to 
complete IBD-STAR to report their child’s actual self-management skills, thereby 
allowing a direct comparison as opposed to providing a summary score for each 
section. In this study we aimed to reduce the chance of this reporting bias by asking 
both the children and parents a series of cross-validation questions to provide 
methodological triangulation of the results.  
The cross-validation questions completed by the children with IBD showed excellent 
levels of agreement with their answers given to the corresponding IBD-STAR items. 




that is easily understood by the target population as they generate responses that are 
an accurate reflection of how the child perceives their self-management abilities. The 
lower, but still acceptable, levels of agreement between the parent cross-validation 
questions when compared to the child’s responses to IBD-STAR confirms our 
previous findings that parents underestimate self-management abilities. 
The methodological and data source triangulation aimed to address the possible 
social desirability bias of answers given by the children to IBD-STAR. Social 
desirability is the tendency of participants to answer items in a way they perceive as 
more socially acceptable than would be their "true" answer in an attempt to project a 
favourable image of themselves 572. The fact that children rated their skills higher 
than those reports given by their parents, and higher than all but one of the clinician 
reports, indicates that social desirability bias may have been present. However, the 
lack of significance between the children and clinicians scores for all but one of the 
sections demonstrated that social desirability bias was unlikely to have affected their 
scores by a substantial amount.   
It is important to acknowledge that IBD-STAR measures a single self-management 
construct while IBD affects all domains of functioning 573. While self-management 
incorporates three elements: medical management (concerning treatment), role 
management (participation in society), and emotion management (the emotional 
consequences of being ill) 10, 124, it was beyond the scope of this skills specific tool to 
address all factors. There are well established HRQoL measures for children with IBD 
such as the IMPACT-III which can assess emotional management and social 
functioning 574, and it was therefore considered that practical self-management skills 
should be measured separately. 
10.5.1 Limitations 
This research was a pilot study to establish initial validity of IBD-STAR and there are, 
therefore, several methodological limitations. The following points establish a need 





The small sample size precluded more in depth analysis. Children with UC were 
under-represented, but this is reflective of the local IBD population. While the ratio 
of children with CD to UC is unlikely to change in the IBD population of the South 
Island (New Zealand), a larger sample size could enable meaningful comparisons to 
be made between disease groups. Similarly, the effect of ethnicity could not be 
studied as 96% of children were from a New Zealand European background. In 
future studies, data on a family history of IBD will be collected in addition to whether 
the parent completing the skills comparison themselves has IBD.  
Generalisability to the wider paediatric IBD population was limited by single-centre 
data collection. Future research could increase the heterogeneity of the study 
population by implementing IBD-STAR in geographically diverse centres.  
Test-retest reliability should be performed in order to establish test consistency over 
time. 
IBD-STAR was only administered at a single time point, therefore precluding 
longitudinal data comparisons.  
In order to establish whether IBD-STAR is sensitive to change it should be used as an 
outcome measure before and after an intervention aimed at improving self-
management skills.  
Information relating to clinical outcomes, disease history, and disease activity were 
not collected for this pilot study, thus preventing analysis of their associations with 
self-management scores on these measures. The studies mentioned above should 
include other outcome measures in their methodology, such as IBD-KID2 to test 
knowledge levels, and IBDnow to allow self-report of disease activity.  
It would not be possible to examine concurrent validity of IBD-STAR with a similar 
tool as it was established in Chapter Nine that no self-management skills assessment 
tools were found to be appropriate for the study population.  
 
10.5.2 Strengths 
The items included in IBD-STAR were developed to be appropriate for young 
children with IBD, aged ten years and over, who are in the target age range of when 




age equivalent of eight to nine years and therefore acceptable for those with low 
health literacy. The answer format was consistent with the preferences of the target 
population and the allocation of responsibility scoring was simple and easily 
understood. IBD-STAR was quick and easy to complete and no participants requested 
help from the researcher when completing the tool. IBD-STAR has good overall 
reliability and validity has been demonstrated in a number of ways.   
10.5.3 Conclusion 
IBD-STAR was developed using empirical evidence and includes skills relating to the 
domains of an established self-management theoretical framework 50. Prior to testing 
IBD-STAR with the target population the content of the tool was confirmed as likely 
to be relevant, effective, and appropriate for the target population. The original 
hypothesis stated that IBD-STAR could enable children to accurately report their 
skills, and that these would be in line with age related expectations. IBD-STAR was 
used by participants to report their allocation of responsibility for self-management 
skills with an appropriate degree of agreement between children and their clinician, 
and with comprehensible differences between children and their parents. The 
reports were also commensurate with the age appropriate guidelines. These results 
lead to the acceptance of the hypothesis and provide support for the continuing 
evaluation of this measure.  
IBD-STAR can provide valuable evidence regarding areas of support where children, 
parents, and clinicians could work collaboratively to promote and facilitate 
opportunities for increasing self-management skills 260. While all indices of self-
management presented in IBD-STAR are unlikely to be achieved by all individuals, it 
can be used to assess a wide range of skills. These skills should be promoted from the 
age when self-management begins, up to the point when adolescents begin transition 
to the adult IBD MDT. The key use of IBD-STAR could be to guide interventions on 
the individual or population scale, thereby helping to prevent negative health 
outcomes that may result from poor acceptance of health autonomy, such as low 
adherence or insufficient self-regulation. Interventions may range from the simplest 
form of actively involving children in discussions about their IBD, to multifaceted and 




the child’s interaction with others more knowledgeable than themselves, such as 
parents and the MDT, and the range of skills they can develop with adult guidance 





Chapter Eleven: Proof of Concept Self-Management Booklet 
Study 
11.1 Introduction 
The theoretical basis for the design of a self-management mHealth app for children 
with IBD (IBD-Tracker) was presented in Chapter Two. It was not possible to 
perform a research study to establish usability, efficacy, and satisfaction of IBD-
Tracker in this body of work, as discussed in the Preface. However, the concept 
behind the app was to provide a series of tools that enabled children with IBD to 
perform specific tasks that may lead to measurable improvements in self-
management of their disease. Having designed the app using the process of 
intervention mapping, whereby evidence-based, effective components were 
combined; it was important to establish whether these components could effectively 
improve self-management skills even when delivered in an alternate format. In 
performing a study using the app content it could provide basic data on whether the 
concept of a self-management intervention for children with IBD was feasible and 
effective. In addition, it could provide information on the importance of engagement 
and delivery when initiating a self-management intervention in the paediatric 
population. The following study was therefore designed as ‘proof of concept’ 
research and imitates, in terms of intervention components and some outcome 
measures, what would have been tested in a pilot study designed to test IBD-Tracker.  
11.1.1 Intervention format 
When considering the format of an alternative self-management intervention to 
present the content of IBD-Tracker, the literature reviews presented in Chapter One 
(Section 1.6.1) were re-visited. Self-management interventions for children (Table 
1.1) and adults (Table 1.2) with IBD were identified in these reviews and the results 




outcomes measured. The reviews provided great insight in to the difficulties of 
delivering a ‘one size fits all’ approach for a disease that shows no uniformity. The 
interventions for children with IBD focussed predominantly on adherence or 
cognitive measures, and no patterns emerged among the paediatric or adult studies 
that identified the most effective components to address. Therefore, in order to 
establish that the concept behind IBD-Tracker was effective regardless of the format, 
the mode of delivery needed to be similar so as to imitate the portability and instant 
accessibility of IBD-Tracker. The format that could provide this capability was a 
booklet. Booklets have previously been used effectively in the self-management of 
adults with IBD 489, and have been incorporated in to the successful 
ImproveCareNow global paediatric IBD care initiative 116, 542, 576-578. 
A booklet developed to deliver IBD-Tracker components would need to provide 
‘static’ versions of the mHealth app sections: symptom self-report, reminder systems 
for drugs and appointments, EN monitoring, growth tracking, and a health passport. 
These areas would need to allow children to individualise the booklet for their own 
treatment regimens. The area of IBD-Tracker designated for delivering disease and 
treatment knowledge was already a series of static pages, however, it was thought 
that including this as part of the self-management booklet would make it overly long, 
and may affect engagement. The knowledge pages were therefore provided as a 
separate booklet to accompany the self-management intervention. The contents of 
the self-management booklet are described in Section 11.2.2.  
11.1.2 Aims and hypothesis 
The aim of this study was to provide a self-management booklet to children with IBD 
to determine whether an intervention similar in content to IBD-Tracker could 
improve a number of self-management and disease outcomes. The following 
hypothesis was developed: 
That a self-management intervention based on the IBD-Tracker app will be 





That IBD-KID2 can be utilised in a cohort of children with IBD to detect sensitivity 
to change pre and post intervention. 
11.2 Methods 
11.2.1 Population and ethics 
Children with a confirmed diagnosis of IBD, aged ten years and over, were recruited 
from three sequential paediatric IBD clinics (due to time constraints) at the 
Paediatric Out-Patient Department at Christchurch Hospital, New Zealand. Written 
consent was obtained from all parents and assent obtained from all children. Ethical 
approval for the study was granted by the Otago University Health Research Ethics 
Board (H16/116). 
11.2.2 Intervention booklets 
Two separate booklets were developed for the study in order to mirror the content 
of IBD-Tracker. IBD-Tracker was designed to be intuitive, easy to navigate, and 
provided simple instructions for each app task. The self-management booklet 
therefore needed to follow a similar approach while also giving consideration to the 
health literacy levels of children aged ten and over. These considerations have 
previously been discussed, but include readability, avoiding too much text per page, 
and the use of pictures to help with explanations and instructions 579. Each page 
contained a brief summary of the purpose of that self-management task, plus an 
explanation of what to do, and a task sheet to fill in. The following content was 
included in the self-management booklet (Appendix P): 
 An explanation of self-management 
 How to monitor symptoms using IBDnow 
 How to keep track of drugs and read a prescription label   
 How to keep track of appointments 
 Monitoring the drinks needed each day (example: EN, water) 
 How to monitor growth 




 Filling in a health passport of their individual IBD history 
 When to order new drugs 
 Support links to access 
 
The knowledge booklet contained pages with information on the following topics: 
 Inflammatory Bowel Disease 
 IBD facts 
 Crohn’s Disease 
 Ulcerative colitis 
 What is an endoscopy? 
 Tests you may have 
 Drugs you may have 
 What is enteral nutrition? 
 My nutrition 
 My gut 
 Self-management 
 Support 
11.2.3 Outcome measures 
The outcome measures for this study were selected to reflect those measurable areas 
of self-management important for children with IBD, as established in Chapter One: 
self-management skills, knowledge, disease activity, and adherence. In addition, user 
satisfaction with the booklet was to be measured on study completion. All outcome 
measures were completed using an online form provider (Cognito Forms) with the 
baseline set being completed with the researcher present in IBD clinic. The final 
outcome measures were completed at home by participants by accessing a link that 
had been emailed to their parents. 
 Knowledge: IBD-KID2 (Development in Chapters Three to Seven) 
 Self-management skills: IBD-STAR (Development in Chapter Ten) 




 Adherence: VAS (Discussed in Chapter One, Section 1.7.5) 
 Satisfaction: novel questionnaire  
11.2.4 Study process 
Baseline demographic and disease data were obtained for all participants. The study 
took place over 4 weeks, commencing once the baseline outcome measures were 
completed. The self-management and knowledge booklets were given to participants 
once the baseline outcome measures had been completed, and the parents were 
emailed a PDF version to allow them to print out any pages the children wished to 
use repeatedly. The schedule of outcome measures is outlined below (Table 11.1): 
Table 11.1. Study outcome measure schedule 
Metric Tool Baseline Four weeks 
Self-management skills IBD-STAR • • 
Knowledge IBD-KID2 • • 
Symptoms IBDnow • • 
Adherence VAS • • 
Satisfaction Novel survey  • 
 
In order to imitate the PUSH notification capability of IBD-Tracker, whereby 
children’s engagement with the app could be encouraged by messages and 
reminders, emails were sent to the parents of the participants half way through the 
study period to prompt the children to use the booklet.  
11.2.5 Statistical analysis  
Mean scores achieved on the outcome measures were compared against independent 
variables. If sufficient numbers were recruited for comparison the difference in mean 
scores achieved on the outcome measures were to be measured for association using 
independent t-tests for categorical variables and linear regression for continuous 
variables. The mean scores of the outcome measures between baseline and the four 
week repeat will be examined for change using the ICC, moderate if between 0.5 and 
0.75, good if between 0.75 to 0.9, and excellent if greater than 0.9 456. The difference 




will be accepted at the level p ≤ 0.05 with a 95% confidence interval. If insufficient 
numbers were recruited to allow statistical comparisons, data would be presented as 
means with standard deviation. 
11.3 Results 
11.3.1 Population 
Ten children were approached to take part in the study during the recruitment time 
frame, and nine agreed to participate. Demographic data were collected on all 
children (Table 11.2).  
Table 11.2. Baseline demographic data 
 Linear variables Mean (SD)  Range 
Age (years) 13.1 (2.0) 10. 8 to 15.7 
Time since diagnosis (years) 3.1 (4.8) 0 to 12 











11.3.2 Baseline outcome measure scores 
All children completed the baseline outcome measures (Table 11.3). The symptom 
assessment tool IBDnow is not scored, as discussed in Chapter Eight (Section 8.4), 
but change in symptom categories over time can be explored.  





IBD-KID2 (15) 6.78 (2.9) 1-12 
IBD-STAR (44) 29.8 (8.9) 12-42 




11.3.3 Repeat outcome measures 
Four of the nine children completed the repeat outcome measures at the end of the 
four week study period. These children were the four youngest, as well as being the 
four most recently diagnosed. Participant numbers were insufficient to calculate the 
significance of the score change, although the overall scores showed a positive 











IBD-KID2 (15) 6.0 (3.5) 8.0 (2.2) + 2 
IBD-STAR (44) 26.25 (9.5) 30.75 (3.3) + 4.5 
Adherence VAS (10) 7.5 (5) 8.25 (1.3) + 0.75 
 
When the answers given to the satisfaction survey were examined, one child 
answered that they had not read the self-management or knowledge booklets. The 
outcome measure scores were re-calculated to reflect whether participants had read 
the self-management and knowledge booklets for the study (Table 11.5). The 
participant numbers were too small to allow for meaningful comparisons between 
groups. 
Table 11.5. Repeat outcome measures categorised by having read the booklet 
 Did not read the booklets 
N=1 












IBD-KID2 (15) 7 10 5.7 (4.2) 7.3 (2.1) 
IBD-STAR (44) 32 30 24.3 (10.7) 31 (4) 
Adherence VAS (10) 10 9 6.7 (5.8) 8.3 (1.5) 
11.3.4 Symptom reports 
The symptom self-reports given using IBDnow by the participants who had read the 
booklets either improved by one level throughout the study period (example: can 
ignore pain improved to no pain) or stayed the same having scored symptoms as not 
having any (example: no blood stayed as no blood) for all. The participant who did 
not read the booklets reported having symptoms at baseline (pain, tiredness, feeling 
poorly) and these metrics all stayed the same at the end of the study. Also, their 
symptoms of blood and consistency were reported to have worsened by one level 




11.3.5 Satisfaction survey 
The responses given to the satisfaction survey regarding the self-management and 
knowledge booklets were examined (Figure 11-1).  
Figure 11-1. Participant response rates to the booklet satisfaction survey 
 
This showed that while none of the participants printed out any of the self-
management pages to use, three out of four children considered that the booklet 
could help them self-manage their disease. All participants thought the knowledge 
booklet could help them learn about their IBD. Three of the four children would use 
an interactive app based on the booklet (IBD-Tracker, Chapter Two), and all four 
considered that an app would be more helpful than the booklets. None of the 
participants provided qualitative feedback on the booklets despite being encouraged 
to do so in the satisfaction questionnaire. 
11.4 Discussion 
The use of two booklets aimed at helping children with IBD learn self-management of 
their condition has shown an overall positive trend towards improving self-
management outcomes. Low response rates to the final outcome measures prevented 
meaningful comparisons between scores at the two study time points. Feedback from 
the majority of study participants completing the satisfaction survey indicated that 
the booklets were considered helpful, but all agreed that a mHealth app would be 
more acceptable.  
The response rate to the completion of the final outcome measures was 




acceptable format for delivering a self-management intervention to children and 
adolescents. The fact that those participants completing the four week outcome 
measures were both the youngest, as well as the most recently diagnosed, suggests 
that these children and their parents may have had an unmet need regarding 
information of IBD self-management. This may have influenced their decision to take 
part in the study, and could also have been a positive factor towards their completion 
of all study outcomes. A simple comparison of the outcome measure mean scores 
showed that those participants who did not complete the study had higher scores at 
baseline than the four who completed the study: IBD-KID2 (mean difference +1.4), 
IBD-STAR (mean difference +6.3) and adherence VAS (mean difference +0.9). This 
may also signify that those participants who did not complete the study considered 
themselves more able to self-manage their disease and therefore did not use the 
booklets. Social desirability bias may also have prevented them from completing the 
final measures as they may not have wished to report that they did not utilise the 
intervention.  
The participant who completed the final outcome measures, but stated they did not 
read the booklet, reported a continuance or worsening of IBD symptoms. This may 
have influenced their decision not to engage with the intervention as it has been 
shown that disease activity negatively affects HRQoL as well as a number of other 
IBD outcomes. Without further data from the participants who did not complete the 
study it is not possible to speculate on their reasons for being non-responders. 
However it should be considered that they may also have experienced an 
exacerbation of symptoms that may influenced their engagement with the booklet.  
The self-management booklet in this study contained the same activities as are 
presented in IBD-Tracker and while every effort was made to simplify the booklet for 
those with low health literacy, the amount of information they contained may have 
been too great and therefore overwhelming. The intervention booklet was designed 
to support low health literate users through the use of images, easy navigation 
prompts, and simple text, in order to reduce the cognitive load for participants 579, 580. 
However, the visual appearance of the booklet itself would have benefited from 





While adults with IBD rank booklets as one of their most favoured sources of health 
education after their specialist 155, 581, it would be a mistake to assume that the same 
findings apply to children or adolescents. No recent information was found that 
studied children’s preferences for health education materials. While a number of 
articles published prior to 1990 focussed on this topic in this population, the 
subsequent emphasis has been on delivering education to parents. As discussed in 
Chapter Six (Section 6.1), parents consider themselves the primary source of health 
information for their child. This opinion is supported by the findings in Chapter 
Seven (Section 7.3.5) that showed mothers knowledge levels were positively 
correlated with those of their child with IBD. However, the acquisition of self-
management skills cannot be considered equal to the provision of passive 
information such as disease and treatment knowledge. This highlights the 
importance of interventions such as IBD-Tracker, and these booklets, that encourage 
children to develop independence and health autonomy regarding the care and 
knowledge of their IBD.  
Only one study was found that that had utilised booklets in the paediatric population, 
however the results presented only informal verbal feedback from children and 
parents regarding helpfulness 578. It was, therefore, not possible to make 
comparisons on the response rates and efficacy found in this study. Positive effects to 
HRQoL and knowledge have been found from reading IBD information booklets in 
the adult population 363, 582, and they have been used with good effect as a self-
management intervention for adults with IBD 489. However, the use of booklets in the 
adult population is predominantly to passively deliver information, not to influence 
patient behaviour as was the primary aim in this study. Enabling participants to 
adapt and individualise this intervention specifically to their needs meant that 
consideration could be given to non-modifiable participant characteristics that could 
otherwise impact effectiveness of the interventions 207, 237. Creating their own unique 
self-management plan in this way is more likely to improve their disease course than 
a standardised presentation that all should follow, and may help users stay 





There was limited time available to recruit participants for this study and 
subsequently the sample size precluded meaningful analysis of the data. The scores 
achieved on the outcome measures could not be tested for their association with 
independent variables, and comparisons between the two study time points allowed 
only for general inferences to be made. This study did not implement the same 
outcome measures as will be used in the IBD-Tracker study as the respondent 
burden was considered too great for proof of concept research. Additional measures 
will be collected in future studies to collect data on HRQoL, school attendance, and 
health literacy.  
It must be considered that the answers given by participants to the final satisfaction 
survey may have introduced social desirability bias. If this bias was present it would 
have caused participants to answer the survey in a way they perceive as socially 
acceptable to the researcher, as opposed to giving their actual opinion of the booklet 
572. However, participants did not universally provide positive feedback so it may be 
assumed that their responses were a true representation of their judgement of the 
booklet.  
 While providing instruction for performing self-management skills was the primary 
focus of the study booklet, this information was delivered as a standalone 
intervention with no active education component included. The addition of a skills 
demonstration session, whereby participants get shown how to use the sections of 
the intervention, may have improved efficacy and engagement 10.  
11.4.2 Strengths 
The use of a booklet to deliver this self-management intervention allowed for a 
number of features of IBD-Tracker to be included. The portability of the booklet 
allowed for access when needed, and all the components of the app were included for 
participants to utilise when required. Interventions that are available in the home or 
community settings have been shown to be more effective than those delivered only 




Self-management intervention programmes should focus on those elements to which 
the target population ascribe priority as these may be the areas they are most 
motivated to improve 10, 539. The booklet written for this study was based on the 
design of IBD-Tracker, which had incorporated the views and opinions of children 
with IBD as to which intervention components may be effective for improving self-
management of their IBD (Chapter Two, Section 2.2). Subsequently, the content of 
the booklet should be aligned with the needs of the target population, however, it 
remains to be seen if the mode of delivery is as effective and engaging as a mHealth 
app.  
11.4.3 Conclusion 
The original hypothesis stated in the aims of this study was that a self-management 
intervention aligned with the content of IBD-Tracker would be beneficial to children 
with IBD and could help them improve their self-management skills. The feedback 
received showed that three quarters of the participants completing the final outcome 
measures found the booklet useful, and the one who reported it as not useful had not 
read the booklet. The measurable self-management skills improved for those who 
utilised the intervention, albeit not in a statistically measurable way. This hypothesis 
is therefore tentatively accepted, as it is clear that further work is required to be able 
to assess efficacy of this intervention. 
In addition, it was hypothesised that this study could provide information on the 
sensitivity to change pre and post intervention of IBD-KID2. This was not able to be 
assessed due to the participant response numbers being inadequate for statistical 
analysis. 
The results of this study are in no way generalisable to the wider population with 
IBD. However, the study has provided a baseline of positive results on which to build 
further evidence. The mode of delivery may not have been appealing and engaging 
for the target population but when the content is delivered as an interactive mHealth 





Chapter Twelve: Discussion/conclusion 
12.1 Introduction 
It was emphasised at the beginning of this thesis that self-management is a critical 
component for achieving positive disease outcomes for children with IBD. The work 
presented throughout is based on an established self-management framework that 
enabled the overall concept to be explored from a number of perspectives among the 
target population. The core processes of self-management according to the 
framework are: knowledge, self-regulation, adherence, communication, and cognitive 
attributes. Self-management for children with IBD is an emerging field, and as such 
few outcome measures were identified that could assess children’s level of 
understanding of these components. This lack of targeted measurement tools 
subsequently hinders the development of self-management interventions for this 
population as it is imperative to identify areas needing targeted support, as well as to 
assess efficacy of any programme designed.  
The work presented in this thesis describes the development and validation process 
of a number of self-management outcome measures for children with IBD, as well as 
multi-component interventions aimed at supporting children as they develop self-
management skills. 
12.1.1 Knowledge assessment 
Section Two presented a series of studies based on the development and testing of a 
knowledge assessment tool for children with IBD. An initial analysis of participant 
response patterns using a validated measurement tool (IBD-KID) identified a number 
of factors that could be addressed to improve its’ validity, feasibility, reliability, and 
generalisability. These changes led to the development of a revised knowledge 
assessment tool: IBD-KID2. An initial study using IBD-KID2 established that the tool 
had internal validity when tested among a number of groups that included children 
with IBD. IBD-KID2 was also shown to have good internal consistency and test-retest 
reliability. The tool was then used to assess the knowledge levels regarding IBD 
among members of the general public in New Zealand. A further study measured the 




intervention, which showed that IBD-KID2 was sensitive to change in this population. 
A multi-centre study was then carried out to establish generalisability of IBD-KID2 to 
the wider population of children with IBD in three different countries, and also 
measured knowledge levels among their parents and siblings. This research showed 
that IBD-KID2 also had external validity, and added to the previous data that 
confirmed test-retest reliability. 
The knowledge levels of a number of population groups were tested using IBD-KID2 
that established a benchmark hierarchy of understanding among these participants 
that can be utilised in future work. Using IBD-KID2 to test the knowledge of siblings, 
fathers, and members of the general public in New Zealand has provided the first 
such information for all of these groups and therefore addressed an important gap in 
the literature. In addition, IBD-KID2 was able to establish the efficacy of a parent 
education session at improving IBD knowledge levels which has not previously been 
tested in this population. This information can be used to improve awareness and 
support for children with IBD, factors both instrumental for their well-being and 
quality of life. IBD-KID2 has been shown to be a valid, reliable, and generalisable tool 
that has been completed by respondents aged eight to eighty years. IBD-KID2 can be 
used to highlight gaps in understanding among children with IBD and their families 
that may be addressed with formal or informal education. 
Future work will see IBD-KID2 translated in to commonly used languages so that it 
may be more widely utilised. It is also of paramount importance to test whether IBD-
KID2 can detect sensitivity to change pre and post intervention among children with 
IBD so that the tool can be utilised to measure the efficacy of knowledge or self-
management interventions. Work to assess the long term retention of knowledge in 
participant groups would be beneficial to highlight the need for reinforced education 
in this population. This series of studies can be used to establish minimally important 
difference estimates for IBD-KID2, thereby increasing its utility in the clinical and 
research field. 
12.1.2 Symptom self-report 
The study presented in Section Three addressed the self-management component of 




children with IBD that were universal to both clinical subtypes, and that could also 
provide clinically relevant data. This gap was addressed by developing a self-report 
tool (IBDnow) for children with IBD that used the same symptom categories as the 
clinical tools used by paediatric gastroenterologists to rate pain and stool metrics. 
This study showed that children from the age of three could use the series of picture 
and text Likert scales in IBDnow to communicate their IBD symptoms to their clinical 
team. The children’s reports using IBDnow had good levels of agreement with the 
reports of their clinician when using the clinical tools. This study was carried out in 
two centres and no difference was seen between the results of the study populations, 
therefore, showing IBDnow to be generalisable to the wider population of children 
with IBD.  
Future work will see IBDnow being incorporated in to the clinical environment to 
help children communicate their symptoms to their MDT. The importance of 
gathering longitudinal symptom data for the process of developing self-regulation 
skills should be emphasised, and children encouraged to regularly complete IBDnow 
to keep track of their disease course. This will be possible using the mHealth app 
presented in Section Four, which incorporated IBDnow in to the pages where 
symptoms are recorded. While the study in this section showed that scoring IBDnow 
according to the clinical tools magnified discrepancies between the reporters, future 
work could examine whether developing a scoring system, or weighted scoring, 
would be effective for IBDnow and would allow the tool to be used in clinical 
research alongside other outcome measures.  
12.1.3 Self-management skills assessment 
Section Four aimed to first establish whether a self-management skills assessment 
tool had been developed for children with IBD. A literature search identified a 
number that were not deemed appropriate for the target population, and therefore, 
demonstrated a gap in the literature. The content of the tools highlighted in the 
literature review were integrated to produce a novel scale: IBD-STAR. This new 
assessment tool allowed children to score their allocation of responsibility for a 
series of self-management tasks. When the children’s reports were compared with 




generally scored their skills higher. In addition, the children’s scores were more 
closely aligned with the assessment done by their clinician than by their parents, 
perhaps indicating parental anxiety about their child developing health autonomy. 
IBD-STAR can be used to highlight areas where children may need additional support 
as they develop self-management skills, and could be incorporated in to transition 
guidelines as a benchmark of skills that should be achieved prior to beginning the 
process of transition to adult services. 
Future work will need to establish generalisability of IBD-STAR to a wider population 
of children with IBD by performing a multi-centre study. IBD-STAR could be 
completed by children as well as their parents in order to further examine where the 
discrepancies lie in their opinion of self-management abilities. In addition, reliability 
over time should be measured using a test-retest study design among the children 
with IBD. Once reliability is established, IBD-STAR may be used to test self-
management skills pre and post intervention so as to detect sensitivity to change. As 
with IBD-KID2, establishing a minimally important difference will enable IBD-STAR 
to be used as a clinical and research outcome measure for the wider paediatric IBD 
population. IBD-STAR could be easily adapted for other chronic diseases of 
childhood, such as cystic fibrosis. It could also be adapted for the other end of the age 
spectrum as a simple measure for older participants with, for example: rheumatoid 
arthritis, to indicate where additional support may be required. 
12.1.4 Self-management interventions 
Sections One and Five presented two multi-component interventions aimed at helping 
children with IBD learn self-management of their disease. The literature review at 
the beginning of the thesis highlighted a lack of interventions that incorporated all 
aspects of self-management, therefore identifying a gap in the literature. The 
adoption of mobile health technology was considered appropriate for the first 
intervention, thus aligning with the contemporary climate of personal health care. 
While mHealth is gaining popularity for the management of chronic conditions in 
adults, few have been developed for the paediatric population and none were 
identified for children with IBD. In addition, many that target the adult IBD 




evidence base to the components aimed at changing behaviours. The mHealth app 
IBD-Tracker was designed using an iterative framework that incorporates end-user 
input, behaviour change theory, intervention mapping, and usability testing prior to 
performing an RCT. Problems during the development phase were prohibitive to 
getting the app completed on time to be used in this thesis, but testing will 
commence as soon as IBD-Tracker has been launched.  
In order to assess the theoretical base used to develop IBD-Tracker, the contents of 
the app were tested in the alternate format of a self-management booklet written for 
children with IBD. This intervention was tested as Proof of Concept research, and 
while recruitment numbers were poor the findings gave a positive view of the effect 
of a multi-component self-management intervention. The poor participant 
engagement to the booklet, evident by the number repeating the follow up outcome 
measures, emphasised the importance of maximising appeal and interaction when 
developing interventions for paediatric participants. 
Future work will see IBD-Tracker undergo rigorous usability testing prior to 
performing a feasibility study to assess the respondent burden of outcome measures, 
as well as monitoring initial engagement and usage data. The follow up RCT will 
provide important information on whether children with IBD maintain their 
engagement with the intervention, whether it was effective at improving their self-
management skills, and which sections were found most useful. Establishing whether 
the app is relevant and effective for specific age groups will be essential to measure, 
as the app could be developed in to different versions with tailored content for each 
age group according to those components used the most. Once the efficacy, 
feasibility, and generalisability of IBD-Tracker has been established the intervention 
could be incorporated in to routine clinical care. Paediatric gastroenterologists may 
present children with an informal ‘prescription’ for the app that contains download 
instructions to encourage children with IBD to view its use as part of their routine 
IBD management. IBD-Tracker could also be adapted for use with different disease 
groups and may be redeveloped to benefit any population who are required to self-





Measures of disease activity should be incorporated into future studies concerning 
self-management to assess whether it has an effect on children’s abilities to self-
manage their disease. Disease activity is a known barrier to self-management in the 
adult population, and notably the absence of symptoms has also been shown to 
diminish self-management efforts, possibly due to a lack of perceived seriousness or 
perceived benefit 154. The series of outcome measures presented in this thesis may be 
used in conjunction to further examine the interplay between self-management 
components and their efficacy at improving disease outcomes for children with IBD.  
There was a consistent focus on health literacy during the development of the 
outcome measures and interventions presented in this thesis. The aim was to ensure 
that the assessment tools and interventions minimised respondent burden and 
maximised their utility and likelihood of completion. Health literacy considerations 
are infrequently reported in the paediatric health literature but should be a primary 
focus during the development process of such measures. 
While the self-management components of adherence, communication, and cognitive 
attributes were not directly addressed in this thesis, the outcome measures and 
interventions presented were developed to influence all elements of self-
management. IBDnow and IBD-Tracker may be used as communications tools, and 
adherence should be positively influenced through improved knowledge as 
measured using IBD-KID2, as well as through use of IBD-Tracker. IBD-STAR contains 
elements from all self-management components and can be used to provide support 
in those areas where children identify as needing help to perform set tasks.    
The concept that self-management should begin prior to the process of transition for 
children with IBD is supported by these findings. This series of studies has shown 
that children as young as three can self-report their symptoms with good levels of 
agreement with their clinician; from the age of eight they have a grasp of IBD and 
treatment knowledge at a level commensurate with some medical staff; and from the 





Encouraging and supporting children with IBD to learn self-management skills may 
be beneficial to their physical and psychological well-being and should become a 
predominant focus during clinical encounters. This deserving and stoical group of 
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Appendix A. Self-management process and behaviour content synthesis 











Author Core-competencies Sub-domain Domain 
Trivedi 157 Disease specific – disease history (diagnosis, extent, location, 
surgeries) 
Personal history Knowledge 
Trivedi 157 Medication history (including adverse effects)  Personal history Knowledge 
Trivedi 157 General information on IBD natural history  General IBD Knowledge 
Trivedi 157 Disease activity and issues of reproductive health  General IBD Knowledge 
Trivedi 157 Effect of diet, smoking, and use of NSAIDs General IBD Knowledge 
Sattoe 108 Risk behaviour (e.g. unsafe sex or drug and alcohol abuse) General IBD Knowledge 
Trivedi 157 Importance of preventive health (including immunizations) General IBD Knowledge 
Sattoe 108 Understanding the disease Health literacy knowledge 
Sattoe 108 Understanding (the necessity of) medication and treatment regimen Health literacy knowledge 
Sattoe 108 Understanding side effects Health literacy knowledge 
Sattoe 108 Mindfully consume available health-related information Health literacy knowledge 
Sattoe 108 Knowing where to find specific information about the disease Health literacy knowledge 
Modi 50 Seeking disease- and treatment-related information Health literacy knowledge 
Trivedi 157 Analyse risks and benefits of treatment Health literacy Knowledge 
Trivedi 157 Interpret tests results Health literacy Knowledge 
Trivedi 157 Communicate with healthcare providers Communication Communication 
Sattoe 108 Communication with healthcare professionals Communication Communication 
Modi 50 Communication with the medical team Communication Communication 
Trivedi 157 Self-efficacy  Self-efficacy Cognitive 
Sattoe 108 Coping with hospitalizations Coping style Cognitive 









Author Core-competencies Sub-domain Domain 
Sattoe 108 Child–parent sharing/teamwork related to disease-specific medical 
management 
Management plan Self-regulation 
Sattoe 108 Drafting an individualized care plan Management plan Self-regulation 
Trivedi 157 Ostomy care Self-care Self-regulation 
Modi 50 Self-care (e.g., dressing changes) Self-care Self-regulation 
Sattoe 108 Dealing with symptoms Symptom recognition Self-regulation 
Henry 10 Responding to symptoms Symptom recognition Self-regulation 
Sattoe 108 Knowing when to ask for (medical) help Symptom recognition Self-regulation 
Trivedi 157 Recognition of disease flare and extra-intestinal manifestations  Symptom recognition Self-regulation 
Henry 10 Monitoring for and recognizing symptoms  Symptom monitoring Self-regulation 
Henry 10 Managing symptoms and recognizing acute episodes Symptom  monitoring Self-regulation 
Sattoe 108 Self-monitoring of clinical outcomes Symptom  monitoring Self-regulation 
Henry 10 Monitoring health status Symptom  monitoring Self-regulation 
Modi 50 Determining health care needs  Symptom  monitoring Self-regulation 
Modi 50 Self-monitoring of symptoms Symptom monitoring Self-regulation 
Henry 10 Monitoring for reactions Symptom monitoring Self-regulation 
Trivedi 157 Smoking cessation Lifestyle Modifications Self-regulation 
Henry 10 Maintaining diet and physical activity recommendations Lifestyle Modifications Self-regulation 
Henry 10 Stress reduction and managing emotions Lifestyle Modifications Self-regulation 
Henry 10 Mindfulness Lifestyle Modifications Self-regulation 
Modi 50 Lifestyle Modifications Lifestyle Modifications Self-regulation 
Trivedi 157 Calling for medication refills Prescription refill Adherence   
Henry 10 Refilling prescription Prescription refill Adherence   
Modi 50 Refilling prescriptions Prescription refill Adherence 
Trivedi 157 Adherence to complex medication regimen  Medication adherence Adherence  










Author Core-competencies Sub-domain Domain 
Sattoe 108 Drug adherence Medication adherence Adherence 
Modi 50 Taking medications or treatments  Medication adherence Adherence 
Trivedi 157 Scheduling clinic visits Appointment adherence Adherence   
Henry 10 Scheduling Appointment adherence Adherence 
Henry 10 Attending Appointment adherence Adherence 
Henry 10 Follow-up Appointment adherence Adherence 
Sattoe 108 Managing doctor visits Appointment adherence Adherence 
Modi 50 Attending clinic appointments Appointment adherence Adherence 
Modi 50 Behavioural compliance - parental instructions and medical 
procedures 
Behavioural adherence Adherence 
Modi 50 Health care utilization Healthcare utilisation Healthcare 
utilisation 
Sattoe 108 Accessing healthcare Healthcare utilisation Healthcare 
utilisation 
Trivedi 157 Navigate the healthcare system  Healthcare utilisation Healthcare 
utilisation 





Appendix B. Phase 1 - Interview schedule  
Mobile use 
Do you have a phone or tablet 
Apple/Android 
Use every day 
What favourite apps 
Any health apps 
 
IBD 
Does IBD affect you every day in some way 
Does IBD affect your family in some way every day 
Any other aspects it affects regularly 
Hardest part of IBD 
Have you read any information about IBD 
Like to learn more / know more about 
 
Self-Management 
What understand SM may mean? 
What sort of things do you do every day towards managing/responsibility for your 
IBD 
What do other family members do to manage your IBD 
Anything you’ve found helpful to SM your IBD 
 
App content 
What do you consider most important part of taking care of your IBD to include in 
app 
What makes biggest difference to your IBD 
What part of managing your IBD most want or need app to help with 
Anything you’ve found helpful to SM your IBD that could include 
 
Overall 
Do you think an app would be good to help SM disease 
Any features that would encourage you to use it 
Anything that would put you off using it 

















Appendix D. Cognitive Walkthrough tasks 
 
  
Area Navigate to Choose Page Sample data to enter/review 
Symptoms 
 
My Pain 1. I have pain. Save 
2. Belly button. Save 
3. I can’t ignore it. Save 
 
My Poo 1. Record 2 poos 
2. During the day 
3. Mushy 
4. I ran 
5. Specks of blood. 
6. Save 
 
My Health 1. Tired 
2. Poorly 
3. No fever. 
4. Save 
 
Sickness and Eating 1. Not sick 
2. Eating some 
3. Save 
 
Other stuff 1. Mouth ulcers 




List of my drugs 1. Add a new drug 
2. Pentasa 
3. 2 ½ 
4. 10am, 2pm, 6pm 
5. Save 
 
 1. Add a new injection/infusion 
2. Methotrexate 
3. Set for 10 days’ time 
4. 10am 




List of my 
reminders 
1. Add a new reminder 
2. Blood tests 
3. Set for 14 days’ time 
4. 12.15pm 




My drinks 1. Set limit at 1000mls 
2. Save 












My triggers 1. Nuts. Save 
2. Sausages. Save 




1. Change name to Boris. 
2. Change disease type. 
3. Save and check. 
 
When to get 
help 
1. Choose the correct action for: 
- Fever, blood in poo and tired. 
 
Support 1. Click on the links  
 
Settings 1. Review instructions 
2. Send a request for help! 
3. Review privacy instructions 
Knowledge 
 
Learning area 1. You are having an endoscopy. 
2. You are starting the drug Methotrexate. 
3. Learn about the anatomy of the gut. 
History 
 
My history 1. Pain graph for 2 weeks 
2. Show me a graph 
3. Poo graph for 1 week 
4. Show me a graph 
5. My health for 2 months 
6. Show me a graph 
7. Sickness and eating for 1 month 
8. Show me a graph 
9. Other symptoms for 2 weeks 
10. Show me a graph 
11. Taking my drugs for 2 months 
12. Show me a graph 
13. Taking my drinks for 1 week 
14. Show me a graph 
15. Growth for 3 months 
16. Show me a graph 
Instructions 
 
Tap the ? icon 1. Review the instructions on any page. 
Dashboard 
 
Tap the ‘home’ 
icon 




































































Appendix G. IBD-KID  
1) The large bowel is longer than the small bowel. 
a) True 
b) False 
c) Don’t know 
 
2) From start to finish, the correct order of the digestive tract is:  
a) mouth stomach esophagus large bowel small bowel anus 
b) mouth esophagus stomach large bowel small bowel anus 
c) mouth small bowel esophagus stomach large bowel anus  
d) mouth esophagus stomach small bowel large bowel anus 
e) Don’t know 
 
3) A person can get IBD if they: 
a) share food with someone who has IBD 
b) use a toilet that someone with IBD has used 
c) both of the above 
d) none of the above 
e) Don’t know 
 
4) Doctors and scientists know what causes IBD. 
a) True 
b) False 
c) Don’t know 
 
5) Emotional stress can trigger a flare-up of IBD. 
a) True 
b) False 
c) Don’t know 
 
6) IBD can affect organs other than the bowels.  
a) True 
b) False 
c) Don’t know 
 
7) Osteoporosis (weakening of bones) can be caused by: 
a) IBD 
b) corticosteroids (a class of drugs also called ‘steroids’; prednisone is an example) 
c) poor nutrition 
d) all of the above 







8) IBD that is in remission can slow down a young person’s growth. 
a) True 
b) False 
c) Don’t know 
 
9) People with IBD that has involved the colon for more than ten years will probably 
develop colon cancer. 
a) True 
b) False 
c) Don’t know 
 
10) People with IBD don’t usually live as long as other people. 
a) True 
b) False 
c) Don’t know 
 
11) The reason(s) a doctor might perform a colonoscopy is/are to: 
a) look for disease in a person’s large bowel 
b) remove a large section of a person’s large bowel   
c) apply medication to a person’s large bowel 
d) all of the above 
e) Don’t know 
 
 
12) For an IBD patient who is free from symptoms, which of the following medications 
can help keep symptoms from coming back. 
a) salicylates (such as sulfasalazine and 5-ASA) 
b) Imuran (also called azathioprine) 
c) both salicylates and Imuran 
d) neither salicylates nor Imuran 
e) Don’t know 
 
13)  If a person with IBD has been free from symptoms for several months, she/he should 
stop taking her/his medications. 
a) True 
b) False 
c) Don’t know 
 
14) Corticosteroids can cause which of the following side effects in children? 
a) hair loss 
b) decreased weight gain  
c) decreased height growth 
d) all of the above 
e) Don’t know 
 
15) If a patient who is taking corticosteroids experiences side effects, she/he should stop 






c) Don’t know 
 
16) Which of the following statements about herbal remedies is/are true? 
a) Herbal remedies are safer than drugs because herbal remedies don’t cause side 
effects 
b) Herbal remedies can interfere with drugs 
c) both a) and b) are true 
d) neither a) nor b) are true 
e) Don’t know     
 
17) Which of the following statements about surgery for IBD is/are true? 
a) If a person with Crohn’s disease has part of his/her small bowel removed, Crohn’s 
disease will never affect another part of the bowels. 
b) If a person with ulcerative colitis has his/her large bowel removed,  
ulcerative colitis will never affect another part of the bowels. 
c) both a) and b) are true 
d) neither a) nor b) are true 
e) Don’t know 
 
18) IBD tends to run in families.  
a) True 
b) False 
c) Don’t know 
 
19) A child whose parents both have IBD will eventually develop IBD. 
a) True 
b) False 
c) Don’t know 
 
 
20) Removing certain foods from the diet (for instance milk) will prevent flare-ups of IBD 
a) True 
b) False 
c) Don’t know 
 
21) IBD patients can always get the nutrients they need if they eat the right foods. 
a) True 
b) False 






22) Enteral nutrition (liquid diets that patients usually take orally or by nasogastric or 
gastric tube feeds): 
a) can be used to control active disease or prevent disease flare-ups in some Crohn’s 
disease patients 
b) can be used to help some patients grow and gain weight 
c) have not been proven to prevent flare-ups in ulcerative colitis patients 
d) all of the above 
e) Don’t know  
 
23) When doctors are testing a new drug for IBD in a study, some study patients might 
receive a “placebo”.  If a person receives a placebo, it means that: 
a) his or her IBD will stay active for a long time 
b) he or she will not be taking the new drug 
c) he or she will have unpleasant side effects 
d) none of the above 












































Appendix I. IBD-KID2 
1) From start to finish, the correct order of the gut is.:  
a) Mouth  stomach  oesophagus  large bowel  small bowel  anus 
b) Mouth  oesophagus  stomach  large bowel  small bowel  anus 
c) Mouth  oesophagus  stomach  small bowel  large bowel  anus 
d) Don’t know 
 
2) Doctors and scientists know what causes IBD. 
a) True 
b) False 
c) Don’t know 
 
3) Stress can trigger an IBD flare. 
a) True 
b) False 
c) Don’t know 
 
4) The reason you might have a colonoscopy of your large bowel is to: 
a) Look for disease  
b) Remove part of it  
c) Apply drugs inside it 
d) Don’t know 
 
5) IBD can affect other organs, not just the gut.  
a) True 
b) False 
c) Don’t know 
 
6) Which one fact about Osteoporosis (weak bones) is true? 
a) It doesn’t affect males or young women 
b) If I drink plenty of milk, I won’t get it 
c) It can be caused by IBD 
d) Don’t know 
 
7) IBD that is in remission can slow down a young person’s growth. 
a) True 
b) False 






8) How do biologic drugs work?  
a) They reduce the chance of infections 
b) They block the chemicals or cells that cause inflammation 
c) They help the body absorb enough nutrients 
d) Don’t know 
 
 
9)  If a person with IBD has had no symptoms for a few months they should stop 
taking their drugs. 
a)  True 
b)  False 
c)  Don’t know 
 
10) If both parents have IBD their children will develop IBD. 
a) True 
b) False 
c) Don’t know 
 
11) Which one fact about complementary and alternative products is true? 
(example – herbal drugs).  
a)  They may interact with prescribed drugs. 
b)  They are natural so do not have side effects. 
c) They are all safe to use with prescribed drugs. 
d)  Don’t know 
     




c) Don’t know 
 
13) Not eating some foods will stop your IBD getting worse. (example - milk). 
a) True 
b) False 
c) Don’t know 
 
14) Which one fact about IBD surgery is true? 
a)  All people with IBD will need surgery  
b) Surgery is not helpful for people with IBD 
c) Surgery is helpful for some people with IBD  
d) Don’t know 
 








Appendix J. IBD-KID2 Translation protocol 
Background 
There are a number of methodologies outlined in the literature for the translation of 
questionnaires into different languages. The central concern of any translation process is to yield 
a linguistic and cultural equivalent of the original that has a comparable connotative meaning 584. 
The focus of any chosen methodology should therefore be to test the translation equivalence, 
which should be done across a number of dimensions as outlined by Flaherty 585: 
 
 Content – the content of each item is relevant to the phenomenon of each culture 
studied 
 Semantic – the meaning of items is the same in each culture after translation 
 Technical – the method of assessment is comparable with respect to the data it yields.  
 Criterion – the interpretation of results is the same in both cultures 
 Conceptual – the instrument is measuring the same theoretical construct in each culture. 
 
Given the relative simplicity of IBD-KID2, the methodological rigour of a process such as the 
‘Emic-Etic’ approach that studies the culture specific phonemic/phonetic ideas, behaviours and 
items of the tool could be considered unnecessary. A simpler, logical process would be better 
suited and considerably easier and quicker (and inexpensive). The following proposal is a 
suggestion that can be done with as many or as few people as is considered methodologically 
sound and is feasible – and of course is open to discussion. 
 
Establishing equivalence  
The process for establishing equivalence will involve the following distinct phases (see Figure 1 
for overview).  
1. A small number of experts will be convened in Israel to establish content equivalence for 
each item using a simple 10-point rating scale for comprehension and cultural relevance. 
Any items not scoring over 78% 586, 587 will be reviewed with a view to modification or 
omission. 
2. The semantic equivalence will then be tested using the ‘Forward-Backward’ process. IBD-
KID2 will be translated into Hebrew by two individuals- ideally one bilingual expert in the 
field and a second person who has a working knowledge of the terminology used in the 
tool. Once complete they meet to agree on a first ‘forward’ draft. This draft is submitted 
to the original experts who reconcile any differences in translation that may have 
changed the overall meaning of items. Once the final ‘forward’ draft is agreed upon a 
third independent translator (or member of the committee) back translates the tool and 
transfers this version to the expert committee in New Zealand for review of the content 
and format. The final ‘forward’ translation is then ready to be tested: IBD-KID2H.  
3. The technical, criterion, and conceptual equivalence will be tested by using IBD-KID2H in a 
short validity study mimicking that done for the original validation study. 
a. 20 children (age 8-18 with IBD) are recruited in Israel to complete IBD-KID2H 
twice - two weeks apart. In addition to this they will be asked to complete a short 
satisfaction questionnaire relating to comprehension, readability, and 
acceptance of the translated tool. 
 
Involvement 
The work involved for our collaborators in Israel is unfortunately going to be greater than in our 
other studies testing IBD-KID2 as the language difference prevents the ethics application for the 




other studies that allowed online consent to be taken and an electronic version of IBD-KID2 to be 
completed, therefore requiring minimal involvement from collaborators beyond identifying 
participants. All documentation can be supplied in English (PIS, consent, ethics form etc) that will 
hopefully aid your ethics application. 
 































Appendix L. Clinician scoring scale (IBDnow study) 
Ulcerative Colitis patients:  complete this ↓ table by scoring with a recall for the last week  
Symptom Score Level 




Pain can be ignored 
Pain cannot be ignored 
Rectal bleeding 0  




Small amount only (in <50% of stool) 
Small amount with most stools 
Large amount (>50% of stool content) 
















Time of day 0  
10 







No limitation of activity 
Occasional limitation of activity 
Severe restricted activity 
 
Crohn’s Disease patients:  complete this ↓ table by scoring with a recall for the last week  
Symptom Score Level 




mild (brief episodes, not interfering with activities) 
moderate/severe (frequent/persistent, affecting activities) 
Rectal bleeding 0  









2-5 liquid or up to 2 semi-formed  
>6 liquid stools  
Stool frequency: 





2-5 liquid or up to 2 semi-formed with small blood 
>6 liquid stools  






No limitation of activities, well 
Occasional difficulties maintaining activities, below par 






Appendix M. Systematic review search strategies 
MEDLINE - searched 15th September 2018 
 
# Search Statement 
1 Self-Management/ 
2 self-manag*.tw. 
3 1 or 2 
4 TRANSITION TO ADULT CARE/ 
5 transition.mp. 
6 4 or 5 
7 exp Inflammatory Bowel Diseases/ 
8 inflammatory bowel disease*.tw. 
9 IBD.tw. 
10 ulcerative colitis.tw. 
11 crohn* disease.tw. 
12 7 or 8 or 9 or 10 or 11 
13 3 and 12 
14 6 and 12 
15 13 or 14 
16 limit 15 to (yr="1998 -Current" and "all child (0 to 18 years)") 
 
EMBASE - searched 15th September 2018 
 
# Search Statement 
1 Self-Management/ 
2 self-manag*.tw. 
3 1 or 2 
4 TRANSITION TO ADULT CARE/ 
5 transition.mp. 
6 4 or 5 
7 exp Inflammatory Bowel Diseases/ 
8 inflammatory bowel disease*.tw. 
9 IBD.tw. 
10 ulcerative colitis.tw. 
11 crohn* disease.tw. 
12 7 or 8 or 9 or 10 or 11 
13 3 and 12 
14 6 and 12 
15 13 or 14 






PSYCHINFO – searched 15th September 2018 
 
# Search Statement 
1 self-management/ 
2 self-management.tw. 
3 1 or 2 
4 transition.mp. 
5 inflammatory bowel disease*.tw. 
6 ulcerative colitis.tw. 
7 crohn* disease.tw. 
8 IBD.mp. 
9 5 or 6 or 7 or 8 
10 3 and 9 
11 4 and 9 
12 10 or 11 
 
Date searched: 1806 to September Week 2 2018 
 
CINAHL – searched 15th September 2018 
 
#  Query  
S1  "self-management" 
S2  TX self-management  
S3  S1 OR S2  
S4  (MH "Inflammatory Bowel Diseases") OR (MH "Colitis, Ulcerative") OR (MH 
"Crohn Disease")  
S5  TX inflammatory bowel disease  
S6  TX ulcerative colitis  
S7  TX crohn* disease  
S8  S4 OR S5 OR S6 OR S7  
S9  "transition"  
S10  S3 AND S8  
S11  S8 AND S9  
S12  S10 OR S11  
S13  S10 OR S11  
 
Limiters - Published Date: 1998/01/01-2018/12/31; Age Groups: Adolescent: 13-18 
years, All Child  
 
Joanna Briggs – searched 15th September 2018 
 
# Search Statement 
1 self-management.mp. [mp=text, heading word, subject area node, title] 
2 inflammatory bowel disease.mp. [mp=text, heading word, subject area node, 
title] 







Cochrane database - searched 16th September 2018 
 
#1 Self-management  
#2 inflammatory bowel disease  
#3 transition  
#1 and #2  
#2 and #3  
 
SCOPUS - searched 16th September 2018 
 
#1 self-management  
#2 inflammatory bowel disease (search within #1) 






























Read each statement about self-management tasks. Put a cross on the line to show how 
much help you think your child needs to do each task. 
 
Example question: Do you think your child can make toast by themselves? 
If they can do everything except get the toast out at the end then put the cross closer to the ‘they 






1. Could your child tell someone the details of their IBD?  





2. Can your child manage and participate in their IBD appointments? 





3. Could your child tell someone about their IBD treatment?  





4. How well do you think your child manages their IBD treatment? 




5. How well do you think your child manages the tasks below on their own? 




6. Overall, how well do you think your child can self-manage their IBD? 
(All of the questions above combined?) 
No, they can’t 
do it at all. 
Yes, they can do 




Appendix P. Self-management booklet 
 
 
429 
 
 
 
430 
 
 
431 
 
 
432 
 
 
433 
 
 
434 
 
 
435 
 
 
436 
 
 
437 
 
 
438 
 
 
439 
 
 
440 
 
 
441 
 
 
442 
 
 
443 
 
 
